<?xml version="1.0" encoding="UTF-8"?>
<search_results count="327625">
  <query>ALL</query>
  <!-- Additional study fields may be added over time -->
  <study rank="45001">
    <nct_id>NCT03651336</nct_id>
    <title>Long-term Safety and Performance of the ARGOS-IO Intraocular Pressure Sensor System in Subjects With Primary Open Angle Glaucoma (POAG)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Primary Open-angle Glaucoma</condition>
    </conditions>
    <interventions>
      <intervention type="Device">ARGOS-IO Sensor Pressure System</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Safety measured by Incidence of medical-device related adverse events and serious adverse events</outcome_measure>
      <outcome_measure>Limits of agreement between IOP measurements made using GAT and the ARGOS-IO system at each study visit.</outcome_measure>
      <outcome_measure>Limits of agreement between IOP measurements made using DCT and the ARGOS-IO system at each study visit.</outcome_measure>
      <outcome_measure>Incidence of observed device malfunctions and nature of device malfunction</outcome_measure>
      <outcome_measure>Patient's compliance in IOP self-monitoring</outcome_measure>
      <outcome_measure>Impact of IOP self-monitoring on glaucoma progression</outcome_measure>
      <outcome_measure>Incidence in glaucoma medication change</outcome_measure>
      <outcome_measure>Number of unscheduled visits due to self-measured increased intraocular pressure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Implandata Ophthalmic Products GmbH</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>ARGOS-03</other_id>
      <other_id>CIV-18-13-023284</other_id>
    </other_ids>
    <start_date>August 15, 2018</start_date>
    <primary_completion_date>October 31, 2021</primary_completion_date>
    <completion_date>November 30, 2021</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>Klinik für Augenheilkunde, Uniklinik RWTH Aachen, Aachen, Germany</location>
      <location>Universitäts-Augenklinik Bochum, Bochum, Germany</location>
      <location>Internationale Innovative Opthalmochirurgie, Düsseldorf, Germany</location>
      <location>nordBLICK Augenklinik Bellevue, Kiel, Germany</location>
      <location>Universitätsaugenklinik Magdeburg, Magdeburg, Germany</location>
      <location>Universitäts-Augenklinik Tübingen, Tübingen, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651336</url>
  </study>
  <study rank="45002">
    <nct_id>NCT03651323</nct_id>
    <title>Latin America Registry on WatchmanTM Outcomes in Real Life</title>
    <acronym>LATINAWERICA</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Atrial Fibrillation</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Left atrial appendage closure with Watchman device</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of Periprocedural complications</outcome_measure>
      <outcome_measure>Incidence of Stroke</outcome_measure>
      <outcome_measure>Incidence of Death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centro Medico Docente la Trinidad</lead_sponsor>
      <collaborator>Boston Scientific Corporation</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ISRCAR00144</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>November 1, 2018</primary_completion_date>
    <completion_date>December 1, 2018</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>Centro Medico Docente la Trinidad, Caracas, Miranda, Venezuela</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651323</url>
  </study>
  <study rank="45003">
    <nct_id>NCT03651310</nct_id>
    <title>Music Listening on Preoperative Anxiety in Female Pelvic Medicine and Reconstructive Surgery</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Preoperative Anxiety</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Music Listening Group</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Preoperative Anxiety</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Loyola University</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>211003</other_id>
    </other_ids>
    <start_date>May 29, 2018</start_date>
    <primary_completion_date>July 15, 2019</primary_completion_date>
    <completion_date>September 30, 2019</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>December 5, 2019</last_update_posted>
    <locations>
      <location>Loyola University Medical Center, Maywood, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651310</url>
  </study>
  <study rank="45004">
    <nct_id>NCT03651297</nct_id>
    <title>Simple Fall-Arrest Harness vs. Adjustable Harness</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fall Accident</condition>
      <condition>Fall Injury</condition>
      <condition>Balancing Interference</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Balance training with Fall-Arrest harness</intervention>
      <intervention type="Other">Balance training with Adjustable harness</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change (improvement) in response to increasingly difficult perturbations, as measured by the Rate of Perceived Stability Score (RPS).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cleveland State University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB-FY2018-324</other_id>
    </other_ids>
    <start_date>November 20, 2018</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>July 25, 2019</last_update_posted>
    <locations>
      <location>Cleveland State University, Cleveland, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651297</url>
  </study>
  <study rank="45005">
    <nct_id>NCT03651284</nct_id>
    <title>Investigating the Efficacy of a Mobile App Intervention to Change Youth and Their Families' Health Behaviours</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Obesity, Pediatric</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Aim2Be app with Live Coach + Fitbit + BMI tracking tools</intervention>
      <intervention type="Behavioral">Aim2Be app waitlist + Canadian Health Recommendations + Fitbit + BMI tracking tools, then flip to Aim2Be app with Virtual Coach + Fitbit + BMI tracking tools</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Body Mass Index z-score (youth)</outcome_measure>
      <outcome_measure>Change in health behaviour knowledge (youth)</outcome_measure>
      <outcome_measure>Change in objective dietary behaviour (youth)</outcome_measure>
      <outcome_measure>Change in number of daily steps (youth)</outcome_measure>
      <outcome_measure>Change in screen behaviour (youth)</outcome_measure>
      <outcome_measure>Adherence</outcome_measure>
      <outcome_measure>Reach</outcome_measure>
      <outcome_measure>Change in Healthy Eating Index score (youth)</outcome_measure>
      <outcome_measure>Change in self-reported dietary behaviour (youth)</outcome_measure>
      <outcome_measure>Change in self-reported physical activity behaviour (youth)</outcome_measure>
      <outcome_measure>Change in self-reported dietary behaviour (parents)</outcome_measure>
      <outcome_measure>Change in self-reported physical activity behaviour (parents)</outcome_measure>
      <outcome_measure>Change in screen behaviour (parents)</outcome_measure>
      <outcome_measure>Change in mediators of behaviour change</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of British Columbia</lead_sponsor>
      <collaborator>Childhood Obesity Foundation</collaborator>
      <collaborator>Ayogo Health Inc.</collaborator>
      <collaborator>Public Health Agency of Canada (PHAC)</collaborator>
      <collaborator>Merck Canada Inc.</collaborator>
      <collaborator>Pacific Blue Cross</collaborator>
      <collaborator>Heart and Stroke Foundation of Canada</collaborator>
      <collaborator>David Suzuki Foundation</collaborator>
      <collaborator>Craving Change</collaborator>
      <collaborator>Diabetes Canada</collaborator>
      <collaborator>Canadian Institutes of Health Research (CIHR)</collaborator>
      <collaborator>British Columbia Children's Hospital</collaborator>
      <collaborator>Children's Hospital of Eastern Ontario Research Institute</collaborator>
      <collaborator>The Hospital for Sick Children</collaborator>
      <collaborator>Hamilton Health Sciences Corporation</collaborator>
      <collaborator>Alberta Health Services</collaborator>
      <collaborator>The Governors of the University of Alberta</collaborator>
      <collaborator>University of Alberta</collaborator>
      <collaborator>Alberta Innovates Health Solutions</collaborator>
      <collaborator>Women and Children's Health Research Institute, Canada</collaborator>
      <collaborator>Canadian Obesity Network</collaborator>
      <collaborator>Ontario Ministry of Health and Long Term Care</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>10 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>H16-03090-b</other_id>
    </other_ids>
    <start_date>November 1, 2018</start_date>
    <primary_completion_date>March 2020</primary_completion_date>
    <completion_date>January 2021</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>April 22, 2019</last_update_posted>
    <locations>
      <location>Alberta Children's Hospital, Calgary, Alberta, Canada</location>
      <location>University of Alberta, Edmonton, Alberta, Canada</location>
      <location>University of British Columbia, Vancouver, British Columbia, Canada</location>
      <location>McMaster University, Hamilton, Ontario, Canada</location>
      <location>Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada</location>
      <location>The Hospital for Sick Children, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651284</url>
  </study>
  <study rank="45006">
    <nct_id>NCT03651271</nct_id>
    <title>Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Advanced Metastatic Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Nivolumab</intervention>
      <intervention type="Biological">Ipilimumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical benefit rate (CBR) of nivolumab with or without ipilimumab</outcome_measure>
      <outcome_measure>Percentage of CD8 cells in on-treatment biopsies</outcome_measure>
      <outcome_measure>Safety of nivolumab with or without ipilimumab measured by AEs based on CTCAE v5.0</outcome_measure>
      <outcome_measure>Objective response rate (ORR) of nivolumab with or without ipilimumab in participants</outcome_measure>
      <outcome_measure>The association of the percentage of CD8 cells in tumor samples with clinical outcomes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Parker Institute for Cancer Immunotherapy</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
      <collaborator>Cancer Research Institute, New York City</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PICI0025</other_id>
    </other_ids>
    <start_date>October 17, 2018</start_date>
    <primary_completion_date>September 14, 2020</primary_completion_date>
    <completion_date>September 14, 2022</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>May 30, 2019</last_update_posted>
    <locations>
      <location>University of California, Los Angeles, Los Angeles, California, United States</location>
      <location>Stanford University, Palo Alto, California, United States</location>
      <location>University of California, San Francisco, San Francisco, California, United States</location>
      <location>Dana-Farber Cancer Institute, Boston, Massachusetts, United States</location>
      <location>Memorial Sloan Kettering Cancer Center, New York, New York, United States</location>
      <location>M.D. Anderson Cancer Center, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651271</url>
  </study>
  <study rank="45007">
    <nct_id>NCT03651258</nct_id>
    <title>Facilitate the Transition From Passive Feeding to Active Feeding in Preterm Infants Through Early Play</title>
    <acronym>ALIJEU</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Immature Newborn</condition>
      <condition>Feeding Behavior</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Implementation of ALIJEU</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>age at the stoppage of enteral nutrition</outcome_measure>
      <outcome_measure>Duration of feeding</outcome_measure>
      <outcome_measure>Quantities drunk</outcome_measure>
      <outcome_measure>Awakening</outcome_measure>
      <outcome_measure>Visual analogic scale for Satisfaction from 0 to 10</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Intercommunal Creteil</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>4 Weeks</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>59</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ALIJEU</other_id>
    </other_ids>
    <start_date>September 19, 2017</start_date>
    <primary_completion_date>May 1, 2018</primary_completion_date>
    <completion_date>July 30, 2018</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>January 15, 2019</last_update_posted>
    <locations>
      <location>CHI Créteil, Créteil, Ile De France, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651258</url>
  </study>
  <study rank="45008">
    <nct_id>NCT03651245</nct_id>
    <title>European Alpha-Mannosidosis Patient Epidemiological Program (EUMAP)</title>
    <acronym>EUMAP</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Immunodeficiency</condition>
      <condition>Skeletal Abnormalities</condition>
      <condition>Deafness</condition>
      <condition>Mental Retardation</condition>
      <condition>Gingival Hypertrophy</condition>
      <condition>Facial Dysmorphism</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Epidemiological analysis of the prevalence of Alpha-Mannosidosis disease in a cohort of patients with suspicion for Alpha-Mannosidosis, based on their clinical symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centogene AG Rostock</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>2 Months</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>EUMAP-2018</other_id>
    </other_ids>
    <start_date>August 20, 2018</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>November 20, 2019</last_update_posted>
    <locations>
      <location>Charité - Universitätsmedizin Berlin, Leitung Sozialpädiatrisches Zentrum, Klinik für Pädiatrie m.S. Neurologie, Berlin, Germany</location>
      <location>Carl-Thiem-Klinikum Cottbus GmbH, Sozialpädiatrisches Zentrum, Cottbus, Germany</location>
      <location>Carl-Thiem-Klinikum Cottbus GmbH, Klinik für Kinder und Jugendmedizin, Cottbus, Germany</location>
      <location>Universitätsklinikum Essen, Klinik für Hals-Nasen und Ohrenheilkunde, Essen, Germany</location>
      <location>Universitätsklinikum Gießen, Zentrum für Kinderheilkunde und Jugendmedizin, Abteilung für Kinderneurologie, Sozialpädiatrie und Epileptologie, Gießen, Germany</location>
      <location>Universitätsklinikum Jena, Klinik für Neuropädiatrie, Jena, Germany</location>
      <location>HNO-Universitätsklinik, Universitätsspital Basel, Basel, Switzerland</location>
      <location>Inselspital Bern Universitätsklinik für Neurologie, Bern, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651245</url>
  </study>
  <study rank="45009">
    <nct_id>NCT03651232</nct_id>
    <title>Prenatal Yoga for Pregnancy Related Back Pain</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pregnancy Related</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">yoga</intervention>
      <intervention type="Behavioral">support group</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>feasibility of recruitment</outcome_measure>
      <outcome_measure>back pain disability</outcome_measure>
      <outcome_measure>back pain severity</outcome_measure>
      <outcome_measure>pregnancy symptoms</outcome_measure>
      <outcome_measure>depression</outcome_measure>
      <outcome_measure>quality of lfe</outcome_measure>
      <outcome_measure>childbirth experience</outcome_measure>
      <outcome_measure>mobility lab- speed</outcome_measure>
      <outcome_measure>acceptability</outcome_measure>
      <outcome_measure>mobility lab- double support</outcome_measure>
      <outcome_measure>mobility lab- TUG</outcome_measure>
      <outcome_measure>mobility lab- turn</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beth Israel Deaconess Medical Center</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>39 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2014P000344</other_id>
    </other_ids>
    <start_date>April 21, 2015</start_date>
    <primary_completion_date>June 30, 2016</primary_completion_date>
    <completion_date>June 30, 2016</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651232</url>
  </study>
  <study rank="45010">
    <nct_id>NCT03651219</nct_id>
    <title>Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Small Cell Lung Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Apatinib</intervention>
      <intervention type="Drug">Irinotecan</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>duration of treatment</outcome_measure>
      <outcome_measure>progress free survival and overall survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beijing Chest Hospital</lead_sponsor>
      <collaborator>Jiangsu HengRui Medicine Co., Ltd.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>20171301</other_id>
    </other_ids>
    <start_date>September 8, 2018</start_date>
    <primary_completion_date>August 8, 2019</primary_completion_date>
    <completion_date>August 8, 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651219</url>
  </study>
  <study rank="45011">
    <nct_id>NCT03651206</nct_id>
    <title>Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib</title>
    <acronym>ROCSAN</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ovarian Carcinosarcoma</condition>
      <condition>Endometrial Carcinosarcoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Niraparib</intervention>
      <intervention type="Combination Product">Niraparib + TSR-042 (Dostarlimab)</intervention>
      <intervention type="Drug">Chemotherapy Drugs</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Response Rate (RR) at 4 months</outcome_measure>
      <outcome_measure>Overall survival (OS)</outcome_measure>
      <outcome_measure>Progression Free Survival (PFS)</outcome_measure>
      <outcome_measure>Time To Subsequent Treatment (TTST)</outcome_measure>
      <outcome_measure>Progression-Free Survival 2 (PFS2)</outcome_measure>
      <outcome_measure>Objective Response Rate (ORR)</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Patient-reported outcomes (PROs)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>ARCAGY/ GINECO GROUP</lead_sponsor>
      <collaborator>Tesaro, Inc.</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>196</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ENGOT-en8</other_id>
    </other_ids>
    <start_date>January 2020</start_date>
    <primary_completion_date>December 2024</primary_completion_date>
    <completion_date>June 2025</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>October 7, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651206</url>
  </study>
  <study rank="45012">
    <nct_id>NCT03651193</nct_id>
    <title>Multi-center Registration Study of Adult Onset Still's Disease in Chinese Population</title>
    <acronym>MAOSDC</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Adult Onset Still Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Exon sequencing and Methylated sequencing</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>gene expression level and methylation level</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Second Xiangya Hospital of Central South University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>MAOSDC20180720</other_id>
    </other_ids>
    <start_date>November 28, 2018</start_date>
    <primary_completion_date>November 28, 2019</primary_completion_date>
    <completion_date>November 28, 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>November 26, 2018</last_update_posted>
    <locations>
      <location>The Second Xiangya Hospital of Central South University, Hunan, Changsha, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651193</url>
  </study>
  <study rank="45013">
    <nct_id>NCT03651180</nct_id>
    <title>Efficacy and Safety of Coronary Amphilimus-ELuting Stent in diAbeTic patiEnts</title>
    <acronym>ESCALATE</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Artery Disease</condition>
      <condition>Diabetes Mellitus</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Incidence of the composite endpoint of cardiac death, definite and probable stent thrombosis, re-PCI, Target Vessel Revascularization and bleeding in the two groups of study</outcome_measure>
      <outcome_measure>Incidence of every single adverse event (cardiac death, definite and probable stent thrombosis, re-PCI, Target Vessel Revascularization and bleeding) in the two groups of study</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ospedale S. Giovanni Bosco</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>3400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>14942</other_id>
    </other_ids>
    <start_date>August 1, 2018</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>October 1, 2023</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>San Giovanni Bosco Hospital - ASL Città di Torino, Turin, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651180</url>
  </study>
  <study rank="45014">
    <nct_id>NCT03651167</nct_id>
    <title>Skin Tone Preferences and Their Influence on Skin Care Behaviors</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dermatology/Skin - Other</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Survey</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Frequency of skin tone differences between ideal and actual</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Northwestern University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>619</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>RVK05222018</other_id>
    </other_ids>
    <start_date>August 1, 2018</start_date>
    <primary_completion_date>December 30, 2019</primary_completion_date>
    <completion_date>December 30, 2019</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 21, 2019</last_update_posted>
    <locations>
      <location>Northwestern University Feinberg School of Medicine Department of Dermatology, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651167</url>
  </study>
  <study rank="45015">
    <nct_id>NCT03651154</nct_id>
    <title>Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections</title>
    <acronym>PRICE2</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Neoplasms</condition>
      <condition>Hepatectomy</condition>
      <condition>Blood Transfusion</condition>
      <condition>Blood Loss, Surgical</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Hypovolemic Phlebotomy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Packed Red Blood Cell Transfusion Rates</outcome_measure>
      <outcome_measure>Blood product transfusion rates</outcome_measure>
      <outcome_measure>Intraoperative blood loss</outcome_measure>
      <outcome_measure>Perioperative morbidity and mortality</outcome_measure>
      <outcome_measure>Changes in physiologic parameters (Central Venous Pressure)</outcome_measure>
      <outcome_measure>Changes in physiologic parameters (Pulse Pressure Variation)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ottawa Hospital Research Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>440</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>502</other_id>
    </other_ids>
    <start_date>September 28, 2018</start_date>
    <primary_completion_date>October 2022</primary_completion_date>
    <completion_date>December 2022</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 13, 2019</last_update_posted>
    <locations>
      <location>The Ottawa Hospital, Ottawa, Ontario, Canada</location>
      <location>Centre Hospitalier de l&quot;Université de Sherbrooke, Montréal, Quebec, Canada</location>
      <location>Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651154</url>
  </study>
  <study rank="45016">
    <nct_id>NCT03651141</nct_id>
    <title>The Effects of Soft Tissue Therapy and Exercise on Hamstring Tightness</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hamstring Tightness</condition>
      <condition>Myofascial Pain</condition>
      <condition>Musculoskeletal Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Neurodynamic Sliding</intervention>
      <intervention type="Other">Myofascial Decompression</intervention>
      <intervention type="Other">Diathermy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hamstring Flexibility change</outcome_measure>
      <outcome_measure>Hamstring muscle strength change</outcome_measure>
      <outcome_measure>Time of Force Development</outcome_measure>
      <outcome_measure>Electromyographic (EMG) Muscle Activation of the Hamstring muscles</outcome_measure>
      <outcome_measure>Disablement of the Physically Active patient outcome survey</outcome_measure>
      <outcome_measure>Functional Patient Outcome survey</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Oklahoma State University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>25 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ED174</other_id>
    </other_ids>
    <start_date>March 27, 2017</start_date>
    <primary_completion_date>April 10, 2017</primary_completion_date>
    <completion_date>June 12, 2017</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 31, 2018</last_update_posted>
    <locations>
      <location>Applied Neuromuscular Physiology Lab, Stillwater, Oklahoma, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651141</url>
  </study>
  <study rank="45017">
    <nct_id>NCT03651128</nct_id>
    <title>Efficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)</title>
    <acronym>KarMMa-3</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Multiple Myeloma</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">bb2121</intervention>
      <intervention type="Drug">Daratumumab</intervention>
      <intervention type="Drug">Pomalidomide</intervention>
      <intervention type="Drug">Dexamethasone</intervention>
      <intervention type="Drug">Bortezomib</intervention>
      <intervention type="Drug">Ixazomib</intervention>
      <intervention type="Drug">Lenalidomide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Progression-free Survival (PFS)</outcome_measure>
      <outcome_measure>Overall Survival (OS)</outcome_measure>
      <outcome_measure>Event-free Survival (EFS)</outcome_measure>
      <outcome_measure>Overall Response Rate (ORR)</outcome_measure>
      <outcome_measure>Minimal Residual Disease (MRD)</outcome_measure>
      <outcome_measure>Complete Response (CR) Rate</outcome_measure>
      <outcome_measure>Duration of Response (DOR)</outcome_measure>
      <outcome_measure>Time to Response (TTR)</outcome_measure>
      <outcome_measure>Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Pharmacokinetics- Cmax</outcome_measure>
      <outcome_measure>Pharmacokinetics- tmax</outcome_measure>
      <outcome_measure>Pharmacokinetics- AUC</outcome_measure>
      <outcome_measure>Pharmacokinetics- t-last</outcome_measure>
      <outcome_measure>Pharmacokinetics- AUC0-28days</outcome_measure>
      <outcome_measure>Subject-reported outcomes as measured by European Organization for Research and Treatment of Cancer Quality-of-Life questionnaire (EORTC-QLQ-C30)</outcome_measure>
      <outcome_measure>Subject-reported outcomes as measured by EuroQoL Group European Quality of Life-5 Dimensions health state classifier to 5 Levels (EQ-5D-5L) Health Questionnaire</outcome_measure>
      <outcome_measure>Subject-reported outcomes as measured by European Quality of Life Multiple Myeloma Module (EORTC-QLQ-MY20)</outcome_measure>
      <outcome_measure>Time to next antimyeloma treatment</outcome_measure>
      <outcome_measure>Progression-free survival after next line therapy (PFS2)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Celgene</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>381</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>BB2121-MM-003</other_id>
      <other_id>U1111-1217-9988</other_id>
      <other_id>2018-001023-38</other_id>
    </other_ids>
    <start_date>October 12, 2018</start_date>
    <primary_completion_date>June 23, 2025</primary_completion_date>
    <completion_date>June 23, 2025</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>November 26, 2019</last_update_posted>
    <locations>
      <location>University of Alabama Birmingham, Birmingham, Alabama, United States</location>
      <location>Mayo Clinic Arizona, Scottsdale, Arizona, United States</location>
      <location>University of Colorado Anschutz Cancer Pavilion, Aurora, Colorado, United States</location>
      <location>Mayo Clinic - Jacksonville, Jacksonville, Florida, United States</location>
      <location>Moffit Cancer Center, Tampa, Florida, United States</location>
      <location>Emory University Hospital, Atlanta, Georgia, United States</location>
      <location>Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States</location>
      <location>Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States</location>
      <location>Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States</location>
      <location>The University of Kansas Hospital, Westwood, Kansas, United States</location>
      <location>Mayo Clinic - Rochester, Rochester, Minnesota, United States</location>
      <location>Washington University School of Medicine, Siteman Cancer Center, Saint Louis, Missouri, United States</location>
      <location>Hackensack University Medical Center, Hackensack, New Jersey, United States</location>
      <location>Mount Sinai Medical Center, New York, New York, United States</location>
      <location>Thomas Jefferson University, Philadelphia, Pennsylvania, United States</location>
      <location>Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States</location>
      <location>University of Pittsburgh Medical Center - William M. Cooper Ambulatory Care Pavilion, Pittsburgh, Pennsylvania, United States</location>
      <location>Sarah Cannon Research Institute Center for Blood, Nashville, Tennessee, United States</location>
      <location>MD Anderson Cancer center, Houston, Texas, United States</location>
      <location>University of Utah Huntsman Cancer Center, Salt Lake City, Utah, United States</location>
      <location>Swedish Cancer Institute, Seattle, Washington, United States</location>
      <location>University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States</location>
      <location>UZ Leuven, Leuven, Belgium</location>
      <location>Tom Baker Cancer center, Calgary, Alberta, Canada</location>
      <location>Hospital Saint-Louis - APHP, Paris, France</location>
      <location>Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi - Istituto di Ematolog, Bologna, Italy</location>
      <location>Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Japan</location>
      <location>Tokai University Hospital, Isehara, Kanagawa, Japan</location>
      <location>Clinica Universidad de Navarra, Pamplona, Spain</location>
      <location>Hospital Universitario de Salamanca, Salamanca, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651128</url>
  </study>
  <study rank="45018">
    <nct_id>NCT03651115</nct_id>
    <title>TDM of Gentamicin and Vancomycin, in Neonates, Using Dried Blood Spot Sampling.</title>
    <acronym>MIDOMEN</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Blood Sample for Routine Care</condition>
      <condition>Term or Premature Newborns (28 to 44 Amenorrhea Weeks)</condition>
      <condition>Gentamicin and/or Vancomycin</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">therapeutic drug monitoring</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sampling time for vancomycin concentration</outcome_measure>
      <outcome_measure>Sampling time for gentamycin concentration</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Caen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>28 Weeks</min_age>
    <max_age>44 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>MIDOMEN 16-024</other_id>
    </other_ids>
    <start_date>December 15, 2017</start_date>
    <primary_completion_date>September 2019</primary_completion_date>
    <completion_date>September 2019</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>CHU de Caen, Caen, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651115</url>
  </study>
  <study rank="45019">
    <nct_id>NCT03651102</nct_id>
    <title>Efficacy and Safety of Low Dose Thalidomide in Thalassemia Intermedia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Thalassemia Intermedia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Thalidomide Oral Product</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Haemoglobin Level</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Blood Diseases Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>5 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TI</other_id>
    </other_ids>
    <start_date>January 1, 2018</start_date>
    <primary_completion_date>November 30, 2018</primary_completion_date>
    <completion_date>December 2018</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>Blood Diseases Clinic, Peshawar, Khyber Pakhtukhwa, Pakistan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651102</url>
  </study>
  <study rank="45020">
    <nct_id>NCT03651089</nct_id>
    <title>SP16 SERPIN-like Peptide Administration in Healthy Individuals</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Participants</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SP16</intervention>
      <intervention type="Drug">Placebos</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Preliminary Safety Assessment: Occurence of adverse events</outcome_measure>
      <outcome_measure>Volume of distribution of SP16 in healthy subjects</outcome_measure>
      <outcome_measure>Clearance of SP16 in healthy subjects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Serpin Pharma, LLC</lead_sponsor>
      <collaborator>George Mason University</collaborator>
      <collaborator>Virginia Commonwealth University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>59 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>01-SP16</other_id>
    </other_ids>
    <start_date>July 16, 2018</start_date>
    <primary_completion_date>February 2, 2019</primary_completion_date>
    <completion_date>August 1, 2019</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>January 15, 2019</last_update_posted>
    <locations>
      <location>Virginia Commonwealth University, Richmond, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651089</url>
  </study>
  <study rank="45021">
    <nct_id>NCT03651076</nct_id>
    <title>Traxi Panniculus Retractor for Cesarean Delivery</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Obesity, Morbid</condition>
      <condition>Cesarean Section Complications</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Traxi panniculus retraction (Clinical Innovations, LLC)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cesarean delivery operative time</outcome_measure>
      <outcome_measure>Change in pulmonary function (forced vital capacity)</outcome_measure>
      <outcome_measure>Change in pulmonary function (forced expiratory volume)</outcome_measure>
      <outcome_measure>Patient satisfaction assessed by a questionnaire</outcome_measure>
      <outcome_measure>Provider satisfaction with a survey</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beth Israel Deaconess Medical Center</lead_sponsor>
      <collaborator>Clinical Innovations, LLC</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018P000369</other_id>
    </other_ids>
    <start_date>October 2, 2018</start_date>
    <primary_completion_date>September 2022</primary_completion_date>
    <completion_date>December 2022</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>April 19, 2019</last_update_posted>
    <locations>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651076</url>
  </study>
  <study rank="45022">
    <nct_id>NCT03651063</nct_id>
    <title>Socially Assistive Robot in Upper-Limb Neurorehabilitation</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Upper Extremity Paralysis</condition>
    </conditions>
    <interventions>
      <intervention type="Other">social robot</intervention>
      <intervention type="Other">computer group</intervention>
      <intervention type="Other">self-training</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sensory Motor Recovery of the upper limb</outcome_measure>
      <outcome_measure>The amount of use of the upper extremity in everyday life</outcome_measure>
      <outcome_measure>index of curvature</outcome_measure>
      <outcome_measure>stroke impact scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ben-Gurion University of the Negev</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>40 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>5273-18-SMC</other_id>
    </other_ids>
    <start_date>May 10, 2019</start_date>
    <primary_completion_date>March 31, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>July 10, 2019</last_update_posted>
    <locations>
      <location>Aleh Negev Rehabilitation Center, Ofakim, South, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651063</url>
  </study>
  <study rank="45023">
    <nct_id>NCT03651050</nct_id>
    <title>Implementing a Digital Child Mental Health Screening, Literacy, and Management Tool in Faith-Based Settings</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mental Health</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Faith Based Outreach (FBO)</intervention>
      <intervention type="Behavioral">community-health-workers (CHW)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Aggression measured by parent report</outcome_measure>
      <outcome_measure>Anxiety measured by parent report</outcome_measure>
      <outcome_measure>Depression measured by parent report</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NYU Langone Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>331</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>18-00728</other_id>
    </other_ids>
    <start_date>August 2019</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>June 14, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651050</url>
  </study>
  <study rank="45024">
    <nct_id>NCT03651037</nct_id>
    <title>Physical Activity Platform to Improve Bone Health in Cancer Survivors</title>
    <acronym>THRIVORS+BH</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Breast Cancer</condition>
      <condition>Physical Activity</condition>
      <condition>Bone Health</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Thrivors+BH</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of participants to complete exercise sessions and surveys</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Thrivors Inc</lead_sponsor>
      <collaborator>Oregon Health and Science University</collaborator>
      <collaborator>Masonic Cancer Center, University of Minnesota</collaborator>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>40 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>THRIVORSBH-01</other_id>
      <other_id>R43CA224412</other_id>
    </other_ids>
    <start_date>January 21, 2019</start_date>
    <primary_completion_date>December 31, 2019</primary_completion_date>
    <completion_date>March 1, 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>September 10, 2019</last_update_posted>
    <locations>
      <location>Thrivors Inc, Saint Paul, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651037</url>
  </study>
  <study rank="45025">
    <nct_id>NCT03651024</nct_id>
    <title>Sano V First In Human Study to Treat ED</title>
    <acronym>FMS</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Erectile Dysfunction (ED)</condition>
    </conditions>
    <interventions>
      <intervention type="Device">ED surgery</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The surgical implant for ED treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sano V Pte Ltd</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>25 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Device Feasibility</study_design>
    </study_designs>
    <other_ids>
      <other_id>CLN0001</other_id>
    </other_ids>
    <start_date>October 2018</start_date>
    <primary_completion_date>December 2018</primary_completion_date>
    <completion_date>October 2019</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651024</url>
  </study>
  <study rank="45026">
    <nct_id>NCT03651011</nct_id>
    <title>Navigated Laser In Branch Retinal Vein Occlusion Study</title>
    <acronym>NIRVANA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Branch Retinal Vein Occlusion</condition>
      <condition>Macular Edema</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aflibercept Injection [Eylea]</intervention>
      <intervention type="Procedure">Navigated laser photocoagulation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Patients with additional need for anti-VEGF after loading phase</outcome_measure>
      <outcome_measure>Additional need for anti-VEGF after loading phase</outcome_measure>
      <outcome_measure>Change in BCVA according to treatment regimen</outcome_measure>
      <outcome_measure>Effect on macular edema according til treatment regimen</outcome_measure>
      <outcome_measure>Retinal oxygen saturation</outcome_measure>
      <outcome_measure>Macular ischemia (area of FAZ)</outcome_measure>
      <outcome_measure>Vessel geometry</outcome_measure>
      <outcome_measure>Visual field</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Odense University Hospital</lead_sponsor>
      <collaborator>Danske Regioner</collaborator>
      <collaborator>Synoptik-Fonden</collaborator>
      <collaborator>Toyota-Fonden</collaborator>
      <collaborator>AP Moeller Foundation</collaborator>
      <collaborator>Yamagata University</collaborator>
      <collaborator>Queen's University, Belfast</collaborator>
      <collaborator>Zealand University Hospital</collaborator>
      <collaborator>Region Sjællands og Region Syddanmarks forskningspulje</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NIRVANA</other_id>
      <other_id>S-20170084</other_id>
    </other_ids>
    <start_date>August 10, 2018</start_date>
    <primary_completion_date>August 10, 2020</primary_completion_date>
    <completion_date>August 10, 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>January 25, 2019</last_update_posted>
    <locations>
      <location>Department of Ophthalmology, Odense University Hospital, Odense, Danmark, Denmark</location>
      <location>Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03651011</url>
  </study>
  <study rank="45027">
    <nct_id>NCT03650998</nct_id>
    <title>Transmuscular Quadratus Lumborum Block for Total Laparoscopic Hysterectomy.</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Postoperative Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ropivacaine</intervention>
      <intervention type="Drug">Saline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Postoperative opioid consumption</outcome_measure>
      <outcome_measure>Postoperative pain intensity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Zealand University Hospital</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ZUH-TQL-TLH</other_id>
    </other_ids>
    <start_date>September 28, 2018</start_date>
    <primary_completion_date>December 1, 2019</primary_completion_date>
    <completion_date>December 1, 2019</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>January 13, 2020</last_update_posted>
    <locations>
      <location>Zealand University Hospital, Department of Anaesthesiology, Roskilde,, Zealand, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650998</url>
  </study>
  <study rank="45028">
    <nct_id>NCT03650985</nct_id>
    <title>Diagnosis and Intervention of Complicated Twin Diseases</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Twin Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Fetoscope technique</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Gene expression of fetuses</outcome_measure>
      <outcome_measure>Change of volume of amniotic fluid in Milliliter</outcome_measure>
      <outcome_measure>Change of umbilical artery blood flow</outcome_measure>
      <outcome_measure>Neurodevelopment at early childhood</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shengjing Hospital</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DICTD</other_id>
    </other_ids>
    <start_date>August 31, 2018</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>August 2022</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>September 5, 2018</last_update_posted>
    <locations>
      <location>Shengjing Hospital, Shenyang, Liaoning, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650985</url>
  </study>
  <study rank="45029">
    <nct_id>NCT03650972</nct_id>
    <title>Implementation of AFL Monitoring in Clinical Use</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Labour Dystocia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Samarin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Spontaneus Vaginal delivery</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Turku University Hospital</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>T194/2018</other_id>
    </other_ids>
    <start_date>September 15, 2018</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650972</url>
  </study>
  <study rank="45030">
    <nct_id>NCT03650959</nct_id>
    <title>Optimizing Resource Utilization During Proficiency-based Training of Suturing Skills to Medical Students</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Education, Medical</condition>
      <condition>Sutures</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Method of learning simple interrupted sutures with instrument tie</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of stitched laid to reach proficiency</outcome_measure>
      <outcome_measure>Number of sutures used to reach proficiency</outcome_measure>
      <outcome_measure>Minutes to reach proficiency</outcome_measure>
      <outcome_measure>Individual costs to reach proficiency</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Queen's University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>SURG-422-18</other_id>
    </other_ids>
    <start_date>June 4, 2018</start_date>
    <primary_completion_date>June 8, 2018</primary_completion_date>
    <completion_date>June 8, 2018</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>Queen's Unviersity, Kingston, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650959</url>
  </study>
  <study rank="45031">
    <nct_id>NCT03650946</nct_id>
    <title>Clinical Application of 68Ga-PSMA PET in Prostate Cancer</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Prostate Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Ga-68 PSMA PET</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Diagnostic accuracy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>40 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>201508052MIND</other_id>
    </other_ids>
    <start_date>August 2018</start_date>
    <primary_completion_date>July 2019</primary_completion_date>
    <completion_date>July 30, 2021</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>National Taiwan University Hospital, Taipei, Taiwan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650946</url>
  </study>
  <study rank="45032">
    <nct_id>NCT03650933</nct_id>
    <title>A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diffuse Large B-Cell Lymphoma, Unspecified Site</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">G-CHOP</intervention>
      <intervention type="Biological">R-CHOP</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Objective response rate (ORR)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nanjing Yoko Biomedical Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>360</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>GB241NHL3</other_id>
    </other_ids>
    <start_date>October 2018</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>October 2021</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650933</url>
  </study>
  <study rank="45033">
    <nct_id>NCT03650920</nct_id>
    <title>HCV Positive Liver Grafts in HCV Negative Recipients</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Liver Transplantation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Patient survival rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Loma Linda University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>5180105</other_id>
    </other_ids>
    <start_date>September 2, 2018</start_date>
    <primary_completion_date>September 2021</primary_completion_date>
    <completion_date>September 2021</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>September 19, 2018</last_update_posted>
    <locations>
      <location>Loma Linda University Transplant Institute, Loma Linda, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650920</url>
  </study>
  <study rank="45034">
    <nct_id>NCT03650907</nct_id>
    <title>Exercise Intervention for Patients With Sarcopenia or Frailty in Long-term Care Institutions</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sarcopenia</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Group exercise program</intervention>
      <intervention type="Behavioral">Self exercise program</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Muscle strength</outcome_measure>
      <outcome_measure>walk speed</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chang Gung Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>110 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SarcExercise</other_id>
    </other_ids>
    <start_date>August 24, 2018</start_date>
    <primary_completion_date>May 31, 2019</primary_completion_date>
    <completion_date>May 31, 2019</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 13, 2019</last_update_posted>
    <locations>
      <location>Bor-Ay Sweet home, Keelung, Taiwan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650907</url>
  </study>
  <study rank="45035">
    <nct_id>NCT03650894</nct_id>
    <title>Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Breast Neoplasm Female</condition>
      <condition>Breast Cancer</condition>
      <condition>Breast Carcinoma</condition>
      <condition>Breast Tumor</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nivolumab</intervention>
      <intervention type="Drug">Ipilimumab</intervention>
      <intervention type="Drug">Bicalutamide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>iRECIST Clinical Benefit Rate (the number of patients with objective response or ongoing stable disease at week 24 using iRECIST guidelines)</outcome_measure>
      <outcome_measure>Assess best overall objective response rate (proportion of patients who achieve a complete or partial response)</outcome_measure>
      <outcome_measure>Duration of progression free survival</outcome_measure>
      <outcome_measure>Overall survival rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Providence Health &amp; Services</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
      <collaborator>Memorial Sloan Kettering Cancer Center</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>138</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CA209-8H3</other_id>
    </other_ids>
    <start_date>April 3, 2019</start_date>
    <primary_completion_date>April 2024</primary_completion_date>
    <completion_date>April 2025</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>April 10, 2019</last_update_posted>
    <locations>
      <location>Providence Oncology &amp; Hematology Care Clinic - Eastside, Portland, Oregon, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650894</url>
  </study>
  <study rank="45036">
    <nct_id>NCT03650881</nct_id>
    <title>The Comparative Efficacy of an Over the Counter Light Therapy Mask vs Over the Counter Topical Benzoyl Peroxide 2.5% and Used in Combination With Over the Counter Adapalene Gel 0.1% for Mild to Moderate Acne</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acne</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Neutrogena ® Light Therapy Acne Mask (MASK)</intervention>
      <intervention type="Drug">Topical OTC benzoyl peroxide 2.5% gel and OTC adapalene</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>change in the Investigator Global Assessment (IGA)</outcome_measure>
      <outcome_measure>change in Acne Q4 quality of life index score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NYU Langone Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <max_age>35 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>17-01725</other_id>
    </other_ids>
    <start_date>September 2019</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>June 14, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650881</url>
  </study>
  <study rank="45037">
    <nct_id>NCT03650868</nct_id>
    <title>The Effect of Thoracal Paravertebral Block on Seroma Reduction in Breast Surgery</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Seroma</condition>
      <condition>Breast Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Thoracal paravertebral block</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Seroma quantitiy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kocaeli University</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>KIA 2018/155</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>February 1, 2019</primary_completion_date>
    <completion_date>February 26, 2019</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>February 28, 2019</last_update_posted>
    <locations>
      <location>Kocaeli University, Kocaeli, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650868</url>
  </study>
  <study rank="45038">
    <nct_id>NCT03650855</nct_id>
    <title>Vertebral Bone Quality and Prediction of Screw Loosening in Spine Fusion</title>
    <acronym>QOAR</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Spine Fusion for Degenerative Spine Disease</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Change of bone-implant interface at 6-month follow up compared to post operative interface assessed on Dual energy CT Scan</outcome_measure>
      <outcome_measure>evolution of bone density of non instrumented levels between T0 and 6 months follow up assessed with Dual Energy CT scan</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>NI17046J</other_id>
    </other_ids>
    <start_date>September 25, 2018</start_date>
    <primary_completion_date>June 2019</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>April 17, 2019</last_update_posted>
    <locations>
      <location>Hôpital Pitié Salpêtrière, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650855</url>
  </study>
  <study rank="45039">
    <nct_id>NCT03650842</nct_id>
    <title>Changes in Cerebral Oxygenation During Laparoscopic Pyloromyotomy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Pyloric Stenosis</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Near infrared spectroscopy (NIRS)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cerebral Regional Oxygen Saturation (rSO2)</outcome_measure>
      <outcome_measure>Renal Regional Oxygen Saturation (rSO2)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nationwide Children's Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB16-00199</other_id>
    </other_ids>
    <start_date>July 7, 2017</start_date>
    <primary_completion_date>October 8, 2018</primary_completion_date>
    <completion_date>October 8, 2018</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <results_first_posted>December 6, 2019</results_first_posted>
    <last_update_posted>December 6, 2019</last_update_posted>
    <locations>
      <location>Nationwide Children's Hospital, Columbus, Ohio, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03650842/Prot_SAP_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03650842</url>
  </study>
  <study rank="45040">
    <nct_id>NCT03650829</nct_id>
    <title>IVF Offspring Born in Guangzhou</title>
    <acronym>IVF-BIG</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>ART</condition>
      <condition>Offspring, Adult</condition>
      <condition>Genetics</condition>
      <condition>Host and Microbiome</condition>
      <condition>Neurodevelopment</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Intelligence quotient of offspring</outcome_measure>
      <outcome_measure>Prevalence of gestational diabetes, pregnancy induced hypertension, and cesarean section</outcome_measure>
      <outcome_measure>Prevalence of stillbirth, preterm birth, small for gestational age, large for gestational age and birth defect</outcome_measure>
      <outcome_measure>Neurodevelopment at early childhood</outcome_measure>
      <outcome_measure>Epegenetic profiles of offspring</outcome_measure>
      <outcome_measure>Changes of body composition and bone density during early childhood</outcome_measure>
      <outcome_measure>Height changes during early childhood</outcome_measure>
      <outcome_measure>Weight changes during early childhood</outcome_measure>
      <outcome_measure>Change of intestinal flora during early childhood</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Guangzhou Women and Children's Medical Center</lead_sponsor>
      <collaborator>University of Birmingham</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>3000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018080103</other_id>
    </other_ids>
    <start_date>February 1, 2012</start_date>
    <primary_completion_date>December 31, 2019</primary_completion_date>
    <completion_date>December 31, 2038</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>September 5, 2018</last_update_posted>
    <locations>
      <location>Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650829</url>
  </study>
  <study rank="45041">
    <nct_id>NCT03650816</nct_id>
    <title>Cerebrovascular Reactivity in Alzheimer's Disease</title>
    <acronym>VARAD-ET</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
      <condition>Subjective Cognitive Impairment</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Doppler ultrasonography</intervention>
      <intervention type="Other">Biospecimen collection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cerebrovascular reactivity during the CO2 inhalation test in AD patients and control subjects (SCI)</outcome_measure>
      <outcome_measure>Correlation between cognitive status and différences in CVR CO2</outcome_measure>
      <outcome_measure>Correlation between cerebrospinal AD markers and CVR CO2</outcome_measure>
      <outcome_measure>Z score of neuropsychological tests and CVR CO2</outcome_measure>
      <outcome_measure>Plasma levels of ET-1, bigET-1, ADMA and their correlation with CVR CO2</outcome_measure>
      <outcome_measure>Plasma renin activity and CVR CO2.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
      <collaborator>Fondation Plan Alzheimer</collaborator>
      <collaborator>Naturalia &amp; Biologia</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>APHP180012</other_id>
      <other_id>IDRCB 2018-A01950-55</other_id>
    </other_ids>
    <start_date>October 22, 2019</start_date>
    <primary_completion_date>December 22, 2021</primary_completion_date>
    <completion_date>June 22, 2022</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>January 22, 2020</last_update_posted>
    <locations>
      <location>Broca Hospital APHP, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650816</url>
  </study>
  <study rank="45042">
    <nct_id>NCT03650803</nct_id>
    <title>Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Breast Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Device">3D MR Fingerprinting scan</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Utility of quantitative MRI in assessment of response to neo-adjuvant chemotherapy in breast cancer</outcome_measure>
      <outcome_measure>Longitudinal relaxation (T1) and transverse relaxation (T2) relaxation times of tumor and normal breast tissue.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Case Comprehensive Cancer Center</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>124</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>CASE3118</other_id>
    </other_ids>
    <start_date>October 28, 2018</start_date>
    <primary_completion_date>September 1, 2020</primary_completion_date>
    <completion_date>September 1, 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>May 21, 2019</last_update_posted>
    <locations>
      <location>University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650803</url>
  </study>
  <study rank="45043">
    <nct_id>NCT03650790</nct_id>
    <title>C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies</title>
    <acronym>CTRP</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pre-Eclampsia</condition>
      <condition>Obesity; Endocrine</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Blood test</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>CTRP 9 level in preeclamptic pregnancies</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Diyarbakir Women's and Children's Diseases Hospital</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>15 Years</min_age>
    <max_age>40 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>DiyarbakirWCDH</other_id>
    </other_ids>
    <start_date>September 3, 2018</start_date>
    <primary_completion_date>January 1, 2019</primary_completion_date>
    <completion_date>January 1, 2019</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>January 8, 2019</last_update_posted>
    <locations>
      <location>Diyarbakır Women's and Children's Hospital, Diyarbakır, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650790</url>
  </study>
  <study rank="45044">
    <nct_id>NCT03650777</nct_id>
    <title>Impact of Telehealth Warfarin Education on Patient Retention</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Educational Problems</condition>
      <condition>Medication Adherence</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Warfarin Telehealth Education</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Knowledge Retention of Warfarin Education post video watching</outcome_measure>
      <outcome_measure>Long Term Knowledge Retention of warfarin education post video watching</outcome_measure>
      <outcome_measure>Self Reported Adherence to Warfarin therapy during duration of study</outcome_measure>
      <outcome_measure>Satisfaction Survey</outcome_measure>
      <outcome_measure>Adverse Events</outcome_measure>
      <outcome_measure>Time of Warfarin in Therapeutic Range for Duration of Study</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Baylor Research Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>015-284</other_id>
    </other_ids>
    <start_date>February 18, 2016</start_date>
    <primary_completion_date>July 31, 2017</primary_completion_date>
    <completion_date>July 31, 2017</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>January 15, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650777</url>
  </study>
  <study rank="45045">
    <nct_id>NCT03650764</nct_id>
    <title>Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Head and Neck Squamous Cell Carcinoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ramucirumab</intervention>
      <intervention type="Drug">Pembrolizumab</intervention>
      <intervention type="Other">EORTC QLQ-30</intervention>
      <intervention type="Other">FACT H&amp;N</intervention>
      <intervention type="Procedure">Peripheral blood</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Recommended phase 2 dose (RP2D) of ramucirumab combined with fixed dose pembrolizumab (Phase I patients only)</outcome_measure>
      <outcome_measure>Overall tumor response rate of ramucirumab and pembrolizumab (Phase II patients only)</outcome_measure>
      <outcome_measure>Adverse event profile of the combination of ramucirumab and pembrolizumab (Phase I and II patients) as measured by the frequency of adverse events</outcome_measure>
      <outcome_measure>Duration of overall response (Phase II patients only)</outcome_measure>
      <outcome_measure>Progression-free survival (PFS) (Phase II patients only)</outcome_measure>
      <outcome_measure>Overall survival (OS) (Phase II patients only)</outcome_measure>
      <outcome_measure>Changes in quality of life as measured by FACT H&amp;N (Phase II patients only)</outcome_measure>
      <outcome_measure>Changes in quality of life as measured by EORTC QLQ-C30 (Phase II patients only)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Washington University School of Medicine</lead_sponsor>
      <collaborator>Eli Lilly and Company</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>201809094</other_id>
    </other_ids>
    <start_date>May 29, 2019</start_date>
    <primary_completion_date>November 30, 2021</primary_completion_date>
    <completion_date>November 30, 2021</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>December 9, 2019</last_update_posted>
    <locations>
      <location>Washington University School of Medicine, Saint Louis, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650764</url>
  </study>
  <study rank="45046">
    <nct_id>NCT03650751</nct_id>
    <title>Clinical Study on Screening of Nursing Evaluation Indicators of Stroke Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Stroke</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Nursing observation indexes</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>construct a nursing evaluation system for stroke patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shenzhen Second People's Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>20173357201830</other_id>
    </other_ids>
    <start_date>September 1, 2017</start_date>
    <primary_completion_date>March 1, 2019</primary_completion_date>
    <completion_date>December 1, 2019</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>Shenzhen second people's hospital, Shenzhen, Guangdong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650751</url>
  </study>
  <study rank="45047">
    <nct_id>NCT03650738</nct_id>
    <title>This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Apatinib</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>pCR rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The First Affiliated Hospital with Nanjing Medical University</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>BL2014084</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>December 30, 2019</primary_completion_date>
    <completion_date>December 31, 2019</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>Jiangsu Provincial Hospital, Nanjing, Jiangsu, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650738</url>
  </study>
  <study rank="45048">
    <nct_id>NCT03650725</nct_id>
    <title>Evaluation of Information on Bowel Preparation for Morning Colonoscopy</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Colonoscopy</condition>
      <condition>Patient Compliance</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Mandatory Split bowel preparation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Quality of bowel cleanliness as measured by Boston Bowel Preparation Scale Score (0-2) in all segments</outcome_measure>
      <outcome_measure>Composite with any of the following: cancellations in the day before colonoscopy; no shows for colonoscopy appointment; phone calls for questions on the bowel preparation and/or rescheduling because of the bowel preparation.</outcome_measure>
      <outcome_measure>Amount of laxative intake</outcome_measure>
      <outcome_measure>Proportion with split dose laxative intake</outcome_measure>
      <outcome_measure>Endoscopic Outcome 1: Cecal intubation (colonoscopy completion)</outcome_measure>
      <outcome_measure>Endoscopic Outcome 2: Withdrawal time during colonoscopy performance</outcome_measure>
      <outcome_measure>Endoscopic Outcome 3: total time for performance of colonoscopy</outcome_measure>
      <outcome_measure>Endoscopic Outcome 4: polyps during colonoscopy</outcome_measure>
      <outcome_measure>Patient experience data outcome 1: use of split dose bowel preparation</outcome_measure>
      <outcome_measure>Patient experience data outcome 2: complete intake of all of the prescribed laxative</outcome_measure>
      <outcome_measure>Patient experience data outcome 3: incontinence episodes while preparing for colonoscopy</outcome_measure>
      <outcome_measure>Patient experience data outcome 4: Sleep in night before colonoscopy</outcome_measure>
      <outcome_measure>Patient experience data outcome 5: willingness to repeat colonoscopy using same laxative preparation</outcome_measure>
      <outcome_measure>Patient experience data outcome 6: pre-colonoscopy anxiety (Likert scale 1-5)</outcome_measure>
      <outcome_measure>Patient experience data outcome 7: difficulty with bowel preparation (Likert scale 1-10)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Harminder Singh</lead_sponsor>
      <collaborator>University of Manitoba</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>H2018:202</other_id>
    </other_ids>
    <start_date>June 30, 2018</start_date>
    <primary_completion_date>April 28, 2020</primary_completion_date>
    <completion_date>August 30, 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>June 14, 2019</last_update_posted>
    <locations>
      <location>Health Sciences Center, Winnipeg, Manitoba, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650725</url>
  </study>
  <study rank="45049">
    <nct_id>NCT03650712</nct_id>
    <title>EnVision CF Multicenter Study of Glucose Tolerance in Cystic Fibrosis</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cystic Fibrosis-related Diabetes</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Oral glucose tolerance test</intervention>
      <intervention type="Diagnostic Test">Continuous glucose monitoring</intervention>
      <intervention type="Diagnostic Test">Dexa scan</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>age- and sex-based nomograms for beta cell glucose sensitivity</outcome_measure>
      <outcome_measure>age- and sex-based nomograms for OGIS (oral glucose insulin sensitivity)</outcome_measure>
      <outcome_measure>evaluate the relationships between age and sex-based quantiles for beta cell glucose sensitivity and BMI Z-score</outcome_measure>
      <outcome_measure>evaluate the relationships between age and sex-based quantiles for beta cell glucose sensitivity and FEV-1</outcome_measure>
      <outcome_measure>evaluate the relationships between age and sex-based quantiles for beta cell glucose sensitivity and pulmonary exacerbations in the previous 12 months</outcome_measure>
      <outcome_measure>evaluate the relationships between age and sex-based quantiles for OGIS and BMI z-score</outcome_measure>
      <outcome_measure>evaluate the relationships between age and sex-based quantiles for OGIS and FEV-1</outcome_measure>
      <outcome_measure>evaluate the relationships between age and sex-based quantiles for OGIS and the number of pulmonary exacerbations in the previous 12 months</outcome_measure>
      <outcome_measure>evaluate the relationships between age and sex-based quantiles for insulin and BMI z-score</outcome_measure>
      <outcome_measure>evaluate the relationships between age and sex-based quantiles for insulin and FEV-1</outcome_measure>
      <outcome_measure>evaluate the relationships between age and sex-based quantiles for insulin and number of pulmonary exacerbations in the previous 12 months</outcome_measure>
      <outcome_measure>evaluate the relationships between age and sex-based quantiles for c-peptide and BMI z-score</outcome_measure>
      <outcome_measure>evaluate the relationships between age and sex-based quantiles for c-peptide and FEV-1</outcome_measure>
      <outcome_measure>evaluate the relationships between age and sex-based quantiles for c-peptide and number of pulmonary exacerbations in the previous 12 months</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Katie Larson Ode</lead_sponsor>
      <collaborator>University of Iowa</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>144</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>EnV1-1</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>August 31, 2021</primary_completion_date>
    <completion_date>August 31, 2021</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>University of Colorado, Aurora, Colorado, United States</location>
      <location>University of Iowa, Iowa City, Iowa, United States</location>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
      <location>Washington University St. Louis, Saint Louis, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650712</url>
  </study>
  <study rank="45050">
    <nct_id>NCT03650699</nct_id>
    <title>Biofeedback Rehabilitation to Improve Speaking and Eating in Public</title>
    <acronym>Biofeedback</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Oral Cavity Squamous Cell Carcinoma</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Electropalatography Biofeedback Training</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Percent Intelligibility of Speech Over 4 Months</outcome_measure>
      <outcome_measure>Change in Rate of Intelligible Speech Over 4 Months</outcome_measure>
      <outcome_measure>Change in Speech Acceptability Over 4 Months</outcome_measure>
      <outcome_measure>Change in Speech and Swallowing Over 4 Months</outcome_measure>
      <outcome_measure>Change in Patient Satisfaction of EPG Biofeedback Over 4 Months</outcome_measure>
      <outcome_measure>Difference in Cost for Intervention versus Standard of Care Over Time</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>17-5105</other_id>
    </other_ids>
    <start_date>September 28, 2018</start_date>
    <primary_completion_date>February 28, 2020</primary_completion_date>
    <completion_date>February 28, 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 30, 2019</last_update_posted>
    <locations>
      <location>University Health Network, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650699</url>
  </study>
  <study rank="45051">
    <nct_id>NCT03650686</nct_id>
    <title>Validity, Reliability and Feasibility of an Automated Photographic Measurement/Assessment of Food Intake in the Hospitalized Elderly</title>
    <acronym>PAMPILLE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Elderly People</condition>
      <condition>Food Intake Measurement</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Food weighing (gold standard)</intervention>
      <intervention type="Other">Automated photographic method (method to be evaluated)</intervention>
      <intervention type="Other">Semi-quantitative method (routine method)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Average percentage quantification of ingesta</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire Dijon</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>Buisson PHRIP 2017 PAMPILLE</other_id>
    </other_ids>
    <start_date>May 3, 2018</start_date>
    <primary_completion_date>May 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>Chu Dijon Bourogne, Dijon, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650686</url>
  </study>
  <study rank="45052">
    <nct_id>NCT03650673</nct_id>
    <title>A Prospective Cohort Study of Patients Suffering From Hand Osteoarthritis With Early Onset Symptoms</title>
    <acronym>COARDIG</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hand Osteoarthritis</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Identification of subgroups of patients with early AD with risk of progression</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Radiographic progression judged by the number of joints whose KL index has evolved</outcome_measure>
      <outcome_measure>The number of painful / swollen or deformed joints in the hands.</outcome_measure>
      <outcome_measure>The location of painful / swollen or deformed joints in the hands.</outcome_measure>
      <outcome_measure>The intensity of pain over the last 48 hours</outcome_measure>
      <outcome_measure>The activity of the disease over the last 48 hours</outcome_measure>
      <outcome_measure>The aesthetic impact of osteoarthritis of the hands</outcome_measure>
      <outcome_measure>The number of consumption of care in the month preceding the visit</outcome_measure>
      <outcome_measure>The number of hand surgery during follow-up 56/5000 The number of a hand surgery during follow-up</outcome_measure>
      <outcome_measure>The grip force measured by a dynamometer</outcome_measure>
      <outcome_measure>The impact on pain and function on the hand measured by the AUSCAN questionnaire</outcome_measure>
      <outcome_measure>The impact on pain and function on the hand measured by the COCHIN functional index</outcome_measure>
      <outcome_measure>The impact on pain and function on the hand measured by a 6-minute walk test</outcome_measure>
      <outcome_measure>The impact on pain and function measured the IPAQ International Physical Activity Questionnaire</outcome_measure>
      <outcome_measure>The professional impact measured by the WPAI questionnaire which measures the deficiencies of paid work and unpaid work over the last 7 days</outcome_measure>
      <outcome_measure>Impact on quality of life measured by the Health Assessment Questionnaire (HAQ)</outcome_measure>
      <outcome_measure>The impact on the quality of life measured by the SF-36 questionnaire</outcome_measure>
      <outcome_measure>The impact on the quality of life measured by the EQ-5D-3L questionnaire (https://euroqol.org)</outcome_measure>
      <outcome_measure>The Impact on Quality of Life Measured by the Michigan Hand Outcome Questionnaire (MHQ)</outcome_measure>
      <outcome_measure>The psychological impact of pain measured by the HAD questionnaire (Hospital Anxiety and Depression)</outcome_measure>
      <outcome_measure>The aesthetic impact of osteoarthritis of the hands with the Michigan Hand Outcome Questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Montpellier</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <other_ids>
      <other_id>7414</other_id>
    </other_ids>
    <start_date>October 31, 2018</start_date>
    <primary_completion_date>October 31, 2019</primary_completion_date>
    <completion_date>October 31, 2021</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>September 10, 2018</last_update_posted>
    <locations>
      <location>Department of Rheumatology, CHU Montpellier, Montpellier, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650673</url>
  </study>
  <study rank="45053">
    <nct_id>NCT03650660</nct_id>
    <title>Concordance Between Echocardiographic Assessment Performed in the Initial Phase of Decompensated Cirrhosis With Edema and Ascites by an Expert Intensive Care Physician and a Non-expert Gastroenterologist</title>
    <acronym>EchoCirrho</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Cirrhoses</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Trans-thoracic ultrasound</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Concordance in Left Ventricular Ejection Fraction measurement on trans-thoracic ultrasound by expert versus a non-specialist gastroenterologist with standard training</outcome_measure>
      <outcome_measure>Concordance in E' wave at the lateral mitral ring and mitral E wave measurement by expert versus a non-specialist gastroenterologist with standard training</outcome_measure>
      <outcome_measure>Concordance in stroke volume measurement by expert versus a non-specialist gastroenterologist with standard training</outcome_measure>
      <outcome_measure>Death rate</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Number of admissions to intensive care</outcome_measure>
      <outcome_measure>Consummation of diuretics</outcome_measure>
      <outcome_measure>albumin infusion necessity</outcome_measure>
      <outcome_measure>Use of vasopressors</outcome_measure>
      <outcome_measure>auto ejection fraction measurement on trans-thoracic ultrasound by expert</outcome_measure>
      <outcome_measure>lateral mitral annulus measurement on trans-thoracic ultrasound by expert</outcome_measure>
      <outcome_measure>Mitral E wave measurement on trans-thoracic ultrasound by expert</outcome_measure>
      <outcome_measure>Mitral A wave measurement on trans-thoracic ultrasound by expert</outcome_measure>
      <outcome_measure>Inferior vena cava collapsibility index measurement on trans-thoracic ultrasound by expert</outcome_measure>
      <outcome_measure>Presence of intrapulmonary shunt</outcome_measure>
      <outcome_measure>Presence of aortic stenosis</outcome_measure>
      <outcome_measure>Presence of mitral insufficiency</outcome_measure>
      <outcome_measure>Presence of mitral stenosis</outcome_measure>
      <outcome_measure>left atrium surface area</outcome_measure>
      <outcome_measure>left ventricle diameter</outcome_measure>
      <outcome_measure>Septal wall thickness</outcome_measure>
      <outcome_measure>Posterior wall thickness</outcome_measure>
      <outcome_measure>tricuspid annular plane systolic excursion</outcome_measure>
      <outcome_measure>tricuspid annular plane systolic velocity</outcome_measure>
      <outcome_measure>heart chamber dilation</outcome_measure>
      <outcome_measure>pulmonary arterial hypertension</outcome_measure>
      <outcome_measure>Pericardial effusion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nīmes</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>Local/2017/JFB-01</other_id>
    </other_ids>
    <start_date>March 30, 2018</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>CHU Nimes, Nimes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650660</url>
  </study>
  <study rank="45054">
    <nct_id>NCT03650647</nct_id>
    <title>Comparison of Conventional Versus Conservative Caries Removal in Primary Teeth</title>
    <acronym>Caries_removal</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dental Caries Extending Into Dentin</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Carious dentin removal</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pulp vitality maintenance diagnosed by clinical exam</outcome_measure>
      <outcome_measure>Pulp vitality maintenance diagnosed by radiograph exam</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universidade Federal Fluminense</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>4 Years</min_age>
    <max_age>6 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ARibeiro</other_id>
    </other_ids>
    <start_date>January 15, 2017</start_date>
    <primary_completion_date>January 15, 2018</primary_completion_date>
    <completion_date>January 5, 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650647</url>
  </study>
  <study rank="45055">
    <nct_id>NCT03650634</nct_id>
    <title>Prevalence of Supernumerary Teeth Among a Group of Egyptian Children Aged From Six to Fifteen Years Old</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Supernumerary Teeth</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>prevalence of supernumerary teeth</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cairo University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <max_age>15 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>CEBD-CU-2018-08-16</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>February 28, 2019</primary_completion_date>
    <completion_date>August 1, 2019</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>September 5, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650634</url>
  </study>
  <study rank="45056">
    <nct_id>NCT03650621</nct_id>
    <title>Magnetic Non-Invasive Acupuncture For Infant Comfort A Pilot Study in Preterm Infants Requiring Eye-exam for Retinopathy of Prematurity</title>
    <acronym>MAGNIFIC-ROP</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Retinopathy of Prematurity</condition>
      <condition>Pain</condition>
      <condition>Acupuncture</condition>
      <condition>Premature Infant</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Magnetic acupuncture</intervention>
      <intervention type="Device">stickers (magnets removed)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in Premature Infant Pain Profile (PIPP) scores</outcome_measure>
      <outcome_measure>Heart rate changes</outcome_measure>
      <outcome_measure>Changes in oxygen saturation</outcome_measure>
      <outcome_measure>changes in cerebral oxygenation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Alberta</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>29 Weeks</min_age>
    <max_age>36 Weeks</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Pro00080714</other_id>
    </other_ids>
    <start_date>August 24, 2018</start_date>
    <primary_completion_date>December 30, 2019</primary_completion_date>
    <completion_date>March 30, 2020</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>October 3, 2019</last_update_posted>
    <locations>
      <location>University of Sydney, Sydney, New South Wales, Australia</location>
      <location>Royal Alexandra Hospital, Edmonton, Alberta, Canada</location>
      <location>Radboudumc Nijmegen, Nijmegen, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650621</url>
  </study>
  <study rank="45057">
    <nct_id>NCT03650608</nct_id>
    <title>A Clinical Trial to Evaluate Tolerability and Pharmacokinetics of HL217 Eye Drop in Healthy Male Subjects</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Subject</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cohort 1: HL217 Ophathalmic Solution QD</intervention>
      <intervention type="Drug">Cohort 2: HL217 Ophathalmic Solution BID</intervention>
      <intervention type="Drug">Cohort 3: HL217 Ophthalmic Solution QID</intervention>
      <intervention type="Drug">Placebo Ophthalmic solution</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical parameter: Adverse Events (AE)</outcome_measure>
      <outcome_measure>Local tolerance: Redness, Tingling and Other ophthalmic adverse events</outcome_measure>
      <outcome_measure>Pharmacokinetic assessment: Cmax</outcome_measure>
      <outcome_measure>Pharmacokinetic assessment: Tmax</outcome_measure>
      <outcome_measure>Pharmacokinetic assessment: AUClast</outcome_measure>
      <outcome_measure>Pharmacokinetic assessment: AUCinf</outcome_measure>
      <outcome_measure>Pharmacokinetic assessment: Kel</outcome_measure>
      <outcome_measure>Pharmacokinetic assessment: T1/2</outcome_measure>
      <outcome_measure>Pharmacokinetic assessment: %AUCextra</outcome_measure>
      <outcome_measure>Pharmacokinetic assessment: Cl/F</outcome_measure>
      <outcome_measure>Pharmacokinetic assessment: Vd/F</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hanlim Pharm. Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>HL217-101</other_id>
    </other_ids>
    <start_date>August 2016</start_date>
    <primary_completion_date>August 2017</primary_completion_date>
    <completion_date>August 2017</completion_date>
    <study_first_posted>August 29, 2018</study_first_posted>
    <last_update_posted>April 1, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650608</url>
  </study>
  <study rank="45058">
    <nct_id>NCT03650595</nct_id>
    <title>MRI Guided Focal Laser Ablation of Prostate Cancer</title>
    <acronym>MRgFLA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Prostate Cancer</condition>
      <condition>Low and Intermediate Risk Prostate Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Device">The TRANBERGCLS|Thermal Therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The proportion of study patients clinically free of clinically significant PCa (i.e. requires definitive treatment)</outcome_measure>
      <outcome_measure>Treatment effect on patients' Quality of Life (QoL), the following validated self-reported urogenital functioning assessment instruments will be used before and following treatment at pre-specified interval</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
      <collaborator>Clinical Laserthermia Systems AB</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>23</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>15-9002</other_id>
    </other_ids>
    <start_date>March 29, 2018</start_date>
    <primary_completion_date>June 30, 2021</primary_completion_date>
    <completion_date>June 30, 2022</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Sangeet Ghai, MD, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650595</url>
  </study>
  <study rank="45059">
    <nct_id>NCT03650582</nct_id>
    <title>Intranasal Glucagon and Energy Balance</title>
    <acronym>INGEB</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Obesity</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Glucagon</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Energy Expenditure</outcome_measure>
      <outcome_measure>Food intake</outcome_measure>
      <outcome_measure>Appetite</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>ING 16-5909</other_id>
    </other_ids>
    <start_date>June 6, 2017</start_date>
    <primary_completion_date>September 30, 2018</primary_completion_date>
    <completion_date>October 30, 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 31, 2018</last_update_posted>
    <locations>
      <location>Toronto General Hospital, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650582</url>
  </study>
  <study rank="45060">
    <nct_id>NCT03650569</nct_id>
    <title>Angelman Syndrome Italian Registry</title>
    <acronym>RISA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Angelman Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Medical and behavioral problems</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fondazione per la Ricerca Ospedale Maggiore</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Family-Based</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>Version 1 08.02.2018</other_id>
    </other_ids>
    <start_date>February 16, 2018</start_date>
    <primary_completion_date>February 16, 2021</primary_completion_date>
    <completion_date>February 16, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>FROM (Fondazione per la Ricerca Ospedale Maggiore di Bergamo ), Bergamo, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650569</url>
  </study>
  <study rank="45061">
    <nct_id>NCT03650556</nct_id>
    <title>Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Persistent Atrial Fibrillation</condition>
    </conditions>
    <interventions>
      <intervention type="Device">TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of device and/or procedure-related SAEs.</outcome_measure>
      <outcome_measure>Freedom from atrial fibrillation (AF), atrial flutter (AFL) or atrial tachycardia (AT) recurrence.</outcome_measure>
      <outcome_measure>Acute Procedural Success</outcome_measure>
      <outcome_measure>15-month Success off of Antiarrhythmic Drugs</outcome_measure>
      <outcome_measure>15 Month Single Procedure Success</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Abbott Medical Devices</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>224</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ABT-CIP-10239</other_id>
    </other_ids>
    <start_date>September 28, 2018</start_date>
    <primary_completion_date>May 2021</primary_completion_date>
    <completion_date>May 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 1, 2019</last_update_posted>
    <locations>
      <location>University Hospital (UAB), Birmingham, Alabama, United States</location>
      <location>St. Bernards, Jonesboro, Arkansas, United States</location>
      <location>Arkansas Heart Hosptial, Little Rock, Arkansas, United States</location>
      <location>Scripps Health, La Jolla, California, United States</location>
      <location>Sequoia Hospital, Redwood City, California, United States</location>
      <location>South Denver Cardiology Associates, Littleton, Colorado, United States</location>
      <location>Florida Hospital, Orlando, Florida, United States</location>
      <location>Emory University Hosptial, Atlanta, Georgia, United States</location>
      <location>Ochsner Medical Center, New Orleans, Louisiana, United States</location>
      <location>Johns Hopkins University Hospital, Baltimore, Maryland, United States</location>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
      <location>Jackson Heart Clinic, Jackson, Mississippi, United States</location>
      <location>Barnes-Jewish Hospital, Saint Louis, Missouri, United States</location>
      <location>Bryan Heart, Lincoln, Nebraska, United States</location>
      <location>Jersey Shore University Medical Center, Neptune, New Jersey, United States</location>
      <location>New York University Hospital, New York, New York, United States</location>
      <location>The Cleveland Clinic Foundation, Cleveland, Ohio, United States</location>
      <location>Medical University of South Carolina, Charleston, South Carolina, United States</location>
      <location>Texas Cardiac Arrhythmia, Austin, Texas, United States</location>
      <location>The Heart Hospital Baylor Plano, Plano, Texas, United States</location>
      <location>Royal Adelaide Hospital, Adelaide, South Australia, Australia</location>
      <location>Royal Melbourne Hospital - City Campus, Parkville, Victoria, Australia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650556</url>
  </study>
  <study rank="45062">
    <nct_id>NCT03650543</nct_id>
    <title>Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>CYP2C19 Polymorphism</condition>
      <condition>H.Pylori Infection</condition>
      <condition>Therapy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">amoxicillin clarithromycin omeprazole 1</intervention>
      <intervention type="Drug">amoxicillin clarithromycin omeprazole 2</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effectiveness of each therapy by protocol (PP)</outcome_measure>
      <outcome_measure>Effectiveness of each therapy by intention to treat (ITT)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Javeriana University</lead_sponsor>
      <collaborator>Universidad Nacional de Colombia</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>133</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>00004554</other_id>
      <other_id>12010U80401200</other_id>
    </other_ids>
    <start_date>September 10, 2012</start_date>
    <primary_completion_date>August 8, 2015</primary_completion_date>
    <completion_date>August 8, 2015</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650543</url>
  </study>
  <study rank="45063">
    <nct_id>NCT03650530</nct_id>
    <title>The Family Talk Intervention in Pediatric Oncology</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pediatric Oncology</condition>
    </conditions>
    <interventions>
      <intervention type="Other">The Family Talk Intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Survey data on family communication</outcome_measure>
      <outcome_measure>Survey data on psychosocial health</outcome_measure>
      <outcome_measure>Survey data regarding knowledge about the illness</outcome_measure>
      <outcome_measure>Survey data on family satisfaction</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ersta Sköndal University College</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>ErstaSUC</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>December 31, 2019</primary_completion_date>
    <completion_date>December 31, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>February 8, 2019</last_update_posted>
    <locations>
      <location>Ersta Sköndal Bräcke University College, Stockholm, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650530</url>
  </study>
  <study rank="45064">
    <nct_id>NCT03650517</nct_id>
    <title>Minimally Invasive Right Colectomy Anastomosis Study</title>
    <acronym>MIRCAST</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Colorectal Cancer</condition>
      <condition>Anastomotic Complication</condition>
      <condition>Colectomy</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Extracorporeal Anastomosis</intervention>
      <intervention type="Procedure">Intracorporeal Anastomosis</intervention>
      <intervention type="Procedure">Robotic Surgery</intervention>
      <intervention type="Procedure">Laparoscopic Surgery</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Surgical wound infection</outcome_measure>
      <outcome_measure>Clavien Dindo Complication</outcome_measure>
      <outcome_measure>Overall Survival</outcome_measure>
      <outcome_measure>Disease Free Survival (DFS)</outcome_measure>
      <outcome_measure>Local Recurrence rate</outcome_measure>
      <outcome_measure>Distant metastases rate</outcome_measure>
      <outcome_measure>Rate of Unplanned Conversions to open surgery</outcome_measure>
      <outcome_measure>Operative time (min)</outcome_measure>
      <outcome_measure>Complete mesocolic excision (CME)</outcome_measure>
      <outcome_measure>Number of Harvested Lymph Nodes</outcome_measure>
      <outcome_measure>R0 Resection</outcome_measure>
      <outcome_measure>Length of Stay (LOS, days)</outcome_measure>
      <outcome_measure>Ventral hernia (assessed 1&amp; 2 years after the right colectomy)</outcome_measure>
      <outcome_measure>Quality of Life Questionnaire (QLQ) of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30</outcome_measure>
      <outcome_measure>Quality of Life Questionnaire (QLQ) of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CR29</outcome_measure>
      <outcome_measure>C-Reactive Protein value (CRP) days 1 &amp; 3 postoperative</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Instituto de Investigación Marqués de Valdecilla</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>IDIVAL CI18/27</other_id>
    </other_ids>
    <start_date>November 1, 2018</start_date>
    <primary_completion_date>June 1, 2021</primary_completion_date>
    <completion_date>December 1, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>September 25, 2019</last_update_posted>
    <locations>
      <location>County Hospital Požega, Požega, Croatia</location>
      <location>Hospital of Southern Denmark, Aabenraa, Denmark</location>
      <location>Zealand University Hospital, Køge, Denmark</location>
      <location>Kanta-Hämeen Keskussairaala, Hämeenlinna, Finland</location>
      <location>Kymenlaakso Central Hospital, Kotka, Finland</location>
      <location>Päijät-Häme Central Hospital, Lahti, Finland</location>
      <location>Oulu University Hospital, Oulu, Finland</location>
      <location>Seinäjoki Central Hospital, Seinäjoki, Finland</location>
      <location>Hôpital Haut-Lévèque- CHU, Bordeaux, France</location>
      <location>CHU Estaing, Clermont-Ferrand, France</location>
      <location>ICM - Institut Régional du Cancer de Montpellier, Montpellier, France</location>
      <location>CHRU de Strasbourg Hôpital Civil, Strasbourg, France</location>
      <location>CHRU Nancy Brabois, Vandœuvre-lès-Nancy, France</location>
      <location>Medizinische Hochschule Hannover, Hannover, Germany</location>
      <location>Eurokliniki Athinou, Athens, Athina, Greece</location>
      <location>AOU-Careggi, Florence, Italy</location>
      <location>Ospedale La Misericordia, Grosseto, Italy</location>
      <location>IEO - European Institute of Oncology, Milan, Italy</location>
      <location>Policlínico Agostino Gemelli, Roma, Italy</location>
      <location>Humanitas Research Hospital, Rozzano, Italy</location>
      <location>IRCCS Istituto di Candiolo, Torino, Italy</location>
      <location>Centro Hospitalar de Leiria, Leiria, Portugal</location>
      <location>Hospital General Universitario de Elche, Elche, Alicante, Spain</location>
      <location>Hospital Central de Asturias, Oviedo, Asturias, Spain</location>
      <location>Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain</location>
      <location>Hospital Universitario Vall d´hebron, Barcelona, Cataluña, Spain</location>
      <location>Hospital Universitario Donostia, San Sebastián, Pais Vasco, Spain</location>
      <location>Complejo hospitalario de Torrecardenas, Almería, Spain</location>
      <location>Hospital de León, León, Spain</location>
      <location>Hospital Clínico San Carlos, Madrid, Spain</location>
      <location>Hospital Universitario 12 de octubre, Madrid, Spain</location>
      <location>Portsmouth Hospital NHS Trust, Portsmouth, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650517</url>
  </study>
  <study rank="45065">
    <nct_id>NCT03650504</nct_id>
    <title>Effects of Catheter Location Relative to Femoral Artery on Postoperative Analgesia for Continuous Adductor Canal Blocks</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Osteoarthritis, Knee</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Above Artery Catheter Placement</intervention>
      <intervention type="Procedure">Between Artery and Vein Placement</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>AVERAGE PAIN</outcome_measure>
      <outcome_measure>Procedure duration</outcome_measure>
      <outcome_measure>Opioid consumption</outcome_measure>
      <outcome_measure>Distance Ambulated</outcome_measure>
      <outcome_measure>Worst pain score (NRS 0-10 reported by patient)</outcome_measure>
      <outcome_measure>Number of vascular pictures during placement</outcome_measure>
      <outcome_measure>Intravascular injection assessed by heart rate response to epinephrine in injection</outcome_measure>
      <outcome_measure>Total local anesthetic infused on first postoperative day</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, San Diego</lead_sponsor>
      <collaborator>Rodney Gabriel MD</collaborator>
      <collaborator>Matthew Swisher MD</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>180718</other_id>
    </other_ids>
    <start_date>August 24, 2018</start_date>
    <primary_completion_date>July 30, 2019</primary_completion_date>
    <completion_date>July 30, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650504</url>
  </study>
  <study rank="45066">
    <nct_id>NCT03650491</nct_id>
    <title>A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Multiple Myeloma</condition>
      <condition>Multiple Myeloma in Relapse</condition>
      <condition>Multiple Myeloma With Failed Remission</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">FOR46</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of adverse events</outcome_measure>
      <outcome_measure>Occurrence of dose-limiting toxicities</outcome_measure>
      <outcome_measure>Disease response</outcome_measure>
      <outcome_measure>Characterize FOR46 plasma concentration</outcome_measure>
      <outcome_measure>Characterize the FOR46 area under the curve</outcome_measure>
      <outcome_measure>Characterize FOR46 elimination</outcome_measure>
      <outcome_measure>Antidrug Antibodies</outcome_measure>
      <outcome_measure>Duration of response</outcome_measure>
      <outcome_measure>Progression-free survival</outcome_measure>
      <outcome_measure>Time to progression</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fortis Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>FOR46-002</other_id>
    </other_ids>
    <start_date>April 3, 2019</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>December 24, 2019</last_update_posted>
    <locations>
      <location>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States</location>
      <location>University of Colorado Cancer Center, Aurora, Colorado, United States</location>
      <location>Winship Cancer Institute, Emory University, Atlanta, Georgia, United States</location>
      <location>Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland, United States</location>
      <location>Karmanos Cancer Institute, Detroit, Michigan, United States</location>
      <location>Washington University in St. Louis-Siteman Cancer Center, Saint Louis, Missouri, United States</location>
      <location>Icahn School of Medicine at Mt. Sinai, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650491</url>
  </study>
  <study rank="45067">
    <nct_id>NCT03650478</nct_id>
    <title>Assessment of NeuroBOX and NeuroPAP in Infants.</title>
    <acronym>NeuroPap2</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pediatric Respiratory Diseases</condition>
      <condition>Bronchiolitis</condition>
      <condition>Infant Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">NeuroPAP ventilation (2h) and NeuroBox monitoring (23h)</intervention>
      <intervention type="Device">NeuroPAP ventilation (4h) and NeuroBox monitoring (25h)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in indices of respiratory unloading</outcome_measure>
      <outcome_measure>Incidence of cardio-respiratory events</outcome_measure>
      <outcome_measure>Change in End expiratory lung volume (EELV) level</outcome_measure>
      <outcome_measure>Change in Indices of cerebral oxygenation and perfusion</outcome_measure>
      <outcome_measure>Change in comfort level in preterm infants</outcome_measure>
      <outcome_measure>Change in comfort level in infants with bronchiolitis.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>St. Justine's Hospital</lead_sponsor>
      <collaborator>Maquet Critical Care</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>4 Months</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CHUSJ-1841</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>December 1, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 9, 2019</last_update_posted>
    <locations>
      <location>St. Justine's Hospital, Montreal, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650478</url>
  </study>
  <study rank="45068">
    <nct_id>NCT03650465</nct_id>
    <title>Comparing Different CBT Approaches in GAD</title>
    <acronym>CBTforGAD</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Generalized Anxiety Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Cognitive-behavioral therapy (CBT)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Generalized anxiety symptoms</outcome_measure>
      <outcome_measure>Worry</outcome_measure>
      <outcome_measure>Automatic thoughts frequency</outcome_measure>
      <outcome_measure>Automatic thoughts believability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Babes-Bolyai University</lead_sponsor>
      <collaborator>Albert Ellis Institute, New York</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>BabesBolyaiU</other_id>
    </other_ids>
    <start_date>May 16, 2009</start_date>
    <primary_completion_date>September 30, 2018</primary_completion_date>
    <completion_date>September 30, 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>January 15, 2019</last_update_posted>
    <locations>
      <location>Babes-Bolyai University, Department of Clinical Psychology and Psychotherapy, Cluj Napoca, Non-US/Non-Canadian, Romania</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650465</url>
  </study>
  <study rank="45069">
    <nct_id>NCT03650452</nct_id>
    <title>A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies</title>
    <acronym>ELEKTRA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Epilepsy</condition>
      <condition>Dravet Syndrome</condition>
      <condition>Lennox-Gastaut Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TAK-935</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percent change from baseline in frequency of all seizures (convulsive and drop) per 28 days in patients receiving TAK-935 (OV935) as compared to placebo during the Maintenance Period</outcome_measure>
      <outcome_measure>Percent change from baseline in all seizures (convulsive and drop) in patients receiving TAK-935 (OV935) as compared to placebo during Treatment Period</outcome_measure>
      <outcome_measure>Percent change from baseline in frequency of convulsive seizures in Dravet patients and drop seizures in Lennox Gastaut syndrome (LGS) patients, respectively, receiving TAK-935 (OV935) as compared to placebo during Maintenance Period</outcome_measure>
      <outcome_measure>Percentage of patients receiving TAK-935 (OV935) as compared to placebo in the Dravet Syndrome Stratum and LGS Stratum, respectively, considered treatment responders throughout Maintenance Period</outcome_measure>
      <outcome_measure>Change in Clinician's and Caregiver's Clinical Global Impression of Severity and Change (CGI-S/C)</outcome_measure>
      <outcome_measure>Correlation of TAK-935 concentration and plasma 24S-hydroxycholesterol (24HC) levels</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Takeda</lead_sponsor>
      <collaborator>Ovid Therapeutics Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>2 Years</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>126</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TAK-935-2002</other_id>
      <other_id>U1111-1206-5522</other_id>
      <other_id>2018‐002484‐25</other_id>
    </other_ids>
    <start_date>August 8, 2018</start_date>
    <primary_completion_date>March 21, 2021</primary_completion_date>
    <completion_date>April 21, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>November 21, 2019</last_update_posted>
    <locations>
      <location>Phoenix Children's Hospital, Phoenix, Arizona, United States</location>
      <location>Children's Hospital Los Angeles, Los Angeles, California, United States</location>
      <location>Colorado Children's Hospital, Aurora, Colorado, United States</location>
      <location>Nicklaus Children's Hospital, Miami, Florida, United States</location>
      <location>Pediatric Neurology PA, Orlando, Florida, United States</location>
      <location>Rare Disease Research, LLC, Atlanta, Georgia, United States</location>
      <location>Center for Rare Neurological Diseases, Norcross, Georgia, United States</location>
      <location>Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States</location>
      <location>Mayo Clinic - PPDS, Rochester, Minnesota, United States</location>
      <location>Northeast Regional Epilepsy Group, Hackensack, New Jersey, United States</location>
      <location>Children's Hospital at Saint Peter's University Hospital, New Brunswick, New Jersey, United States</location>
      <location>Columbia University Medical Center, New York, New York, United States</location>
      <location>Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States</location>
      <location>Medical University of South Carolina, Charleston, South Carolina, United States</location>
      <location>Cook Children's Medical Center, Fort Worth, Texas, United States</location>
      <location>Monash Children's Hospital, Clayton, Victoria, Australia</location>
      <location>Austin Hospital, Heidelberg West, Victoria, Australia</location>
      <location>Hospital For Sick Children, Toronto, Ontario, Canada</location>
      <location>Peking University First Hospital, Beijing, China</location>
      <location>Capital Medical University (CMU) - Beijing Children's Hospital, Beijing, China</location>
      <location>Beijing Children's Hospital,Capital Medical University, Beijing, China</location>
      <location>Xiangya Hospital Central South University, Changsha, China</location>
      <location>Children's Hospital of Fudan University, Shanghai, China</location>
      <location>Shenzhen Children's Hospital, Shenzhen, China</location>
      <location>Sheba Medical Center-PPDS, Tel Hashomer,, Ramat Gan, Israel</location>
      <location>Soroka University Medical Centre, Bear Sheva, Israel</location>
      <location>Bnai Zion Medical Center, Haifa, Israel</location>
      <location>Edith Wolfson Medical Center, Holon, Israel</location>
      <location>Hadassah Medical Center, Jerusalem, Israel</location>
      <location>Schneider Childrens Medical Center of Israel, Petach Tikva, Israel</location>
      <location>Tel Aviv Sourasky Medical Center, Tel Aviv, Israel</location>
      <location>Uniwersyteckie Centrum Kliniczne - PPDS, Gdansk, Pomorskie, Poland</location>
      <location>NZOZ Centrum Neurologii Dzieciecej i Leczenia Padaczki, Kielce, Swietokrzyskie, Poland</location>
      <location>Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, Poznan, Wielkopolskie, Poland</location>
      <location>Centrum Medyczne Plejady, Krakow, Poland</location>
      <location>Samodzielny Publiczny Dzieciecy Szpital Kliniczny w Warszawie, Warsaw, Poland</location>
      <location>Instytut Pomnik Centrum Zdrowia Dziecka, Warsaw, Poland</location>
      <location>Centro Hospitalar Lisboa Central- Hospital Dona Estefania, Lisboa, Portugal</location>
      <location>Centro Hospitalar Lisboa Norte, E.P.E. Hospital de Santa Maria, Lisboa, Portugal</location>
      <location>Largo da Maternidade de Julio DinisCentro Materno Infantil do Norte, Porto, Portugal</location>
      <location>Clinica Universidad Navarra, Pamplona, Navarra, Spain</location>
      <location>Hospital Vithas La Salud, Granada, Spain</location>
      <location>Hospital Ruber Internacional, Madrid, Spain</location>
      <location>Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650452</url>
  </study>
  <study rank="45070">
    <nct_id>NCT03650439</nct_id>
    <title>Fungal Infections in Patients With Hematological Malignancies</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fungal Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">culture on Sabouraud's Dextrose Agar (SDA)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>identification of endemic fungal pathogen in patients with hematological malignancies south Egypt cancer institute.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assiut University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>fungal infections</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>September 30, 2019</primary_completion_date>
    <completion_date>October 31, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650439</url>
  </study>
  <study rank="45071">
    <nct_id>NCT03650426</nct_id>
    <title>Comparison Between the Onlay and Inlay Techniques for Patellar Resurfacing in Posterior Cruciate Ligament-Substituting Total Knee Arthroplasty</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Onlay Patellar Resurfacing Technique</condition>
      <condition>Inlay Patellar Resurfacing Technique</condition>
      <condition>Patellar Resurfacing</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Total knee with onlay patellar resurfacing technique</intervention>
      <intervention type="Procedure">Total knee with inlay patellar resurfacing technique</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change of post-operative anterior knee pain</outcome_measure>
      <outcome_measure>range of motion of knee</outcome_measure>
      <outcome_measure>Knee Society and Knee Society function score</outcome_measure>
      <outcome_measure>New patellar score</outcome_measure>
      <outcome_measure>Oxford knee score</outcome_measure>
      <outcome_measure>Prevalence of anterior knee pain ,AKP</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Navamindradhiraj University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>COA 017/2561</other_id>
    </other_ids>
    <start_date>September 30, 2018</start_date>
    <primary_completion_date>March 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>July 23, 2019</last_update_posted>
    <locations>
      <location>Navamindradhiraj University, Dusit, Bangkok,, Thailand</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650426</url>
  </study>
  <study rank="45072">
    <nct_id>NCT03650413</nct_id>
    <title>An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ulcerative Colitis</condition>
      <condition>Crohn's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">UTTR1147A</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of Participants with Severe Adverse Events (Grade ≥3), Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 Scale (NCI CTCAE v4.0)</outcome_measure>
      <outcome_measure>Percentage of Participants with Adverse Events of Clinically Significant Changes From Baseline in Targeted Vital Signs</outcome_measure>
      <outcome_measure>Percentage of Participants with Adverse Events of Clinically Significant Changes From Baseline in Physical Examination Findings</outcome_measure>
      <outcome_measure>Percentage of Participants with Adverse Events of Clinically Significant Changes From Baseline in Laboratory Test Results</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Genentech, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>320</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>GA40209</other_id>
      <other_id>2017-004997-32</other_id>
    </other_ids>
    <start_date>January 14, 2019</start_date>
    <primary_completion_date>December 17, 2022</primary_completion_date>
    <completion_date>December 17, 2022</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>January 21, 2020</last_update_posted>
    <locations>
      <location>QWay Research, Hialeah, Florida, United States</location>
      <location>University of Miami, Miami, Florida, United States</location>
      <location>Gastroenterology Group of Naples, Naples, Florida, United States</location>
      <location>University of Chicago Medical Center, Chicago, Illinois, United States</location>
      <location>Chevy Chase Clinical Research, Chevy Chase, Maryland, United States</location>
      <location>Atlantic Health System, Morristown, New Jersey, United States</location>
      <location>NYU Langone Long Island Clinical Research Associates, Great Neck, New York, United States</location>
      <location>Southtowns Gastroenterology, PLLC, Orchard Park, New York, United States</location>
      <location>University of Rochester Medical Center, Rochester, New York, United States</location>
      <location>Syracuse VA Medical Center - NAVREF; Pharmacy, Syracuse, New York, United States</location>
      <location>Carolina Digestive Diseases, Greenville, North Carolina, United States</location>
      <location>University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States</location>
      <location>Gastro One, Germantown, Tennessee, United States</location>
      <location>Vanderbilt University Medical Center; IBD Clinic, Nashville, Tennessee, United States</location>
      <location>Baylor College of Medicine, Houston, Texas, United States</location>
      <location>Biopharma Informatic Inc.; Research Center, Houston, Texas, United States</location>
      <location>BI Research Center, Houston, Texas, United States</location>
      <location>Tyler Research Institute, LLC, Tyler, Texas, United States</location>
      <location>Texas Digestive Disease Consultants - PPDS, Webster, Texas, United States</location>
      <location>University of Utah; Division of Gastroenterology/Hepatology, Salt Lake City, Utah, United States</location>
      <location>MHAT Saint Karidad EAD, Plovdiv, Bulgaria</location>
      <location>Multiprofile Hospital for Active Treatment Hadji Dimitar OOD, Sliven, Bulgaria</location>
      <location>Diagnostic and Consulting Center Aleksandrovska EOOD, Sofia, Bulgaria</location>
      <location>Medical center CONVEX EOOD, Sofia, Bulgaria</location>
      <location>Medical Center Medica Plus OOD, Veliko Tarnovo, Bulgaria</location>
      <location>Beijing Chaoyang Hospital Capital Medical University, Beijing City, China</location>
      <location>Peking University Third Hospital, Beijing, China</location>
      <location>Third Xiangya Hospital Centrel South University, Changsha, China</location>
      <location>Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu City, China</location>
      <location>The First Affiliated Hospital of Sun Yat-sen University, Guangzhou City, China</location>
      <location>The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China</location>
      <location>Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China</location>
      <location>Nanjing First Hospital, Nanjing City, China</location>
      <location>Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai City, China</location>
      <location>Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai City, China</location>
      <location>Zhongshan Hospital Fudan University, Shanghai, China</location>
      <location>Shanghai General Hospital, Shanghai, China</location>
      <location>Shanghai East Hospital, Shanghai, China</location>
      <location>Tianjin Medical University General Hospital, Tianjin (天津), China</location>
      <location>Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China</location>
      <location>Zhongshan Hospital Xiamen University, Xiamen, China</location>
      <location>CHU Amiens Picardie- Hôpital Nord, Amiens, France</location>
      <location>Hopital Cote De Nacre; Hematologie Clinique, Caen, France</location>
      <location>CHU de GRENOBLE; Clinique Medicale De Pediatrie, Grenoble, France</location>
      <location>CHRU Lille, Lille, France</location>
      <location>Hôpital L'archet 2, Nice, France</location>
      <location>CHU du Reims - Hopital Robert Debré, Reims, France</location>
      <location>Charite Campus Mitte, Berlin, Germany</location>
      <location>Gastroenterologische Spezialpraxis-Berlin-Karlshorst, Berlin, Germany</location>
      <location>Universitätsklinikum &quot;Carl Gustav Carus&quot; der Technischen Universität Dresden, Dresden, Germany</location>
      <location>Asklepios Westklinikum Hamburg Ggmbh; Gastroenterologie, Hamburg, Germany</location>
      <location>KRH Klinikum Siloah, Hannover, Germany</location>
      <location>Universitätsklinikum Jena; Klinik und Poliklinik für Frauenheilkunde und Fortpflanzungsmedizin, Jena, Germany</location>
      <location>Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel, Germany</location>
      <location>St. Marien Krankenhaus; Med. Klinik, Ludwigshafen, Germany</location>
      <location>Klinikum Mannheim GmbH Universitätsklinikum, Mannheim, Germany</location>
      <location>Universitätsklinikum Münster, Münster, Germany</location>
      <location>Klinikum der Universität Regensburg, Regensburg, Germany</location>
      <location>Universitätsklinikum Ulm; Klinik für Innere Medizin II, Ulm, Germany</location>
      <location>University General Hospital of Heraklion; Department of Ophthalmology, Heraklion, Greece</location>
      <location>University General Hospital of Larissa; University Gastroenterology Clinic, Larissa, Greece</location>
      <location>Iatriko Palaiou Falirou; Gastrointestinal Department, Palaio Faliro, Greece</location>
      <location>EUROMEDICA General Clinic of Thessaloniki; Gastroenterology Department, Thessaloniki, Greece</location>
      <location>CMC Déli Klinika, Budapest, Hungary</location>
      <location>Szent Margit Korhaz; IV.sz. Belgyogyaszati Osztaly, Budapest, Hungary</location>
      <location>Magyar Honvédség Egészségügyi Központ; Országos Haemophilia Központ, Budapest, Hungary</location>
      <location>Szent Pantaleon Korhaz-Rendelointezet; Gastroenterologiai Osztaly, Dunaújváros, Hungary</location>
      <location>Csongrad Megyei Dr. Bugyi Istvan Korhaz; Belgyogyaszati Osztaly, Szentes, Hungary</location>
      <location>Fejer Megyei Szent Gyorgy Egyetemi Oktato Korhaz; I. sz. Belgyogyaszati Osztaly, Székesfehérvár, Hungary</location>
      <location>Csolnoky Ferenc Kórház, Veszprém, Hungary</location>
      <location>Portiuncula Hospital, Ballinasloe, Co Galway, Ireland</location>
      <location>Our Lady of Lourdes Hospital, Louth, County Louth, Ireland</location>
      <location>Soroka University Medical Centre, Beer Sheva, Israel</location>
      <location>Shaare Zedek Medical Center; Bait Vagan, Jerusalem, Israel</location>
      <location>Meir Medical Center, Kfar- Saba, Israel</location>
      <location>The Galilli Medical Center, Nahariyya, Israel</location>
      <location>Rabin Medical Center; PPDS; Pharmacy, Petach Tiqwa, Israel</location>
      <location>Chaim Sheba Medical Center, Ramat Gan, Israel</location>
      <location>Kaplan Medical Center, Rehovot, Israel</location>
      <location>Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi; UO Farmacia Clinica, Bologna, Emilia-Romagna, Italy</location>
      <location>Azienda Sanitaria Universitaria Integrata di Udine - PO Universitario Santa Maria della, Udine, Friuli-Venezia Giulia, Italy</location>
      <location>Policlinico Universitario Campus Biomedico Di Roma, Roma, Lazio, Italy</location>
      <location>Complesso Integrato Columbus, Roma, Lazio, Italy</location>
      <location>ASST FATEBENEFRATELLI SACCO (Sacco), Milano, Lombardia, Italy</location>
      <location>ASST di Monza - Azienda Ospedaliera San Gerardo; U.O. Farmacia -Settore A - Corpo Posteriore, Monza, Lombardia, Italy</location>
      <location>ASST Rhodense - Ospedale di Rho, Rho, Lombardia, Italy</location>
      <location>Istituto Clinico Humanitas, Rozzano (MI), Lombardia, Italy</location>
      <location>Azienda Ospedaliera Ordine Mauriziano di Torino, Torino, Piemonte, Italy</location>
      <location>Azienda Ospedaliera Di Padova, Padova, Veneto, Italy</location>
      <location>ETZ-Elisabeth; Cardiologie, Tilburg, Netherlands</location>
      <location>Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy; Centrum Endoskopii Zabiegowej, Bydgoszcz, Poland</location>
      <location>Centrum Medycyny i Stomatologii SILESIA MED Sp. z o.o., Katowice, Poland</location>
      <location>Economicus - NZOZ ALL-MEDICUS; Zaklad Gastroenterologii, Katowice, Poland</location>
      <location>ETG Kielce, Kielce, Poland</location>
      <location>Gastromed SPK Niepubliczny Zaklad Opieki Zdrowotnej, Lublin, Poland</location>
      <location>Klimed Marek Klimkiewicz, Piotrków Trybunalski, Poland</location>
      <location>Clinical Research Center Sp. z o.o. MEDIC-R Spółka Komandytowa, Poznań, Poland</location>
      <location>Gabinet Lekarski, Bartosz Korczowski, Rzeszów, Poland</location>
      <location>Endoskopia Sp. z o.o., Sopot, Poland</location>
      <location>Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj, Toruń, Poland</location>
      <location>Centrum Zdrowia MDM, Warszawa, Poland</location>
      <location>WIP Warsaw IBD Point Profesor Kierkus, Warszawa, Poland</location>
      <location>Centrum Medyczne NeuroProtect, Warszawa, Poland</location>
      <location>BioVirtus Research Site, Warszawa, Poland</location>
      <location>EMC Instytut Medyczny S.A., Wrocław, Poland</location>
      <location>Melita Medical, Wrocław, Poland</location>
      <location>PlanetMed, Wrocław, Poland</location>
      <location>SPZOZ Uniwersytecki SK nr 1 im N. Barlickiego UM w Lodzi; Oddz. Klin. Gastroenter. Og. i Onk., Łódź, Poland</location>
      <location>Medical Center Stolitsa-Medikl, Moscow, Moskovskaja Oblast, Russian Federation</location>
      <location>Saint Martyr Elizabeth City Hospital, Sankt-peterburg, Sankt Petersburg, Russian Federation</location>
      <location>Irkutsk Research Centre Hospital of Siberian department of Russian Academy of Science, Irkutsk, Russian Federation</location>
      <location>Kuban State Medical University, Krasnodar, Russian Federation</location>
      <location>Rostov State Medical University; Cardiorheumatology Department, Rostov-na-Donu, Russian Federation</location>
      <location>Medical University Reaviz, Samara, Russian Federation</location>
      <location>North-West State Medical University n.a. I.I. Mechnikov, St. Petersburg, Russian Federation</location>
      <location>Russian Medical Military Academy n.a. S.M. Kirov, St. Petersburg, Russian Federation</location>
      <location>Clinical Center of Serbia, Belgrade, Serbia</location>
      <location>Clinical Hospital Center Zvezdara, Belgrade, Serbia</location>
      <location>KBC Dr Dragisa Misovic Dedinje, Belgrade, Serbia</location>
      <location>Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia</location>
      <location>Clinical Center Kragujevac; Clinic Of Psychiatry, Kragujevac, Serbia</location>
      <location>Clinical Center Nis, NIS, Serbia</location>
      <location>General Hospital Vrsac, Vrsac, Serbia</location>
      <location>Clinical Hospital Centre Zemun, Zemun, Serbia</location>
      <location>General Hospital Djordje Joanovic - Zrenjanin, Zrenjanin, Serbia</location>
      <location>Hospital de Gran Canaria Dr. Negrin; Servicio de Aparato Digestivo, Las Palmas de Gran Canaria, LAS Palmas, Spain</location>
      <location>Hospital Universitario de Torrejon, Torrejon de Ardoz, Madrid, Spain</location>
      <location>Hospital Universitari de Girona Dr Josep Trueta, Girona, Spain</location>
      <location>Hospital Universitario de La Princesa; Aparato Digestivo, Madrid, Spain</location>
      <location>Complejo Asistencial Universitario de Salamanca - H. Clinico, Salamanca, Spain</location>
      <location>Hospital Clinico Universitario de Valencia; Servicio de Neurologia, Valencia, Spain</location>
      <location>Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Spain</location>
      <location>Regional Municipal Institution Chernivtsi Regional Clinical Hospital, Chernivtsi, Chernihiv Governorate, Ukraine</location>
      <location>Medical Centre of PE First Private Clinic, Zhytomir, Crimean Regional Governmenta, Ukraine</location>
      <location>Ternopil University Hospital; Regional Center of Gastroenterology with Hepatology, Ternopil, Katerynoslav Governorate, Ukraine</location>
      <location>Municipal Nonprofit Enterprise CCH #2 n.a. prof. O.O. Shalimov of Kharkiv City Council, Kharkiv, Kharkiv Governorate, Ukraine</location>
      <location>Medical Centre of LLC CARDIOCOM, Kozyn, Kharkiv Governorate, Ukraine</location>
      <location>City Clinical Hospital #1; Department of Gastroenterology, Vinnytsia, Kharkiv Governorate, Ukraine</location>
      <location>Municipal Institution Zaporizhzhia Regional Clinical Hospital of Zaporizhzhia Regional Council, Zaporizhzhia, Kharkiv Governorate, Ukraine</location>
      <location>Medical Center of LLC Medical Center Dopomoga Plus, Kyiv, KIEV Governorate, Ukraine</location>
      <location>Med Center of International Institute of Clinical Trials LLC, Kyiv, KIEV Governorate, Ukraine</location>
      <location>Clinic of SRI of Invalid Rehab. (ESTC) of VNMU n.a. M.I.Pyrohov, Vinnytsia, Podolia Governorate, Ukraine</location>
      <location>Medical Center of LLC Medical Center Family Medicine Clinic; Endoscopy &amp; Gastroenterology, Dnipr, Polissya Okruha, Ukraine</location>
      <location>Transcarpathian Regional Clinical Hospital n.a. A. Novak; Rheumatology Department, Uzhgorod, Ukraine</location>
      <location>Medical Center of Diaservice LLC; Division of clinical trials conduct, Department #3, Zaporizhzhia, Ukraine</location>
      <location>SI Dept. Clin. Hospital of Zaporizhzhia-2 Railway Station of SE Prydniprovska Zaliznytsia, Zaporizhzhia, Ukraine</location>
      <location>Kings College Hospital, London, United Kingdom</location>
      <location>Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650413</url>
  </study>
  <study rank="45073">
    <nct_id>NCT03650400</nct_id>
    <title>Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to &lt; 12 Years With Asthma</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Asthma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Fevipiprant</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Plasma concentration of fevipiprant at steady state (ss), after at least four consecutive days of dosing)) by area under the curve (AUC0-24h,ss)</outcome_measure>
      <outcome_measure>Maximum plasma concentration of fevipiprant at steady state (ss), after at least four consecutive days of dosing)) by Cmax,ss</outcome_measure>
      <outcome_measure>Plasma concentration at steady state (ss), after at least four consecutive days of dosing)) by oral clearance (CL/F)</outcome_measure>
      <outcome_measure>Pharmacokinetics of the metabolite CCN362 by AUC0-24h,ss</outcome_measure>
      <outcome_measure>Pharmacokinetics of the metabolite CCN362 by Cmin,ss</outcome_measure>
      <outcome_measure>Pharmacokinetics of the metabolite CCN362 by Cmax,ss</outcome_measure>
      <outcome_measure>Pharmacokinetics of the metabolite CCN362 by CL/F</outcome_measure>
      <outcome_measure>Pharmacokinetics of the metabolite CCN362 by Tmax,ss</outcome_measure>
      <outcome_measure>Urinary excretion of fevipiprant and CCN362</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <max_age>11 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CQAW039B2201</other_id>
    </other_ids>
    <start_date>May 1, 2019</start_date>
    <primary_completion_date>June 23, 2020</primary_completion_date>
    <completion_date>July 23, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 23, 2019</last_update_posted>
    <locations>
      <location>Novartis Investigative Site, Orange, California, United States</location>
      <location>Novartis Investigative Site, Stockbridge, Georgia, United States</location>
      <location>Novartis Investigative Site, Minneapolis, Minnesota, United States</location>
      <location>Novartis Investigative Site, Columbia, Missouri, United States</location>
      <location>Novartis Investigative Site, Charlotte, North Carolina, United States</location>
      <location>Novartis Investigative Site, Oklahoma City, Oklahoma, United States</location>
      <location>Novartis Investigative Site, Tulsa, Oklahoma, United States</location>
      <location>Novartis Investigative Site, Medford, Oregon, United States</location>
      <location>Novartis Investigative Site, Boerne, Texas, United States</location>
      <location>Novartis Investigative Site, El Paso, Texas, United States</location>
      <location>Novartis Investigative Site, San Antonio, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650400</url>
  </study>
  <study rank="45074">
    <nct_id>NCT03650387</nct_id>
    <title>Safety, Effectiveness and Subject Satisfaction Study of a Dermal Filler ( of RADIESSE® (+) Lidocaine) in the Treatment of Ageing Signs in the Face</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Signs of Facial Aging With Volume Loss in the Upper Cheeks, Nasolabial Folds and Marionette Lines</condition>
    </conditions>
    <interventions>
      <intervention type="Device">RADIESSE® (+) Lidocaine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Responder rate for nasolabial folds after treatment with RADIESSE® (+) Lidocaine based on the blinded rater's evaluation on the Merz Nasolabial Folds Scale at week 12/16 (depending on touch-up performed).</outcome_measure>
      <outcome_measure>Responder rate for marionette lines after treatment with RADIESSE® (+) Lidocaine based on the blinded rater's evaluation on the Merz Marionette Lines Scale (MNLS) at week 12/16 (depending on touch-up performed).</outcome_measure>
      <outcome_measure>Responder rate for upper cheek fullness after treatment with RADIESSE® (+) Lidocaine based on the blinded rater's evaluation on the Merz Upper Cheek Fullness Scale (MUFS) at week 12/16 (depending on touch-up performed).</outcome_measure>
      <outcome_measure>Occurrence of treatment emergent adverse events</outcome_measure>
      <outcome_measure>Responder rate for nasolabial folds based on the blinded rater's evaluation on the Merz Nasolabial Folds Scale at Visit 2 (Week 4) pre optional touch-ups, at Week 24/28, at Week 48/52, and at Week 72/76 (depending on touch-up performed).</outcome_measure>
      <outcome_measure>Responder rate for marionette lines based on the blinded rater's evaluation on the Merz Marionette Lines Scale at Visit 2 (Week 4) pre optional touch-ups, at Week 24/28, at Week 48/52, and at Week 72/76 (depending on touch-up performed).</outcome_measure>
      <outcome_measure>Responder rate for cheek fullness based on the blinded rater's evaluation on the Merz Upper Cheek Fullness Scale at Visit 2 (Week 4) pre optional touch-ups, at Week 24/28, at Week 48/52, and at Week 72/76 (depending on touch-up performed).</outcome_measure>
      <outcome_measure>Treating investigator's evaluation of the global aesthetic improvement on the investigator Global Aesthetic Improvement Scale (iGAIS) from Day 1 pre-injection photos to Week 4 pre optional touch ups, to Weeks 12/16, 24/28, 48/52, and to Week 72/76.</outcome_measure>
      <outcome_measure>Subject's evaluation of the global aesthetic improvement on the subject Global Aesthetic Improvement Scale (sGAIS) from Day 1 pre-injection photos to Week 4 pre optional touch ups, to Weeks 12/16, t24/28, 48/52, and to Week 72/76.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Merz Pharmaceuticals GmbH</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>207</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>M900391005</other_id>
    </other_ids>
    <start_date>September 17, 2018</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>December 17, 2019</last_update_posted>
    <locations>
      <location>Universität Hamburg Fachbereich Chemie Institut für Biologie und Molekularbiologie , Merz Investigational Site #490095, Hamburg, Germany</location>
      <location>Derma Science GmbH Hamburg, Merz Investigational Site #490345, Hamburg, Germany</location>
      <location>Privatpraxis für Dermatologie und Ästhetik, Merz Investigational Site #490371, Munich, Germany</location>
      <location>Dermatologie München-Neuhausen, Merz Investigational Site #490372, Munich, Germany</location>
      <location>Haut-und Lasercentrum, Merz Investigational Site #0490362, Potsdam, Germany</location>
      <location>Centroderm GmbH, Merz Investigational Site #490367, Wuppertal, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650387</url>
  </study>
  <study rank="45075">
    <nct_id>NCT03650374</nct_id>
    <title>Effects of Contralateral Strength Training on Postoperative Strength Deficits in the Immobilized Lower Extremity</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Meniscus; Detachment, Current Injury</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Standard of Care Rehabilitation</intervention>
      <intervention type="Other">Experimental Strength Training</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>KOOS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NYU Langone Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>18-01100</other_id>
    </other_ids>
    <start_date>August 9, 2018</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>June 1, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>November 26, 2019</last_update_posted>
    <locations>
      <location>New York University School of Medicine, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650374</url>
  </study>
  <study rank="45076">
    <nct_id>NCT03650361</nct_id>
    <title>Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acne Vulgaris</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Adapalene Gel 0.3%</intervention>
      <intervention type="Drug">Differin 0.3% Topical Gel</intervention>
      <intervention type="Drug">Adapalene Gel 0.3% Vehicle Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mean percent change from baseline to week 12 in the inflammatory (papules and pustules) and in the non-inflammatory (open and closed comedones) lesion counts</outcome_measure>
      <outcome_measure>The secondary endpoint is the Investigator Global Assessment (IGA) score, expressed in terms of treatment success or failure.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Aleor Dermaceuticals Limited</lead_sponsor>
      <collaborator>Catawba Research, LLC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <max_age>40 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>755</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ADPG 1807</other_id>
    </other_ids>
    <start_date>September 17, 2018</start_date>
    <primary_completion_date>February 16, 2019</primary_completion_date>
    <completion_date>February 16, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>April 26, 2019</last_update_posted>
    <locations>
      <location>Unison Center for Clinical Trials, Sherman Oaks, California, United States</location>
      <location>Moore Clinical Research Institute, Inc., Brandon, Florida, United States</location>
      <location>FXM Research Corp., Miami, Florida, United States</location>
      <location>FXM Research Miramar, Miramar, Florida, United States</location>
      <location>Moore Clinical Research Institute, Inc., Tampa, Florida, United States</location>
      <location>Moore Clinical Research Institute, Inc., Tampa, Florida, United States</location>
      <location>Dermatology Consulting Services, PLLC, High Point, North Carolina, United States</location>
      <location>3A Research, LLC, El Paso, Texas, United States</location>
      <location>3A Research, LLC, El Paso, Texas, United States</location>
      <location>FXM Research International, Belize City, Belize</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650361</url>
  </study>
  <study rank="45077">
    <nct_id>NCT03650348</nct_id>
    <title>PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HER2-positive Breast Cancer</condition>
      <condition>HER2-positive Gastric Cancer</condition>
      <condition>HER2-positive Bladder Cancer</condition>
      <condition>HER2-positive Solid Tumor</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PRS-343 in Combination with Atezolizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of DLTs and recommended Phase 2 dose (RP2D) of PRS-343 administered in combination with atezolizumab</outcome_measure>
      <outcome_measure>Overall response rate (ORR) per RECIST v1.1</outcome_measure>
      <outcome_measure>Duration of response (DOR) per RECIST v1.1</outcome_measure>
      <outcome_measure>Rate of complete response (CR) per RECIST v1.1</outcome_measure>
      <outcome_measure>Incidence and severity of AEs graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03, and changes in clinical laboratory parameters</outcome_measure>
      <outcome_measure>Peak Plasma Concentration (Cmax)</outcome_measure>
      <outcome_measure>Area under the plasma concentration versus time curve (AUC)</outcome_measure>
      <outcome_measure>Time to maximum dose concentration (Tmax)</outcome_measure>
      <outcome_measure>Terminal half life (t1/2)</outcome_measure>
      <outcome_measure>Presence and/or concentration of anti-PRS-343 and anti-atezolizumab antibodies (anti-drug antibodies [ADAs])</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pieris Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PRS-343-PCS_08_18</other_id>
    </other_ids>
    <start_date>August 21, 2018</start_date>
    <primary_completion_date>April 1, 2020</primary_completion_date>
    <completion_date>August 1, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>July 15, 2019</last_update_posted>
    <locations>
      <location>USC Norris Comprehensive Cancer Center, Los Angeles, California, United States</location>
      <location>Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States</location>
      <location>UCLA Health, Santa Monica, California, United States</location>
      <location>Ochsner Cancer Institute, New Orleans, Louisiana, United States</location>
      <location>Memorial Sloan Kettering Cancer Center, New York, New York, United States</location>
      <location>The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States</location>
      <location>M.D. Anderson Cancer Center, Houston, Texas, United States</location>
      <location>NEXT Oncology, San Antonio, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650348</url>
  </study>
  <study rank="45078">
    <nct_id>NCT03650335</nct_id>
    <title>Effect of Bupivacaine in Ultrasound-guided Erector Spinae Plane</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Thoracotomy</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>postoperative opioid consumption</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yuzuncu Yıl University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ESP</other_id>
    </other_ids>
    <start_date>February 15, 2019</start_date>
    <primary_completion_date>November 30, 2019</primary_completion_date>
    <completion_date>December 20, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>February 1, 2019</last_update_posted>
    <locations>
      <location>Celaleddin Soyalp, VAN, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650335</url>
  </study>
  <study rank="45079">
    <nct_id>NCT03650322</nct_id>
    <title>Effects of Yoga, Strength Training and Aerobic Exercise on Cognition in Adult Cancer Survivors</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cancer</condition>
      <condition>Cancer-related Problem/Condition</condition>
      <condition>Exercise</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Yoga</intervention>
      <intervention type="Behavioral">Stretching and Toning</intervention>
      <intervention type="Behavioral">Aerobic Walking</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cognitive Function</outcome_measure>
      <outcome_measure>Cardiovascular Function</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Illinois at Urbana-Champaign</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>30 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>18922</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>December 30, 2019</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>September 13, 2019</last_update_posted>
    <locations>
      <location>University of Illinois at Urbana-Champaign, Urbana, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650322</url>
  </study>
  <study rank="45080">
    <nct_id>NCT03650309</nct_id>
    <title>Deep Brain Stimulation for Morbid Obesity</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Obesity</condition>
      <condition>Obesity, Morbid</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Deep Brain Stimulation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of Treatment-Emergent Adverse Events</outcome_measure>
      <outcome_measure>Weight</outcome_measure>
      <outcome_measure>'Quality of Life Scale' Questionnaire</outcome_measure>
      <outcome_measure>'Behavioral Inhibition System/Behavioral Activation System Scales (BIS/BAS Scales)' Questionnaire</outcome_measure>
      <outcome_measure>'Patient Health Questionnaire (PHQ-9)' Questionnaire</outcome_measure>
      <outcome_measure>'Generalized Anxiety Disorder 7-item (GAD-7)' Questionnaire</outcome_measure>
      <outcome_measure>'Difficulties in Emotion Regulation Scale (DERS)' Questionnaire</outcome_measure>
      <outcome_measure>'Yale-Brown Obsessive Compulsive Scale (Y-BOCS)' Questionnaire</outcome_measure>
      <outcome_measure>'Binge Eating Scale (BES)' Questionnaire</outcome_measure>
      <outcome_measure>'Yale-Brown-Cornell Eating Disorder Scale (YBC-EDS)' Questionnaire</outcome_measure>
      <outcome_measure>'Emotional Eating Scale (EES)' Questionnaire</outcome_measure>
      <outcome_measure>'Power of Food (POF)' Questionnaire</outcome_measure>
      <outcome_measure>'Eating Disorder Examination Questionnaire (EDE-Q)'</outcome_measure>
      <outcome_measure>'Yale Food Addiction Scale (YFAS)' Questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>17-5899</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>January 23, 2021</primary_completion_date>
    <completion_date>July 23, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>April 30, 2019</last_update_posted>
    <locations>
      <location>Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650309</url>
  </study>
  <study rank="45081">
    <nct_id>NCT03650296</nct_id>
    <title>Evaluating Different Pediatric Emergency Rulers in a Manikin Study - How Fast and Correct Are They</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Time Until Identification of Defined Parameter</condition>
    </conditions>
    <interventions>
      <intervention type="Device">ePER vs PS vs PaedER</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to identification</outcome_measure>
      <outcome_measure>Correctness</outcome_measure>
      <outcome_measure>Percentage deviation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Children's Hospital, Zurich</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ePER vs PS vs PNL</other_id>
    </other_ids>
    <start_date>April 2, 2018</start_date>
    <primary_completion_date>June 5, 2018</primary_completion_date>
    <completion_date>June 28, 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Department of Anaesthesia and Children's Research Centre, Zürich, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650296</url>
  </study>
  <study rank="45082">
    <nct_id>NCT03650283</nct_id>
    <title>Relation Between PRST Score, Skin Conductance and BIS</title>
    <acronym>RB</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Awakeness, Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Other">monitoring</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Correlation between NFSC, PRST and BIS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Diskapi Yildirim Beyazit Education and Research Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>40/19</other_id>
    </other_ids>
    <start_date>March 4, 2019</start_date>
    <primary_completion_date>April 30, 2019</primary_completion_date>
    <completion_date>May 31, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>February 11, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650283</url>
  </study>
  <study rank="45083">
    <nct_id>NCT03650270</nct_id>
    <title>Childhood Convulsive Status Epilepticus Management In A Resource Limited Setting</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pediatric Status Epilepticus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Phenobarbital</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Differences in anticonvulsant efficacy between different second-line anticonvulsant treatment protocols</outcome_measure>
      <outcome_measure>Differences in how patients tolerate each of the two second-line anticonvulsant treatment protocols</outcome_measure>
      <outcome_measure>Differences in need for pediatric intensive care between the two second-line anticonvulsant protocols</outcome_measure>
      <outcome_measure>Differences in admission time between patients who receive on of the two second-line anticonvulsant protocols</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Cape Town</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>1 Month</min_age>
    <max_age>15 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>198</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>297/2005</other_id>
    </other_ids>
    <start_date>March 1, 2015</start_date>
    <primary_completion_date>March 1, 2018</primary_completion_date>
    <completion_date>March 1, 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Red Cross War Memorial Children's Hospital, Cape Town, Western Cape, South Africa</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650270</url>
  </study>
  <study rank="45084">
    <nct_id>NCT03650257</nct_id>
    <title>A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Glioma of Brain</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">gp96</intervention>
      <intervention type="Drug">Temozolomide</intervention>
      <intervention type="Radiation">radiotherapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>overall survive</outcome_measure>
      <outcome_measure>Progression-free survival</outcome_measure>
      <outcome_measure>survival rate</outcome_measure>
      <outcome_measure>changes in antigen specific T cells</outcome_measure>
      <outcome_measure>Number of participants with adverse events related to gp96 immunotherapy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cure&amp;Sure Biotech Co., LTD</lead_sponsor>
      <collaborator>Beijing Tiantan Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CS-TT-G-02</other_id>
    </other_ids>
    <start_date>August 20, 2018</start_date>
    <primary_completion_date>August 20, 2021</primary_completion_date>
    <completion_date>August 20, 2023</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650257</url>
  </study>
  <study rank="45085">
    <nct_id>NCT03650244</nct_id>
    <title>Nationwide Observation Study to Evaluate the Efficacy and Tolerance of the Adjustable Medical Device REMEEX® in the Treatment of Male Stress Urinary Incontinence</title>
    <acronym>Remeex</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Urinary Incontinence,Stress</condition>
    </conditions>
    <interventions>
      <intervention type="Device">REMEEX implantation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evaluate efficacy of REMEEX® on urinary incontinence post radical prostatectomy</outcome_measure>
      <outcome_measure>Normal clinical examination</outcome_measure>
      <outcome_measure>urinary output</outcome_measure>
      <outcome_measure>Volume of urine</outcome_measure>
      <outcome_measure>Post-void residual urine volume</outcome_measure>
      <outcome_measure>cystoscopy</outcome_measure>
      <outcome_measure>readjustment of the REMEEX medical device</outcome_measure>
      <outcome_measure>General improvement of symptoms</outcome_measure>
      <outcome_measure>Improvement of urinary symptoms</outcome_measure>
      <outcome_measure>Side effects or complications</outcome_measure>
      <outcome_measure>Reliability and ease of use of the device</outcome_measure>
      <outcome_measure>Patient incontinence-related quality of life</outcome_measure>
      <outcome_measure>Patient sexual-related quality of life</outcome_measure>
      <outcome_measure>Satisfaction of use by the surgeon.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nīmes</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>LOCAL/2016/LW-01</other_id>
    </other_ids>
    <start_date>November 16, 2016</start_date>
    <primary_completion_date>November 2023</primary_completion_date>
    <completion_date>November 2023</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>CHU de Besançon, Besançon, France</location>
      <location>APHP Hôpital Henry Mondor, Créteil, France</location>
      <location>CHU de Dijon, Dijon, France</location>
      <location>CHU de Limoges, Limoges, France</location>
      <location>CHU Nancy, Nancy, France</location>
      <location>CHU Nice, Nice, France</location>
      <location>CHU Nimes, Nîmes, France</location>
      <location>CHU Strasbourg, Strasbourg, France</location>
      <location>Hôpital Foch, Suresnes, France</location>
      <location>CHU Toulouse, Toulouse, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650244</url>
  </study>
  <study rank="45086">
    <nct_id>NCT03650231</nct_id>
    <title>Comparison of Technics for Determination of Epstein-Barr Virus Serological Diagnosis</title>
    <acronym>DIAGEPS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>EBV</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Serological giagnosis</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Capacity of the three assays to detect VCA IgM</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire, Amiens</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>3 Years</min_age>
    <max_age>82 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>91</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PI2017_843_0042</other_id>
    </other_ids>
    <start_date>January 1, 2015</start_date>
    <primary_completion_date>October 29, 2017</primary_completion_date>
    <completion_date>October 29, 2017</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650231</url>
  </study>
  <study rank="45087">
    <nct_id>NCT03650218</nct_id>
    <title>Safety and Effectiveness of THIODERM STRONG in the Correction of Nasolabial Folds</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Correction of Nasolabial Folds</condition>
    </conditions>
    <interventions>
      <intervention type="Device">THIODERM STRONG</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cohort 1: Frequency, severity, seriousness and causal relationship of AEs</outcome_measure>
      <outcome_measure>Cohort 1: Local tolerability assessment based on presence and intensity of erythema, swelling and skin hardening</outcome_measure>
      <outcome_measure>Cohort 2: Improvement of at least 1 point on the Nasolabial Folds Severity Rating Scale (NLF-SRS) based on investigator's live assessment</outcome_measure>
      <outcome_measure>Cohort 2: Response rate based on investigator's assessment of Nasolabial Folds Severity Rating Scale (NLF-SRS)</outcome_measure>
      <outcome_measure>Cohort 2: Gloabl aesthetic improvement scale (GAIS) determined by the investigator</outcome_measure>
      <outcome_measure>Cohort 2: Gloabl aesthetic improvement scale (GAIS) determined by the subject</outcome_measure>
      <outcome_measure>Cohort 2: Subject satisfaction based on Face-Q questionnaire &quot;Satisfaction with Outcome&quot; Scale</outcome_measure>
      <outcome_measure>Cohort 2: Response rate based on blinded photographic reviewer's assessment of Nasolabial Folds Severity Rating Scale (NLF-SRS)</outcome_measure>
      <outcome_measure>Cohort 2: Mean pain intensity score using the Numeric Pain Rating Scale (NPRS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Croma-Pharma GmbH</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>85</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>CPH-201-201334</other_id>
    </other_ids>
    <start_date>July 10, 2018</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>March 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Medizinsche Universität Graz-Klinikum für Dermatologie und Venerologie, Graz, Austria</location>
      <location>Yuvell, Vienna, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650218</url>
  </study>
  <study rank="45088">
    <nct_id>NCT03650205</nct_id>
    <title>Ivabradine to Prevent Anthracycline-induced Cardiotoxicity</title>
    <acronym>IPAC</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Neoplasms</condition>
      <condition>Heart Failure</condition>
      <condition>Cardiotoxicity</condition>
      <condition>Chemotherapy Effect</condition>
      <condition>Oncology</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ivabradine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Ventricular function</outcome_measure>
      <outcome_measure>Composite endpoint of mortality or major cardiovascular outcomes</outcome_measure>
      <outcome_measure>Left ventricular dysfunction</outcome_measure>
      <outcome_measure>Incidence of myocardial injury</outcome_measure>
      <outcome_measure>Diastolic dysfunction</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Sao Paulo</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>42559415520020065</other_id>
    </other_ids>
    <start_date>January 22, 2019</start_date>
    <primary_completion_date>October 1, 2021</primary_completion_date>
    <completion_date>December 1, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>April 2, 2019</last_update_posted>
    <locations>
      <location>Instituto do Cancer do Estado de Sao Paulo, Sao Paulo, SP, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650205</url>
  </study>
  <study rank="45089">
    <nct_id>NCT03650192</nct_id>
    <title>[Trial of device that is not approved or cleared by the U.S. FDA]</title>
    <acronym/>
    <status open="N">Withheld</status>
    <study_results>No Results Available</study_results>
    <conditions/>
    <interventions/>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>[Redacted]</lead_sponsor>
    </sponsors>
    <age_groups/>
    <phases/>
    <funded_bys/>
    <exp_acc_types/>
    <study_designs/>
    <other_ids>
      <other_id>TP-19415</other_id>
    </other_ids>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 4, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650192</url>
  </study>
  <study rank="45090">
    <nct_id>NCT03650179</nct_id>
    <title>Influence of the Urine Stream Interruption Exercise on the Micturition</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Voiding Function</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Observational study : No intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>post-void residual volume</outcome_measure>
      <outcome_measure>maximal flow rate</outcome_measure>
      <outcome_measure>time to reach the maximal flow rate</outcome_measure>
      <outcome_measure>voiding time</outcome_measure>
      <outcome_measure>the slope of the uroflowmetry (corresponding to the flow velocity acceleration)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pierre and Marie Curie University</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P GREEN GRC 01</other_id>
    </other_ids>
    <start_date>August 23, 2018</start_date>
    <primary_completion_date>September 30, 2018</primary_completion_date>
    <completion_date>September 30, 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>September 25, 2019</last_update_posted>
    <locations>
      <location>Department of Neuro-urology, Tenon hospital, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650179</url>
  </study>
  <study rank="45091">
    <nct_id>NCT03650166</nct_id>
    <title>High BP and Home Monitoring Experience (HoME) Study</title>
    <acronym>HoME</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>High Blood Pressure</condition>
    </conditions>
    <interventions>
      <intervention type="Other">MyBP</intervention>
      <intervention type="Other">Personal BP monitor</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in systolic BP from baseline to trial completion</outcome_measure>
      <outcome_measure>Change in participants' hypertension self-efficacy (confidence in ability to fully understand and manage his or her high BP)</outcome_measure>
      <outcome_measure>Change in systolic BP from baseline to trial mid-point</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pittsburgh</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>62</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <other_ids>
      <other_id>PRO18050328</other_id>
    </other_ids>
    <start_date>September 21, 2018</start_date>
    <primary_completion_date>August 2, 2019</primary_completion_date>
    <completion_date>August 30, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 25, 2019</last_update_posted>
    <locations>
      <location>University of Pittsburgh, Pittsburgh, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650166</url>
  </study>
  <study rank="45092">
    <nct_id>NCT03650153</nct_id>
    <title>Randomized Controlled Trial of MRI Target Biopsy: Transrectal vs. Transperineal</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Prostate Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Trans-rectal MRI targeted Biopsy</intervention>
      <intervention type="Procedure">Trans-perineal MRI targeted Biopsy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>the rate of positive detections</outcome_measure>
      <outcome_measure>the incidence rate of each complication</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Princess Al-Johara Al-Ibrahim Cancer Research Center</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>118</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>Danny Rabah Study 2018</other_id>
    </other_ids>
    <start_date>January 1, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 29, 2019</last_update_posted>
    <locations>
      <location>King Khalid University Hospital, Riyadh, Saudi Arabia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650153</url>
  </study>
  <study rank="45093">
    <nct_id>NCT03650140</nct_id>
    <title>Pharmacokinetics and Pharmacodynamics of Anthocyanins</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gout</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Tart cherry extract 60 mL</intervention>
      <intervention type="Dietary Supplement">Tart cherry extract 120 mL</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Highly sensitive C-reactive protein (hs-CRP)</outcome_measure>
      <outcome_measure>Area under the curve (AUC)</outcome_measure>
      <outcome_measure>Change in inflammatory marker expression</outcome_measure>
      <outcome_measure>Peak plasma concentration (Cmax)</outcome_measure>
      <outcome_measure>Time to peak plasma concentration (Tmax)</outcome_measure>
      <outcome_measure>Half-life (t1/2)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rutgers, The State University of New Jersey</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>Pro20170001180</other_id>
    </other_ids>
    <start_date>February 1, 2019</start_date>
    <primary_completion_date>September 1, 2020</primary_completion_date>
    <completion_date>October 1, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 9, 2019</last_update_posted>
    <locations>
      <location>Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650140</url>
  </study>
  <study rank="45094">
    <nct_id>NCT03650127</nct_id>
    <title>Returning Genome and Metabolome Data to FinTerveys 2017 Participants: P5.fi FinTerveys Study</title>
    <acronym>P5</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Heart Disease</condition>
      <condition>Type 2 Diabetes</condition>
      <condition>Deep Vein Thrombosis</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Coronary heart disease/Type 2 diabetes/Venous thromboembolism diagnosis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Markus Perola</lead_sponsor>
      <collaborator>Helsinki University</collaborator>
      <collaborator>Institute for Molecular Medicine</collaborator>
      <collaborator>National Institute for Health and Welfare, Finland</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>3300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>1474/6.00.00/2018</other_id>
    </other_ids>
    <start_date>February 2, 2018</start_date>
    <primary_completion_date>December 31, 2027</primary_completion_date>
    <completion_date>December 31, 2027</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>National Institute of Health and Welfare, Helsinki, Uusimaa, Finland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650127</url>
  </study>
  <study rank="45095">
    <nct_id>NCT03650114</nct_id>
    <title>Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Relapsing Multiple Sclerosis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Ofatumumab</intervention>
      <intervention type="Biological">Tetanus toxoid (TT) containing vaccine (Td, Tdap)</intervention>
      <intervention type="Biological">13-valent pneumococcal conjugate vaccine (13-PCV)</intervention>
      <intervention type="Biological">23-valent pneumococcal polysaccharide vaccine (23-PPV)</intervention>
      <intervention type="Biological">Seasonal Quadrivalent influenza vaccine</intervention>
      <intervention type="Biological">Keyhole limpet hemocyanin (KLH) neo-antigen</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients that experience an adverse event or abnormal laboratory, vital and/or ECG results and positive suicidiality outcomes</outcome_measure>
      <outcome_measure>Number of relapse rates per year</outcome_measure>
      <outcome_measure>Patients with confirmed 3 and 6 month disability worsening</outcome_measure>
      <outcome_measure>Patients with confirmed 6, 12 and 24 month disability improvement and improvement until end of study</outcome_measure>
      <outcome_measure>Patients with changes in Expanded Disability Status Scale (EDSS) scores</outcome_measure>
      <outcome_measure>Changes in and time to 6 month confirmed worsening of Symbol Digit Modalities Test Scores</outcome_measure>
      <outcome_measure>Changes in the Magnetic Resonance Image (MRI) related to brain volume loss</outcome_measure>
      <outcome_measure>Changes in the Magnetic Resonance Image (MRI) related to T2 lesions</outcome_measure>
      <outcome_measure>Changes in the Magnetic Resonance Image (MRI) related to Gd-enhancing lesions</outcome_measure>
      <outcome_measure>Changes in neurofilament light change serum concentration</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2010</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>COMB157G2399</other_id>
    </other_ids>
    <start_date>December 28, 2018</start_date>
    <primary_completion_date>June 4, 2025</primary_completion_date>
    <completion_date>June 4, 2025</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 1, 2019</last_update_posted>
    <locations>
      <location>Novartis Investigative Site, Birmingham, Alabama, United States</location>
      <location>Novartis Investigative Site, Cullman, Alabama, United States</location>
      <location>Novartis Investigative Site, Phoenix, Arizona, United States</location>
      <location>Novartis Investigative Site, Fullerton, California, United States</location>
      <location>Novartis Investigative Site, Sacramento, California, United States</location>
      <location>Novartis Investigative Site, Aurora, Colorado, United States</location>
      <location>Novartis Investigative Site, Basalt, Colorado, United States</location>
      <location>Novartis Investigative Site, Boulder, Colorado, United States</location>
      <location>Novartis Investigative Site, Colorado Springs, Colorado, United States</location>
      <location>Novartis Investigative Site, Denver, Colorado, United States</location>
      <location>Novartis Investigative Site, Fort Collins, Colorado, United States</location>
      <location>Novartis Investigative Site, Fort Collins, Colorado, United States</location>
      <location>Novartis Investigative Site, Newark, Delaware, United States</location>
      <location>Novartis Investigative Site, Washington, District of Columbia, United States</location>
      <location>Novartis Investigative Site, Atlantis, Florida, United States</location>
      <location>Novartis Investigative Site, Bradenton, Florida, United States</location>
      <location>Novartis Investigative Site, Delray Beach, Florida, United States</location>
      <location>Novartis Investigative Site, Maitland, Florida, United States</location>
      <location>Novartis Investigative Site, Miami, Florida, United States</location>
      <location>Novartis Investigative Site, Miami, Florida, United States</location>
      <location>Novartis Investigative Site, Naples, Florida, United States</location>
      <location>Novartis Investigative Site, Oldsmar, Florida, United States</location>
      <location>Novartis Investigative Site, Ormond Beach, Florida, United States</location>
      <location>Novartis Investigative Site, Pensacola, Florida, United States</location>
      <location>Novartis Investigative Site, Pompano Beach, Florida, United States</location>
      <location>Novartis Investigative Site, Port Charlotte, Florida, United States</location>
      <location>Novartis Investigative Site, Sarasota, Florida, United States</location>
      <location>Novartis Investigative Site, Tallahassee, Florida, United States</location>
      <location>Novartis Investigative Site, Tampa, Florida, United States</location>
      <location>Novartis Investigative Site, Tampa, Florida, United States</location>
      <location>Novartis Investigative Site, Tampa, Florida, United States</location>
      <location>Novartis Investigative Site, West Palm Beach, Florida, United States</location>
      <location>Novartis Investigative Site, Savannah, Georgia, United States</location>
      <location>Novartis Investigative Site, Suwanee, Georgia, United States</location>
      <location>Novartis Investigative Site, Honolulu, Hawaii, United States</location>
      <location>Novartis Investigative Site, Northbrook, Illinois, United States</location>
      <location>Novartis Investigative Site, Indianapolis, Indiana, United States</location>
      <location>Novartis Investigative Site, Des Moines, Iowa, United States</location>
      <location>Novartis Investigative Site, Kansas City, Kansas, United States</location>
      <location>Novartis Investigative Site, Overland Park, Kansas, United States</location>
      <location>Novartis Investigative Site, Alexandria, Louisiana, United States</location>
      <location>Novartis Investigative Site, Baton Rouge, Louisiana, United States</location>
      <location>Novartis Investigative Site, Wellesley, Massachusetts, United States</location>
      <location>Novartis Investigative Site, Detroit, Michigan, United States</location>
      <location>Novartis Investigative Site, Detroit, Michigan, United States</location>
      <location>Novartis Investigative Site, Golden Valley, Minnesota, United States</location>
      <location>Novartis Investigative Site, Chesterfield, Missouri, United States</location>
      <location>Novartis Investigative Site, Ozark, Missouri, United States</location>
      <location>Novartis Investigative Site, Saint Louis, Missouri, United States</location>
      <location>Novartis Investigative Site, Billings, Montana, United States</location>
      <location>Novartis Investigative Site, Great Falls, Montana, United States</location>
      <location>Novartis Investigative Site, Las Vegas, Nevada, United States</location>
      <location>Novartis Investigative Site, Albuquerque, New Mexico, United States</location>
      <location>Novartis Investigative Site, Latham, New York, United States</location>
      <location>Novartis Investigative Site, Asheville, North Carolina, United States</location>
      <location>Novartis Investigative Site, Charlotte, North Carolina, United States</location>
      <location>Novartis Investigative Site, Greensboro, North Carolina, United States</location>
      <location>Novartis Investigative Site, Raleigh, North Carolina, United States</location>
      <location>Novartis Investigative Site, Winston-Salem, North Carolina, United States</location>
      <location>Novartis Investigative Site, Akron, Ohio, United States</location>
      <location>Novartis Investigative Site, Cleveland, Ohio, United States</location>
      <location>Novartis Investigative Site, Columbus, Ohio, United States</location>
      <location>Novartis Investigative Site, Westerville, Ohio, United States</location>
      <location>Novartis Investigative Site, Oklahoma City, Oklahoma, United States</location>
      <location>Novartis Investigative Site, Portland, Oregon, United States</location>
      <location>Novartis Investigative Site, Willow Grove, Pennsylvania, United States</location>
      <location>Novartis Investigative Site, Greer, South Carolina, United States</location>
      <location>Novartis Investigative Site, Spartanburg, South Carolina, United States</location>
      <location>Novartis Investigative Site, Cordova, Tennessee, United States</location>
      <location>Novartis Investigative Site, Johnson City, Tennessee, United States</location>
      <location>Novartis Investigative Site, Knoxville, Tennessee, United States</location>
      <location>Novartis Investigative Site, Knoxville, Tennessee, United States</location>
      <location>Novartis Investigative Site, El Paso, Texas, United States</location>
      <location>Novartis Investigative Site, Houston, Texas, United States</location>
      <location>Novartis Investigative Site, Lubbock, Texas, United States</location>
      <location>Novartis Investigative Site, Round Rock, Texas, United States</location>
      <location>Novartis Investigative Site, San Antonio, Texas, United States</location>
      <location>Novartis Investigative Site, Sherman, Texas, United States</location>
      <location>Novartis Investigative Site, Salt Lake City, Utah, United States</location>
      <location>Novartis Investigative Site, Salt Lake City, Utah, United States</location>
      <location>Novartis Investigative Site, Virginia Beach, Virginia, United States</location>
      <location>Novartis Investigative Site, Kirkland, Washington, United States</location>
      <location>Novartis Investigative Site, Tacoma, Washington, United States</location>
      <location>Novartis Investigative Site, Green Bay, Wisconsin, United States</location>
      <location>Novartis Investigative Site, Madison, Wisconsin, United States</location>
      <location>Novartis Investigative Site, Milwaukee, Wisconsin, United States</location>
      <location>Novartis Investigative Site, Rosario, Santa Fe, Argentina</location>
      <location>Novartis Investigative Site, Rosario, Santa Fe, Argentina</location>
      <location>Novartis Investigative Site, Buenos Aires, Argentina</location>
      <location>Novartis Investigative Site, Cordoba, Argentina</location>
      <location>Novartis Investigative Site, Tucuman, Argentina</location>
      <location>Novartis Investigative Site, Liverpool, New South Wales, Australia</location>
      <location>Novartis Investigative Site, New Lambton Heights, New South Wales, Australia</location>
      <location>Novartis Investigative Site, St Leonards, New South Wales, Australia</location>
      <location>Novartis Investigative Site, Vienna, Austria</location>
      <location>Novartis Investigative Site, Vienna, Austria</location>
      <location>Novartis Investigative Site, Edegem, Antwerpen, Belgium</location>
      <location>Novartis Investigative Site, Brasschaat, Belgium</location>
      <location>Novartis Investigative Site, Brugge, Belgium</location>
      <location>Novartis Investigative Site, Bruxelles, Belgium</location>
      <location>Novartis Investigative Site, Gent, Belgium</location>
      <location>Novartis Investigative Site, Sofia, Bulgaria</location>
      <location>Novartis Investigative Site, Sofia, Bulgaria</location>
      <location>Novartis Investigative Site, Sofia, Bulgaria</location>
      <location>Novartis Investigative Site, Sofia, Bulgaria</location>
      <location>Novartis Investigative Site, London, Ontario, Canada</location>
      <location>Novartis Investigative Site, Ottawa, Ontario, Canada</location>
      <location>Novartis Investigative Site, Toronto, Ontario, Canada</location>
      <location>Novartis Investigative Site, Gatineau, Quebec, Canada</location>
      <location>Novartis Investigative Site, Greenfield Park, Quebec, Canada</location>
      <location>Novartis Investigative Site, Montreal, Quebec, Canada</location>
      <location>Novartis Investigative Site, Quebec, Canada</location>
      <location>Novartis Investigative Site, Osijek, Croatia</location>
      <location>Novartis Investigative Site, Zagreb, Croatia</location>
      <location>Novartis Investigative Site, Brno, Czech Republic, Czechia</location>
      <location>Novartis Investigative Site, Havirov, Czech Republic, Czechia</location>
      <location>Novartis Investigative Site, Teplice, Czech Republic, Czechia</location>
      <location>Novartis Investigative Site, Hradec Kralove, CZE, Czechia</location>
      <location>Novartis Investigative Site, JIhlava, Czechia</location>
      <location>Novartis Investigative Site, Ostrava-Poruba, Czechia</location>
      <location>Novartis Investigative Site, Pardubice, Czechia</location>
      <location>Novartis Investigative Site, Praha 10, Czechia</location>
      <location>Novartis Investigative Site, Praha 4, Czechia</location>
      <location>Novartis Investigative Site, Praha 5, Czechia</location>
      <location>Novartis Investigative Site, Copenhagen, Denmark</location>
      <location>Novartis Investigative Site, Odense C, Denmark</location>
      <location>Novartis Investigative Site, Tallinn, Estonia</location>
      <location>Novartis Investigative Site, Tartu, Estonia</location>
      <location>Novartis Investigative Site, Tampere, Finland</location>
      <location>Novartis Investigative Site, Turku, Finland</location>
      <location>Novartis Investigative Site, Nice, Cedex1, France</location>
      <location>Novartis Investigative Site, Lille Cedex, France</location>
      <location>Novartis Investigative Site, Montpellier, France</location>
      <location>Novartis Investigative Site, Nantes Cedex 1, France</location>
      <location>Novartis Investigative Site, Nimes Cedex, France</location>
      <location>Novartis Investigative Site, Paris Cedex 13, France</location>
      <location>Novartis Investigative Site, Strasbourg, France</location>
      <location>Novartis Investigative Site, Barsinghausen, Germany</location>
      <location>Novartis Investigative Site, Bayreuth, Germany</location>
      <location>Novartis Investigative Site, Bielefeld, Germany</location>
      <location>Novartis Investigative Site, Bochum, Germany</location>
      <location>Novartis Investigative Site, Dresden, Germany</location>
      <location>Novartis Investigative Site, Essen, Germany</location>
      <location>Novartis Investigative Site, Hamburg, Germany</location>
      <location>Novartis Investigative Site, Hannover, Germany</location>
      <location>Novartis Investigative Site, Heidelberg, Germany</location>
      <location>Novartis Investigative Site, Koln, Germany</location>
      <location>Novartis Investigative Site, Leipzig, Germany</location>
      <location>Novartis Investigative Site, Marburg, Germany</location>
      <location>Novartis Investigative Site, Minden, Germany</location>
      <location>Novartis Investigative Site, Muenchen, Germany</location>
      <location>Novartis Investigative Site, Muenchen, Germany</location>
      <location>Novartis Investigative Site, Neuburg an der Donau, Germany</location>
      <location>Novartis Investigative Site, Potsdam, Germany</location>
      <location>Novartis Investigative Site, Siegen, Germany</location>
      <location>Novartis Investigative Site, Ulm, Germany</location>
      <location>Novartis Investigative Site, Unterhaching, Germany</location>
      <location>Novartis Investigative Site, Athens, GR, Greece</location>
      <location>Novartis Investigative Site, Thessaloniki, Greece</location>
      <location>Novartis Investigative Site, Budapest, HUN, Hungary</location>
      <location>Novartis Investigative Site, Budapest, HUN, Hungary</location>
      <location>Novartis Investigative Site, Esztergom, HUN, Hungary</location>
      <location>Novartis Investigative Site, Budapest, Hungary</location>
      <location>Novartis Investigative Site, Kistarcsa, Hungary</location>
      <location>Novartis Investigative Site, Szeged, Hungary</location>
      <location>Novartis Investigative Site, Pune, Maharashtra, India</location>
      <location>Novartis Investigative Site, Mangalore, India</location>
      <location>Novartis Investigative Site, Ashkelon, Israel</location>
      <location>Novartis Investigative Site, Haifa, Israel</location>
      <location>Novartis Investigative Site, Sefad, Israel</location>
      <location>Novartis Investigative Site, Tel Aviv, Israel</location>
      <location>Novartis Investigative Site, Sendai city, Miyagi, Japan</location>
      <location>Novartis Investigative Site, Sendai city, Miyagi, Japan</location>
      <location>Novartis Investigative Site, Kawagoe, Saitama, Japan</location>
      <location>Novartis Investigative Site, Shinjuku-ku, Tokyo, Japan</location>
      <location>Novartis Investigative Site, Chiba, Japan</location>
      <location>Novartis Investigative Site, Niigata, Japan</location>
      <location>Novartis Investigative Site, Osaka, Japan</location>
      <location>Novartis Investigative Site, Riga, LV, Latvia</location>
      <location>Novartis Investigative Site, Riga, Latvia</location>
      <location>Novartis Investigative Site, Riga, Latvia</location>
      <location>Novartis Investigative Site, Kaunas, LTU, Lithuania</location>
      <location>Novartis Investigative Site, Vilnius, Lithuania</location>
      <location>Novartis Investigative Site, Amsterdam, Netherlands</location>
      <location>Novartis Investigative Site, Rotterdam, Netherlands</location>
      <location>Novartis Investigative Site, Sittard-Geleen, Netherlands</location>
      <location>Novartis Investigative Site, Drammen, Norway</location>
      <location>Novartis Investigative Site, Cercado De Lima, Lima, Peru</location>
      <location>Novartis Investigative Site, San Isidro, Lima, Peru</location>
      <location>Novartis Investigative Site, Lima, Peru</location>
      <location>Novartis Investigative Site, Bydgoszcz, Poland</location>
      <location>Novartis Investigative Site, Gdansk, Poland</location>
      <location>Novartis Investigative Site, Gdansk, Poland</location>
      <location>Novartis Investigative Site, Gdansk, Poland</location>
      <location>Novartis Investigative Site, Glogow, Poland</location>
      <location>Novartis Investigative Site, Katowice, Poland</location>
      <location>Novartis Investigative Site, Kielce, Poland</location>
      <location>Novartis Investigative Site, Lodz, Poland</location>
      <location>Novartis Investigative Site, Rzeszow, Poland</location>
      <location>Novartis Investigative Site, Warszawa, Poland</location>
      <location>Novartis Investigative Site, Wroclaw, Poland</location>
      <location>Novartis Investigative Site, Zabrze, Poland</location>
      <location>Novartis Investigative Site, Matosinhos, Porto, Portugal</location>
      <location>Novartis Investigative Site, Braga, Portugal</location>
      <location>Novartis Investigative Site, Coimbra, Portugal</location>
      <location>Novartis Investigative Site, Lisboa, Portugal</location>
      <location>Novartis Investigative Site, Loures, Portugal</location>
      <location>Novartis Investigative Site, Porto, Portugal</location>
      <location>Novartis Investigative Site, Santa Maria da Feira, Portugal</location>
      <location>Novartis Investigative Site, Ekaterinburg, Russian Federation</location>
      <location>Novartis Investigative Site, Kazan, Russian Federation</location>
      <location>Novartis Investigative Site, Kemerovo, Russian Federation</location>
      <location>Novartis Investigative Site, Krasnoyarsk, Russian Federation</location>
      <location>Novartis Investigative Site, Moscow, Russian Federation</location>
      <location>Novartis Investigative Site, Nizhny Novgorod, Russian Federation</location>
      <location>Novartis Investigative Site, Nizhny Novgorod, Russian Federation</location>
      <location>Novartis Investigative Site, Novosibirsk, Russian Federation</location>
      <location>Novartis Investigative Site, Novosibirsk, Russian Federation</location>
      <location>Novartis Investigative Site, Saint Petersburg, Russian Federation</location>
      <location>Novartis Investigative Site, Saint-Petersburg, Russian Federation</location>
      <location>Novartis Investigative Site, Saransk, Russian Federation</location>
      <location>Novartis Investigative Site, Sestroretsk, Russian Federation</location>
      <location>Novartis Investigative Site, St Petersburg, Russian Federation</location>
      <location>Novartis Investigative Site, St. Petersburg, Russian Federation</location>
      <location>Novartis Investigative Site, Tyumen, Russian Federation</location>
      <location>Novartis Investigative Site, Banska Bystrica, Slovakia</location>
      <location>Novartis Investigative Site, Bratislava, Slovakia</location>
      <location>Novartis Investigative Site, Bratislava, Slovakia</location>
      <location>Novartis Investigative Site, Bratislava, Slovakia</location>
      <location>Novartis Investigative Site, Martin, Slovakia</location>
      <location>Novartis Investigative Site, Nitra, Slovakia</location>
      <location>Novartis Investigative Site, Trnava, Slovakia</location>
      <location>Novartis Investigative Site, Pretoria, South Africa</location>
      <location>Novartis Investigative Site, Rosebank, South Africa</location>
      <location>Novartis Investigative Site, Cadiz, Andalucia, Spain</location>
      <location>Novartis Investigative Site, Malaga, Andalucia, Spain</location>
      <location>Novartis Investigative Site, Sevilla, Andalucia, Spain</location>
      <location>Novartis Investigative Site, Barcelona, Cataluna, Spain</location>
      <location>Novartis Investigative Site, Barcelona, Cataluna, Spain</location>
      <location>Novartis Investigative Site, Barcelona, Catalunya, Spain</location>
      <location>Novartis Investigative Site, Barcelona, Catalunya, Spain</location>
      <location>Novartis Investigative Site, L Hospitalet De Llobregat, Catalunya, Spain</location>
      <location>Novartis Investigative Site, Salt, Cataluña, Spain</location>
      <location>Novartis Investigative Site, Pozuelo de Alarcon, Madrid, Spain</location>
      <location>Novartis Investigative Site, El Palmar, Murcia, Spain</location>
      <location>Novartis Investigative Site, San Sebastian, Pais Vasco, Spain</location>
      <location>Novartis Investigative Site, Castilleja de la cuesta, Sevilla, Spain</location>
      <location>Novartis Investigative Site, Baracaldo, Vizcaya, Spain</location>
      <location>Novartis Investigative Site, Madrid, Spain</location>
      <location>Novartis Investigative Site, Madrid, Spain</location>
      <location>Novartis Investigative Site, Madrid, Spain</location>
      <location>Novartis Investigative Site, Madrid, Spain</location>
      <location>Novartis Investigative Site, Valencia, Spain</location>
      <location>Novartis Investigative Site, Goeteborg, Sweden</location>
      <location>Novartis Investigative Site, Stockholm, Sweden</location>
      <location>Novartis Investigative Site, Basel, Switzerland</location>
      <location>Novartis Investigative Site, Lugano, Switzerland</location>
      <location>Novartis Investigative Site, Tainan, Taiwan</location>
      <location>Novartis Investigative Site, Khon Kaen, THA, Thailand</location>
      <location>Novartis Investigative Site, Haseki / Istanbul, Turkey</location>
      <location>Novartis Investigative Site, Istanbul, Turkey</location>
      <location>Novartis Investigative Site, Izmir, Turkey</location>
      <location>Novartis Investigative Site, Izmir, Turkey</location>
      <location>Novartis Investigative Site, Kocaeli, Turkey</location>
      <location>Novartis Investigative Site, Mersin, Turkey</location>
      <location>Novartis Investigative Site, Samsun, Turkey</location>
      <location>Novartis Investigative Site, Trabzon, Turkey</location>
      <location>Novartis Investigative Site, Luton, Beds, United Kingdom</location>
      <location>Novartis Investigative Site, Headington, Oxfordshire, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650114</url>
  </study>
  <study rank="45096">
    <nct_id>NCT03650101</nct_id>
    <title>Improving Infant Hydrocephalus Outcomes in Uganda</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hydrocephalus</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">ETV/CPC</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Bayley Scales of Infant Development, Third Edition (BSID-3), cognitive scaled score</outcome_measure>
      <outcome_measure>Incidence of ETV/CPC treatment failure</outcome_measure>
      <outcome_measure>Cerebral oxygen metabolism</outcome_measure>
      <outcome_measure>brain volume</outcome_measure>
      <outcome_measure>Bayley Scales of Infant Development, Third Edition (BSID-3), cognitive scaled score at 12 months post-treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Boston Children’s Hospital</lead_sponsor>
      <collaborator>Penn State University</collaborator>
      <collaborator>The Hospital for Sick Children</collaborator>
      <collaborator>CURE Children's Hospital, Uganda</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>180 Days</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P00029806</other_id>
    </other_ids>
    <start_date>March 2020</start_date>
    <primary_completion_date>September 2023</primary_completion_date>
    <completion_date>September 2023</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>December 3, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650101</url>
  </study>
  <study rank="45097">
    <nct_id>NCT03650088</nct_id>
    <title>Adaptation of a Digital Weight Loss Intervention Promoting Self-regulation for Use in Type 2 Diabetes</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes Mellitus, Type 2</condition>
      <condition>Overweight and Obesity</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Behavioral weight loss with digital tools</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in weight from Baseline to Month 3</outcome_measure>
      <outcome_measure>Change in Body Mass Index from Baseline to Month 3</outcome_measure>
      <outcome_measure>Change in HbA1c from Baseline to Month 3</outcome_measure>
      <outcome_measure>Change in compliance behavior and efforts at diabetes self-control</outcome_measure>
      <outcome_measure>Change in Diabetes-related Quality of Life: The Diabetes Obstacles Questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of North Carolina, Chapel Hill</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>18-1078</other_id>
    </other_ids>
    <start_date>October 20, 2019</start_date>
    <primary_completion_date>January 2020</primary_completion_date>
    <completion_date>March 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>November 1, 2019</last_update_posted>
    <locations>
      <location>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650088</url>
  </study>
  <study rank="45098">
    <nct_id>NCT03650075</nct_id>
    <title>To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Idiopathic Pulmonary Fibrosis (IPF)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MG-S-2525</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>maximum tolerated dose (MTD) (Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) parts)</outcome_measure>
      <outcome_measure>dose limiting toxicity (DLT) (Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) parts)</outcome_measure>
      <outcome_measure>total exposure by area under the curve (AUC) (Food Effect Part)</outcome_measure>
      <outcome_measure>peak concentration (Cmax) under fasting/fed condition (Food Effect Part)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Metagone Biotech Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MEOMGSA20180103</other_id>
    </other_ids>
    <start_date>February 25, 2019</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>June 25, 2019</last_update_posted>
    <locations>
      <location>Taipei Medical University Hospital, Taipei, Taiwan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650075</url>
  </study>
  <study rank="45099">
    <nct_id>NCT03650062</nct_id>
    <title>Patient-reported Outcome Scale in Acute Pancreatitis</title>
    <acronym>PAN-PROMISE</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Pancreatitis</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Severity of acute pancreatitis according to the revised Atlanta classification [incidence of local and/or systemic complications]</outcome_measure>
      <outcome_measure>PAN-PROMISE patient reported outcome measurement instrument</outcome_measure>
      <outcome_measure>EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30) Version 3.0</outcome_measure>
      <outcome_measure>C-reactive protein</outcome_measure>
      <outcome_measure>Local complications (incidence of pancreatic/peripancreatic necrosis and acute peripancreatic fluid collections)</outcome_measure>
      <outcome_measure>Need for invasive treatment</outcome_measure>
      <outcome_measure>Need for nutritional support</outcome_measure>
      <outcome_measure>Admission in the Intensive Care Unit</outcome_measure>
      <outcome_measure>Hospital stay</outcome_measure>
      <outcome_measure>Organ failure</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Hospital readmission</outcome_measure>
      <outcome_measure>Systemic Inflammatory Response Syndrome (SIRS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Enrique de-Madaria</lead_sponsor>
      <collaborator>Hospital General Universitario de Alicante</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>525</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PI2016/69</other_id>
    </other_ids>
    <start_date>May 30, 2017</start_date>
    <primary_completion_date>February 3, 2019</primary_completion_date>
    <completion_date>February 3, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>February 5, 2019</last_update_posted>
    <locations>
      <location>Johns Hopkins Medical Center, Baltimore, Maryland, United States</location>
      <location>Hospital Universitario San Ignacio, Bogotá, Colombia</location>
      <location>Attikon University Hospital, Athens, Greece</location>
      <location>Centre for Translational Medicine, University of Pécs, Pécs, Hungary</location>
      <location>University of Szeged, Szeged, Hungary</location>
      <location>Dip.Medicina-Università degli Studi di Verona, Verona, Italy</location>
      <location>Konkuk University School of Medicine, Seoul, Korea, Republic of</location>
      <location>Vilnius University, Vilnius, Lithuania</location>
      <location>Servicio de Cirugía General, IMSS, León, Guanajuato, Mexico</location>
      <location>Medical University of Łódź, Łódź, Poland</location>
      <location>Fernando Fonseca Hospital, Amadora, Portugal</location>
      <location>Centro Hospitalar Tondela-Viseu, Viseu, Portugal</location>
      <location>Emergency Hospital of Bucharest, Bucharest, Romania</location>
      <location>Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania</location>
      <location>Immanuel Kant Baltic Federal University, Kaliningrad, Russian Federation</location>
      <location>Hospital General Universitario de Alicante, Alicante, Spain</location>
      <location>Hospital Santa María, Lleida, Spain</location>
      <location>Hospital San Pedro, Logroño, Spain</location>
      <location>Hospital Central de Asturias, Oviedo, Spain</location>
      <location>Complejo Hospitalario de Navarra, Pamplona, Spain</location>
      <location>Complejo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain</location>
      <location>Hospital Clínico Universitario de Valladolid, Valladolid, Spain</location>
      <location>Hospital Alvaro Cunqueiro, Vigo, Spain</location>
      <location>Hospital Lozano Blesa, Zaragoza, Spain</location>
      <location>Hospital Miguel Servet, Zaragoza, Spain</location>
      <location>Medical Institute Lviv, Lviv, Ukraine</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650062</url>
  </study>
  <study rank="45100">
    <nct_id>NCT03650049</nct_id>
    <title>Food Protein-induced Enterocolitis Syndrome (FPIES) in 14 Children</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Allergy</condition>
      <condition>Pediatric Disorder</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>symptoms due to FPIES</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Central Hospital, Nancy, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>14</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>R2016-20</other_id>
    </other_ids>
    <start_date>November 2013</start_date>
    <primary_completion_date>June 2016</primary_completion_date>
    <completion_date>June 2016</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 31, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650049</url>
  </study>
  <study rank="45101">
    <nct_id>NCT03650036</nct_id>
    <title>Root Canal Treatment in Primary Molars With Necrotic Pulp Using Two Different Pulp Therapies</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dental Pulp Necrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pulp Therapy CTZ Paste</intervention>
      <intervention type="Drug">Pulp Therapy ZOE Paste</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Infection control of deciduous molars with necrotic pulp by clinical examination</outcome_measure>
      <outcome_measure>Infection control of deciduous molars with necrotic pulp by Radiographic examination</outcome_measure>
      <outcome_measure>1. The improvement in the Quality of life of children after pulp therapy using a questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Federal University of Piaui</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>3 Years</min_age>
    <max_age>9 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>86</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Ppgo2018</other_id>
    </other_ids>
    <start_date>June 4, 2018</start_date>
    <primary_completion_date>May 21, 2019</primary_completion_date>
    <completion_date>June 4, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>July 30, 2019</last_update_posted>
    <locations>
      <location>Federal University of Piaui, Teresina, Piaui, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650036</url>
  </study>
  <study rank="45102">
    <nct_id>NCT03650023</nct_id>
    <title>A Crossover Trial of Chitosan Oligosaccharide on Post Prandial Glucose Control in Subjects With Normal, IFG and IGT</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Normal</condition>
      <condition>Impaired Fasting Glucose</condition>
      <condition>Impaired Glucose Tolerance</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Chitosan Oligosaccharide (GO2KA1)</intervention>
      <intervention type="Dietary Supplement">White egg</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Glucose levels</outcome_measure>
      <outcome_measure>The areas under the curve (AUC) of glucose</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yonsei University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>74 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RCK_OFTT</other_id>
    </other_ids>
    <start_date>May 9, 2018</start_date>
    <primary_completion_date>July 25, 2018</primary_completion_date>
    <completion_date>July 25, 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Laboratory of Clinical Nutrigenetics/Nutrigenomics, Yonsei University., Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650023</url>
  </study>
  <study rank="45103">
    <nct_id>NCT03650010</nct_id>
    <title>Total Ankle Replacement: Clinical and Radiological Outcomes</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ankle Arthritis</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Total ankle replacement</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in American orthopaedic foot and ankle society (AOFAS) ankle-hindfoot score</outcome_measure>
      <outcome_measure>Changes in Short form 12 (SF 12)</outcome_measure>
      <outcome_measure>Anterior distal tibial angle</outcome_measure>
      <outcome_measure>Changes in beta angle</outcome_measure>
      <outcome_measure>Changes in alpha angle</outcome_measure>
      <outcome_measure>Medial distal tibial angle</outcome_measure>
      <outcome_measure>Changes in visual analogue scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istituto Ortopedico Galeazzi</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1066</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>Tarus</other_id>
    </other_ids>
    <start_date>May 11, 2016</start_date>
    <primary_completion_date>March 31, 2026</primary_completion_date>
    <completion_date>March 31, 2027</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Irccs Istituto Ortopedico Galeazzi, Milan, Milano, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03650010</url>
  </study>
  <study rank="45104">
    <nct_id>NCT03649997</nct_id>
    <title>A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">JNJ-61393215</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">JNJ-61393215</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Part 1: Maximum Observed Analyte Concentration (Cmax) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 1: Time to Reach Maximum Observed Analyte Concentration (Tmax) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 1: Area Under the Analyte Concentration-time Curve from Time Zero to the Time of Last Measurable Concentration (AUC[0-last]) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 1: Area Under the Analyte Concentration-time Curve from Time Zero to Infinity (AUC [0-infinity]) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 1: Apparent Terminal Elimination Rate Constant (lambda[z]) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 1: Apparent Elimination Half-Life (t1/2) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 1: Apparent Oral Clearance (CL/F) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 1: Apparent Volume of Distribution (Vdz/F) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 1: Number of Participants with Adverse Events as a Measure of Safety and Tolerability of JNJ 61393215 Suspension</outcome_measure>
      <outcome_measure>Part 2: Maximum Observed Analyte Concentration (Cmax) of JNJ-61393215 Capsule</outcome_measure>
      <outcome_measure>Part 2: Area Under the Analyte Concentration-time Curve from Time Zero to the Time of Last Measurable Concentration (AUC[0-last]) of JNJ-61393215 Capsule</outcome_measure>
      <outcome_measure>Part 2: Area Under the Analyte Concentration-time Curve from Time Zero to Infinity (AUC [0-infinity]) of JNJ-61393215 Capsule</outcome_measure>
      <outcome_measure>Part 3: Maximum Observed Analyte Concentration (Cmax) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 3: Time to Reach Maximum Observed Analyte Concentration (Tmax) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 3: Area Under the Analyte Concentration-time Curve from Time 0 to 24 Hours (AUC [0-24]) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 3: Maximum Trough Concentration (Ctrough) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 3: Minimum Observed Analyte Concentration (Cmin) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 3: Average Analyte Concentration (Cavg) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 3: Fluctuation Index (FI) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 3: Volume of Distribution at Steady-State (Vss) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 3: Apparent Oral Clearance (CL/F) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 3: Apparent Terminal Elimination Rate Constant (lambda[z]) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 3: Apparent Elimination Half-Life (t1/2) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 3: Peak by Trough Ratio of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 3: Observed Accumulation Index Based on AUC (AR AUC) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 3: Observed Accumulation Index Based on Cmax (ARCmax) of JNJ-61393215 Suspension</outcome_measure>
      <outcome_measure>Part 2: Number of Participants with Adverse Events as a Measure of Safety and Tolerability of JNJ 61393215</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Janssen Research &amp; Development, LLC</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>57</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR108492</other_id>
      <other_id>2018-001944-80</other_id>
      <other_id>61393215EDI1004</other_id>
    </other_ids>
    <start_date>August 28, 2018</start_date>
    <primary_completion_date>December 14, 2018</primary_completion_date>
    <completion_date>December 14, 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>January 24, 2019</last_update_posted>
    <locations>
      <location>PRA Health Sciences, Groningen, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649997</url>
  </study>
  <study rank="45105">
    <nct_id>NCT03649984</nct_id>
    <title>Implementation of the Symptom Navi© Program</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Symptom Navi© Program</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in patient-reported symptom interference with daily function</outcome_measure>
      <outcome_measure>Reach of intervention in terms of proportion of eligible vs. participating patients</outcome_measure>
      <outcome_measure>Change in patient-reported self-efficacy</outcome_measure>
      <outcome_measure>Change in patient-reported symptom severity</outcome_measure>
      <outcome_measure>Change in patient-reported quality of nursing care</outcome_measure>
      <outcome_measure>Incidence of Intervention-Emergent Adverse Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Manuela Eicher</lead_sponsor>
      <collaborator>University of Lausanne</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>Symptom Navi© Pilot Study</other_id>
    </other_ids>
    <start_date>October 17, 2017</start_date>
    <primary_completion_date>March 31, 2019</primary_completion_date>
    <completion_date>June 30, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 31, 2018</last_update_posted>
    <locations>
      <location>Kantonsspital Aarau, Aarau, Switzerland</location>
      <location>Gynäkologisches Tumorzentrum Universitätsspital Basel, Basel, Switzerland</location>
      <location>Oncocare, Klinik Engeried Bern, Bern, Switzerland</location>
      <location>Kantonsspital Graubünden, Chur, Switzerland</location>
      <location>Hôpital fribourgeois - Meyriez-Murten / Tagers, Murten, Switzerland</location>
      <location>Tumor- und Brustzentrum ZeTuP Rapperswil, Rapperswil, Switzerland</location>
      <location>Rundum Onkologie am Bahnhofpark Sargans, Sargans, Switzerland</location>
      <location>Solothurner Spitäler AG - Kantonsspital Olten / Bürgerspital Solothurn, Solothurn, Switzerland</location>
      <location>Spital STS AG - Thun, Thun, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649984</url>
  </study>
  <study rank="45106">
    <nct_id>NCT03649971</nct_id>
    <title>A Study of Guselkumab in Participants With Familial Adenomatous Polyposis</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Adenomatous Polyposis Coli</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Guselkumab</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage Change from Baseline in Rectal/pouch Polyp Burden at Week 24</outcome_measure>
      <outcome_measure>Percentage Change from Baseline in Number of Colorectal Polyps</outcome_measure>
      <outcome_measure>Percentage Change from Baseline in Number of J-pouch Polyps</outcome_measure>
      <outcome_measure>Percentage Change from Baseline in J-pouch Polyp Burden</outcome_measure>
      <outcome_measure>Percentage Change from Baseline in Number of Duodenal Polyps</outcome_measure>
      <outcome_measure>Percentage Change from Baseline in Duodenal Polyp Burden</outcome_measure>
      <outcome_measure>Change in International Society for Gastrointestinal Hereditary Tumors (InSiGHT) Stage</outcome_measure>
      <outcome_measure>Change in Spigelman Stage Score</outcome_measure>
      <outcome_measure>Trough Concentration of Guselkumab</outcome_measure>
      <outcome_measure>Number of Participants with Anti-guselkumab Antibodies</outcome_measure>
      <outcome_measure>Anti-guselkumab Antibodies Serum Titers</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events as a Measure of Safety</outcome_measure>
      <outcome_measure>Number of Participants with Vital Sign Abnormalities as a Measure of Safety and Tolerability</outcome_measure>
      <outcome_measure>Number of Participants with Clinical Laboratory Abnormalities as a Measure of Safety and Tolerability</outcome_measure>
      <outcome_measure>Relative Changes to Baseline in Levels of Interleukin (IL)-23 Effector Proteins in Biopsy Tissue</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Janssen Research &amp; Development, LLC</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CR108515</other_id>
      <other_id>CNTO1959COR1001</other_id>
      <other_id>2019-001980-57</other_id>
    </other_ids>
    <start_date>November 19, 2018</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>November 30, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>December 23, 2019</last_update_posted>
    <locations>
      <location>Mayo Clinic, Phoenix, Arizona, United States</location>
      <location>Yale University, New Haven, Connecticut, United States</location>
      <location>Mayo Clinic Jacksonville, Jacksonville, Florida, United States</location>
      <location>University of Miami, Miami, Florida, United States</location>
      <location>University of South Florida, Tampa, Florida, United States</location>
      <location>The University Of Chicago Medicine, Chicago, Illinois, United States</location>
      <location>Ochsner Medical Center, New Orleans, Louisiana, United States</location>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
      <location>Dana Farber Cancer Institute, Boston, Massachusetts, United States</location>
      <location>Washington University School of Medicine, Saint Louis, Missouri, United States</location>
      <location>Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York, United States</location>
      <location>Cleveland Clinic, Cleveland, Ohio, United States</location>
      <location>Wexner Medical Center at the Ohio State University, Columbus, Ohio, United States</location>
      <location>University of Pennsylvania - Perelman School of Medicine, Philadelphia, Pennsylvania, United States</location>
      <location>Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States</location>
      <location>University of Texas MD Anderson Cancer Center, Houston, Texas, United States</location>
      <location>University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, United States</location>
      <location>University of Washington, Seattle, Washington, United States</location>
      <location>Mount Sinai Hospital, Toronto, Canada</location>
      <location>Hopital Edouard Herriot - CHU Lyon, Lyon, France</location>
      <location>APHM Hopital Timone, Marseille, France</location>
      <location>Universitatsklinikum Bonn, Bonn, Germany</location>
      <location>Klinikum Herford, Herford, Germany</location>
      <location>Universitätsklinikum Ulm, Ulm, Germany</location>
      <location>Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam, Netherlands</location>
      <location>Leiden University Medical Center, Leiden, Netherlands</location>
      <location>Erasmus MC, Rotterdam, Netherlands</location>
      <location>Szpital Kliniczny im. Heliodora Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Po, Poznan, Poland</location>
      <location>Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie, Warszawa, Poland</location>
      <location>Pan American Center for Oncology Trials LLC, San Juan, Puerto Rico</location>
      <location>Nya Karolinska Solna, IBD mottagningen, Solna, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649971</url>
  </study>
  <study rank="45107">
    <nct_id>NCT03649958</nct_id>
    <title>Neurotechnology Following Traumatic Brain Injury</title>
    <acronym>Cereset</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Post-Concussion Symptoms</condition>
      <condition>Insomnia</condition>
      <condition>Pain, Chronic</condition>
      <condition>Depressive Symptoms</condition>
    </conditions>
    <interventions>
      <intervention type="Device">HIRREM-SOP</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Neurobehavioral Symptom Inventory (NSI)</outcome_measure>
      <outcome_measure>PATIENT'S GLOBAL IMPRESSION OF CHANGE (PGIC) SCALE</outcome_measure>
      <outcome_measure>PITTSBURGH SLEEP QUALITY INDEX</outcome_measure>
      <outcome_measure>HIT-6 Headache Impact Test</outcome_measure>
      <outcome_measure>The Dizziness Handicap Inventory ( DHI )</outcome_measure>
      <outcome_measure>PCL-5 The PTSD Checklist for DSM-5</outcome_measure>
      <outcome_measure>Patient Health Questionnaire-9 (PHQ-9)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Brain State Technologies, LLC</lead_sponsor>
      <collaborator>Uniformed Services University of the Health Sciences</collaborator>
      <collaborator>Womack Army Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>106</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MED-83-8754</other_id>
      <other_id>W81XWH1720057</other_id>
    </other_ids>
    <start_date>August 28, 2018</start_date>
    <primary_completion_date>March 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>January 18, 2020</last_update_posted>
    <locations>
      <location>Uniformed Services University, Bethesda, Maryland, United States</location>
      <location>Womack Army Medical Center, Fort Bragg, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649958</url>
  </study>
  <study rank="45108">
    <nct_id>NCT03649945</nct_id>
    <title>Endostatin Combined With Chemotherapy for Adjuvant Treatment of Esophageal Cancer</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Esophageal Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Docetaxel</intervention>
      <intervention type="Drug">Nedaplatin</intervention>
      <intervention type="Drug">Endostar</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>3 year disease-free survival rate</outcome_measure>
      <outcome_measure>overall survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>First Affiliated Hospital of Guangxi Medical University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>186</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HRGX06</other_id>
    </other_ids>
    <start_date>November 2018</start_date>
    <primary_completion_date>November 2020</primary_completion_date>
    <completion_date>May 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649945</url>
  </study>
  <study rank="45109">
    <nct_id>NCT03649932</nct_id>
    <title>Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Bronchopulmonary Dysplasia</condition>
      <condition>Bronchopulmonary Dysplasia Associated Pulmonary Hypertension</condition>
      <condition>Pulmonary Hypertension</condition>
      <condition>Premature Birth</condition>
      <condition>Chronic Lung Disease of Prematurity</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Enteral L-citrulline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in plasma levels of L-arginine and L-citrulline as measured by LCMS approach</outcome_measure>
      <outcome_measure>Safety of L-citrulline in preterm infants: Measured by at least one adverse event</outcome_measure>
      <outcome_measure>Dose of enteral L-citrulline required to increase plasma level of &gt; 37 micromol/L</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The University of Texas Medical Branch, Galveston</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>30 Weeks</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>17-0194</other_id>
    </other_ids>
    <start_date>September 25, 2018</start_date>
    <primary_completion_date>September 10, 2019</primary_completion_date>
    <completion_date>December 31, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 23, 2018</last_update_posted>
    <locations>
      <location>University of Texas Medical Branch, Galveston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649932</url>
  </study>
  <study rank="45110">
    <nct_id>NCT03649919</nct_id>
    <title>Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Xlsma</condition>
      <condition>DMD</condition>
      <condition>X-ALD</condition>
      <condition>TSC</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>spinal muscular atrophy, SMA</outcome_measure>
      <outcome_measure>DMD</outcome_measure>
      <outcome_measure>X-linked adrenoleukodystrophy X-ALD</outcome_measure>
      <outcome_measure>tuberous sclerosis complex，TSC</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Children's Hospital of Fudan University</lead_sponsor>
      <collaborator>Children's Hospital of Shanghai Jiaotong University</collaborator>
      <collaborator>Children's Medical Center of Shanghai Jiaotong University</collaborator>
      <collaborator>Xinhua Hospital of Shanghai Jiaotong University</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>EKYY-MCSDTMRNDC</other_id>
    </other_ids>
    <start_date>October 30, 2019</start_date>
    <primary_completion_date>October 30, 2021</primary_completion_date>
    <completion_date>December 30, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>February 15, 2019</last_update_posted>
    <locations>
      <location>Children's Hospital of Fudan University, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649919</url>
  </study>
  <study rank="45111">
    <nct_id>NCT03649906</nct_id>
    <title>A Clinical Study of Optimized CT-guided Pulmonary Nodule Microcoil Localization Technique</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pulmonary Nodule, Solitary</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Optimized Localization Technique</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The proportion of patients with pneumothorax.</outcome_measure>
      <outcome_measure>Positioning success rate</outcome_measure>
      <outcome_measure>Operation time</outcome_measure>
      <outcome_measure>Number of operators</outcome_measure>
      <outcome_measure>Proportion of patients with complications other than pneumothorax</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beijing Aerospace General Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Z181100001718055</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>August 31, 2021</primary_completion_date>
    <completion_date>August 31, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>November 19, 2019</last_update_posted>
    <locations>
      <location>Beijing aerospace general hospital, Beijing, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649906</url>
  </study>
  <study rank="45112">
    <nct_id>NCT03649893</nct_id>
    <title>Effectivness of Active Office Intervention</title>
    <acronym>ActiveOffice</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sedentary Lifestyle</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Active Office</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Weekly physical activity levels</outcome_measure>
      <outcome_measure>Weekly sitting time</outcome_measure>
      <outcome_measure>Heart rate</outcome_measure>
      <outcome_measure>Blood Pressure</outcome_measure>
      <outcome_measure>Global Physical Activity Questionnaire</outcome_measure>
      <outcome_measure>Sedentary Behavior Questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Primorska</lead_sponsor>
      <collaborator>Innorenew CoE</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Device Feasibility</study_design>
    </study_designs>
    <other_ids>
      <other_id>Active Office</other_id>
    </other_ids>
    <start_date>December 5, 2019</start_date>
    <primary_completion_date>February 1, 2020</primary_completion_date>
    <completion_date>March 1, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 2, 2019</last_update_posted>
    <locations>
      <location>InnoRenew, Izola, Slovenia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649893</url>
  </study>
  <study rank="45113">
    <nct_id>NCT03649880</nct_id>
    <title>Feasibility of FMISO in Brain Tumors</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Malignant Brain Neoplasm</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">¹⁸F-Fluoromisonidazole</intervention>
      <intervention type="Procedure">Computed Tomography</intervention>
      <intervention type="Procedure">Magnetic Resonance Imaging</intervention>
      <intervention type="Procedure">Positron Emission Tomography</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Macro-imaging level feasibility</outcome_measure>
      <outcome_measure>Technical feasibility of PET/MRI</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>OHSU Knight Cancer Institute</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>STUDY00016043</other_id>
      <other_id>NCI-2018-01479</other_id>
      <other_id>P01CA042045</other_id>
      <other_id>P30CA069533</other_id>
    </other_ids>
    <start_date>June 1, 2019</start_date>
    <primary_completion_date>September 30, 2021</primary_completion_date>
    <completion_date>September 30, 2024</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 15, 2019</last_update_posted>
    <locations>
      <location>OHSU Knight Cancer Institute, Portland, Oregon, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649880</url>
  </study>
  <study rank="45114">
    <nct_id>NCT03649867</nct_id>
    <title>What Have Been the Experiences of Female Survivors of Interpersonal Trauma on the Survive &amp; Thrive Course</title>
    <acronym>EoFSoITotS&amp;TC</acronym>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Interpersonal Trauma</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Semi-structured interviews</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Participants Experience of the Survive &amp; Thrive Course - Themes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NHS Tayside</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>3-003-18</other_id>
    </other_ids>
    <start_date>October 17, 2018</start_date>
    <primary_completion_date>January 30, 2019</primary_completion_date>
    <completion_date>January 30, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <results_first_posted>January 18, 2020</results_first_posted>
    <last_update_posted>January 18, 2020</last_update_posted>
    <locations>
      <location>Dundee Adult Psychological Therapies Service, Dundee, Tayside, United Kingdom</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03649867/Prot_SAP_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03649867</url>
  </study>
  <study rank="45115">
    <nct_id>NCT03649854</nct_id>
    <title>Measurement of Tricuspid AnnularPlane Systolic Excursion in Transesophageal Echocardiography</title>
    <acronym>TAPSE</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Right Heart Dysfunction</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>New method for assessing right heart function</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National University Hospital, Singapore</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2014/00576</other_id>
    </other_ids>
    <start_date>August 15, 2014</start_date>
    <primary_completion_date>March 23, 2015</primary_completion_date>
    <completion_date>August 14, 2015</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>National university Hospital, Singapore, Singapore</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649854</url>
  </study>
  <study rank="45116">
    <nct_id>NCT03649841</nct_id>
    <title>Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Castration-resistant Prostate Cancer</condition>
      <condition>Metastatic Prostate Carcinoma</condition>
      <condition>Prostate Adenocarcinoma</condition>
      <condition>Prostate Carcinoma Metastatic in the Bone</condition>
      <condition>Prostate Small Cell Carcinoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Antiandrogen Therapy</intervention>
      <intervention type="Drug">Abiraterone Acetate</intervention>
      <intervention type="Drug">Prednisone</intervention>
      <intervention type="Radiation">Radiation Therapy</intervention>
      <intervention type="Drug">Abiraterone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percent change in peripheral blood effector T-cells (CCR7-/CD45RO)</outcome_measure>
      <outcome_measure>Rate of undetectable PSA (&lt; 0.2)</outcome_measure>
      <outcome_measure>Incidence of adverse events per Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Washington</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RG1001784</other_id>
      <other_id>NCI-2018-01548</other_id>
      <other_id>9938</other_id>
      <other_id>P30CA015704</other_id>
      <other_id>P50CA097186</other_id>
    </other_ids>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>September 16, 2022</primary_completion_date>
    <completion_date>November 16, 2022</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>January 6, 2020</last_update_posted>
    <locations>
      <location>Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649841</url>
  </study>
  <study rank="45117">
    <nct_id>NCT03649828</nct_id>
    <title>Kefir and Metabolic Syndrome</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Metabolic Syndrome</condition>
      <condition>Cardiovascular Diseases</condition>
      <condition>Hypertension</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">probiotic milk fermented with kefir grains</intervention>
      <intervention type="Dietary Supplement">curd</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Ultra-sensitive C reactive Protein</outcome_measure>
      <outcome_measure>Framinghan score (the Coronay Heart Disease risk in 10 years)</outcome_measure>
      <outcome_measure>Glycosylated hemoglobin</outcome_measure>
      <outcome_measure>Oxidized LDL-cholesterol</outcome_measure>
      <outcome_measure>Lipid profile</outcome_measure>
      <outcome_measure>Blood glucose</outcome_measure>
      <outcome_measure>Blood pressure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Vila Velha</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>43028115.8.0000.5064</other_id>
    </other_ids>
    <start_date>July 1, 2016</start_date>
    <primary_completion_date>April 30, 2017</primary_completion_date>
    <completion_date>April 30, 2017</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649828</url>
  </study>
  <study rank="45118">
    <nct_id>NCT03649815</nct_id>
    <title>Feasibility and Outcomes of a Digital Health Support for the Schizophrenia Spectrum</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Schizophrenia Spectrum and Other Psychotic Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Combination Product">App4Independence</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptomatology</outcome_measure>
      <outcome_measure>Recovery Process Engagement</outcome_measure>
      <outcome_measure>Treatment Adherence</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre for Addiction and Mental Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>38</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>84-2016</other_id>
    </other_ids>
    <start_date>April 18, 2017</start_date>
    <primary_completion_date>May 8, 2018</primary_completion_date>
    <completion_date>May 8, 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Centre for Addiction and Mental Health, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649815</url>
  </study>
  <study rank="45119">
    <nct_id>NCT03649802</nct_id>
    <title>Vitamin D and Arterial Stiffness in Elderly</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Vitamin D Deficiency</condition>
      <condition>Arterial Stiffness</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Low dose vitamin D3</intervention>
      <intervention type="Dietary Supplement">High dose vitamin D3</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Carotid-femoral pulse wave velocity measured by equipment provided by Complior pulse wave analysis</outcome_measure>
      <outcome_measure>24 hour BP ambulatory monitoring</outcome_measure>
      <outcome_measure>Heart rate variability</outcome_measure>
      <outcome_measure>Plasma sulphoraphane and F2-isoprostanes. Isoprostanes will be measured by gas chromatography mass spectrometry and sulphoraphane will be measured using LC-MS/MS techniques</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Texas Tech University Health Sciences Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>65 Years</min_age>
    <max_age>89 Years</max_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>L18-174</other_id>
    </other_ids>
    <start_date>August 16, 2018</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>January 21, 2020</last_update_posted>
    <locations>
      <location>Texas Tech University Health Sciences Center, Lubbock, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649802</url>
  </study>
  <study rank="45120">
    <nct_id>NCT03649789</nct_id>
    <title>Periodontal Outcomes After Sanative Therapy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Periodontal Pocket</condition>
      <condition>Xerostomia</condition>
      <condition>Dry Mouth</condition>
      <condition>Periodontal Diseases</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Probing Depth</outcome_measure>
      <outcome_measure>Bleeding on Probing</outcome_measure>
      <outcome_measure>O'Leary Index of Plaque Control</outcome_measure>
      <outcome_measure>Gingival Index (used to assess gingival condition to distinguish between the quality of gingiva and the location of gingival concerns).</outcome_measure>
      <outcome_measure>Thickness of Periodontal Tissue</outcome_measure>
      <outcome_measure>Body Mass Index (BMI)</outcome_measure>
      <outcome_measure>Dry Mouth Inventory Questionnaire Completed by the Patient (to assess impact of dry mouth on quality of life)</outcome_measure>
      <outcome_measure>The Hygienist Observational Symptom Questionnaire (to assess whether a patient has dry mouth)</outcome_measure>
      <outcome_measure>Frequency of Periodontal Maintenance Appointment at the Periodontal Clinic and General Dental Clinic</outcome_measure>
      <outcome_measure>Frequency of Periodontal Maintenance Appointment only at the Periodontal Clinic</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Brock University</lead_sponsor>
      <collaborator>Dr. Peter C. Fritz, Periodontal Wellness &amp; Implant Surgery</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>17-387-WARD</other_id>
    </other_ids>
    <start_date>August 1, 2018</start_date>
    <primary_completion_date>March 30, 2019</primary_completion_date>
    <completion_date>May 1, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>January 2, 2020</last_update_posted>
    <locations>
      <location>Dr. Peter C. Fritz, Periodontal Wellness &amp; Implant Surgery, Fonthill, Ontario, Canada</location>
      <location>Brock University, St. Catharines, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649789</url>
  </study>
  <study rank="45121">
    <nct_id>NCT03649776</nct_id>
    <title>Training Church Leaders in Mental Health First Aid</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Stigma</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Mental Health First Aid</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from Baseline Confidence in Providing Help at 3 months</outcome_measure>
      <outcome_measure>Change from Baseline in Stigma at 3 months</outcome_measure>
      <outcome_measure>Change from Baseline in Functional Health Status at 3 months</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Research Foundation for Mental Hygiene, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>324</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>7224</other_id>
    </other_ids>
    <start_date>February 27, 2016</start_date>
    <primary_completion_date>September 2021</primary_completion_date>
    <completion_date>June 2022</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>December 23, 2019</last_update_posted>
    <locations>
      <location>New York State Psychiatric Institute, New York, New York, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03649776/Prot_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03649776</url>
  </study>
  <study rank="45122">
    <nct_id>NCT03649763</nct_id>
    <title>Onset and Duration of Forearm Nerve Blockade</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Carpal Tunnel Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lidocaine</intervention>
      <intervention type="Drug">Bupivacaine</intervention>
      <intervention type="Drug">Lidocaine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>onset of successful block and duration of sensory-motor blockade of the median and ulnar nerves</outcome_measure>
      <outcome_measure>postoperative Numeric Rating Scale (NRS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>New York School of Regional Anesthesia</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1801</other_id>
    </other_ids>
    <start_date>March 7, 2018</start_date>
    <primary_completion_date>December 31, 2018</primary_completion_date>
    <completion_date>December 31, 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>February 26, 2019</last_update_posted>
    <locations>
      <location>Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649763</url>
  </study>
  <study rank="45123">
    <nct_id>NCT03649750</nct_id>
    <title>Mucinex® ER 600 mg Bi-Layer Tablet Fed and Fasted</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Healthy Subjects</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mucinex®</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Maximum Observed Plasma Concentration (Cmax) of Guaifenesin</outcome_measure>
      <outcome_measure>Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Plasma Concentration (AUCt) of Guaifenesin</outcome_measure>
      <outcome_measure>Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin</outcome_measure>
      <outcome_measure>Area Under Plasma Concentration-time Curve From Time 0 to Infinity (AUCinf) of Guaifenesin</outcome_measure>
      <outcome_measure>Terminal Elimination Rate Constant (Kel) of Guaifenesin</outcome_measure>
      <outcome_measure>Terminal Elimination Half-life (T½) of Guaifenesin</outcome_measure>
      <outcome_measure>Relative Bioavailability (RF) of Guaifenesin</outcome_measure>
      <outcome_measure>Number of Adverse Events(AEs) Experienced by Participants</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Reckitt Benckiser LLC</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>2013-MUC-01</other_id>
    </other_ids>
    <start_date>May 29, 2013</start_date>
    <primary_completion_date>August 7, 2013</primary_completion_date>
    <completion_date>August 7, 2013</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <results_first_posted>February 22, 2019</results_first_posted>
    <last_update_posted>March 27, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649750</url>
  </study>
  <study rank="45124">
    <nct_id>NCT03649737</nct_id>
    <title>Exercise Program Among Lung Cancer Dyads</title>
    <acronym>PEP-LC</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lung Cancer</condition>
      <condition>Depression</condition>
      <condition>Physical Activity</condition>
      <condition>Quality of Life</condition>
      <condition>Pain</condition>
      <condition>Lung Cancer Symptoms</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Exercise</intervention>
      <intervention type="Other">Questionnaire Administration</intervention>
      <intervention type="Other">Survey Administration</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Study Feasibility: Proportion enrolled</outcome_measure>
      <outcome_measure>Study Acceptability: Average attendance</outcome_measure>
      <outcome_measure>Incidence of Depression</outcome_measure>
      <outcome_measure>Change in physical function over time: 6-minute walk</outcome_measure>
      <outcome_measure>Change in physical function over time: Hand grip test</outcome_measure>
      <outcome_measure>Change in physical function over time: Short Physical Performance Battery</outcome_measure>
      <outcome_measure>Quality of Life for participants with lung cancer assessed by FACT-L</outcome_measure>
      <outcome_measure>Quality of Life for exercise partners assessed by CQOLC</outcome_measure>
      <outcome_measure>Fatigue assessed by PROMIS Short-Form</outcome_measure>
      <outcome_measure>Pain assessed by PROMIS Short-Form</outcome_measure>
      <outcome_measure>Sleep assessed by PROMIS Short-Form</outcome_measure>
      <outcome_measure>Relationship Distress assessed by DAS-SF</outcome_measure>
      <outcome_measure>Social Support assessed by PSSS</outcome_measure>
      <outcome_measure>Level of exercise outside the exercise intervention assessed by GLTEQ</outcome_measure>
      <outcome_measure>Incidence of Malnutrition</outcome_measure>
      <outcome_measure>Subjective evaluation of PEP-LC participant experience from phone interviews</outcome_measure>
      <outcome_measure>Incidence of Relationship Strain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>OHSU Knight Cancer Institute</lead_sponsor>
      <collaborator>Portland VA Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>STUDY00018245</other_id>
    </other_ids>
    <start_date>July 16, 2018</start_date>
    <primary_completion_date>November 1, 2019</primary_completion_date>
    <completion_date>November 1, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2019</last_update_posted>
    <locations>
      <location>Oregon Health and Science University, Portland, Oregon, United States</location>
      <location>VA Portland Health Care System, Portland, Oregon, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649737</url>
  </study>
  <study rank="45125">
    <nct_id>NCT03649724</nct_id>
    <title>The LUCINDA Trial: LUpron Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's</title>
    <acronym>LUCINDA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alzheimer Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">LUPRON DEPOT 22.5 mg</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Weill Medical College of Cornell University</lead_sponsor>
      <collaborator>National Institute on Aging (NIA)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>65 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>057681</other_id>
      <other_id>R01AG057681-01A1</other_id>
    </other_ids>
    <start_date>February 2020</start_date>
    <primary_completion_date>February 2025</primary_completion_date>
    <completion_date>February 2026</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>September 30, 2019</last_update_posted>
    <locations>
      <location>Weill Medical College of Cornell University, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649724</url>
  </study>
  <study rank="45126">
    <nct_id>NCT03649711</nct_id>
    <title>Chronic Kidney Disease (CKD) Platelet Study</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Diseases</condition>
      <condition>Heart Attack</condition>
      <condition>Stroke, Ischemic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ticagrelor 90mg</intervention>
      <intervention type="Drug">Clopidogrel 75mg</intervention>
      <intervention type="Drug">Aspirin 81 mg</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>ADP induced platelet aggregation</outcome_measure>
      <outcome_measure>Platelet surface P-selectin expression</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Arkansas</lead_sponsor>
      <collaborator>American Society of Nephrology</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>91 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>81</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>227997</other_id>
      <other_id>1241997</other_id>
    </other_ids>
    <start_date>November 1, 2018</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>November 19, 2019</last_update_posted>
    <locations>
      <location>Central Arkansas Veterans Affairs Hospital, Little Rock, Arkansas, United States</location>
      <location>University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649711</url>
  </study>
  <study rank="45127">
    <nct_id>NCT03649698</nct_id>
    <title>Exercise and Nutrition for Healthy AgeiNg</title>
    <acronym>ENHANce</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sarcopenia</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Home-based training program</intervention>
      <intervention type="Dietary Supplement">High-quality protein supplement</intervention>
      <intervention type="Dietary Supplement">Omega-3 fatty acid</intervention>
      <intervention type="Drug">Placebo protein powder</intervention>
      <intervention type="Drug">Placebo omega-3</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in physical functioning</outcome_measure>
      <outcome_measure>Percentage of participants with change in physical functioning</outcome_measure>
      <outcome_measure>Change in muscle mass (after intervention-baseline)</outcome_measure>
      <outcome_measure>Change in muscle strength (after intervention-baseline)</outcome_measure>
      <outcome_measure>Compliance to the exercise intervention, subjective</outcome_measure>
      <outcome_measure>Compliance to the exercise intervention, objective</outcome_measure>
      <outcome_measure>Compliance to the exercise intervention, subjective, detailed</outcome_measure>
      <outcome_measure>Compliance to the protein supplementation, objective</outcome_measure>
      <outcome_measure>Compliance to the protein supplementation, subjective</outcome_measure>
      <outcome_measure>Compliance to the protein supplementation objective</outcome_measure>
      <outcome_measure>Compliance to the omega-3 supplementation, subjective</outcome_measure>
      <outcome_measure>Compliance to the omega-3 supplementation, objective</outcome_measure>
      <outcome_measure>Functional status: fraitly</outcome_measure>
      <outcome_measure>Functional status: activities of daily living</outcome_measure>
      <outcome_measure>Functional status: balance</outcome_measure>
      <outcome_measure>Functional status: change in physical activity</outcome_measure>
      <outcome_measure>Functional status: health-related quality of life</outcome_measure>
      <outcome_measure>Functional status: falls</outcome_measure>
      <outcome_measure>Cognitive status: immediate and delayed memory, attention, language and visuospatial skills</outcome_measure>
      <outcome_measure>Cognitive status: inhibition</outcome_measure>
      <outcome_measure>Cognitive status</outcome_measure>
      <outcome_measure>Nutritional status: malnutrition</outcome_measure>
      <outcome_measure>Nutritional status: nutriënt intake</outcome_measure>
      <outcome_measure>Patient reported benefits and adverse effects</outcome_measure>
      <outcome_measure>Change in CRP</outcome_measure>
      <outcome_measure>Change in hemoglobin</outcome_measure>
      <outcome_measure>Change in creatinine</outcome_measure>
      <outcome_measure>Change in ureum</outcome_measure>
      <outcome_measure>Change in serum albumin</outcome_measure>
      <outcome_measure>Change in glucose</outcome_measure>
      <outcome_measure>Change in cholesterol (HDL, LDL, total, Triglycerides)</outcome_measure>
      <outcome_measure>Change in insulin</outcome_measure>
      <outcome_measure>Change in IGF-1</outcome_measure>
      <outcome_measure>Change in 25-hydroxy-vitamin D</outcome_measure>
      <outcome_measure>Change in creatinine kinase</outcome_measure>
      <outcome_measure>Change in indoxyl sulfate</outcome_measure>
      <outcome_measure>Change in IL-6</outcome_measure>
      <outcome_measure>Change in IL-1b</outcome_measure>
      <outcome_measure>Change in TNF-alpha</outcome_measure>
      <outcome_measure>Change in myostatin</outcome_measure>
      <outcome_measure>Change in activin A</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universitaire Ziekenhuizen Leuven</lead_sponsor>
      <collaborator>KU Leuven</collaborator>
      <collaborator>VISTA-Life</collaborator>
      <collaborator>Nestlé Health Science Belgium</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>65 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>S60763</other_id>
    </other_ids>
    <start_date>February 12, 2018</start_date>
    <primary_completion_date>March 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 18, 2018</last_update_posted>
    <locations>
      <location>Gerontology and Geriatrics, Department of chronic diseases, metabolism and ageing (CHROMETA) KU Leuven, Leuven, Vlaams-Brabant, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649698</url>
  </study>
  <study rank="45128">
    <nct_id>NCT03649685</nct_id>
    <title>Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Obsessive Compulsive Disorder</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Obsessive-Compulsive Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Continuous theta burst stimulation (cTBS)</intervention>
      <intervention type="Device">shame rTMS</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptom improvement assessed by the Yale-Brown Obsessive Compulsive Scale</outcome_measure>
      <outcome_measure>The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS)</outcome_measure>
      <outcome_measure>The Barratt Impulsiveness Scale-11 (BIS-11)</outcome_measure>
      <outcome_measure>The Beck Depression Inventory-II(BDI-II)</outcome_measure>
      <outcome_measure>The Beck Anxiety Inventory (BAI)</outcome_measure>
      <outcome_measure>State-trait Anxiety Inventory(STAI)</outcome_measure>
      <outcome_measure>Perceived Stress Scale(PSS)</outcome_measure>
      <outcome_measure>Pittsburgh sleep quality index(PSQI)</outcome_measure>
      <outcome_measure>The Obsessive-Compulsive Inventory-Revised(OCI-R)</outcome_measure>
      <outcome_measure>side effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shanghai Mental Health Center</lead_sponsor>
      <collaborator>RenJi Hospital</collaborator>
      <collaborator>Shanghai 10th People's Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SMHC-OCD-003</other_id>
    </other_ids>
    <start_date>July 15, 2019</start_date>
    <primary_completion_date>October 31, 2021</primary_completion_date>
    <completion_date>October 31, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>July 18, 2019</last_update_posted>
    <locations>
      <location>Shanghai Mental Health Center, Shanghai, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649685</url>
  </study>
  <study rank="45129">
    <nct_id>NCT03649672</nct_id>
    <title>The Validity and Tolerability of Awake Calibration of the TOF Watch SX Monitor</title>
    <acronym>CaliRev</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Neuromuscular Blockade</condition>
    </conditions>
    <interventions>
      <intervention type="Device">TOF Watch SX</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Total recovery time</outcome_measure>
      <outcome_measure>Onset time</outcome_measure>
      <outcome_measure>Dur TOFc1</outcome_measure>
      <outcome_measure>Dur TOF 25%</outcome_measure>
      <outcome_measure>Dur TOF 50%</outcome_measure>
      <outcome_measure>Dur TOF 75%</outcome_measure>
      <outcome_measure>TOF pain: VAS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Christoph Czarnetzki</lead_sponsor>
      <collaborator>Hôpital du Valais</collaborator>
      <collaborator>University Hospital, Geneva</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>CaliRev</other_id>
    </other_ids>
    <start_date>May 1, 2019</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>April 16, 2019</last_update_posted>
    <locations>
      <location>University Hospital of Geneva, Anesthesia Department, Geneva, Canton Of Geneva, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649672</url>
  </study>
  <study rank="45130">
    <nct_id>NCT03649659</nct_id>
    <title>Effectiveness of Silver Diamine Fluoride (SDF) in Arresting Cavitated Caries Lesions</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cavities of Teeth</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Silver Diamine Fluoride</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The proportion of arrested trial lesions per child in each treatment arm after one treatment with SDF or Placebo</outcome_measure>
      <outcome_measure>The proportion of arrested trial lesions per child in each treatment arm after two treatments with SDF or Placebo</outcome_measure>
      <outcome_measure>Change in proportion of arrested trial lesions per child in each treatment arm after one treatment with SDF or Placebo</outcome_measure>
      <outcome_measure>Proportion of Children in Each Treatment Arm experiencing Toothache Pain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Michigan</lead_sponsor>
      <collaborator>NYU Langone Health</collaborator>
      <collaborator>University of Iowa</collaborator>
      <collaborator>National Institute of Dental and Craniofacial Research (NIDCR)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Months</min_age>
    <max_age>71 Months</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1060</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HUM00147622</other_id>
      <other_id>U01DE027372</other_id>
    </other_ids>
    <start_date>October 8, 2018</start_date>
    <primary_completion_date>January 30, 2023</primary_completion_date>
    <completion_date>January 30, 2023</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 2, 2019</last_update_posted>
    <locations>
      <location>University of Iowa College of Dentistry, Iowa City, Iowa, United States</location>
      <location>University of Michigan School of Dentistry, Ann Arbor, Michigan, United States</location>
      <location>New York University College of Dentistry, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649659</url>
  </study>
  <study rank="45131">
    <nct_id>NCT03649646</nct_id>
    <title>FimasaRtan-basEd BP Targets After Drug SwitcHing</title>
    <acronym>FRESH</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Essential Hypertension</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Blood pressure (BP) (Systolic and Diastolic)</outcome_measure>
      <outcome_measure>Target BP (&lt;140/90 mmHg) (Systolic and Diastolic)</outcome_measure>
      <outcome_measure>Target BP(&lt;130/80mmHg) (Systolic and Diastolic)</outcome_measure>
      <outcome_measure>Investigator's target BP (Systolic and Diastolic)</outcome_measure>
      <outcome_measure>Target BP pattern (Systolic and Diastolic)</outcome_measure>
      <outcome_measure>BP control rate (Systolic and Diastolic)</outcome_measure>
      <outcome_measure>Framingham score (10-year risk of cardiovascular disease)</outcome_measure>
      <outcome_measure>Difference in the proportion of target BP attainment (Systolic and Diastolic)</outcome_measure>
      <outcome_measure>Descriptive statistics of BP (Systolic and Diastolic)</outcome_measure>
      <outcome_measure>Drugs (antihypertensive, prior to study enrollment)</outcome_measure>
      <outcome_measure>Drugs (antihypertensive)</outcome_measure>
      <outcome_measure>Drugs (antidiabetic, antidyslipidemic)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Boryung Pharmaceutical Co., Ltd</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>BR-FMS-OS-404</other_id>
    </other_ids>
    <start_date>July 3, 2018</start_date>
    <primary_completion_date>September 9, 2020</primary_completion_date>
    <completion_date>September 9, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Ajou University Hospital, Suwon, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649646</url>
  </study>
  <study rank="45132">
    <nct_id>NCT03649633</nct_id>
    <title>Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock</title>
    <acronym>CORVICTES-ΥΜ</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Septic Shock</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Stress-dose Hydrocortisone plus Vitamin C</intervention>
      <intervention type="Drug">isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cerebral autoregulation</outcome_measure>
      <outcome_measure>Cerebral blood flow</outcome_measure>
      <outcome_measure>Neurologic failure free days</outcome_measure>
      <outcome_measure>Ventilator-free days</outcome_measure>
      <outcome_measure>Favorable, Inhospital, Neurological Outcome</outcome_measure>
      <outcome_measure>Patient-reported health-related quality of life: SF-36</outcome_measure>
      <outcome_measure>Biomarkers</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Athens</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>163-10-5-2018</other_id>
    </other_ids>
    <start_date>September 6, 2018</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>September 17, 2019</last_update_posted>
    <locations>
      <location>Evaggelismos General Hospital, Athens, Attica, Greece</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649633</url>
  </study>
  <study rank="45133">
    <nct_id>NCT03649620</nct_id>
    <title>Efficacy and Safety of Unripe Bokbunja Extract on Improvement of Blood Cholesterol</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Blood Cholesterol</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">unripe Bokbunja Extract</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes of Total cholesterol</outcome_measure>
      <outcome_measure>Changes of Lipid profile(total cholesterol, LDL-cholesterol, triglyceride, HDL-cholesterol, free fatty acid, Apolipoprotein A1, Apolipoprotein B, Lipoprotein a, hs-CRP)</outcome_measure>
      <outcome_measure>Changes of Arteriosclerosis index(total cholesterol/HDL-cholesterol, LDL-cholesterol/HDL-cholesterol, triglyceride/HDL-cholesterol, (total HDL-cholesterol-HDL-cholesterol)/HDL-cholesterol, Apolipoprotein B/Apolipoprotein A1)</outcome_measure>
      <outcome_measure>Changes of Anthropometric index(weight, body mass index, waist hip ratio, waist, hip, fat percentage, lean body mass)</outcome_measure>
      <outcome_measure>Changes of Oxidized LDL</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yonsei University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>BC_cholesterol</other_id>
    </other_ids>
    <start_date>December 2016</start_date>
    <primary_completion_date>May 2017</primary_completion_date>
    <completion_date>February 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649620</url>
  </study>
  <study rank="45134">
    <nct_id>NCT03649607</nct_id>
    <title>Accelerated Resolution Therapy for HIV Positive African, Caribbean and Black</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV</condition>
      <condition>Post Traumatic Stress Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Accelerated Resolution Therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>HIV Symptom Distress Scale (SDS).</outcome_measure>
      <outcome_measure>HIV Associated Neurocognitive Disease (HAND).</outcome_measure>
      <outcome_measure>Working and learning memory</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>St. Michael's Hospital, Toronto</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>18028</other_id>
    </other_ids>
    <start_date>September 2019</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>April 10, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649607</url>
  </study>
  <study rank="45135">
    <nct_id>NCT03649594</nct_id>
    <title>Risk Stratification Post TAVI Using TEG</title>
    <acronym>RISTRATAVI</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Platelet Function Tests</condition>
      <condition>Predictive Value of Tests</condition>
      <condition>Thrombelastography</condition>
      <condition>Cardiovascular Diseases</condition>
      <condition>Aortic Valve Stenosis</condition>
      <condition>Thrombosis</condition>
      <condition>Transcatheter Aortic Valve Replacement</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Global TEG(R)-based prediction of hypoattenuating leaflet thickening (HALT)</outcome_measure>
      <outcome_measure>Platelet TEG(R)-based prediction of hypoattenuating leaflet thickening (HALT)</outcome_measure>
      <outcome_measure>All-cause mortality within 12 months</outcome_measure>
      <outcome_measure>Cardiovascular mortality within 12 months</outcome_measure>
      <outcome_measure>Thromboembolic events within 12 months</outcome_measure>
      <outcome_measure>Bleeding events within 12 months</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Torben Pottgiesser</lead_sponsor>
      <collaborator>University Hospital Freiburg</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>RISTRATAVI-1-2019</other_id>
    </other_ids>
    <start_date>December 1, 2019</start_date>
    <primary_completion_date>August 31, 2021</primary_completion_date>
    <completion_date>August 31, 2022</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 8, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649594</url>
  </study>
  <study rank="45136">
    <nct_id>NCT03649581</nct_id>
    <title>Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders</title>
    <acronym>NeuroSplitsz</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Schizophrenia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">compare the two groups of schizophrenic patients</intervention>
      <intervention type="Other">compare the two groups of schizophrenic patients versus volunteers</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Index of affect</outcome_measure>
      <outcome_measure>Index of psychomotoricity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Strasbourg, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>7058</other_id>
    </other_ids>
    <start_date>February 28, 2019</start_date>
    <primary_completion_date>February 2, 2023</primary_completion_date>
    <completion_date>February 2, 2023</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 20, 2019</last_update_posted>
    <locations>
      <location>Service de Psychiatrie I, Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649581</url>
  </study>
  <study rank="45137">
    <nct_id>NCT03649568</nct_id>
    <title>Protein Source on Plasma Amino Acid Concentrations</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Protein Deposition</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Pork</intervention>
      <intervention type="Other">Egg</intervention>
      <intervention type="Other">Black beans</intervention>
      <intervention type="Other">Almonds</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Plasma amino acid concentrations</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Purdue University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>39 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>1804020520</other_id>
    </other_ids>
    <start_date>August 24, 2018</start_date>
    <primary_completion_date>December 31, 2019</primary_completion_date>
    <completion_date>December 31, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 4, 2019</last_update_posted>
    <locations>
      <location>Purdue University, West Lafayette, Indiana, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649568</url>
  </study>
  <study rank="45138">
    <nct_id>NCT03649555</nct_id>
    <title>Reliability of [18F]-FTC-146 Brain Uptake in Healthy Controls</title>
    <acronym>rSIG</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Controls</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">[18F]-FTC-146</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Reliability under test retest conditions</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>45678</other_id>
    </other_ids>
    <start_date>February 1, 2019</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>October 1, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>December 18, 2019</last_update_posted>
    <locations>
      <location>Department of Psychiatry and Behavioral Sciences, Stanford, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649555</url>
  </study>
  <study rank="45139">
    <nct_id>NCT03649542</nct_id>
    <title>The Effects of Fluidotherapy® Exercise</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Wrist Fracture</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Fluidotherapy plus exercise</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>active range of motion (AROM)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pacific Northwest University of Health Sciences</lead_sponsor>
      <collaborator>Summa Health</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>37</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SUMMA IRB - FLUIDOTHERAPY</other_id>
    </other_ids>
    <start_date>July 27, 2009</start_date>
    <primary_completion_date>January 13, 2014</primary_completion_date>
    <completion_date>January 13, 2014</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649542</url>
  </study>
  <study rank="45140">
    <nct_id>NCT03649529</nct_id>
    <title>Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Malignant Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">GPA-TriMAR-T</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>safety （Incidence of treatment-related adverse events as assessed by CTCAE v4.03）</outcome_measure>
      <outcome_measure>Complete response rate[CR] （Complete response rate per the revised International Working Group (IWG) Response Criteria）</outcome_measure>
      <outcome_measure>Partial response rate [PR] （Partial response rate per the revised International Working Group (IWG) Response Criteria）</outcome_measure>
      <outcome_measure>Duration of Response （The time from response to relapse or progression）</outcome_measure>
      <outcome_measure>Progression Free Survival （The time from the first day of treatment to the date on which disease progresses.）</outcome_measure>
      <outcome_measure>Overall Survival （The number of patient alive, with or without signs of cancer）</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Timmune Biotech Inc.</lead_sponsor>
      <collaborator>The Second Affiliated Hospital of Hainan Medical University</collaborator>
      <collaborator>Hainan Cancer Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>69 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>6</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>T2018-7</other_id>
    </other_ids>
    <start_date>September 27, 2018</start_date>
    <primary_completion_date>September 15, 2021</primary_completion_date>
    <completion_date>January 1, 2022</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>December 6, 2019</last_update_posted>
    <locations>
      <location>Hainan Cancer Hospital, Haikou, Hainan, China</location>
      <location>The Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649529</url>
  </study>
  <study rank="45141">
    <nct_id>NCT03649516</nct_id>
    <title>The Impact of Mobile APP Intervention ( iCKD APP) on Chronic Kidney Disease Care</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Kidney Disease</condition>
      <condition>Hypertension</condition>
    </conditions>
    <interventions>
      <intervention type="Device">iCKD APP</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Compare clinics and home blood pressure</outcome_measure>
      <outcome_measure>Achievement of Blood pressure control target</outcome_measure>
      <outcome_measure>The monitor rate of Home Blood pressure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kaohsiung Medical University Chung-Ho Memorial Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>330</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>KMUHIRB-F(II)-20180055</other_id>
    </other_ids>
    <start_date>June 26, 2018</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 16, 2019</last_update_posted>
    <locations>
      <location>Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649516</url>
  </study>
  <study rank="45142">
    <nct_id>NCT03649503</nct_id>
    <title>The National Registry Study For the Real-world Patients With Parkinsonian Disorders in China</title>
    <acronym>ForPDCN</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinsonian Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Other">No intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from Baseline in the Short-Form 8-Item Parkinson's Disease Questionnaire (PDQ-8) Score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Huashan Hospital</lead_sponsor>
      <collaborator>First Affiliated Hospital, Sun Yat-Sen University</collaborator>
      <collaborator>Tianjin Medical University General Hospital</collaborator>
      <collaborator>Peking Union Medical College Hospital</collaborator>
      <collaborator>Chinese PLA General Hospital</collaborator>
      <collaborator>Shanghai Zhongshan Hospital</collaborator>
      <collaborator>The First Affiliated Hospital of the Fourth Military Medical University</collaborator>
      <collaborator>Afﬁliated Hospital of North Sichuan Medical College</collaborator>
      <collaborator>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</collaborator>
      <collaborator>Changshu Hospital of Traditional Chinese Medicine</collaborator>
      <collaborator>The Affiliated Hospital of Qingdao University</collaborator>
      <collaborator>Guangxi Ruikang Hospital</collaborator>
      <collaborator>Xi'an Central Hospital</collaborator>
      <collaborator>First Affiliated Hospital of Chongqing Medical University</collaborator>
      <collaborator>The First Hospital of Hebei Medical University</collaborator>
      <collaborator>Jieyang People's Hospital</collaborator>
      <collaborator>Luoyang Central Hospital</collaborator>
      <collaborator>Taian City Central Hospital</collaborator>
      <collaborator>Gansu Provincial Hospital</collaborator>
      <collaborator>First Affiliated Hospital of Harbin Medical University</collaborator>
      <collaborator>Daqing Oil Field Hospital</collaborator>
      <collaborator>Fujian Provincial Hospital</collaborator>
      <collaborator>The Affiliated Hospital of Xuzhou Medical University</collaborator>
      <collaborator>Taizhou Hospital</collaborator>
      <collaborator>Zhejiang Hospital</collaborator>
      <collaborator>The 101st Hospital of Chinese People's Liberation Army</collaborator>
      <collaborator>The First Affiliated Hospital of Zhengzhou University</collaborator>
      <collaborator>The First Affiliated Hospital of Dalian Medical University</collaborator>
      <collaborator>China-Japan Union Hospital, Jilin University</collaborator>
      <collaborator>Wuhan No.1 Hospital</collaborator>
      <collaborator>Shanghai Jiao Tong University Affiliated Sixth People’s Hospital</collaborator>
      <collaborator>Northern Jiangsu Province People's Hospital</collaborator>
      <collaborator>Shanghai Tongji Hospital, Tongji University School of Medicine</collaborator>
      <collaborator>Shanghai 5th People's Hospital</collaborator>
      <collaborator>Third People's Hospital, Huzhou City, Zhejiang Province, China</collaborator>
      <collaborator>Suzhou Municipal Hospital</collaborator>
      <collaborator>Ningbo No. 1 Hospital</collaborator>
      <collaborator>The First People's Hospital of Changzhou</collaborator>
      <collaborator>Affiliated Hospital of Jiangsu University</collaborator>
      <collaborator>The Second Affiliated Hospital of Harbin Medical University</collaborator>
      <collaborator>The First Affiliated Hospital with Nanjing Medical University</collaborator>
      <collaborator>Fujian Medical University Union Hospital</collaborator>
      <collaborator>Shanghai Changzheng Hospital</collaborator>
      <collaborator>Second Affiliated Hospital of Nanchang University</collaborator>
      <collaborator>Jingjiang People's Hospital</collaborator>
      <collaborator>Qingdao Municipal Hospital</collaborator>
      <collaborator>Xi'an No.3 Hospital</collaborator>
      <collaborator>Lianyungang Hospital Affiliated Bengbu Medical College</collaborator>
      <collaborator>The First People's Hospital of Jingzhou</collaborator>
      <collaborator>Shanghai 10th People's Hospital</collaborator>
      <collaborator>Huadong Hospital</collaborator>
      <collaborator>No. 102 Hospital of Chinese People's Liberation Army</collaborator>
      <collaborator>Shandong Provincial Hospital</collaborator>
      <collaborator>Anhui Provincial Hospital</collaborator>
      <collaborator>The Affiliated Hospital of Guangdong Medical College</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>KY2016-214</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>September 30, 2028</primary_completion_date>
    <completion_date>September 30, 2033</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 31, 2018</last_update_posted>
    <locations>
      <location>Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China</location>
      <location>Huashan Hospital, Shanghai, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649503</url>
  </study>
  <study rank="45143">
    <nct_id>NCT03649490</nct_id>
    <title>Advanced Materials Science in XLIF Study</title>
    <acronym>AMS in XLIF</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Degenerative Disc Disease</condition>
      <condition>Spondylolisthesis</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Extreme Lateral Interbody Fusion</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Radiographic Fusion Success</outcome_measure>
      <outcome_measure>MCID and SCB threshold for each PRO: VAS (back/leg pain), ODI, and EQ-5D, within each treatment group</outcome_measure>
      <outcome_measure>Fusion Rates at Follow-up Timepoints</outcome_measure>
      <outcome_measure>Maintenance of Radiographic Correction</outcome_measure>
      <outcome_measure>Complications</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NuVasive</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>NUVA.X1801</other_id>
    </other_ids>
    <start_date>August 19, 2018</start_date>
    <primary_completion_date>August 1, 2022</primary_completion_date>
    <completion_date>August 1, 2022</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 23, 2019</last_update_posted>
    <locations>
      <location>Lyerly Neurosurgery, Jacksonville, Florida, United States</location>
      <location>University of South Florida Department of Neurosurgery, Tampa General Hospital, Tampa, Florida, United States</location>
      <location>Rush University Medical Center, Chicago, Illinois, United States</location>
      <location>Columbia Orthopedic Group Research, Columbia, Missouri, United States</location>
      <location>OrthoCarolina, Charlotte, North Carolina, United States</location>
      <location>The Spine Clinic of OKC, Oklahoma City, Oklahoma, United States</location>
      <location>UT Health San Antonio, San Antonio, Texas, United States</location>
      <location>University of Virginia Health System, Charlottesville, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649490</url>
  </study>
  <study rank="45144">
    <nct_id>NCT03649477</nct_id>
    <title>Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome</title>
    <acronym>CARE-PWS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Prader-Willi Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">intranasal carbetocin Dose 1</intervention>
      <intervention type="Drug">intranasal carbetocin Dose 2</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hyperphagia behavior</outcome_measure>
      <outcome_measure>Obsessive and compulsive behaviors</outcome_measure>
      <outcome_measure>Anxiety</outcome_measure>
      <outcome_measure>Global impression</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Levo Therapeutics, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>7 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>175</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>LV-101-3-01</other_id>
    </other_ids>
    <start_date>November 20, 2018</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>January 18, 2020</last_update_posted>
    <locations>
      <location>University of Alabama at Birmingham, Birmingham, Alabama, United States</location>
      <location>Phoenix Children's Hospital, Phoenix, Arizona, United States</location>
      <location>Children's Hospital of Los Angeles (USC), Los Angeles, California, United States</location>
      <location>Stanford Children's Health, Palo Alto, California, United States</location>
      <location>Rady Children's Hospital San Diego, San Diego, California, United States</location>
      <location>Children's Hospital Colorado, Aurora, Colorado, United States</location>
      <location>Children's National, Washington, District of Columbia, United States</location>
      <location>University of Florida, Gainesville, Florida, United States</location>
      <location>Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States</location>
      <location>Kansas University Medical Center, Kansas City, Kansas, United States</location>
      <location>University of Harvard Boston Children's Hospital, Boston, Massachusetts, United States</location>
      <location>Children's Hospitals and Clinics of Minnesota, Saint Paul, Minnesota, United States</location>
      <location>Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States</location>
      <location>University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States</location>
      <location>Nationwide Children's Hospital, Columbus, Ohio, United States</location>
      <location>Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States</location>
      <location>Vanderbilt University School of Medicine, Nashville, Tennessee, United States</location>
      <location>Texas Children's Hospital, Houston, Texas, United States</location>
      <location>Children's Hospital of San Antonio, San Antonio, Texas, United States</location>
      <location>University of Utah, Salt Lake City, Utah, United States</location>
      <location>Sydney Children's Hospital, Randwick, New South Wales, Australia</location>
      <location>The Children's Hospital at Westmead, Westmead, New South Wales, Australia</location>
      <location>Queensland Children's Hospital, South Brisbane, Queensland, Australia</location>
      <location>University of Alberta, Edmonton, Alberta, Canada</location>
      <location>British Columbia Children's Hospital, Vancouver, British Columbia, Canada</location>
      <location>Toronto Hospital for Sick Kids, Toronto, Ontario, Canada</location>
      <location>CHU Ste Justine, Montréal, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649477</url>
  </study>
  <study rank="45145">
    <nct_id>NCT03649464</nct_id>
    <title>Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Glioblastoma</condition>
      <condition>Astrocytoma</condition>
      <condition>Oligodendroglioma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">OKN-007</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Participants with DLTs (Dose Limiting Toxicities) and AEs (Adverse Events)</outcome_measure>
      <outcome_measure>Number of Participants with Best Overall Response Rate in the brain</outcome_measure>
      <outcome_measure>Proportion of Participants as Assessed by 6-month Progression-Free Survival (PFS)</outcome_measure>
      <outcome_measure>Proportion of Participants as Assessed by Overall Survival (OS)</outcome_measure>
      <outcome_measure>The Cmax of OKN-007 in plasma</outcome_measure>
      <outcome_measure>The Tmax (time to maximum concentration) of OKN-007 in plasma</outcome_measure>
      <outcome_measure>AUC (area under the time curve) of OKN-007 in plasma</outcome_measure>
      <outcome_measure>Plasma concentration of OKN-007</outcome_measure>
      <outcome_measure>OKN-007 plasma levels over time for food-effect study</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Oblato, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>OKN-007-OL-RMG-201</other_id>
    </other_ids>
    <start_date>April 2019</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649464</url>
  </study>
  <study rank="45146">
    <nct_id>NCT03649451</nct_id>
    <title>Reference Dose Levels During Fluoroscopically Guided Procedures in Operating Rooms</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Radiation Exposure</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Total KAP (Kerma-Air-Product)</outcome_measure>
      <outcome_measure>Year of construction of the equipment and date of the last external quality control (QC) (yyyy)</outcome_measure>
      <outcome_measure>Image receptor type of the equipment</outcome_measure>
      <outcome_measure>DACS Connection</outcome_measure>
      <outcome_measure>Patient weight (kg) and height (cm)</outcome_measure>
      <outcome_measure>Size of Fields of View (FOV) (cm)</outcome_measure>
      <outcome_measure>Differences between the displayed and measured X-ray doses (percentage)</outcome_measure>
      <outcome_measure>Total air kerma of the procedure including the one performed of an O-arm equipment</outcome_measure>
      <outcome_measure>Total number of image frames (number)</outcome_measure>
      <outcome_measure>Fluoroscopy mode used during the procedure</outcome_measure>
      <outcome_measure>Fluoroscopy pulse rate ( pulses/second)</outcome_measure>
      <outcome_measure>Fluoroscopy time (hh:mm:ss) of the procedure including the one performed of an O-arm equipment</outcome_measure>
      <outcome_measure>KAP (Kerma-Area-Product) attributable to fluoroscopy</outcome_measure>
      <outcome_measure>Medical specialty of the procedure</outcome_measure>
      <outcome_measure>Name/type of the procedure</outcome_measure>
      <outcome_measure>Additional information about the procedure giving further indications about the used materials or the anatomical region of interest.</outcome_measure>
      <outcome_measure>Total KAP for procedures performed on an O-arm equipment</outcome_measure>
      <outcome_measure>Total DLP (Dose-Length-Product) of the procedures performed on an O-arm equipment.DLP is always expressed in mGy.cm.</outcome_measure>
      <outcome_measure>CTDIvol (Volume Computed Tomography Dose Index) of the procedures performed on an O-arm equipment. CTDI is always expressed in mGy.</outcome_measure>
      <outcome_measure>Type of the dosimetric phantom used to calculate the CTDI of an acquisition for the procedures performed on an O-arm equipment.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Societe Francaise de Physique Medicale</lead_sponsor>
      <collaborator>Hopital Lariboisière</collaborator>
      <collaborator>University hospital, Angers, FRANCE</collaborator>
      <collaborator>University hospital of Montpellier, FRANCE</collaborator>
      <collaborator>Fréjus-Saint-Raphaël hospital, FRANCE</collaborator>
      <collaborator>C2i Santé, FRANCE</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>22980</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>gtsfpmnrbloc2017</other_id>
    </other_ids>
    <start_date>September 3, 2018</start_date>
    <primary_completion_date>January 1, 2019</primary_completion_date>
    <completion_date>March 4, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations/>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/51/NCT03649451/Prot_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03649451</url>
  </study>
  <study rank="45147">
    <nct_id>NCT03649438</nct_id>
    <title>131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Relapsed Neuroblastoma</condition>
      <condition>Metastatic Pheochromocytoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">131 I-Metaiodobenzylguanidine</intervention>
      <intervention type="Drug">Potassium Iodide</intervention>
      <intervention type="Drug">G-csf</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients who receive 131 I-MIBG</outcome_measure>
      <outcome_measure>Disease Outcome</outcome_measure>
      <outcome_measure>Incidence of hematologic toxicities</outcome_measure>
      <outcome_measure>Incidence of hepatic toxicities</outcome_measure>
      <outcome_measure>Incidence of thyroid toxicities</outcome_measure>
      <outcome_measure>Improvement of pain symptoms</outcome_measure>
      <outcome_measure>Improvement of fatigue</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Texas Southwestern Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>STU-2019-0665</other_id>
    </other_ids>
    <start_date>May 28, 2019</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>June 14, 2019</last_update_posted>
    <locations>
      <location>The University of Texas Southwestern Medical Center, Dallas, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649438</url>
  </study>
  <study rank="45148">
    <nct_id>NCT03649425</nct_id>
    <title>COMPARATIVE PROSPECTIVE STUDY OF COMPLICATIONS FOUND IN THE PINS OF EXTERNAL FIXERS COMPARING STEEL PINS AND PINS COATED WITH HYDROXIAPATITA</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>External Fixation Pin Site Infection</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>compare infectious complications</outcome_measure>
      <outcome_measure>Evaluate the incidence of loosening of the pins</outcome_measure>
      <outcome_measure>risk factors and comorbities associated</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Faculdade de Ciências Médicas da Santa Casa de São Paulo</lead_sponsor>
      <collaborator>Instituto de Ortopedia e Traumatologia de Passo Fundo</collaborator>
      <collaborator>Universidade de Passo Fundo</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>119</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>84939418.6.0000.5342</other_id>
    </other_ids>
    <start_date>May 14, 2018</start_date>
    <primary_completion_date>November 25, 2019</primary_completion_date>
    <completion_date>May 15, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649425</url>
  </study>
  <study rank="45149">
    <nct_id>NCT03649412</nct_id>
    <title>A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Autoimmune Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">GSK2982772 Modified Release</intervention>
      <intervention type="Drug">GSK2982772 Immediate Release</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Area under the curve from time zero to infinity (AUC [0-inf]) of GSK2982772 for MR coated tablet formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>AUC (0-inf) of GSK2982772 for IR formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>Area under the curve from time zero to the last measurable concentration (AUC[0-t]) of GSK2982772 for MR coated tablet formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>AUC (0-t) of GSK2982772 for IR formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>Area under the curve from time zero to 24 hours (AUC[0-24]) of GSK2982772 for MR coated tablet formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>AUC (0-24) of GSK2982772 for IR formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>Maximum observed concentration (Cmax) of GSK2982772 for MR coated tablet formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>Cmax of GSK2982772 for IR formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>Concentration at 24 hours post-dose (C24h) of GSK2982772 for MR coated tablet formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>C24h of GSK2982772 for IR formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>Time to Cmax (Tmax) of GSK2982772 for MR coated tablet formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>Tmax of GSK2982772 for IR formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>Terminal half-life (t1/2) of GSK2982772 for MR coated tablet formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>t1/2 of GSK2982772 for IR formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>AUC(0-inf) of GSK2982772 for MR coated tablet formulation (240 mg) after a high fat breakfast in Part A</outcome_measure>
      <outcome_measure>AUC(0-inf) of GSK2982772 for MR coated tablet formulation after a high fat breakfast in Part B</outcome_measure>
      <outcome_measure>AUC(0-t) of GSK2982772 for MR coated tablet formulation (240 mg) after a high fat breakfast in Part A</outcome_measure>
      <outcome_measure>AUC(0-t) of GSK2982772 for MR coated tablet formulation after a high fat breakfast in Part B</outcome_measure>
      <outcome_measure>Cmax of GSK2982772 for MR coated tablet formulation (240 mg) after a high fat breakfast in Part A</outcome_measure>
      <outcome_measure>Cmax of GSK2982772 for MR coated tablet formulation after a high fat breakfast in Part B</outcome_measure>
      <outcome_measure>Tmax of GSK2982772 for MR coated tablet formulation (240 mg) after a high fat breakfast in Part A</outcome_measure>
      <outcome_measure>Tmax of GSK2982772 for MR coated tablet formulation after a high fat breakfast in Part B</outcome_measure>
      <outcome_measure>C24h of GSK2982772 for MR coated tablet formulation (240 mg) after a high fat breakfast in Part A</outcome_measure>
      <outcome_measure>C24h of GSK2982772 for MR coated tablet formulation after a high fat breakfast in Part B</outcome_measure>
      <outcome_measure>t1/2 of GSK2982772 for MR coated tablet formulation (240 mg) after a high fat breakfast in Part A</outcome_measure>
      <outcome_measure>t1/2 of GSK2982772 for MR coated tablet formulation after a high fat breakfast in Part B</outcome_measure>
      <outcome_measure>Relative bioavailability in fed versus fasted conditions (FrelFE) based on AUC of GSK2982772 for MR coated tablet formulation in Part A</outcome_measure>
      <outcome_measure>FrelFE based on Cmax of GSK2982772 for MR coated tablet formulation in Part A</outcome_measure>
      <outcome_measure>FrelFE of GSK2982772 based on AUC for MR coated tablet formulation in Part B</outcome_measure>
      <outcome_measure>FrelFE of GSK2982772 based on Cmax for MR coated tablet formulation in Part B</outcome_measure>
      <outcome_measure>Relative bioavailability (Frelformulation) based on AUC of GSK2982772 for MR coated tablet formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>Frelformulation based on Cmax of GSK2982772 for MR coated tablet formulation (240 mg) in Part A</outcome_measure>
      <outcome_measure>Frelformulation based on AUC of GSK2982772 for MR coated tablet formulation in Part B</outcome_measure>
      <outcome_measure>Frelformulation based on Cmax of GSK2982772 for MR coated tablet formulation in Part B</outcome_measure>
      <outcome_measure>Number of subjects with adverse events (AEs) and serious adverse events (SAEs) in Part A</outcome_measure>
      <outcome_measure>Number of subjects with clinically significant abnormality in clinical chemistry parameters in Part A</outcome_measure>
      <outcome_measure>Number of subjects with clinically significant abnormality in hematology parameters in Part A</outcome_measure>
      <outcome_measure>Number of subjects with clinically significant abnormality in urinalysis parameters in Part A</outcome_measure>
      <outcome_measure>Number of subjects with clinically significant abnormal systolic blood pressure (SBP) and diastolic blood pressure (DBP) in Part A</outcome_measure>
      <outcome_measure>Number of subjects with clinically significant abnormal heart rate in Part A</outcome_measure>
      <outcome_measure>Number of subjects with clinically significant abnormal respiratory rate in Part A</outcome_measure>
      <outcome_measure>Number of subjects with clinically significant abnormal body temperature in Part A</outcome_measure>
      <outcome_measure>Number of subjects with clinically significant abnormal electrocardiogram (ECG) findings in Part A</outcome_measure>
      <outcome_measure>Frelformulation based on AUC of GSK2982772 for MR coated tablet formulation in Part A</outcome_measure>
      <outcome_measure>Frelformulation based on Cmax of GSK2982772 for MR coated tablet formulation in Part A</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GlaxoSmithKline</lead_sponsor>
      <collaborator>Quotient Sciences</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>33</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>209261</other_id>
      <other_id>2018-002370-48</other_id>
    </other_ids>
    <start_date>September 26, 2018</start_date>
    <primary_completion_date>May 7, 2019</primary_completion_date>
    <completion_date>May 7, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>June 19, 2019</last_update_posted>
    <locations>
      <location>GSK Investigational Site, Nottingham, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649412</url>
  </study>
  <study rank="45150">
    <nct_id>NCT03649399</nct_id>
    <title>Sonographic Detection of Prophylactic Pancreatic Stents</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pancreatitis</condition>
      <condition>Stent Dislodgement</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Abdominal ultrasound</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Positive predictive value of the sonographic detection of pancreatic stents</outcome_measure>
      <outcome_measure>Negative predictive value of the sonographic detection of pancreatic stents</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johann Wolfgang Goethe University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>419/17</other_id>
    </other_ids>
    <start_date>March 1, 2018</start_date>
    <primary_completion_date>March 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Klinikum der J.W. Goethe-Universität, Frankfurt am Main, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649399</url>
  </study>
  <study rank="45151">
    <nct_id>NCT03649386</nct_id>
    <title>Heated Circuit for One-lung Ventilation</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>One-lung Ventilation</condition>
      <condition>Oxygenation</condition>
      <condition>Temperature</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Heated and humidified breathing circuit on</intervention>
      <intervention type="Device">Heated and humidified breathing circuit off</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Arterial oxygenation</outcome_measure>
      <outcome_measure>Mean arterial pressure</outcome_measure>
      <outcome_measure>Heart rate</outcome_measure>
      <outcome_measure>Temperature</outcome_measure>
      <outcome_measure>Central venous pressure</outcome_measure>
      <outcome_measure>Cardiac index</outcome_measure>
      <outcome_measure>Pressure peak</outcome_measure>
      <outcome_measure>Pressure plateau</outcome_measure>
      <outcome_measure>Arterial carbon dioxide</outcome_measure>
      <outcome_measure>Arterial blood acidosis</outcome_measure>
      <outcome_measure>Oxygen saturation of arterial blood</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Keimyung University Dongsan Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>104</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>HeatOLV</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>September 1, 2019</primary_completion_date>
    <completion_date>December 1, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649386</url>
  </study>
  <study rank="45152">
    <nct_id>NCT03649373</nct_id>
    <title>The Noergaard Technique for Anterior Shoulder Dislocation</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anterior Shoulder Dislocation</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Noergaard technique</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Successful shoulder reduction after anterior shoulder dislocation.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Copenhagen University Hospital, Hvidovre</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>14 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>151</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>Noergaard Study</other_id>
    </other_ids>
    <start_date>January 1, 2014</start_date>
    <primary_completion_date>December 31, 2014</primary_completion_date>
    <completion_date>December 15, 2016</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649373</url>
  </study>
  <study rank="45153">
    <nct_id>NCT03649360</nct_id>
    <title>Knee Pain After Intramedullary Nailing in the Tibia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tibia Fracture</condition>
      <condition>Knee Pain Chronic</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Knee Pain after Tibial Shaft Fracture Treated with Intramedullary Nailing</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Copenhagen University Hospital, Hvidovre</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>223</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>IMN Study</other_id>
    </other_ids>
    <start_date>November 1, 2009</start_date>
    <primary_completion_date>October 31, 2014</primary_completion_date>
    <completion_date>December 15, 2016</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Copenhagen University Hospital of Hvidovre, Hvidovre, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649360</url>
  </study>
  <study rank="45154">
    <nct_id>NCT03649347</nct_id>
    <title>Bringing Exposure Therapy to Real-Life Context With Augmented Reality</title>
    <acronym>ARET</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Phobia Snakes</condition>
      <condition>Phobias Spiders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Augmented reality exposure therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Spider Phobia</outcome_measure>
      <outcome_measure>Behavioral Approach Test--Ability to confront phobia</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Wayne State University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1711000968</other_id>
    </other_ids>
    <start_date>August 30, 2018</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 29, 2019</last_update_posted>
    <locations>
      <location>Wayne State U Department of Psychiatry, Detroit, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649347</url>
  </study>
  <study rank="45155">
    <nct_id>NCT03649334</nct_id>
    <title>Ketamine-ketorolac Versus Fentanyl- Ketorolac I.M in Children During Bone Marrow Biopsy</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hematological Malignancy (Leukemia- Lymphoma)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ketamine-ketorolac</intervention>
      <intervention type="Drug">fentanyl- ketorolac</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Postoperative pain</outcome_measure>
      <outcome_measure>Heart rate</outcome_measure>
      <outcome_measure>systolic blood pressure</outcome_measure>
      <outcome_measure>The time to the first demand for rescue analgesic</outcome_measure>
      <outcome_measure>total number of children who required postoperative pain medication</outcome_measure>
      <outcome_measure>emergence behavior</outcome_measure>
      <outcome_measure>nausea, vomiting</outcome_measure>
      <outcome_measure>respiratory difficulty</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mansoura University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>2 Years</min_age>
    <max_age>7 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>R/18.06.213</other_id>
    </other_ids>
    <start_date>August 26, 2018</start_date>
    <primary_completion_date>October 1, 2018</primary_completion_date>
    <completion_date>October 15, 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649334</url>
  </study>
  <study rank="45156">
    <nct_id>NCT03649321</nct_id>
    <title>Chemotherapy With Nab-paclitaxel/Germcitabine/Cisplatin +/- BGB324 With Pancreatic Cancer</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cancer of Pancreas</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BGB324</intervention>
      <intervention type="Drug">Nab-paclitaxel</intervention>
      <intervention type="Drug">Gemcitabine</intervention>
      <intervention type="Drug">Cisplatin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Complete Response Rate (CR)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Texas Southwestern Medical Center</lead_sponsor>
      <collaborator>Triligent International</collaborator>
      <collaborator>Translational Genomics Research Institute</collaborator>
      <collaborator>BerGenBio ASA</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>74</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>STU 062018-024</other_id>
    </other_ids>
    <start_date>January 3, 2019</start_date>
    <primary_completion_date>July 2021</primary_completion_date>
    <completion_date>July 2022</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>January 10, 2019</last_update_posted>
    <locations>
      <location>University of Texas Southwestern Medical Center, Dallas, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649321</url>
  </study>
  <study rank="45157">
    <nct_id>NCT03649308</nct_id>
    <title>Negative Pressure Wound Therapy Compared to Traditional Care After Skin Grafting</title>
    <acronym>TRUTH</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Wound of Skin</condition>
      <condition>Wound Heal</condition>
      <condition>Wound</condition>
      <condition>Wound Open</condition>
      <condition>Wound Breakdown</condition>
      <condition>Skin Wound</condition>
      <condition>Skin Scarring</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Negative Pressure Wound Therapy</intervention>
      <intervention type="Procedure">Conventional treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Between group difference in skin graft take</outcome_measure>
      <outcome_measure>Strength of pain (wound)</outcome_measure>
      <outcome_measure>Strength of pain (donor site)</outcome_measure>
      <outcome_measure>POSAS score (wound)</outcome_measure>
      <outcome_measure>POSAS score (donor site)</outcome_measure>
      <outcome_measure>Change in quality of life</outcome_measure>
      <outcome_measure>Overall satisfaction</outcome_measure>
      <outcome_measure>Strength of itching (wound)</outcome_measure>
      <outcome_measure>Strength of itching (donor site)</outcome_measure>
      <outcome_measure>Length of stay</outcome_measure>
      <outcome_measure>Number of visits</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Central Finland Hospital District</lead_sponsor>
      <collaborator>Tampere University Hospital</collaborator>
      <collaborator>University of Eastern Finland</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>6U/2018</other_id>
    </other_ids>
    <start_date>September 19, 2018</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 12, 2018</last_update_posted>
    <locations>
      <location>Central Finland Hospital, Jyväskylä, Finland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649308</url>
  </study>
  <study rank="45158">
    <nct_id>NCT03649295</nct_id>
    <title>Combined Conventional Speech Therapy and Functional Electrical Stimulation in Dysphagia Following Stroke</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dysphagia, Oropharyngeal</condition>
      <condition>Stroke, Ischemic</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Functional Electrical Stimulation</intervention>
      <intervention type="Other">Conventional Speech Therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Level of dysphagia assessed by videoendoscopy of swallowing</outcome_measure>
      <outcome_measure>Safe food Intake assessed by Functional Scale Oral Ingestion - FOIS</outcome_measure>
      <outcome_measure>Clinical evaluation of swallowing through the risk assessment protocol for dysphagia - PARD</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Geral de Fortaleza</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>40 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2388931</other_id>
    </other_ids>
    <start_date>February 20, 2018</start_date>
    <primary_completion_date>December 26, 2019</primary_completion_date>
    <completion_date>February 20, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>February 26, 2019</last_update_posted>
    <locations>
      <location>Ubiversidade Federal do Ceará, Fortaleza, Ceará, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649295</url>
  </study>
  <study rank="45159">
    <nct_id>NCT03649282</nct_id>
    <title>HFNC and NCPAP in Extremely Preterm Infants</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Extreme Prematurity</condition>
    </conditions>
    <interventions>
      <intervention type="Other">HFNC</intervention>
      <intervention type="Other">NCPAP</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Differences on Heart Rate Variability in extremely preterm infants receiving HFNC and NCPAP</outcome_measure>
      <outcome_measure>Differences on Respiratory Variability in extremely preterm infants receiving HFNC and NCPAP</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Guilherme Sant'Anna, MD</lead_sponsor>
      <collaborator>McGill University Health Centre/Research Institute of the McGill University Health Centre</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>12-342-PED</other_id>
    </other_ids>
    <start_date>October 2013</start_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <completion_date>April 2016</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Montreal Children's Hospital, Montreal, Quebec, Canada</location>
      <location>Royal Victoria Hospital, Montreal, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649282</url>
  </study>
  <study rank="45160">
    <nct_id>NCT03649269</nct_id>
    <title>PC-300 Tea Effect on Triglyceride Levels</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hypertriglyceridemia</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">PC-300 tea.</intervention>
      <intervention type="Drug">Bezafibrate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Triglycerides serum levels.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ciprés Grupo Médico CGM SC</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>34</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2014/02</other_id>
    </other_ids>
    <start_date>January 1, 2014</start_date>
    <primary_completion_date>November 30, 2014</primary_completion_date>
    <completion_date>December 31, 2014</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649269</url>
  </study>
  <study rank="45161">
    <nct_id>NCT03649256</nct_id>
    <title>Deficient Lower Segment Cesarean Section Scar, Does the Type of Suture Matter?</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2 Arms, Conventional Suture, Barbed Suture</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Thickness of lower uterine segment scar</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Uterine Thickness</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ziv Hospital</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>202</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ZIV-0085-18</other_id>
    </other_ids>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>January 9, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649256</url>
  </study>
  <study rank="45162">
    <nct_id>NCT03649243</nct_id>
    <title>Propolis as Adjuvant in the Healing of Human Diabetic Foot Wounds</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes Mellitus, Type 2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Propolis spray</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>allergenic to propolis analysis</outcome_measure>
      <outcome_measure>obtaining biopses</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Talca</lead_sponsor>
      <collaborator>Hospital Regional de Talca</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>31</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>2015-c03</other_id>
    </other_ids>
    <start_date>October 2015</start_date>
    <primary_completion_date>March 2016</primary_completion_date>
    <completion_date>March 2017</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649243</url>
  </study>
  <study rank="45163">
    <nct_id>NCT03649230</nct_id>
    <title>Observational Study on the Use of Akynzeo® in Patients Receiving HEC</title>
    <acronym>EVOLVE_CINV</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chemotherapy-Induced Nausea and Vomiting</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">300mg netupitant/0.5mg palonosetron hydrochloride</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Total Functional Living Index-Emesis (FLIE) score at cycle 1</outcome_measure>
      <outcome_measure>Complete Response</outcome_measure>
      <outcome_measure>Severity of Nausea</outcome_measure>
      <outcome_measure>Time to failure</outcome_measure>
      <outcome_measure>incidence of treatment-Emergent Adverse Events [Safety and Tolerability]</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Purdue Pharma, Canada</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>207</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CAN-PRO-NEPA-001</other_id>
    </other_ids>
    <start_date>October 3, 2018</start_date>
    <primary_completion_date>January 30, 2020</primary_completion_date>
    <completion_date>March 30, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>November 4, 2019</last_update_posted>
    <locations>
      <location>Tom Baker Cancer Center, Calgary, Alberta, Canada</location>
      <location>The Moncton Hospital, Moncton, New Brunswick, Canada</location>
      <location>NSHA-QEII Health Sciences Centre, Halifax, Nova Scotia, Canada</location>
      <location>Cape Breton Cancer Centre, Sydney, Nova Scotia, Canada</location>
      <location>Royal Victoria Regional Health Centre, Barrie, Ontario, Canada</location>
      <location>William Osler Health System, Brampton, Ontario, Canada</location>
      <location>Grand River Regional Cancer Centre, Kitchener, Ontario, Canada</location>
      <location>London Health Sciences Centre, London, Ontario, Canada</location>
      <location>Thunder Bay Regional Health Sciences Centre, Thunder Bay, Ontario, Canada</location>
      <location>St. Michael's Hospital, Toronto, Ontario, Canada</location>
      <location>Sunnybrook Health Sciences Center, Toronto, Ontario, Canada</location>
      <location>Windsor Regional Cancer Centre, Windsor, Ontario, Canada</location>
      <location>Centre Integre de Sante et de Services Sociaux de la Monteregie-Centre, Greenfield Park, Quebec, Canada</location>
      <location>Cisss de Chaudiere-Appalaches, Lévis, Quebec, Canada</location>
      <location>Segal Cancer Centre-Jewish General Hospital, Montréal, Quebec, Canada</location>
      <location>Centre de recherche du CHUS and Hopital Fleurimont, Sherbrooke, Quebec, Canada</location>
      <location>Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649230</url>
  </study>
  <study rank="45164">
    <nct_id>NCT03649217</nct_id>
    <title>Active Limb Orthosis for Home-Use Stroke Hemiparetic Gait Rehabilitation</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Stroke</condition>
    </conditions>
    <interventions>
      <intervention type="Device">wearing the iStride device</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Percentage change in step length asymmetry</outcome_measure>
      <outcome_measure>Change in Percentage change in double support asymmetry</outcome_measure>
      <outcome_measure>Change in Ten minute walk test (10MWT)</outcome_measure>
      <outcome_measure>Change in Timed up and Go (TUG)</outcome_measure>
      <outcome_measure>Change in Berg Balance Scale</outcome_measure>
      <outcome_measure>Change in Functional Gait Assessment (FGA)</outcome_measure>
      <outcome_measure>Change in Stroke Specific Quality of Life</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of South Florida</lead_sponsor>
      <collaborator>Moterum Technologies Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Moterum-iStride</other_id>
    </other_ids>
    <start_date>July 9, 2018</start_date>
    <primary_completion_date>August 31, 2019</primary_completion_date>
    <completion_date>December 31, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 11, 2018</last_update_posted>
    <locations>
      <location>University of South Florida, Tampa, Florida, United States</location>
      <location>homes throughout Charlotte, NC, Charlotte, North Carolina, United States</location>
      <location>homes throughout Memphis, TN, Memphis, Tennessee, United States</location>
      <location>homes throughout Burlington, VT, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649217</url>
  </study>
  <study rank="45165">
    <nct_id>NCT03649204</nct_id>
    <title>Effect of a Hybrid Rehabilitation Program on Walking, Quality of Life &amp; Cardiovascular Risk in People With PAD</title>
    <acronym>HY-PAD</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Peripheral Arterial Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">HY-PAD</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>6MWT</outcome_measure>
      <outcome_measure>Improvements in quality of life</outcome_measure>
      <outcome_measure>improvements in Walking Impairment Questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ottawa Heart Institute Research Corporation</lead_sponsor>
      <collaborator>AFP Innovation Fund</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>774</other_id>
    </other_ids>
    <start_date>July 9, 2019</start_date>
    <primary_completion_date>September 1, 2020</primary_completion_date>
    <completion_date>September 1, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>July 24, 2019</last_update_posted>
    <locations>
      <location>University of Ottawa Heart Institute, Ottawa, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649204</url>
  </study>
  <study rank="45166">
    <nct_id>NCT03649191</nct_id>
    <title>BABEL Advance Care Planning in Long-term Care</title>
    <acronym>BABEL</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Nursing Homes</condition>
      <condition>Aged</condition>
      <condition>Frail Elderly Syndrome</condition>
      <condition>Dementia</condition>
      <condition>Chronic Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">The BABEL Approach to Advance Care Planning in Nursing Homes</intervention>
      <intervention type="Other">Control group Advance Care Planning</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Advance Care Planning (ACP) Audit</outcome_measure>
      <outcome_measure>Comfort in Dying of Nursing Home Residents (CAD-EOLD)</outcome_measure>
      <outcome_measure>Rate of transfer from nursing home to emergency department or hospital.</outcome_measure>
      <outcome_measure>Rate of admission to hospital</outcome_measure>
      <outcome_measure>Time from study entry to death</outcome_measure>
      <outcome_measure>Rate of use in nursing home of feeding tubes</outcome_measure>
      <outcome_measure>Rate of use in nursing home of systemic antibiotics</outcome_measure>
      <outcome_measure>Rate in nursing home of transition to palliative (comfort) care</outcome_measure>
      <outcome_measure>Discordance in care at the end of life</outcome_measure>
      <outcome_measure>ACP Self-efficacy of Nursing Home Resident Subjects</outcome_measure>
      <outcome_measure>Nursing Home staff self-efficacy in Advance Care Planning (ACP)</outcome_measure>
      <outcome_measure>Thematic analysis of experiences and feelings of nursing home staff about Advance Care Planning.</outcome_measure>
      <outcome_measure>Satisfaction with Care at End of Life (SWC-EOLD)</outcome_measure>
      <outcome_measure>Whether plan of care was followed.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Manitoba</lead_sponsor>
      <collaborator>University of Waterloo</collaborator>
      <collaborator>University of Calgary</collaborator>
      <collaborator>Conestoga College</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>65 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1129</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>CFN TG2015-15</other_id>
    </other_ids>
    <start_date>August 25, 2018</start_date>
    <primary_completion_date>March 31, 2020</primary_completion_date>
    <completion_date>March 31, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>September 5, 2018</last_update_posted>
    <locations>
      <location>University of Calgary, Calgary, Alberta, Canada</location>
      <location>University of Manitoba, Winnipeg, Manitoba, Canada</location>
      <location>Waterloo University, Waterloo, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649191</url>
  </study>
  <study rank="45167">
    <nct_id>NCT03649178</nct_id>
    <title>Dietary Salt in Rheumatoid Arthritis</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Rheumatoid Arthritis</condition>
    </conditions>
    <interventions>
      <intervention type="Other">salt</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Tissue sodium</outcome_measure>
      <outcome_measure>Change in DAS 28</outcome_measure>
      <outcome_measure>Change in blood pressure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vanderbilt University Medical Center</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
      <collaborator>National Heart, Lung, and Blood Institute (NHLBI)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>22</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>141610</other_id>
      <other_id>R01HL140145</other_id>
    </other_ids>
    <start_date>January 2020</start_date>
    <primary_completion_date>July 2022</primary_completion_date>
    <completion_date>October 2022</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>January 9, 2020</last_update_posted>
    <locations>
      <location>Vanderbilt University Medical Center, Nashville, Tennessee, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649178</url>
  </study>
  <study rank="45168">
    <nct_id>NCT03649165</nct_id>
    <title>A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)</condition>
      <condition>Healthy Participants</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Treatment A</intervention>
      <intervention type="Drug">Treatment B</intervention>
      <intervention type="Drug">Treatment C</intervention>
      <intervention type="Drug">Treatment D</intervention>
      <intervention type="Drug">Acetaminophen</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: Dose normalized area under plasma concentration-time curve from time zero to infinity (AUC/D)</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: Dose normalized area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast/D)</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: Dose normalized maximum observed plasma concentration (Cmax/D)</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: Fraction of administered selumetinib granule dose systemically available relative to the capsule reference (Frel)</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: Area under plasma concentration time curve from time zero to infinity (AUC)</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUClast)</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: Area under the plasma concentration-time curve from zero to 12 hours post-dose [AUC(0-12)]</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: Maximum observed plasma concentration (Cmax)</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: Ratio of AUC in fed state to AUC in the fasted state (FRAUC)</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: Ratio of Cmax in fed state to Cmax in the fasted state (FRCmax)</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: Time to reach maximum observed plasma concentration (tmax)</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: Terminal elimination rate constant (λz)</outcome_measure>
      <outcome_measure>Selumetinib plasma PK parameters: Apparent total body clearance of drug from plasma after extravascular administration (parent drug only) (CL/F)</outcome_measure>
      <outcome_measure>Selumetinib plasma PK parameters: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: AUC</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: AUClast</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: AUC(0-12)</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: Cmax</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: FRAUC</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: FRCmax</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: t½λz</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: tmax</outcome_measure>
      <outcome_measure>Selumetinib and N-desmethyl selumetinib plasma PK parameter: λz</outcome_measure>
      <outcome_measure>Selumetinib plasma PK parameters: CL/F</outcome_measure>
      <outcome_measure>Selumetinib plasma PK parameters: Vz/F</outcome_measure>
      <outcome_measure>Taste questionnaire</outcome_measure>
      <outcome_measure>Number of participants with adverse events (AEs)</outcome_measure>
      <outcome_measure>Vital signs (systolic blood pressure [BP])</outcome_measure>
      <outcome_measure>Vital signs (diastolic BP)</outcome_measure>
      <outcome_measure>Pulse rate</outcome_measure>
      <outcome_measure>12-lead electrocardiogram (ECG)</outcome_measure>
      <outcome_measure>Number of participants with abnormal findings in physical examination</outcome_measure>
      <outcome_measure>Ophthalmic examinations</outcome_measure>
      <outcome_measure>Laboratory assessments: hematology - Hemoglobin (Hb)</outcome_measure>
      <outcome_measure>Laboratory assessments: hematology - erythrocyte count</outcome_measure>
      <outcome_measure>Laboratory assessments: hematology: Platelet count</outcome_measure>
      <outcome_measure>Laboratory assessments: hematology: leucocyte differential count (absolute count)</outcome_measure>
      <outcome_measure>Laboratory assessments: hematology: leucocyte cell count</outcome_measure>
      <outcome_measure>Laboratory assessments:hematology - differential count</outcome_measure>
      <outcome_measure>Laboratory assessments: Serum clinical chemistry - electrolytes</outcome_measure>
      <outcome_measure>Laboratory assessments: Serum clinical chemistry - urea nitrogen</outcome_measure>
      <outcome_measure>Laboratory assessments: Serum clinical chemistry - creatinine</outcome_measure>
      <outcome_measure>Laboratory assessments: Serum clinical chemistry: albumin</outcome_measure>
      <outcome_measure>Laboratory assessments: Serum clinical chemistry: Total Calcium</outcome_measure>
      <outcome_measure>Laboratory assessments: Serum clinical chemistry: Total protein</outcome_measure>
      <outcome_measure>Laboratory assessments: Serum clinical chemistry: Total bilirubin</outcome_measure>
      <outcome_measure>Laboratory assessments: Serum clinical chemistry: Creatine phosphokinase (CPK)</outcome_measure>
      <outcome_measure>Laboratory assessments: Serum clinical chemistry: Troponin (isoform as per institutional norm)</outcome_measure>
      <outcome_measure>Laboratory assessments: Serum clinical chemistry - Liver enzymes</outcome_measure>
      <outcome_measure>Laboratory assessments: Clinical urinalysis - glucose</outcome_measure>
      <outcome_measure>Laboratory assessments: Clinical Urinalysis - protein</outcome_measure>
      <outcome_measure>Laboratory assessments: Clinical Urinalysis - blood</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>D1532C00089</other_id>
    </other_ids>
    <start_date>September 5, 2018</start_date>
    <primary_completion_date>October 21, 2018</primary_completion_date>
    <completion_date>October 21, 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>November 8, 2018</last_update_posted>
    <locations>
      <location>Research Site, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649165</url>
  </study>
  <study rank="45169">
    <nct_id>NCT03649152</nct_id>
    <title>Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan</title>
    <acronym>ACTION</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Focal Segmental Glomerulosclerosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Propagermanium</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The Number of Adverse Events with the Adjunct use of Propagermanium Compared to Placebo in Participants with FSGS who are Receiving Irbesartan</outcome_measure>
      <outcome_measure>The Frequency of Proteinuria-Based Responses to Treatment Compared to Placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dimerix Bioscience Pty Ltd</lead_sponsor>
      <collaborator>Iqvia Pty Ltd</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DMX-200-202 A</other_id>
      <other_id>ACTRN12618000910202p</other_id>
    </other_ids>
    <start_date>September 17, 2018</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>November 28, 2018</last_update_posted>
    <locations>
      <location>Renal Research, Gosford, New South Wales, Australia</location>
      <location>Liverpool Hospital, Liverpool, New South Wales, Australia</location>
      <location>Royal North Shore Hospital, St Leonards, New South Wales, Australia</location>
      <location>Westmead, Westmead, New South Wales, Australia</location>
      <location>Sunshine Coast University Hospital, Birtinya, Queensland, Australia</location>
      <location>Princess Alexandra Hospital, Woolloongabba, Queensland, Australia</location>
      <location>Box Hill Hospital, Box Hill, Victoria, Australia</location>
      <location>Austion Hospital, Heidelberg, Victoria, Australia</location>
      <location>Sunshine Hospital, Melbourne, Victoria, Australia</location>
      <location>Epworth Hospital, Richmond, Victoria, Australia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649152</url>
  </study>
  <study rank="45170">
    <nct_id>NCT03649139</nct_id>
    <title>Effect and Underlying Immunological Mechanisms of Sublingual Immunotherapy in Allergic Rhinitis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Seasonal Allergic Rhinitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">sublingual immunotherapy drops</intervention>
      <intervention type="Drug">Placebo drops</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>change from baseline symptom scores at Week 16</outcome_measure>
      <outcome_measure>Quality of life</outcome_measure>
      <outcome_measure>Medication scores</outcome_measure>
      <outcome_measure>Immunologic Changes-IgE</outcome_measure>
      <outcome_measure>Immunologic Changes-M2 population</outcome_measure>
      <outcome_measure>Change of symptom scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beijing Tongren Hospital</lead_sponsor>
      <collaborator>Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>71</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TR-SLIT-IMMUNO</other_id>
    </other_ids>
    <start_date>April 1, 2017</start_date>
    <primary_completion_date>October 30, 2018</primary_completion_date>
    <completion_date>October 30, 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>June 11, 2019</last_update_posted>
    <locations>
      <location>Beijing Tongren Hospital, Beijing, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649139</url>
  </study>
  <study rank="45171">
    <nct_id>NCT03649126</nct_id>
    <title>Nationwide Implementation of Standardized Structured Reporting</title>
    <acronym>IMPROVING</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Standardized Structured Reporting</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Implementation tools</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Barriers and facilitators in implementation of SSR in MDT - focus groups and self-developed questionnaire</outcome_measure>
      <outcome_measure>Effectiveness of implementation tools - frequencies of use of SSR templates in pathology in the Netherlands</outcome_measure>
      <outcome_measure>Determinants of barriers and facilitators in implementation of SSR - focus groups and a self-developed questionnaire</outcome_measure>
      <outcome_measure>Experiences with implementation tools - questionnaire</outcome_measure>
      <outcome_measure>Use of implementation tools - questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Radboud University</lead_sponsor>
      <collaborator>Dutch Cancer Society</collaborator>
      <collaborator>PALGA foundation</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>68 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>KWF-8281</other_id>
      <other_id>2018-4124</other_id>
    </other_ids>
    <start_date>August 21, 2018</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Radboud University Nijmegen Medical Center, Nijmegen, Gelderland, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649126</url>
  </study>
  <study rank="45172">
    <nct_id>NCT03649113</nct_id>
    <title>Percutaneous Sclerotherapy of Symptomatic Liver Hemangioma With Bleomycin</title>
    <acronym>Hemangioma</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hemangioma Liver</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">sclerotherapy arm</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in patient satisfaction assessed by the Visual Analog Scale (VAS) after 6 months</outcome_measure>
      <outcome_measure>Incidence of major adverse events</outcome_measure>
      <outcome_measure>Change in hemangioma size</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tehran University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Liver Hemangioma Sclerotherapy</other_id>
    </other_ids>
    <start_date>September 15, 2018</start_date>
    <primary_completion_date>November 15, 2019</primary_completion_date>
    <completion_date>May 15, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 29, 2019</last_update_posted>
    <locations>
      <location>Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649113</url>
  </study>
  <study rank="45173">
    <nct_id>NCT03649100</nct_id>
    <title>Osseointegration With a New Hydrophilic Surface</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dental Implant Stability</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Implant placement</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Implant and prosthetic success rates</outcome_measure>
      <outcome_measure>Technical or biological complications</outcome_measure>
      <outcome_measure>Implant stability quotient (ISQ)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Osstem AIC</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Osstem_002</other_id>
    </other_ids>
    <start_date>November 1, 2017</start_date>
    <primary_completion_date>December 31, 2018</primary_completion_date>
    <completion_date>May 30, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>June 25, 2019</last_update_posted>
    <locations>
      <location>Nicola Baldini, Florence, Italy</location>
      <location>Fulvio Gatti, Milan, Italy</location>
      <location>Studio Odontoiatrico Marco Tallarico, Rome, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649100</url>
  </study>
  <study rank="45174">
    <nct_id>NCT03649087</nct_id>
    <title>Vitrification for Ovarian Tissue Harvesting</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ovary; Anomaly</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Vitrification</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>survival of ovarian tissue</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maximilian Franz, M.D.</lead_sponsor>
      <collaborator>Medical University of Vienna</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>2204</other_id>
    </other_ids>
    <start_date>October 1, 2017</start_date>
    <primary_completion_date>October 1, 2018</primary_completion_date>
    <completion_date>December 1, 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>University Clinic of Obstetrics and Gynaecology of the Medical University of Vienna, Vienna, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649087</url>
  </study>
  <study rank="45175">
    <nct_id>NCT03649074</nct_id>
    <title>Software Treatment for Actively Reducing Severity of ADHD as Adjunctive Treatment to Stimulant</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Attention Deficit Hyperactivity Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Device">AKL-T01</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Impairment Rating Scale (Clinician Report) Overall Impairment; Cohort 1: Stimulant</outcome_measure>
      <outcome_measure>Change in Impairment Rating Scale (Clinician Report) Overall Impairment; Cohort 2: Non-Stimulant</outcome_measure>
      <outcome_measure>Change in ADHD-Rating Scale Total Score; Cohort 1: Stimulant</outcome_measure>
      <outcome_measure>Change in ADHD-Rating Scale Total Score; Cohort 2: Non-Stimulant</outcome_measure>
      <outcome_measure>Clinical Global Impression-Improvement Score; Cohort 1: Stimulant</outcome_measure>
      <outcome_measure>Clinical Global Impression-Improvement Score; Cohort 2: Non-Stimulant</outcome_measure>
      <outcome_measure>Change TOVA Attention Composite Score (ACS); Cohort 1: Stimulant</outcome_measure>
      <outcome_measure>Change TOVA Attention Composite Score (ACS); Cohort 2: Non-Stimulant</outcome_measure>
      <outcome_measure>Change in Test of Silent Reading Efficiency and Comprehension (TOSREC); Cohort 1: Stimulant</outcome_measure>
      <outcome_measure>Change in Test of Silent Reading Efficiency and Comprehension (TOSREC); Cohort 2: Non-Stimulant</outcome_measure>
      <outcome_measure>Change in Mathematics Fluency and Calculation Test (MFaCTS); Cohort 1: Stimulant</outcome_measure>
      <outcome_measure>Change in Mathematics Fluency and Calculation Test (MFaCTS); Cohort 2: Non-Stimulant</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Akili Interactive Labs, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <max_age>14 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>203</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>001S-A</other_id>
    </other_ids>
    <start_date>December 28, 2018</start_date>
    <primary_completion_date>September 23, 2019</primary_completion_date>
    <completion_date>February 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>January 7, 2020</last_update_posted>
    <locations>
      <location>Melmed Center, Scottsdale, Arizona, United States</location>
      <location>Center for Psychiatry and Behavioral Medicine, Las Vegas, Nevada, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649074</url>
  </study>
  <study rank="45176">
    <nct_id>NCT03649061</nct_id>
    <title>COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA</title>
    <acronym>CareRA2020</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Arthritis, Rheumatoid</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Etanercept 50 MG/ML</intervention>
      <intervention type="Drug">Leflunomide 10 milligram (MG)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Area Under Curve (AUC) DAS28 C reactive protein (CRP)</outcome_measure>
      <outcome_measure>Remission</outcome_measure>
      <outcome_measure>EULAR response</outcome_measure>
      <outcome_measure>Health Assessment Questionnaire (HAQ) response</outcome_measure>
      <outcome_measure>Radiographic progression</outcome_measure>
      <outcome_measure>Analysis of reported (Serious) Adverse Reactions</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>P. Verschueren</lead_sponsor>
      <collaborator>Belgium Health Care Knowledge Centre</collaborator>
      <collaborator>Universitaire Ziekenhuizen Leuven</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>442</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>KCE-16002</other_id>
      <other_id>2017-004054-41</other_id>
    </other_ids>
    <start_date>June 8, 2018</start_date>
    <primary_completion_date>June 2022</primary_completion_date>
    <completion_date>December 2022</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Imelda Ziekenhuis Bonheiden, Bonheiden, Antwerpen, Belgium</location>
      <location>UZA, Edegem, Antwerpen, Belgium</location>
      <location>AZ Herentals, Herentals, Antwerpen, Belgium</location>
      <location>ZNA Jan Palfijn, Merksem, Antwerpen, Belgium</location>
      <location>GHdC Saint Joseph, Gilly, Henegouwen, Belgium</location>
      <location>Reuma centrum Genk, Genk, Limburg, Belgium</location>
      <location>Reuma Clinic Genk, Genk, Limburg, Belgium</location>
      <location>Reuma Instituut Hasselt, Hasselt, Limburg, Belgium</location>
      <location>OLV Ziekenhuis Aalst, Aalst, Oost Vlaanderen, Belgium</location>
      <location>Regionaal Ziekenhuis Heilig Hart Leuven, Leuven, Vlaams Brabant, Belgium</location>
      <location>UZ Leuven, Leuven, Vlaams Brabant, Belgium</location>
      <location>AZ St Lucas Brugge, Brugge, West Vlaanderen, Belgium</location>
      <location>CHU Saint Pierre, Brussel, Belgium</location>
      <location>Cliniques Universitaire Saint Luc (UCL), Brussel, Belgium</location>
      <location>CHU Liège, Liège, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649061</url>
  </study>
  <study rank="45177">
    <nct_id>NCT03649048</nct_id>
    <title>Low-Dose Weekly vs High-Dose Cisplatin</title>
    <acronym>RADIO</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Locally Advanced Head and Neck Squamous Cell Carcinoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">High-Dose Cisplatin</intervention>
      <intervention type="Drug">Low-Dose Cisplatin</intervention>
      <intervention type="Radiation">Radiotherapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hearing related quality of life (QOL)</outcome_measure>
      <outcome_measure>Compare Incidence of &gt; Grade 2 hearing loss</outcome_measure>
      <outcome_measure>Compare Incidence of &gt; Grade 1 hearing loss</outcome_measure>
      <outcome_measure>Proportion of patients recommended for hearing amplification</outcome_measure>
      <outcome_measure>Compare incidence of &gt; grade 2 hearing loss</outcome_measure>
      <outcome_measure>Change in Health related Quality of Life (HRQOL)</outcome_measure>
      <outcome_measure>Incidence of &gt; Grade 3 treatment-related neuropathy</outcome_measure>
      <outcome_measure>Change in neuropathy-associated QOL</outcome_measure>
      <outcome_measure>Incidence of any treatment related nephropathy</outcome_measure>
      <outcome_measure>Prevalence of persistent &gt; Grade 3 nephropathy</outcome_measure>
      <outcome_measure>Evaluate the validity of MATE1 SNPs as a predictor of ototoxicity</outcome_measure>
      <outcome_measure>Evaluate the validity of COMT SNPs as a predictor of ototoxicity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lawson Health Research Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>Cisplatin HD vs LD</other_id>
    </other_ids>
    <start_date>November 5, 2018</start_date>
    <primary_completion_date>February 2020</primary_completion_date>
    <completion_date>February 2025</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>February 15, 2019</last_update_posted>
    <locations>
      <location>Juravinski Cancer Centre, Hamilton, Ontario, Canada</location>
      <location>London Regional Cancer Program, London, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649048</url>
  </study>
  <study rank="45178">
    <nct_id>NCT03649035</nct_id>
    <title>Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pancreatic Adenocarcinoma</condition>
      <condition>Pancreatic Cancer</condition>
      <condition>Pancreas Neoplasm</condition>
    </conditions>
    <interventions>
      <intervention type="Device">HTP treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of participants with feasible EUS-guided Cryothermal Ablation</outcome_measure>
      <outcome_measure>Progression-free survival</outcome_measure>
      <outcome_measure>Number of participants with treatment-related adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istituto Clinico Humanitas</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HTP1</other_id>
    </other_ids>
    <start_date>July 12, 2018</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>January 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Istituto Clinico Humanitas, Rozzano, Milano, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649035</url>
  </study>
  <study rank="45179">
    <nct_id>NCT03649022</nct_id>
    <title>&quot;Ventricular Tachycardia Ablation Registry&quot;.</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ventricular Tachycardia</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Catheter ablation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Late potential abolition and ventricular tachycardia noninducibility</outcome_measure>
      <outcome_measure>Ventricular tachycardia recurrence</outcome_measure>
      <outcome_measure>Complications</outcome_measure>
      <outcome_measure>Procedural parameters</outcome_measure>
      <outcome_measure>Assessment of cardiac mapping system EnSite Precision™ software (St.Jude, now Abbott)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Paolo Della Bella</lead_sponsor>
      <collaborator>IRCCS San Raffaele</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>OSR-ARITM-001</other_id>
    </other_ids>
    <start_date>July 25, 2017</start_date>
    <primary_completion_date>July 25, 2020</primary_completion_date>
    <completion_date>July 25, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>IRCCS San Raffaele, Milan, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649022</url>
  </study>
  <study rank="45180">
    <nct_id>NCT03649009</nct_id>
    <title>Thiamine As An Adjuvant Therapy For Hyperlactatemia In Septic Shock Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hyperlactatemia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Normal Saline</intervention>
      <intervention type="Drug">Thiamine</intervention>
      <intervention type="Drug">Hydrocortisone</intervention>
      <intervention type="Other">Metoclopramide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Assessment of the relative lactate level change over 24 hours</outcome_measure>
      <outcome_measure>Assessment of the time for shock reversal</outcome_measure>
      <outcome_measure>Assessment of the disease severity</outcome_measure>
      <outcome_measure>Assessment of patients' length of stay</outcome_measure>
      <outcome_measure>Assessment of the rate of the lactate change over 72 hours</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universiti Kebangsaan Malaysia Medical Centre</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>FF-2017-389</other_id>
    </other_ids>
    <start_date>January 1, 2018</start_date>
    <primary_completion_date>December 1, 2018</primary_completion_date>
    <completion_date>March 31, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 31, 2018</last_update_posted>
    <locations>
      <location>Universiti Kebangsaan Malaysia Medical Centre, Cheras, Kuala Lumpur, Malaysia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03649009</url>
  </study>
  <study rank="45181">
    <nct_id>NCT03648996</nct_id>
    <title>Sex-related Differences in Arterial Stiffness in Type 2 Diabetics: Role of Uric Acid</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes Mellitus, Type 2</condition>
      <condition>Hyperuricemia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Low-fructose diet</intervention>
      <intervention type="Drug">Allopurinol</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>carotid femoral pulse wave velocity (cfPWV)</outcome_measure>
      <outcome_measure>Brachial artery flow mediated dilation (FMD)</outcome_measure>
      <outcome_measure>Insulin-stimulated leg blood flow</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Missouri-Columbia</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>55 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2012106</other_id>
    </other_ids>
    <start_date>November 1, 2018</start_date>
    <primary_completion_date>September 30, 2021</primary_completion_date>
    <completion_date>September 30, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>May 7, 2019</last_update_posted>
    <locations>
      <location>University of Missouri, Columbia, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648996</url>
  </study>
  <study rank="45182">
    <nct_id>NCT03648983</nct_id>
    <title>Arm Circumference Measurement With or Without Bioimpedance Spectroscopy in Finding Lymphedema Early in Patients With Stage I-III Breast Cancer</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Lymphedema</condition>
      <condition>Breast Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">arm circumference measurement</intervention>
      <intervention type="Device">Bioimpedance spectroscopy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rates of Enhanced Lymphedema Detection</outcome_measure>
      <outcome_measure>Severity of Enhanced Lymphedema</outcome_measure>
      <outcome_measure>Percentage of Subjects With Complete Resolution of Signs of Enhanced Lymphedema</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Albert Einstein College of Medicine</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>95</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>11-06-235</other_id>
      <other_id>NCI-2014-01480</other_id>
      <other_id>11-06-235E</other_id>
      <other_id>11-047</other_id>
      <other_id>LDEX</other_id>
      <other_id>P30CA013330</other_id>
    </other_ids>
    <start_date>November 2011</start_date>
    <primary_completion_date>August 2015</primary_completion_date>
    <completion_date>August 2015</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <results_first_posted>October 1, 2018</results_first_posted>
    <last_update_posted>October 1, 2018</last_update_posted>
    <locations>
      <location>Albert Einstein College of Medicine, Bronx, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648983</url>
  </study>
  <study rank="45183">
    <nct_id>NCT03648970</nct_id>
    <title>Indonesia Pravastatin to Prevent Preeclampsia Study</title>
    <acronym>INOVASIA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pre-Eclampsia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pravastatin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Preeclampsia</outcome_measure>
      <outcome_measure>Preterm delivery</outcome_measure>
      <outcome_measure>Maternal complication</outcome_measure>
      <outcome_measure>Perinatal outcome</outcome_measure>
      <outcome_measure>Composite neonatal morbidity and mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universitas Airlangga</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>15 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>280</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>IND012018</other_id>
    </other_ids>
    <start_date>March 1, 2018</start_date>
    <primary_completion_date>March 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Sanglah General Hospital, Denpasar, Bali, Indonesia</location>
      <location>Dr. Moewardi Hospital, Surakarta, Central Java, Indonesia</location>
      <location>Ramelan Naval Hospital, Surabaya, East Java, Indonesia</location>
      <location>Dr. Soetomo Hospital, Surabaya, East Java, Indonesia</location>
      <location>Adam Malik General Hospital, Medan, North Sumatra, Indonesia</location>
      <location>Dr. Wahidin Sudirohusodo General Hospital, Makasar, South Sulawesi, Indonesia</location>
      <location>Hasan Sadikin General Hospital, Bandung, West Java, Indonesia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648970</url>
  </study>
  <study rank="45184">
    <nct_id>NCT03648957</nct_id>
    <title>Lifestyle Counselling as Secondary Prevention in Patients With Minor Stroke and Transient Ischemic Attack</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Stroke, Ischemic</condition>
      <condition>Stroke Hemorrhagic</condition>
      <condition>Transient Ischemic Attack</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Lifestyle counselling</intervention>
      <intervention type="Behavioral">Usual care</intervention>
      <intervention type="Device">Activity tracker</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Systolic blood pressure</outcome_measure>
      <outcome_measure>Recruitment rate</outcome_measure>
      <outcome_measure>Adherence rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nordsjaellands Hospital</lead_sponsor>
      <collaborator>Rigshospitalet, Denmark</collaborator>
      <collaborator>Metropolitan University College</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>H-17040484</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>March 31, 2020</primary_completion_date>
    <completion_date>March 31, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>April 18, 2019</last_update_posted>
    <locations>
      <location>Department of neurology, Nordsjællands Hospital, Hillerød, Denmark</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03648957/Prot_SAP_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03648957</url>
  </study>
  <study rank="45185">
    <nct_id>NCT03648944</nct_id>
    <title>Accelerated vs Non-Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction: A Pilot Study</title>
    <acronym>AVON ACL</acronym>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anterior Cruciate Ligament Reconstruction</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Accelerated Rehabillitation</intervention>
      <intervention type="Other">Non-Accelerated Rehabillitation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IKDC data completion</outcome_measure>
      <outcome_measure>KOOS data completion</outcome_measure>
      <outcome_measure>Tegner data completion</outcome_measure>
      <outcome_measure>EQ5D data completion</outcome_measure>
      <outcome_measure>Anterior/Posterior knee translation completion</outcome_measure>
      <outcome_measure>Lower Limb Symmetry completion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>North Bristol NHS Trust</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>7</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>R&amp;I 3181</other_id>
    </other_ids>
    <start_date>December 2014</start_date>
    <primary_completion_date>September 19, 2016</primary_completion_date>
    <completion_date>September 19, 2016</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>North Bristol NHS Trust, Bristol, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648944</url>
  </study>
  <study rank="45186">
    <nct_id>NCT03648931</nct_id>
    <title>Microbicide/PrEP Acceptability Among Mothers and Male Partners in Africa</title>
    <acronym>MAMMA</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Prevention</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Focus Group Discussion (FGD)</intervention>
      <intervention type="Behavioral">In-depth Interview (IDI)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Acceptability of VR during pregnancy and breastfeeding, including willingness to use the VR or support its use</outcome_measure>
      <outcome_measure>Acceptability of oral PrEP during pregnancy and breastfeeding, including willingness to use oral PrEP or support its use</outcome_measure>
      <outcome_measure>Product preferences during pregnancy and breastfeeding</outcome_measure>
      <outcome_measure>Sexual activity and contraceptive use during pregnancy and breastfeeding</outcome_measure>
      <outcome_measure>Perceptions of HIV risk during pregnancy and breastfeeding</outcome_measure>
      <outcome_measure>Community beliefs and practices related to pregnancy and breastfeeding, including use of oral medications and intravaginal products</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Microbicide Trials Network</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>232</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>MTN-041</other_id>
      <other_id>UM1AI068633</other_id>
      <other_id>UM1AI068615</other_id>
      <other_id>UM1AI106707</other_id>
      <other_id>38161</other_id>
    </other_ids>
    <start_date>May 31, 2018</start_date>
    <primary_completion_date>November 2, 2018</primary_completion_date>
    <completion_date>November 2, 2018</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>February 25, 2019</last_update_posted>
    <locations>
      <location>Blantyre Clinical Research Site, Blantyre, Malawi</location>
      <location>Wits Reproductive Health and HIV Institute (WRHI) Clinical Research Site, Johannesburg, South Africa</location>
      <location>Makerere University - Johns Hopkins University (MU-JHU) Research Collaboration Clinical Research Site, Kampala, Uganda</location>
      <location>Zengeza Clinical Research Site, Harare, Zimbabwe</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648931</url>
  </study>
  <study rank="45187">
    <nct_id>NCT03648918</nct_id>
    <title>Genetics Of Autoimmunity In Type I Diabetes</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Type1diabetes</condition>
      <condition>Diabetes Mellitus, Type 1</condition>
      <condition>Type1 Diabetes Mellitus</condition>
      <condition>Diabetes Mellitus</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Blood Collection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Onset of Type 1 diabetes</outcome_measure>
      <outcome_measure>Autoantibody Measurement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical College of Wisconsin</lead_sponsor>
      <collaborator>Benaroya Research Institute</collaborator>
      <collaborator>Indiana University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>2 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>4000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Family-Based</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>142618</other_id>
      <other_id>McGee Family Study</other_id>
    </other_ids>
    <start_date>August 2001</start_date>
    <primary_completion_date>January 2050</primary_completion_date>
    <completion_date>January 2050</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>October 28, 2019</last_update_posted>
    <locations>
      <location>Medical College of Wisconsin, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648918</url>
  </study>
  <study rank="45188">
    <nct_id>NCT03648905</nct_id>
    <title>Clinical Laboratory Evaluation of Chronic Autonomic Failure</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
      <condition>Multiple System Atrophy</condition>
      <condition>Autonomic Failure</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Pathophysiological classification based on clinical laboratory test results</outcome_measure>
      <outcome_measure>Estimated non-specific binding of 11C-methylreboxetine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Neurological Disorders and Stroke (NINDS)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>180140</other_id>
      <other_id>18-N-0140</other_id>
    </other_ids>
    <start_date>September 6, 2018</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 5, 2019</last_update_posted>
    <locations>
      <location>National Institutes of Health Clinical Center, Bethesda, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648905</url>
  </study>
  <study rank="45189">
    <nct_id>NCT03648892</nct_id>
    <title>Brain Dopamine Function in Human Obesity</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Obesity</condition>
      <condition>Healthy Volunteers</condition>
      <condition>Overweight</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>To determine if D2BP is related to BMI and whether there is a linear or quadratic relationship.</outcome_measure>
      <outcome_measure>To determine correlations between D2BP, as measured by [18F]fallypride and [11C]raclopride time-activity curves.</outcome_measure>
      <outcome_measure>To determine the effect of palatable meal consumption on D2BP in individuals with a wide BMI range. Binding potential estimates will be estimated within subjects using [11C]raclopride</outcome_measure>
      <outcome_measure>Investigate the associations between brain dopamine D2BP and neural bases of food perception and preference</outcome_measure>
      <outcome_measure>Investigate the metabolic and endocrine correlates of brain dopamine D2BP and neural bases of food perception and preference.</outcome_measure>
      <outcome_measure>Investigate the behavioral correlates of brain dopamine D2BP such as free-living physical activity, ad libitum meal consumption, and body weight changes over a one year period.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Crossover</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>180132</other_id>
      <other_id>18-DK-0132</other_id>
    </other_ids>
    <start_date>September 21, 2018</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>November 29, 2019</last_update_posted>
    <locations>
      <location>National Institutes of Health Clinical Center, Bethesda, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648892</url>
  </study>
  <study rank="45190">
    <nct_id>NCT03648879</nct_id>
    <title>Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gastric Cancer</condition>
      <condition>Gastric Neoplasms</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Endoscope+Cellvizio(R) 100 microscope</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Determine if confocal endoscopic microscopy (CEM) affords greater sensitivity for detection of SRC foci in CDH1 germline mutation carriers compared to the current method of standard white light endoscopy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Cancer Institute (NCI)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>180141</other_id>
      <other_id>18-C-0141</other_id>
    </other_ids>
    <start_date>February 11, 2019</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>January 13, 2020</last_update_posted>
    <locations>
      <location>National Institutes of Health Clinical Center, Bethesda, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648879</url>
  </study>
  <study rank="45191">
    <nct_id>NCT03648866</nct_id>
    <title>A Thematic Analysis of Compassion Rounds</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Spiritual Wellness</condition>
    </conditions>
    <interventions>
      <intervention type="Other">interview</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Validated Thematic Framework to Explain the Effects of Compassion Rounding</outcome_measure>
      <outcome_measure>Compendium of Evidence-Based Best Practices for the Implementation of Compassion Rounding</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Florida Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>1320386</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>August 30, 2019</primary_completion_date>
    <completion_date>August 30, 2019</completion_date>
    <study_first_posted>August 28, 2018</study_first_posted>
    <last_update_posted>August 1, 2019</last_update_posted>
    <locations>
      <location>AdventHealth Orlando, Orlando, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648866</url>
  </study>
  <study rank="45192">
    <nct_id>NCT03648853</nct_id>
    <title>Effect of Location of Tetanic Stimuli on Photoplethysmogram</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Stress Reaction</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Tetanic Stimulus</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Photoplethysmography (PPG)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, San Francisco</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>PT1801</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>November 30, 2018</primary_completion_date>
    <completion_date>November 30, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 10, 2019</last_update_posted>
    <locations>
      <location>University of California San Francisco, San Francisco, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648853</url>
  </study>
  <study rank="45193">
    <nct_id>NCT03648840</nct_id>
    <title>Human Alcohol Seeking Despite Aversion</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Alcohol Abuse</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Aversive cue</intervention>
      <intervention type="Behavioral">Neutral cue</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IV alcohol self-administration</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Indiana University</lead_sponsor>
      <collaborator>Purdue University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>1709318986</other_id>
    </other_ids>
    <start_date>April 1, 2018</start_date>
    <primary_completion_date>March 1, 2022</primary_completion_date>
    <completion_date>March 1, 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>December 5, 2019</last_update_posted>
    <locations>
      <location>University Hospital, Indianapolis, Indiana, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648840</url>
  </study>
  <study rank="45194">
    <nct_id>NCT03648827</nct_id>
    <title>A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Duchenne Muscular Dystrophy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ataluren</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percent Change From Baseline in Dystrophin Levels at Week 40, as Measured by ECL</outcome_measure>
      <outcome_measure>Percent Change From Baseline in Dystrophin Levels/Intensity at Week 40, as Determined by a Validated Immunohistochemistry Assay</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>PTC Therapeutics</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>2 Years</min_age>
    <max_age>7 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PTC124-GD-045-DMD</other_id>
    </other_ids>
    <start_date>December 21, 2018</start_date>
    <primary_completion_date>March 24, 2020</primary_completion_date>
    <completion_date>March 24, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>December 12, 2019</last_update_posted>
    <locations>
      <location>Phoenix Childrens Hospital, Phoenix, Arizona, United States</location>
      <location>University of California, Los Angeles (UCLA), Los Angeles, California, United States</location>
      <location>University of California (UC) Davis Medical Center, Sacramento, California, United States</location>
      <location>University of Kansas Medical Center, Kansas City, Kansas, United States</location>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
      <location>Columbia University College of Physicians &amp; Surgeons, New York, New York, United States</location>
      <location>Texas Children's Hospital, Houston, Texas, United States</location>
      <location>University of Texas Heath Science Center at San Antonio, San Antonio, Texas, United States</location>
      <location>Children's Hospital of the King's Daughters, Norfolk, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648827</url>
  </study>
  <study rank="45195">
    <nct_id>NCT03648814</nct_id>
    <title>Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Glaucoma, Neovascular</condition>
      <condition>Vascular Endothelial Growth Factor Overexpression</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Intracameral injection</intervention>
      <intervention type="Procedure">Intravitreal injection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>regression of nevolascularization</outcome_measure>
      <outcome_measure>IOP reduction</outcome_measure>
      <outcome_measure>Injection complication</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Prince of Songkla University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>REC6100321</other_id>
    </other_ids>
    <start_date>August 1, 2018</start_date>
    <primary_completion_date>July 1, 2021</primary_completion_date>
    <completion_date>July 1, 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 30, 2019</last_update_posted>
    <locations>
      <location>Glaucoma unit , Department of Ophthalmology Faculty of Medicine Prince of Songkla University, Hat-yai, Songkhla, Thailand</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648814</url>
  </study>
  <study rank="45196">
    <nct_id>NCT03648801</nct_id>
    <title>A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab.</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hypertension, Dyslipidemia</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Incidence of adverse event after this drug administration in general medical practice</outcome_measure>
      <outcome_measure>Incidence of serious adverse event after this drug administration in general medical practice</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>IlDong Pharmaceutical Co Ltd</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ID-TAR-P401</other_id>
    </other_ids>
    <start_date>September 2018</start_date>
    <primary_completion_date>May 2024</primary_completion_date>
    <completion_date>August 2024</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 31, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648801</url>
  </study>
  <study rank="45197">
    <nct_id>NCT03648788</nct_id>
    <title>A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mixed Dyslipidemia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">NA (Observation study)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of adverse event after this drug administration in general medical practice</outcome_measure>
      <outcome_measure>Incidence of serious adverse event after this drug administration in general medical practice</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>IlDong Pharmaceutical Co Ltd</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ID-DRT-401</other_id>
    </other_ids>
    <start_date>September 2018</start_date>
    <primary_completion_date>June 2024</primary_completion_date>
    <completion_date>August 2024</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 6, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648788</url>
  </study>
  <study rank="45198">
    <nct_id>NCT03648775</nct_id>
    <title>Evaluation of the Clinical Efficacy of Y-STRUT® Medical Device Implanted for Contralateral Percutaneous Internal Fixation of Proximal Femur, in Patient With a Low Energy Per Trochanteric Fracture on the First Side</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fracture of Hip</condition>
      <condition>Osteoporosis</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Y-STRUT® (Hyprevention, Pessac, France)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Frequency of post-operative fracture [Clinical efficacy of the device]</outcome_measure>
      <outcome_measure>Recording of concomitants treatments [safety and feasibility of the device]</outcome_measure>
      <outcome_measure>Pain [safety and feasibility of the device]</outcome_measure>
      <outcome_measure>Walking conditions [safety and feasibility of the device]</outcome_measure>
      <outcome_measure>Recording of adverse events and device effects [safety and feasibility of the device]</outcome_measure>
      <outcome_measure>Surgical procedure duration [learning curve of the procedure]</outcome_measure>
      <outcome_measure>Hospitalisation duration [learning curve of the procedure]</outcome_measure>
      <outcome_measure>Rate of complications [learning curve of the procedure]</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hyprevention</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HIP50</other_id>
    </other_ids>
    <start_date>December 6, 2017</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>February 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>July 8, 2019</last_update_posted>
    <locations>
      <location>Hôpital Privé d'Ambérieu, Ambérieu-en-Bugey, France</location>
      <location>Hôpital Antoine Béclère, Clamart, France</location>
      <location>Centre Hospitalier Universitaire Grenoble Alpes, La Tronche, France</location>
      <location>Centre Hospitalier Régional Orléans, Orléans, France</location>
      <location>Nouvelle Clinique de Tours Plus St Gatien, Tours, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648775</url>
  </study>
  <study rank="45199">
    <nct_id>NCT03648762</nct_id>
    <title>Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit</title>
    <acronym>EXT-HF</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heart Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Aerobic Exercise Intervention</intervention>
      <intervention type="Behavioral">Combined Aerobic and Strength Exercise Intervention</intervention>
      <intervention type="Behavioral">Inspiratory Muscle Training Exercise Intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Oxygen uptake (VO2) peak</outcome_measure>
      <outcome_measure>One Repetition Maximum- Leg press</outcome_measure>
      <outcome_measure>Gene Expression - proteolytic genes (Forkhead box O3 [Foxo3] and Ubiquitin)</outcome_measure>
      <outcome_measure>Gene Expression anabolic genes Peroxisome proliferator-activated receptor gamma coactivator 1-alpha and Insulin-like growth factor 1</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>O0834-R</other_id>
    </other_ids>
    <start_date>May 8, 2017</start_date>
    <primary_completion_date>September 30, 2019</primary_completion_date>
    <completion_date>September 30, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>October 11, 2019</last_update_posted>
    <locations>
      <location>VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts, United States</location>
      <location>VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648762</url>
  </study>
  <study rank="45200">
    <nct_id>NCT03648749</nct_id>
    <title>Evaluation of a Speech-to-noise Feedback Device for Treatment of Hypophonia in Parkinson's Disease</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Speech-to-noise feedback</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Average speech-to-noise ratio</outcome_measure>
      <outcome_measure>Percent Speech Intelligibility Score (PSIS)</outcome_measure>
      <outcome_measure>Ratings of Experience with the Device</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lawson Health Research Institute</lead_sponsor>
      <collaborator>University of Western Ontario, Canada</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>45 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>LawsonHRI5264</other_id>
      <other_id>111861</other_id>
    </other_ids>
    <start_date>March 1, 2019</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>February 11, 2019</last_update_posted>
    <locations>
      <location>LawsonHRI, London, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648749</url>
  </study>
  <study rank="45201">
    <nct_id>NCT03648736</nct_id>
    <title>Time Course of Circulating Myocardial Biomarkers After a TASH Procedure.</title>
    <acronym>TASH</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiac Insufficiency</condition>
    </conditions>
    <interventions>
      <intervention type="Other">blood withdrawal</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time course of FGF23 (c-terminal)</outcome_measure>
      <outcome_measure>Time course of FGF23 (intact)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>RWTH Aachen University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>17-164</other_id>
    </other_ids>
    <start_date>October 10, 2018</start_date>
    <primary_completion_date>May 2021</primary_completion_date>
    <completion_date>May 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>October 16, 2018</last_update_posted>
    <locations>
      <location>Aachen University Hospital; Medical Clinic I - Cardiology, Pneumology, Angiology and Internal Intensive Medicine, Aachen, NRW, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648736</url>
  </study>
  <study rank="45202">
    <nct_id>NCT03648723</nct_id>
    <title>The Effect of Periodontal Disease Treatment in Patients With Kidney Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Periodontal Diseases</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Periodontal disease parameters change</outcome_measure>
      <outcome_measure>Biochemical parameters change</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>TC Erciyes University</lead_sponsor>
    </sponsors>
    <min_age>31 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>43</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>Ztasdemir</other_id>
    </other_ids>
    <start_date>January 10, 2016</start_date>
    <primary_completion_date>January 10, 2017</primary_completion_date>
    <completion_date>May 10, 2017</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648723</url>
  </study>
  <study rank="45203">
    <nct_id>NCT03648710</nct_id>
    <title>Community Health Workers and mHealth for Sickle Cell Disease Care</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sickle Cell Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Peer Community Health Worker</intervention>
      <intervention type="Other">Mobile Health</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Health-Related Quality of Life (HRQOL)</outcome_measure>
      <outcome_measure>Sickle cell disease knowledge</outcome_measure>
      <outcome_measure>Transition Readiness</outcome_measure>
      <outcome_measure>Social Support</outcome_measure>
      <outcome_measure>Coping skills</outcome_measure>
      <outcome_measure>Education and vocational planning</outcome_measure>
      <outcome_measure>Quality of care received</outcome_measure>
      <outcome_measure>Medical Adherence Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Children's Hospital of Philadelphia</lead_sponsor>
      <collaborator>St. Christopher's Hospital for Children</collaborator>
      <collaborator>Children's Hospital Medical Center, Cincinnati</collaborator>
      <collaborator>Steven and Alexandra Cohen Children’s Medical Center of Northwell Health</collaborator>
      <collaborator>Connecticut Children's Medical Center</collaborator>
      <collaborator>Patient-Centered Outcomes Research Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>17 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>450</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>18-015106</other_id>
    </other_ids>
    <start_date>January 15, 2019</start_date>
    <primary_completion_date>May 31, 2021</primary_completion_date>
    <completion_date>November 30, 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 24, 2019</last_update_posted>
    <locations>
      <location>Cohen's Children's Medical Center, New Hyde Park, New York, United States</location>
      <location>Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648710</url>
  </study>
  <study rank="45204">
    <nct_id>NCT03648697</nct_id>
    <title>EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Nasopharyngeal Carcinoma</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">EBV-TCR-T (YT-E001) cells</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
      <outcome_measure>Number of participants with clinical responses</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fujian Cancer Hospital</lead_sponsor>
      <collaborator>China Immunotech Co., Ltd.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>FJZL20180823</other_id>
    </other_ids>
    <start_date>October 10, 2018</start_date>
    <primary_completion_date>October 8, 2019</primary_completion_date>
    <completion_date>October 10, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>Fujian Cancer Hospital, Fuzhou, Fujian, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648697</url>
  </study>
  <study rank="45205">
    <nct_id>NCT03648684</nct_id>
    <title>Examining Expectancy Challenges to Prevent Nonmedical Prescription Stimulant Use</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Prescription Drug Abuse (Not Dependent)</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Caffeine-Based Expectancy Challenge</intervention>
      <intervention type="Behavioral">Placebo-Based Expectancy Challenge</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prescription Stimulant Expectancy Modification</outcome_measure>
      <outcome_measure>Incidence of nonmedical prescription stimulant use</outcome_measure>
      <outcome_measure>Achievement Needs Modification - Self Efficacy for Learning</outcome_measure>
      <outcome_measure>Achievement Needs Modification - Academic Achievement Goals</outcome_measure>
      <outcome_measure>Intention to Use</outcome_measure>
      <outcome_measure>Modification of Caffeine Expectancy Effects</outcome_measure>
      <outcome_measure>Modification of Alcohol Expectancy Effects</outcome_measure>
      <outcome_measure>Subjective Mood and Arousal</outcome_measure>
      <outcome_measure>Subjective Drug Effects</outcome_measure>
      <outcome_measure>Conners' Continuous Performance Test III</outcome_measure>
      <outcome_measure>Selective Reminding Test</outcome_measure>
      <outcome_measure>Paced Auditory Serial Addition Test</outcome_measure>
      <outcome_measure>Stroop Test</outcome_measure>
      <outcome_measure>Letter-Number Sequencing</outcome_measure>
      <outcome_measure>Verbal Fluency</outcome_measure>
      <outcome_measure>Symbol Search</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Wyoming</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>25 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>126</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>20180620AL02017</other_id>
    </other_ids>
    <start_date>September 4, 2018</start_date>
    <primary_completion_date>April 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>October 10, 2018</last_update_posted>
    <locations>
      <location>University of Wyoming, Laramie, Wyoming, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648684</url>
  </study>
  <study rank="45206">
    <nct_id>NCT03648671</nct_id>
    <title>Pain in Parkinson's Disease With Motor Fluctuations.</title>
    <acronym>PAINinPD</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">safinamide metansolfonato (12 weeks)</intervention>
      <intervention type="Drug">safinamide metansolfonato (12 weeks)</intervention>
      <intervention type="Drug">rasagilina mesilato (12 weeks)</intervention>
      <intervention type="Drug">rasagilina mesilato (12 weeks)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Latency (ms) of N1/P1 complex.</outcome_measure>
      <outcome_measure>Latency (ms) of N2/P2 complex.</outcome_measure>
      <outcome_measure>Amplitude (microvolt) of N1/P1 complex.</outcome_measure>
      <outcome_measure>Amplitude (microvolt) of N2/P2 complex.</outcome_measure>
      <outcome_measure>Body localization</outcome_measure>
      <outcome_measure>King's Pain Scale for Parkinson's Disease</outcome_measure>
      <outcome_measure>Italian version of the brief pain inventory short form</outcome_measure>
      <outcome_measure>Clinical global impression of change</outcome_measure>
      <outcome_measure>The 39-Item Parkinson's Disease Questionnaire (PDQ-39)</outcome_measure>
      <outcome_measure>Numeric Rating Scale (NRS)</outcome_measure>
      <outcome_measure>Unified Parkinson's Disease Rating Scale</outcome_measure>
      <outcome_measure>Total daily off time</outcome_measure>
      <outcome_measure>Off time following the first morning L-dopa dose</outcome_measure>
      <outcome_measure>Age</outcome_measure>
      <outcome_measure>Gender</outcome_measure>
      <outcome_measure>Schooling</outcome_measure>
      <outcome_measure>Job</outcome_measure>
      <outcome_measure>Weight</outcome_measure>
      <outcome_measure>Disease duration</outcome_measure>
      <outcome_measure>Age at PD onset</outcome_measure>
      <outcome_measure>Laterality of PD symptom onset</outcome_measure>
      <outcome_measure>Most Affected Side</outcome_measure>
      <outcome_measure>Pain symptoms at PD onset</outcome_measure>
      <outcome_measure>Dominant phenotype</outcome_measure>
      <outcome_measure>Modified H&amp;Y</outcome_measure>
      <outcome_measure>Pharmacologic therapy for PD</outcome_measure>
      <outcome_measure>Comorbilities</outcome_measure>
      <outcome_measure>Mini-Mental State Examination</outcome_measure>
      <outcome_measure>Montreal Cognitive Assessment (MoCA)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universita di Verona</lead_sponsor>
      <collaborator>Azienda Ospedaliera Universitaria Integrata Verona</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>1470CESC</other_id>
    </other_ids>
    <start_date>March 28, 2018</start_date>
    <primary_completion_date>March 28, 2019</primary_completion_date>
    <completion_date>November 30, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Azienda ospedaliera universitaria integrata verona, Verona, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648671</url>
  </study>
  <study rank="45207">
    <nct_id>NCT03648658</nct_id>
    <title>Paracetamol Study in Patients With Low Muscle Mass</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SMA II</condition>
      <condition>Cerebral Palsy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Paracetamol 120Mg/5mL Oral Suspension</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clearance paracetamol</outcome_measure>
      <outcome_measure>Volume of distribution of paracetamol</outcome_measure>
      <outcome_measure>Liver function tests: ALT, AST, LDH, Alkaline Phosphatase, Bilirubin (U/L)</outcome_measure>
      <outcome_measure>Concentration-time data on liver function and paracetamolparametres</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mette Cathrine Oerngreen</lead_sponsor>
      <collaborator>Elsass Foundation</collaborator>
      <collaborator>Rigshospitalet, Denmark</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>08-06-2018-paracet</other_id>
      <other_id>2018-002295-40</other_id>
    </other_ids>
    <start_date>February 18, 2019</start_date>
    <primary_completion_date>July 2021</primary_completion_date>
    <completion_date>July 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>February 27, 2019</last_update_posted>
    <locations>
      <location>Copenhagen Neuromuscular Center, Copenhagen, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648658</url>
  </study>
  <study rank="45208">
    <nct_id>NCT03648645</nct_id>
    <title>Hypertensive Pregnant Women Monitored by Teletransmitted Self-measurements of Blood Pressure</title>
    <acronym>FETH</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hypertension in Pregnancy</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Self measurement of blood pressure</intervention>
      <intervention type="Other">Standard follow-up consultation in the hospital</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hypertension specific intervention</outcome_measure>
      <outcome_measure>Number of significant alerts</outcome_measure>
      <outcome_measure>Number of alerts</outcome_measure>
      <outcome_measure>Likert scale to assess patients' satisfaction</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rennes University Hospital</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>270</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>35RC17_8837</other_id>
      <other_id>2018-A01118-47</other_id>
    </other_ids>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>May 9, 2022</primary_completion_date>
    <completion_date>September 9, 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>December 30, 2019</last_update_posted>
    <locations>
      <location>CHU Caen, Caen, France</location>
      <location>CHU Lille, Lille, France</location>
      <location>Chu Rennes, Rennes, France</location>
      <location>CH St-Malo, Saint-Malo, France</location>
      <location>CHU Tours, Tours, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648645</url>
  </study>
  <study rank="45209">
    <nct_id>NCT03648632</nct_id>
    <title>Stereotactic Radiotherapy (SBRT) in Patients With Locally Advanced Pancreatic Cancer (LAPC)</title>
    <acronym>SBRT-PC-01</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Locally Advanced Pancreatic Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Radiation">Stereotactic Radiotherapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Resection rate for all patients starting SBRT</outcome_measure>
      <outcome_measure>1 year survival for all patients starting SBRT</outcome_measure>
      <outcome_measure>PFS</outcome_measure>
      <outcome_measure>OS</outcome_measure>
      <outcome_measure>Adverse events grade 2-5 (NCI-CTCAE 4.1)</outcome_measure>
      <outcome_measure>Surgical complications, including IRE (Clavien)</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Per Pfeiffer</lead_sponsor>
      <collaborator>Odense University Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>KFE 18.13</other_id>
    </other_ids>
    <start_date>August 22, 2018</start_date>
    <primary_completion_date>August 1, 2019</primary_completion_date>
    <completion_date>September 1, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Odense University Hospital, Odense, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648632</url>
  </study>
  <study rank="45210">
    <nct_id>NCT03648619</nct_id>
    <title>Automatized &quot;Semi-Whole-Body&quot;-MRI Protocol for Cancer Staging</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Oncology</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Semi whole-body MRI</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>to compare lesion detectability between wb-MRI and the gold standard PET/CT</outcome_measure>
      <outcome_measure>Secondary outcome will be the number of lesions</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kantonsspital Baden</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>2017-00964</other_id>
    </other_ids>
    <start_date>September 1, 2017</start_date>
    <primary_completion_date>January 1, 2020</primary_completion_date>
    <completion_date>January 1, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations>
      <location>Kantonsspital Baden, Institute of Radiology, Baden, Aargau, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648619</url>
  </study>
  <study rank="45211">
    <nct_id>NCT03648606</nct_id>
    <title>Management and Thermal Comfort of Premature Infants Under 32 Weeks</title>
    <acronym>CTNNP</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Thermoregulation</condition>
    </conditions>
    <interventions>
      <intervention type="Other">mesure of skin temperature</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mesure of the Thermal confort of preterm infants less than 32 weeks</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire, Amiens</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>10 Days</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>29</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PI10-PR-TOURNEUX-1</other_id>
    </other_ids>
    <start_date>June 4, 2010</start_date>
    <primary_completion_date>January 25, 2017</primary_completion_date>
    <completion_date>January 25, 2017</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648606</url>
  </study>
  <study rank="45212">
    <nct_id>NCT03648593</nct_id>
    <title>Promo@Work Entrepreneurs</title>
    <acronym>Promo@Work</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Work Ability</condition>
      <condition>Work-Related Condition</condition>
      <condition>Health Behavior</condition>
      <condition>Intervention</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">work recovery intervention</intervention>
      <intervention type="Behavioral">waiting list control</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>change from baseline in need for recovery scale at 6 months</outcome_measure>
      <outcome_measure>change from baseline in perceived work ability at 6 months. One item of work ability index</outcome_measure>
      <outcome_measure>change from baseline in 3-item version of the Utrecht Work Engagement Scale at 6 months</outcome_measure>
      <outcome_measure>Change from baseline in Recovery Experiences Questionnaire at 6 months</outcome_measure>
      <outcome_measure>World health organization Health and work performance questionnaire</outcome_measure>
      <outcome_measure>sleep deprivation questions</outcome_measure>
      <outcome_measure>Frequency of insomnia symptoms</outcome_measure>
      <outcome_measure>nutritional behaviour</outcome_measure>
      <outcome_measure>Alcohol Use Disorders Identification Test Consumption (Audit-C)</outcome_measure>
      <outcome_measure>physical activity questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Finnish Institute of Occupational Health</lead_sponsor>
      <collaborator>University of Oulu</collaborator>
      <collaborator>Tampere University</collaborator>
      <collaborator>University Hospital of Cologne</collaborator>
      <collaborator>Academy of Finland</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>68 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1256</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>3522101</other_id>
      <other_id>303430</other_id>
    </other_ids>
    <start_date>October 18, 2017</start_date>
    <primary_completion_date>August 30, 2018</primary_completion_date>
    <completion_date>March 31, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Finnish Institute of Occupational Health, Oulu, Finland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648593</url>
  </study>
  <study rank="45213">
    <nct_id>NCT03648580</nct_id>
    <title>Intervention for the Elderly With Malnutrition, Hidden Hunger and Low Skeletal Muscle Mass</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Malnutrition Risk in Elder</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Ensure Complete powder</intervention>
      <intervention type="Other">verbal nutrition education</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mini Nutritional Assessment short-form (MNA®-SF) score</outcome_measure>
      <outcome_measure>Muscle mass--The change of percentage of skeletal muscle mass</outcome_measure>
      <outcome_measure>The change of BMI</outcome_measure>
      <outcome_measure>Muscle strength--The change of Calf circumference</outcome_measure>
      <outcome_measure>Muscle strength--The change of Grip strength</outcome_measure>
      <outcome_measure>Muscle strength--6 meters gait speed</outcome_measure>
      <outcome_measure>Hidden Hunger Assessment Scale</outcome_measure>
      <outcome_measure>Dietary Nutrients</outcome_measure>
      <outcome_measure>The change of DETERMINE score</outcome_measure>
      <outcome_measure>Questionnaire--Healthy lifestyle questionnaire</outcome_measure>
      <outcome_measure>Questionnaire--Self-satisfaction questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The First Affiliated Hospital with Nanjing Medical University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>65 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>78</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>JYX201603</other_id>
    </other_ids>
    <start_date>May 20, 2017</start_date>
    <primary_completion_date>December 31, 2018</primary_completion_date>
    <completion_date>June 30, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>December 16, 2019</last_update_posted>
    <locations>
      <location>The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648580</url>
  </study>
  <study rank="45214">
    <nct_id>NCT03648567</nct_id>
    <title>GLILD Diagnosed in Children and Young Adults With Common Variable Immunodeficiency</title>
    <acronym>pGLILD</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>GLILD in a Population of Children and Young Adults</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Lung biopsy</outcome_measure>
      <outcome_measure>Clinical symptomatology</outcome_measure>
      <outcome_measure>Immunology</outcome_measure>
      <outcome_measure>Pulmonary function tests</outcome_measure>
      <outcome_measure>CT chest in GLILD</outcome_measure>
      <outcome_measure>Broncho-alveolar lavage</outcome_measure>
      <outcome_measure>GLILD Management</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Central Hospital, Nancy, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>25 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PSS2017/p-GLILD-FOUYSSAC/NK</other_id>
    </other_ids>
    <start_date>March 1, 2018</start_date>
    <primary_completion_date>September 1, 2018</primary_completion_date>
    <completion_date>September 15, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Chu Besancon, Besançon, France</location>
      <location>CHRU Bordeaux, Bordeaux, France</location>
      <location>Chru Dijon Bourgogne, Dijon, France</location>
      <location>CHU Montpellier, Montpellier, France</location>
      <location>CHRU Nancy, Nancy, France</location>
      <location>Hôpital Necker Enfants Malades, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648567</url>
  </study>
  <study rank="45215">
    <nct_id>NCT03648554</nct_id>
    <title>Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)</title>
    <acronym>REALIST</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes Mellitus, Type 2</condition>
      <condition>NASH - Nonalcoholic Steatohepatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">dulaglutide (TRULICITY®) 1.5 mg</intervention>
      <intervention type="Other">reinforced dietary monitoring</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Responder's proportion difference between the two groups (dulaglutide (TRULICITY®) on top of dietary reinforcement vs. dietary reinforcement alone)</outcome_measure>
      <outcome_measure>Fibrosis Kleiner score</outcome_measure>
      <outcome_measure>Fibrosis using Fibrotest score</outcome_measure>
      <outcome_measure>Fibrosis marker parameter</outcome_measure>
      <outcome_measure>Changes in serum levels of liver enzymes ALT and AST</outcome_measure>
      <outcome_measure>Changes in Lipid parameters</outcome_measure>
      <outcome_measure>Improvement in the glycemic control</outcome_measure>
      <outcome_measure>overall glycemic control improvement</outcome_measure>
      <outcome_measure>Change in body composition assessed by dual-energy x-ray absorptiometry scans</outcome_measure>
      <outcome_measure>Change in quality of life</outcome_measure>
      <outcome_measure>Change in weight</outcome_measure>
      <outcome_measure>ALT and AST levels</outcome_measure>
      <outcome_measure>Weight</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Central Hospital, Nancy, France</lead_sponsor>
      <collaborator>Eli Lilly and Company</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>93</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018-002162-38</other_id>
      <other_id>PSS2018/REALIST-GUERCI/AS</other_id>
    </other_ids>
    <start_date>September 1, 2019</start_date>
    <primary_completion_date>September 30, 2023</primary_completion_date>
    <completion_date>March 30, 2024</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>June 25, 2019</last_update_posted>
    <locations>
      <location>CHU de CAEN, Caen, France</location>
      <location>CHU de DIJON, Dijon, France</location>
      <location>Chu Marseille, Marseille, France</location>
      <location>CHRU de MONTPELLIER, Montpellier, France</location>
      <location>CHU de REIMS, Reims, France</location>
      <location>CHU de ROUEN, Rouen, France</location>
      <location>CHU de TOULOUSE, Toulouse, France</location>
      <location>CHRU de NANCY, Vandœuvre-lès-Nancy, France</location>
      <location>G.H.M les Portes du Sud, Venissieux, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648554</url>
  </study>
  <study rank="45216">
    <nct_id>NCT03648541</nct_id>
    <title>BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Colitis, Ulcerative</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Spesolimab IV infusion</intervention>
      <intervention type="Drug">Spesolimab SC solution for injection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The exposure adjusted rate of patients reporting a treatment emergent adverse event (TEAE)</outcome_measure>
      <outcome_measure>Proportion of patients with clinical remission</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Boehringer Ingelheim</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>535</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1368-0017</other_id>
      <other_id>2018-000334-35</other_id>
    </other_ids>
    <start_date>October 29, 2018</start_date>
    <primary_completion_date>March 30, 2031</primary_completion_date>
    <completion_date>March 30, 2031</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 22, 2020</last_update_posted>
    <locations>
      <location>Medical Research Center of Connecticut, LLC, Hamden, Connecticut, United States</location>
      <location>AdventHealth Orlando, Orlando, Florida, United States</location>
      <location>University of Chicago, Chicago, Illinois, United States</location>
      <location>Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States</location>
      <location>Vanderbilt University Medical Center, Nashville, Tennessee, United States</location>
      <location>Baylor College of Medicine, Houston, Texas, United States</location>
      <location>Southern Star Research Institute, LLC, San Antonio, Texas, United States</location>
      <location>Texas Digestive Disease Consultants - Southlake, Southlake, Texas, United States</location>
      <location>Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States</location>
      <location>Ordensklinikum Linz GmbH - Barmherzige Schwestern, Linz, Austria</location>
      <location>AKH - Medical University of Vienna, Wien, Austria</location>
      <location>UZ Leuven, Leuven, Belgium</location>
      <location>Centre Hospitalier Universitaire de Liège, Liège, Belgium</location>
      <location>Victoria Hospital (LHSC), London, Ontario, Canada</location>
      <location>Universitätsklinikum Erlangen, Erlangen, Germany</location>
      <location>Klinikum Esslingen GmbH, Esslingen, Germany</location>
      <location>Asklepios Kliniken Westklinikum Hamburg, Hamburg, Germany</location>
      <location>Medizinische Hochschule Hannover, Hannover, Germany</location>
      <location>Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany</location>
      <location>Universitätsklinikum Ulm, Ulm, Germany</location>
      <location>Azienda Ospedaliera Universitaria di Padova, Padova, Italy</location>
      <location>Istituto Clinico Humanitas, Rozzano (MI), Italy</location>
      <location>Sapporo Tokushukai Hospital, Hokkaido, Sapporo, Japan</location>
      <location>Sapporo Higashi Tokushukai Hospital, Hokkaido, Sapporo, Japan</location>
      <location>Hyogo College of Medicine Hospital, Hyogo, Nishinomiya, Japan</location>
      <location>Ofuna Chuo Hospital, Kanagawa, Kamakura, Japan</location>
      <location>Tokyo Medical and Dental University, Tokyo, Bunkyo-ku, Japan</location>
      <location>Tokyo Yamate Medical Center, Tokyo, Shinjuku, Japan</location>
      <location>Inje University Haeundae Paik Hospital, Busan, Korea, Republic of</location>
      <location>Yeungnam University Medical Center, Daegu, Korea, Republic of</location>
      <location>Kangbuk Samsung Hospital, Seoul, Korea, Republic of</location>
      <location>Severance Hospital, Seoul, Korea, Republic of</location>
      <location>The Catholic University of Korea, St.Vincent's Hospital, Suwon, Korea, Republic of</location>
      <location>FSB Instit. HC Irkutsk Scient.Cent. Sibirian Branch of Russ. Acad. Scien., Irkutsk, Russian Federation</location>
      <location>Federal State Budgetary Institution &quot; State Scientific Center of Coloproctology&quot; MOH Russia, Moscow, Russian Federation</location>
      <location>The limited liability company &quot;Clinic USI 4D&quot;, Pyatigorsk, Russian Federation</location>
      <location>Military Medical Academy n.a. C. M. Kirov, St. Petersburg, St. Petersburg, Russian Federation</location>
      <location>Hospital Virgen del Rocío, Sevilla, Spain</location>
      <location>Hospital Politècnic La Fe, Valencia, Spain</location>
      <location>Barnsley Hospital, Barnsley, United Kingdom</location>
      <location>Doncaster Royal Infirmary, Doncaster, United Kingdom</location>
      <location>Guy's Hospital, London, United Kingdom</location>
      <location>Whiston Hospital, Prescot, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648541</url>
  </study>
  <study rank="45217">
    <nct_id>NCT03648528</nct_id>
    <title>Cholecalciferol Supplementation Effect on Parathyroid Hormone in Hemodialysis Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Vitamin D Deficiency</condition>
      <condition>Hemodialysis Patient</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">cholecalciferol</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>20 % Change in iPTH levels</outcome_measure>
      <outcome_measure>normalization of 25VD levels</outcome_measure>
      <outcome_measure>change of 0.5 g/dL on Hb level or 10% change in erythropoietin dose</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cooperativa Asistencia Sindicato Médico Uruguay</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2014/004</other_id>
    </other_ids>
    <start_date>October 15, 2015</start_date>
    <primary_completion_date>May 2018</primary_completion_date>
    <completion_date>May 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations/>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03648528/Prot_000.pdf</url>
      </study_document>
      <study_document>
        <label>Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03648528/ICF_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03648528</url>
  </study>
  <study rank="45218">
    <nct_id>NCT03648515</nct_id>
    <title>Evaluation of the Accuracy of Measurements Made on Images Taken From the Mouth for Dental Arches</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Malocclusion</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Plaster models</intervention>
      <intervention type="Diagnostic Test">Digital Images of the dental arches</intervention>
      <intervention type="Diagnostic Test">Digital images of models</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Little's Index of Irregularity (LII)</outcome_measure>
      <outcome_measure>Partial Bolton's Ratio</outcome_measure>
      <outcome_measure>Overall Bolton's Ratio</outcome_measure>
      <outcome_measure>Tooth-size-arch-length-discrepancy (TSALD)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Damascus University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>15 Years</min_age>
    <max_age>30 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>UDDS-Ortho-11-2018</other_id>
    </other_ids>
    <start_date>June 15, 2018</start_date>
    <primary_completion_date>August 19, 2018</primary_completion_date>
    <completion_date>September 15, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>July 18, 2019</last_update_posted>
    <locations>
      <location>Department of Orthodontics, University of Damascus Dental School, Damascus, Syrian Arab Republic</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648515</url>
  </study>
  <study rank="45219">
    <nct_id>NCT03648502</nct_id>
    <title>Validation of Cognitive Screenings for the Hearing Impaired</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dementia</condition>
      <condition>Hearing Loss</condition>
      <condition>Auditory Processing Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Cognitive tests and hearing tests</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The adapted version Montreal Cognitive Assessment (MoCA) questionnaire total score among dementia/mild cognitive impairment/normal cognition group of hearing impaired older adult.</outcome_measure>
      <outcome_measure>The adapted version Addenbrooke's Cognitive Examination III (ACE-III) questionnaire total score among dementia/mild cognitive impairment/normal cognition group of hearing impaired older adult.</outcome_measure>
      <outcome_measure>Hearing handicap score from the Modified Amsterdam Inventory for Auditory Disability and Handicap (mAIAD) (total score ranging from 0-84 with higher score indicate smaller perceived hearing difficulty)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University College, London</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>65 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>18/0306</other_id>
    </other_ids>
    <start_date>November 9, 2018</start_date>
    <primary_completion_date>February 2020</primary_completion_date>
    <completion_date>September 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>July 25, 2019</last_update_posted>
    <locations>
      <location>Royal National Throat Nose Ear Hospital, London, United Kingdom</location>
      <location>Camden and Islington NHS memory service, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648502</url>
  </study>
  <study rank="45220">
    <nct_id>NCT03648489</nct_id>
    <title>Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)</title>
    <acronym>DICE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ovarian Cancer</condition>
      <condition>Ovarian Neoplasms</condition>
      <condition>Ovarian Carcinosarcoma</condition>
      <condition>Ovarian Serous Adenocarcinoma</condition>
      <condition>Ovarian Endometrioid Adenocarcinoma</condition>
      <condition>Ovarian Clear Cell Adenocarcinoma</condition>
      <condition>Fallopian Tube Cancer</condition>
      <condition>Fallopian Tube Neoplasms</condition>
      <condition>Primary Peritoneal Carcinoma</condition>
      <condition>Primary Peritoneal Serous Adenocarcinoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Paclitaxel</intervention>
      <intervention type="Drug">TAK228</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Progression Free Survival (PFS)</outcome_measure>
      <outcome_measure>Progression Free Survival (PFS) at 24 weeks</outcome_measure>
      <outcome_measure>Overall Response Rate (ORR)</outcome_measure>
      <outcome_measure>Duration of Response (DOR)</outcome_measure>
      <outcome_measure>Time to Progression (TTP)</outcome_measure>
      <outcome_measure>Clinical Benefit Rate (CBR) at 4 months</outcome_measure>
      <outcome_measure>Response according to Gynecologic Cancer Intergroup (GCIG) CA125 criteria</outcome_measure>
      <outcome_measure>Overall Survival (OS)</outcome_measure>
      <outcome_measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.03</outcome_measure>
      <outcome_measure>Change from baseline quality of life (QOL) as assessed by EORTC QLQ-C30 questionnaire Global Health Status Domain</outcome_measure>
      <outcome_measure>Change from baseline QOL as assessed by EORTC QLQ-OV28 questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Imperial College London</lead_sponsor>
      <collaborator>Takeda Pharmaceuticals International, Inc.</collaborator>
      <collaborator>North Eastern German Society of Gynaecological Oncology</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>126</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>C/30/2011</other_id>
    </other_ids>
    <start_date>September 21, 2018</start_date>
    <primary_completion_date>March 2022</primary_completion_date>
    <completion_date>March 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>October 29, 2019</last_update_posted>
    <locations>
      <location>Furness General Hospital, Barrow In Furness, Cumbria, United Kingdom</location>
      <location>The Royal Marsden NHS Foundation Trust, London Borough of Sutton, Greater London, United Kingdom</location>
      <location>St George's University Hospitals NHS Foundation Trust, London, Greater London, United Kingdom</location>
      <location>The Royal Marsden NHS Foundation Trust, London, Greater London, United Kingdom</location>
      <location>Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom</location>
      <location>The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom</location>
      <location>Royal Lancaster Infirmary, Lancaster, Lancashire, United Kingdom</location>
      <location>Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom</location>
      <location>Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom</location>
      <location>Churchill Hospital, Oxford, United Kingdom</location>
      <location>Southampton General Hospital, Southampton, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648489</url>
  </study>
  <study rank="45221">
    <nct_id>NCT03648476</nct_id>
    <title>Intervention to Change Attributions That Are Negative (ICAN)</title>
    <acronym>ICAN</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Trauma, Brain</condition>
      <condition>Brain Injuries</condition>
      <condition>Traumatic Brain Injury</condition>
      <condition>Brain Injuries, Traumatic</condition>
      <condition>Brain, Trauma</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">ICAN</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Buss-Perry Aggression Questionnaire Score</outcome_measure>
      <outcome_measure>Change in Anger Affect</outcome_measure>
      <outcome_measure>Global Impression of Change for Anger and Aggression</outcome_measure>
      <outcome_measure>Global Impression of Change for Perspective taking and Empathy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Indiana University</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
      <collaborator>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1806829789</other_id>
      <other_id>1R21HD094232-01</other_id>
    </other_ids>
    <start_date>November 2, 2018</start_date>
    <primary_completion_date>August 1, 2020</primary_completion_date>
    <completion_date>August 1, 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 21, 2019</last_update_posted>
    <locations>
      <location>The Rehabilitation Hospital of Indiana, Indianapolis, Indiana, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648476</url>
  </study>
  <study rank="45222">
    <nct_id>NCT03648463</nct_id>
    <title>Use of MRI Labeling Technique to Track Mesenchymal Stem Cell Survival in Orthopaedic Conditions</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cartilage Degeneration</condition>
      <condition>Rotator Cuff Tear</condition>
      <condition>Osteoarthritis, Knee</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">arthroscopy of the affected knee/ Bone Marrow Concentrate Injection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Integration of the mesenchymal stem cells.</outcome_measure>
      <outcome_measure>Knee Injury and Osteoarthritis Outcome Score (pain subscale)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>30 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB-46711</other_id>
    </other_ids>
    <start_date>October 1, 2019</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>March 28, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648463</url>
  </study>
  <study rank="45223">
    <nct_id>NCT03648450</nct_id>
    <title>Feasibility and Acceptability of the Hailie Monitoring System in Children With Persistent Asthma</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Asthma</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Hailie Smart Inhaler EMD</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Regular device use at three months</outcome_measure>
      <outcome_measure>Acceptability of the Hailie Smartinhaler as determined by the Adolescent Medical Devices Assessment Toolkit (AMDAT)</outcome_measure>
      <outcome_measure>Asthma Control</outcome_measure>
      <outcome_measure>Device use at one month</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Connecticut Children's Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>10 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>Adherium Asthma Study</other_id>
    </other_ids>
    <start_date>January 1, 2020</start_date>
    <primary_completion_date>August 31, 2022</primary_completion_date>
    <completion_date>December 31, 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>July 25, 2019</last_update_posted>
    <locations>
      <location>Connecticut Children's Medical Center, Hartford, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648450</url>
  </study>
  <study rank="45224">
    <nct_id>NCT03648437</nct_id>
    <title>Paracetamol And Ibuprofen in Closing Patent Ductus Arteriosus</title>
    <acronym>PAI</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Patent Ductus Arteriosus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Paracetamol 10Mg/mL</intervention>
      <intervention type="Drug">0.45% Sodium Chloride</intervention>
      <intervention type="Drug">Ibuprofen</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Ductal closure</outcome_measure>
      <outcome_measure>Need for ductal therapies</outcome_measure>
      <outcome_measure>Cardiac ultrasound findings</outcome_measure>
      <outcome_measure>Duration of any ventilation assist</outcome_measure>
      <outcome_measure>Paracetamol serum levels</outcome_measure>
      <outcome_measure>Paracetamol side effects</outcome_measure>
      <outcome_measure>Long term complications of prematurity</outcome_measure>
      <outcome_measure>Other long-term morbidity, and mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Oulu</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>4 Months</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>38/2018</other_id>
    </other_ids>
    <start_date>September 3, 2018</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>March 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 10, 2019</last_update_posted>
    <locations>
      <location>Department of Pediatrics, Oulu University Hospital, Oulu, Finland</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT03648437/Prot_SAP_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03648437</url>
  </study>
  <study rank="45225">
    <nct_id>NCT03648424</nct_id>
    <title>Prediction of Findings From the Ongoing CAROLINA Trial Using Healthcare Database Analyses</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Type 2 Diabetes Mellitus</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Composite Cardiovascular (CV) Outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Brigham and Women's Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>40 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2013P002157</other_id>
    </other_ids>
    <start_date>May 1, 2011</start_date>
    <primary_completion_date>January 1, 2019</primary_completion_date>
    <completion_date>January 1, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Brigham and Women's Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648424</url>
  </study>
  <study rank="45226">
    <nct_id>NCT03648411</nct_id>
    <title>Drug Resistance Among Asymptomatic Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Drug Resistant Malaria</condition>
      <condition>Asymptomatic Infections</condition>
      <condition>Migrant Workers</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">Drug resistance molecular markers</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevalence of the asymptomatic infection among the study population</outcome_measure>
      <outcome_measure>Proportion of the drug resistance molecular markers among asymptomatic infections</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Department of Medical Research, Lower Myanmar</lead_sponsor>
      <collaborator>National Malaria Control Program, Myanmar</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>760</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>DMR_2018-108</other_id>
    </other_ids>
    <start_date>January 12, 2019</start_date>
    <primary_completion_date>August 2019</primary_completion_date>
    <completion_date>December 30, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>February 7, 2019</last_update_posted>
    <locations>
      <location>Dr. Myat Phone Kyaw, Yangon, Myanmar</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648411</url>
  </study>
  <study rank="45227">
    <nct_id>NCT03648398</nct_id>
    <title>Pilot Study of an Online Therapeutic Education Program for Patients With Inflammatory Bowel Disease</title>
    <acronym>EDUMICILOR</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Crohn's Disease</condition>
      <condition>Ulcerative Colitis</condition>
    </conditions>
    <interventions>
      <intervention type="Other">EDUMICILOR</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Frequency of participation in the online therapeutic education program</outcome_measure>
      <outcome_measure>Score of the Crohn and Colitis Knowledge Score</outcome_measure>
      <outcome_measure>Score of the short Inflammatory Bowel Disease Questionnaire (short-IBDQ)</outcome_measure>
      <outcome_measure>Score of the Inflammatory Bowel Disease Disability Index (IBD Disability Index)</outcome_measure>
      <outcome_measure>Score of the Hospital Anxiety and Depression Scale</outcome_measure>
      <outcome_measure>Score of the Girerd Scale</outcome_measure>
      <outcome_measure>Score of a satisfaction survey on the online therapeutic education program</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Central Hospital, Nancy, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>APPARA2018/EDUMICILOR-VELTIN</other_id>
    </other_ids>
    <start_date>May 1, 2019</start_date>
    <primary_completion_date>January 1, 2021</primary_completion_date>
    <completion_date>January 1, 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>February 11, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648398</url>
  </study>
  <study rank="45228">
    <nct_id>NCT03648385</nct_id>
    <title>Effects of DHEA in Pulmonary Hypertension</title>
    <acronym>EDIPHY</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pulmonary Arterial Hypertension</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DHEA tablet</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Right ventricular (RV) longitudinal strain</outcome_measure>
      <outcome_measure>RV ejection fraction</outcome_measure>
      <outcome_measure>NT-proBNP</outcome_measure>
      <outcome_measure>Sex hormone levels</outcome_measure>
      <outcome_measure>Six minute walk distance (6MWD)</outcome_measure>
      <outcome_measure>World Health Organization (WHO) Functional Class</outcome_measure>
      <outcome_measure>Short Form-36</outcome_measure>
      <outcome_measure>emPHasis-10</outcome_measure>
      <outcome_measure>Treatment-related side effects and adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rhode Island Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>R01HL141268</other_id>
    </other_ids>
    <start_date>January 9, 2019</start_date>
    <primary_completion_date>April 2023</primary_completion_date>
    <completion_date>April 2023</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>October 23, 2019</last_update_posted>
    <locations>
      <location>Rhode Island Hospital Pulmonary Hypertension Center, Providence, Rhode Island, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/85/NCT03648385/ICF_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03648385</url>
  </study>
  <study rank="45229">
    <nct_id>NCT03648372</nct_id>
    <title>A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Metastatic Solid Tumors or Lymphomas</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Neoplasms</condition>
      <condition>Lymphoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TAK-981</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Participants Reporting one or More Treatment Emergent Adverse Events (TEAEs)</outcome_measure>
      <outcome_measure>Number of Participants With Dose Limiting Toxicities (DLTs)</outcome_measure>
      <outcome_measure>Number of Participants With one or More Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations</outcome_measure>
      <outcome_measure>Number of Participants With Greater Than or Equal to (&gt;=) Grade 3 TEAEs</outcome_measure>
      <outcome_measure>Number of Participants With Clinically Significant Laboratory Values</outcome_measure>
      <outcome_measure>Number of Participants With Clinically Significant Vital Sign Measurements</outcome_measure>
      <outcome_measure>Cmax: Maximum Observed Plasma Concentration for TAK-981</outcome_measure>
      <outcome_measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-981</outcome_measure>
      <outcome_measure>AUCt: Area Under the Plasma Concentration-time Curve from Time 0 to Time t Over the Dosing Interval for TAK-981</outcome_measure>
      <outcome_measure>AUC∞: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for TAK-981</outcome_measure>
      <outcome_measure>Terminal Disposition Phase Half-life (t1/2z) for TAK-981</outcome_measure>
      <outcome_measure>Total Clearance After Intravenous Administration (CL) for TAK-981</outcome_measure>
      <outcome_measure>Volume of Distribution at Steady State After Intravenous Administration (Vss) for TAK-981</outcome_measure>
      <outcome_measure>Overall Response Rate (ORR)</outcome_measure>
      <outcome_measure>Duration of Response (DOR)</outcome_measure>
      <outcome_measure>Disease Control Rate (DCR)</outcome_measure>
      <outcome_measure>Progression-free Survival (PFS)</outcome_measure>
      <outcome_measure>Time to Response (TTR)</outcome_measure>
      <outcome_measure>Percentage of Participants at Each Dose Level Demonstrating Adduct Formation in Post-dose Skin or Tumor Biopsies</outcome_measure>
      <outcome_measure>Percent Change in Small Ubiquitin-like Modifier (SUMO) 2/3 Signal With Pre and Post-dose Skin or Tumor Biopsies at Each Dose Level</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Millennium Pharmaceuticals, Inc.</lead_sponsor>
      <collaborator>Takeda</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>TAK-981-1002</other_id>
      <other_id>U1111-1214-4537</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>February 16, 2021</primary_completion_date>
    <completion_date>October 6, 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 21, 2019</last_update_posted>
    <locations>
      <location>University of California San Diego Moores Cancer Center, La Jolla, California, United States</location>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
      <location>Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States</location>
      <location>HealthPartners Cancer Care Center - Regions Hospital, Saint Paul, Minnesota, United States</location>
      <location>University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States</location>
      <location>Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States</location>
      <location>The University of Texas MD Anderson Cancer Center, Houston, Texas, United States</location>
      <location>Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648372</url>
  </study>
  <study rank="45230">
    <nct_id>NCT03648359</nct_id>
    <title>Multiparametric MRI in Men With Prostate Cancer Enrolled in Active Surveillance</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Prostatic Neoplasms</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">multiparametric MRI Diagnostics</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in treatment from active surveillance (observation) to active treatment based on mp-MRI results.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Herlev Hospital</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>AS</other_id>
    </other_ids>
    <start_date>September 2019</start_date>
    <primary_completion_date>January 2020</primary_completion_date>
    <completion_date>January 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 6, 2019</last_update_posted>
    <locations>
      <location>Department of Urology, Herlev University Hospital Herlev, Herlev, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648359</url>
  </study>
  <study rank="45231">
    <nct_id>NCT03648346</nct_id>
    <title>A Dose-escalation Clinical Trial After Multiple Dosing of HL217 Eye Drop in Healthy Male Subjects</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Subjects</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Cohort 1: HL217 Ophathalmic Solution BID</intervention>
      <intervention type="Drug">Cohort 2: HL217 Ophathalmic Solution QID</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical parameter: Adverse Events (AE)</outcome_measure>
      <outcome_measure>Clinical parameter: Physical examination</outcome_measure>
      <outcome_measure>Clinical parameter: Vital signs</outcome_measure>
      <outcome_measure>Clinical parameter: ECG (ElectroCardioGram)</outcome_measure>
      <outcome_measure>Clinical parameter: Laboratory parameters</outcome_measure>
      <outcome_measure>Local tolerance test</outcome_measure>
      <outcome_measure>Pharmacokinetic assessments: Cmax</outcome_measure>
      <outcome_measure>Pharmacokinetic assessments: Tmax</outcome_measure>
      <outcome_measure>Pharmacokinetic assessments: AUCt</outcome_measure>
      <outcome_measure>Pharmacokinetic assessments: AUCinf</outcome_measure>
      <outcome_measure>Pharmacokinetic assessments: Kel</outcome_measure>
      <outcome_measure>Pharmacokinetic assessments: t1/2</outcome_measure>
      <outcome_measure>Pharmacokinetic assessments: %AUCextra</outcome_measure>
      <outcome_measure>Pharmacokinetic assessments: Vd/F</outcome_measure>
      <outcome_measure>Pharmacokinetic assessments: CL/F</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hanlim Pharm. Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>HL217-102</other_id>
    </other_ids>
    <start_date>April 4, 2018</start_date>
    <primary_completion_date>July 25, 2018</primary_completion_date>
    <completion_date>January 25, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>March 29, 2019</last_update_posted>
    <locations>
      <location>Eurofins OPTIMED, Gières, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648346</url>
  </study>
  <study rank="45232">
    <nct_id>NCT03648333</nct_id>
    <title>Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=27)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Male Subjects</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Exforge tab. 10/160mg</intervention>
      <intervention type="Drug">Lodivixx tab. 5/160mg</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cmax (maximum concentration)</outcome_measure>
      <outcome_measure>AUC(area under curve)</outcome_measure>
      <outcome_measure>Number of participants with adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hanlim Pharm. Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>20 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>27</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>HL-LDV-103</other_id>
    </other_ids>
    <start_date>December 2013</start_date>
    <primary_completion_date>February 2014</primary_completion_date>
    <completion_date>June 2014</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648333</url>
  </study>
  <study rank="45233">
    <nct_id>NCT03648320</nct_id>
    <title>The Grown Up Peanut Immunotherapy Study</title>
    <acronym>GUPI</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Peanut Allergy</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Peanut oral immunotherapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Desensitisation to 1.4g peanut</outcome_measure>
      <outcome_measure>Desensitisation to 4.4g peanut</outcome_measure>
      <outcome_measure>Incidence of adverse events related to treatment (safety)</outcome_measure>
      <outcome_measure>Reactions with ara h 8 sensitisation</outcome_measure>
      <outcome_measure>Skin prick test reactivity</outcome_measure>
      <outcome_measure>Immunoglobulin G (IgG) levels</outcome_measure>
      <outcome_measure>Quality of life measure</outcome_measure>
      <outcome_measure>Food Neophobia score</outcome_measure>
      <outcome_measure>Food Situations score</outcome_measure>
      <outcome_measure>Study compliance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Guy's and St Thomas' NHS Foundation Trust</lead_sponsor>
      <collaborator>National Institute for Health Research, United Kingdom</collaborator>
      <collaborator>King's College London</collaborator>
      <collaborator>Imperial College London</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>40 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>225583</other_id>
    </other_ids>
    <start_date>May 18, 2018</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>September 30, 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648320</url>
  </study>
  <study rank="45234">
    <nct_id>NCT03648307</nct_id>
    <title>Long Term Effect of Splenectomy on Metabolism</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Trauma Splenic</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Blood sample</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Glucose tolerance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Imam Hossein General Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>154</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ImamHGH</other_id>
    </other_ids>
    <start_date>July 2008</start_date>
    <primary_completion_date>July 2018</primary_completion_date>
    <completion_date>August 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations/>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT03648307/Prot_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03648307</url>
  </study>
  <study rank="45235">
    <nct_id>NCT03648294</nct_id>
    <title>Long-term Blood Pressure Outcome After Unilateral Adrenalectomy for Primary Hyperaldosteronism</title>
    <acronym>Hyperaldo</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Adrenalectomy; Status</condition>
    </conditions>
    <interventions>
      <intervention type="Other">adrenalectomy for primary addosteronism</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adrenalectomy for primary hyperaldosteronism</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire, Amiens</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>43</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PI2017_843_0040</other_id>
    </other_ids>
    <start_date>December 1, 2013</start_date>
    <primary_completion_date>January 31, 2017</primary_completion_date>
    <completion_date>January 31, 2017</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648294</url>
  </study>
  <study rank="45236">
    <nct_id>NCT03648281</nct_id>
    <title>A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes Mellitus, Type 2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Semaglutide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Glycated Haemoglobin A1c (HbA1c)</outcome_measure>
      <outcome_measure>Change in HbA1c</outcome_measure>
      <outcome_measure>Change in body weight</outcome_measure>
      <outcome_measure>Change in waist circumference</outcome_measure>
      <outcome_measure>HbA1c level at end of study: &lt;8.0% (64 mmol/mol) (yes/no)</outcome_measure>
      <outcome_measure>HbA1c level at end of study: &lt;7.5% (59 mmol/mol) (yes/no)</outcome_measure>
      <outcome_measure>HbA1c level at end of study: &lt;7.0% (53 mmol/mol) (yes/no)</outcome_measure>
      <outcome_measure>Reduction in HbA1c of 1.0% point or more (yes/no)</outcome_measure>
      <outcome_measure>Weight reduction of 3.0% or more (yes/no)</outcome_measure>
      <outcome_measure>Weight reduction of 5.0% or more (yes/no)</outcome_measure>
      <outcome_measure>HbA1c reduction of 1.0% point or more and weight reduction of 3.0% or more (yes/no)</outcome_measure>
      <outcome_measure>Patient reported severe or documented hypoglycaemia (yes/no)</outcome_measure>
      <outcome_measure>Change in score for Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) (absolute treatment satisfaction): Total treatment satisfaction</outcome_measure>
      <outcome_measure>Change in score for Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) (relative treatment satisfaction): Total treatment satisfaction</outcome_measure>
      <outcome_measure>Change in score for Short Form (SF)-36 v2: Physical summary component</outcome_measure>
      <outcome_measure>Change in score for SF-36 v2: Mental summary component</outcome_measure>
      <outcome_measure>Patient completed the study under treatment with semaglutide (yes/no)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Novo Nordisk A/S</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>325</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>NN9535-4367</other_id>
      <other_id>U1111-1204-5181</other_id>
    </other_ids>
    <start_date>August 24, 2018</start_date>
    <primary_completion_date>February 4, 2020</primary_completion_date>
    <completion_date>February 19, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 18, 2020</last_update_posted>
    <locations>
      <location>Novo Nordisk Investigational Site, Søborg, Denmark</location>
      <location>Novo Nordisk Investigational Site, Avesta, Sweden</location>
      <location>Novo Nordisk Investigational Site, Bjärred, Sweden</location>
      <location>Novo Nordisk Investigational Site, Bollnäs, Sweden</location>
      <location>Novo Nordisk Investigational Site, Charlottenberg, Sweden</location>
      <location>Novo Nordisk Investigational Site, Eslöv, Sweden</location>
      <location>Novo Nordisk Investigational Site, Falköping, Sweden</location>
      <location>Novo Nordisk Investigational Site, Flen, Sweden</location>
      <location>Novo Nordisk Investigational Site, Göteborg, Sweden</location>
      <location>Novo Nordisk Investigational Site, Helsingborg, Sweden</location>
      <location>Novo Nordisk Investigational Site, Huskvarna, Sweden</location>
      <location>Novo Nordisk Investigational Site, Härnösand, Sweden</location>
      <location>Novo Nordisk Investigational Site, Karlskoga, Sweden</location>
      <location>Novo Nordisk Investigational Site, Kungsbacka, Sweden</location>
      <location>Novo Nordisk Investigational Site, Laholm, Sweden</location>
      <location>Novo Nordisk Investigational Site, Luleå, Sweden</location>
      <location>Novo Nordisk Investigational Site, Lund, Sweden</location>
      <location>Novo Nordisk Investigational Site, Mölndal, Sweden</location>
      <location>Novo Nordisk Investigational Site, Nybro, Sweden</location>
      <location>Novo Nordisk Investigational Site, Nässjö, Sweden</location>
      <location>Novo Nordisk Investigational Site, Sala, Sweden</location>
      <location>Novo Nordisk Investigational Site, Staffanstorp, Sweden</location>
      <location>Novo Nordisk Investigational Site, Stockholm, Sweden</location>
      <location>Novo Nordisk Investigational Site, Sundsvall, Sweden</location>
      <location>Novo Nordisk Investigational Site, Uddevalla, Sweden</location>
      <location>Novo Nordisk Investigational Site, Upplands Väsby, Sweden</location>
      <location>Novo Nordisk Investigational Site, Västerås, Sweden</location>
      <location>Novo Nordisk Investigational Site, Ängelholm, Sweden</location>
      <location>Novo Nordisk Investigational Site, Åkersberga, Sweden</location>
      <location>Novo Nordisk Investigational Site, Örebro, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648281</url>
  </study>
  <study rank="45237">
    <nct_id>NCT03648268</nct_id>
    <title>Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Schizophrenia</condition>
      <condition>Negative Type; Schizophrenic</condition>
    </conditions>
    <interventions>
      <intervention type="Device">repetitive Transcranial Magnetic Stimulation (rTMS)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Negative Symptom Severity</outcome_measure>
      <outcome_measure>Change in Cerebellar - Prefrontal Functional Connectivity</outcome_measure>
      <outcome_measure>Change in Auditory Hallucination Severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beth Israel Deaconess Medical Center</lead_sponsor>
      <collaborator>Mclean Hospital</collaborator>
      <collaborator>Harvard University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>68</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018P000321</other_id>
    </other_ids>
    <start_date>February 4, 2019</start_date>
    <primary_completion_date>December 2023</primary_completion_date>
    <completion_date>December 2023</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 22, 2019</last_update_posted>
    <locations>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648268</url>
  </study>
  <study rank="45238">
    <nct_id>NCT03648255</nct_id>
    <title>TolerUp Enteral Feeding Protocol</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gastrointestinal Tolerance</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Gastro-Intestinal Tolerance</outcome_measure>
      <outcome_measure>Anthropometrics</outcome_measure>
      <outcome_measure>Care Giver Satisfaction of Enteral Product</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Abbott Nutrition</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>1 Year</min_age>
    <max_age>12 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>290</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>DA15</other_id>
    </other_ids>
    <start_date>February 19, 2018</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>December 17, 2019</last_update_posted>
    <locations>
      <location>Ankara State Hospital, Çankaya, Ankara, Turkey</location>
      <location>Çukurova University Medical Faculty, Adana, Turkey</location>
      <location>Ankara Dr. Sami Ulus Women and Child Disesase Research and Training Hospital, Ankara, Turkey</location>
      <location>Hacettepe Üniversitesi University Medical Faculty, Ankara, Turkey</location>
      <location>Ankara Dışkapı Child Disease Hospital, Ankara, Turkey</location>
      <location>Ankara Research and Training Hospital, Ankara, Turkey</location>
      <location>Gazi University Medical Faculty, Ankara, Turkey</location>
      <location>Ankara University Medical Faculty, Ankara, Turkey</location>
      <location>Balıkesir University Medical Faculty, Balıkesir, Turkey</location>
      <location>Bursa Yüksek İhtisas Research and Training Hospital, Bursa, Turkey</location>
      <location>Pamukkale Üniversitesi University Medical Faculty, Denizli, Turkey</location>
      <location>Elazığ University Medical Faculty, Elazığ, Turkey</location>
      <location>Eskişehir Osmangazi University Medical Faculty, Eskişehir, Turkey</location>
      <location>Gaziantep University Medical Faculty, Gaziantep, Turkey</location>
      <location>Koç University Medical Faculty, Istanbul, Turkey</location>
      <location>İstanbul University İstanbul Medical Faculty, İstanbul, Turkey</location>
      <location>İstanbul Kanuni Sultan Süleyman Research and Training Hospital, İstanbul, Turkey</location>
      <location>Liv Hospital, İstanbul, Turkey</location>
      <location>İstanbul Şişli Hamidiye Etfal Research and Training Hospital, İstanbul, Turkey</location>
      <location>İstanbul Altunizade Acıbadem Hospital, İstanbul, Turkey</location>
      <location>Ataşehir Memorial Hospital, İstanbul, Turkey</location>
      <location>İstanbul Ümraniye Research and Training Hospital, İstanbul, Turkey</location>
      <location>Marmara University Medical Faculty, İstanbul, Turkey</location>
      <location>İzmir Behçet Uz Child Disease Hospital, İzmir, Turkey</location>
      <location>Dokuz Eylül University Medical Faculty, İzmir, Turkey</location>
      <location>Kocaeli Üniversitesi University Medical Faculty, Kocaeli, Turkey</location>
      <location>Kırıkkale University Medical Faculty, Kırıkkale, Turkey</location>
      <location>Adana City Training and Research Hospital, Malatya, Turkey</location>
      <location>İnönü Üniversitesi University Medical Faculty, Malatya, Turkey</location>
      <location>Ondokuz Mayıs University Medical Faculty, Samsun, Turkey</location>
      <location>Karadeniz Teknik University Medical Faculty, Trabzon, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648255</url>
  </study>
  <study rank="45239">
    <nct_id>NCT03648242</nct_id>
    <title>Improving Pediatric Obesity Practice Using Prompts</title>
    <acronym>iPOP-UP</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pediatric Obesity</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Interruptive Clinical Decision Support</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in body mass index (BMI)</outcome_measure>
      <outcome_measure>Change in percent BMI above the 95th percentile (%BMIp95)</outcome_measure>
      <outcome_measure>Change in documentation of elevated BMI diagnosis</outcome_measure>
      <outcome_measure>Change in proportion of patients with obesity</outcome_measure>
      <outcome_measure>Change in proportion of patients with obesity who have counseling for obesity-related behavior change documented in the EHR</outcome_measure>
      <outcome_measure>Change in proportion of patients with obesity with follow-up or referral orders</outcome_measure>
      <outcome_measure>Change in provider knowledge, attitudes and practice around obesity management in primary care assessed via an electronic surveys and qualitative interviews of clinicians</outcome_measure>
      <outcome_measure>System usability scale (SUS) score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>Boston Children’s Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB-P00029050</other_id>
      <other_id>1K08HS024332-01A1</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>July 5, 2019</last_update_posted>
    <locations>
      <location>Boston Children's Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648242</url>
  </study>
  <study rank="45240">
    <nct_id>NCT03648229</nct_id>
    <title>African Glaucoma Laser Trial</title>
    <acronym>AGLT</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Open-angle Glaucoma</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Selective laser trabeculoplasty (SLT)</intervention>
      <intervention type="Drug">Latanoprost ophthalmic solution</intervention>
      <intervention type="Drug">Timolol ophthalmic solution</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>12-month survival using Step 1 of assigned therapy</outcome_measure>
      <outcome_measure>12-month survival using Step 1 +/- Step 2 of assigned therapy</outcome_measure>
      <outcome_measure>Nature and incidence of treatment-emergent adverse events</outcome_measure>
      <outcome_measure>Clinical utility of repeat SLT</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>West Virginia University</lead_sponsor>
      <collaborator>University of Pittsburgh</collaborator>
      <collaborator>University of Michigan</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>325</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>AGLT</other_id>
    </other_ids>
    <start_date>September 1, 2019</start_date>
    <primary_completion_date>June 30, 2022</primary_completion_date>
    <completion_date>June 30, 2024</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648229</url>
  </study>
  <study rank="45241">
    <nct_id>NCT03648216</nct_id>
    <title>The Effect of Experimentally Increasing Sedentary Behaviour on Subjective Well-being</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sedentary Lifestyle</condition>
      <condition>Quality of Life</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">HAPA behavioural counseling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from pre-randomization Subjective Well-Being (Affect) at 1-week post-intervention and 1-week follow-up</outcome_measure>
      <outcome_measure>Change from pre-randomization Subjective Well-Being (Life Satisfaction) at 1-week post-intervention and 1-week follow-up</outcome_measure>
      <outcome_measure>Change from pre-randomization Subjective Well-Being (Eudaimonic Well-Being) at 1-week post-intervention and 1-week follow-up</outcome_measure>
      <outcome_measure>Change from pre-randomization Subjective Well-Being at 1-week post-intervention and 1-week follow-up</outcome_measure>
      <outcome_measure>Change from pre-randomization self-reported Physical Activity at 1-week post-intervention and 1-week follow-up</outcome_measure>
      <outcome_measure>Change from pre-randomization self-reported Sedentary Behaviour at 1-week post-intervention and 1-week follow-up</outcome_measure>
      <outcome_measure>Change from pre-randomization Depression at 1-week post-intervention and 1-week follow-up</outcome_measure>
      <outcome_measure>Change from pre-randomization Anxiety (State) at 1-week post-intervention and 1-week follow-up</outcome_measure>
      <outcome_measure>Change from pre-randomization objectively-measured Sedentary Behaviour at 1-week post-intervention and 1-week follow-up</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Western University, Canada</lead_sponsor>
      <collaborator>Social Sciences and Humanities Research Council of Canada</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>112536</other_id>
    </other_ids>
    <start_date>January 7, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>October 2, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648216</url>
  </study>
  <study rank="45242">
    <nct_id>NCT03648203</nct_id>
    <title>Technology Enabled Asthma Management System (TEAMS) Pilot Study</title>
    <acronym>TEAMS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Asthma</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Technology Enabled Asthma Management System</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Acceptability of the TEAMS program for routine asthma management for patients as assessed by USE-Q at end of study</outcome_measure>
      <outcome_measure>Change in asthma control from baseline to end of study at 6 months</outcome_measure>
      <outcome_measure>Change in Forced Expiratory Volume over 1 second (FEV1) from baseline to end of study at 6 months</outcome_measure>
      <outcome_measure>Change in Asthma-related Quality of life from baseline to end of study at 6 months</outcome_measure>
      <outcome_measure>Change in frequency of acute healthcare utilization from baseline to end of study at 6 month</outcome_measure>
      <outcome_measure>(Qualitative) Participant experiences with and perceptions of TEAMS program</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Rochester</lead_sponsor>
      <collaborator>University of Rhode Island</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>SON2018-003</other_id>
    </other_ids>
    <start_date>February 15, 2018</start_date>
    <primary_completion_date>January 2020</primary_completion_date>
    <completion_date>January 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>February 15, 2019</last_update_posted>
    <locations>
      <location>University of Rochester, Rochester, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648203</url>
  </study>
  <study rank="45243">
    <nct_id>NCT03648190</nct_id>
    <title>Platelet Glycoproteins in Inherited Thrombocytopathy: Association With Aggregation Studies and Bleeding Severity</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Bleeding</condition>
      <condition>Platelet Dysfunction</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Flowcytometry analysis of platelets surface receptors</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Establishment of a protocol for Flowcytometry device to be used in routinely diagnosing cases with inherited platelets function defects.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assiut University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>17200237</other_id>
    </other_ids>
    <start_date>December 1, 2018</start_date>
    <primary_completion_date>December 30, 2019</primary_completion_date>
    <completion_date>August 30, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Assiut University Hospital, Assiut, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648190</url>
  </study>
  <study rank="45244">
    <nct_id>NCT03648177</nct_id>
    <title>Integrative Psychosocial Group Treatment</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Pain</condition>
      <condition>Opioid Misuse</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">IPGT</intervention>
      <intervention type="Behavioral">Treatment as Usual</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Feasibility of attrition</outcome_measure>
      <outcome_measure>Acceptability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pittsburgh</lead_sponsor>
      <collaborator>Staunton Farm Foundation</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PRO18040067</other_id>
    </other_ids>
    <start_date>November 2, 2018</start_date>
    <primary_completion_date>February 28, 2019</primary_completion_date>
    <completion_date>February 28, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>May 6, 2019</last_update_posted>
    <locations>
      <location>UPMC Pain Medicine Program, Pittsburgh, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648177</url>
  </study>
  <study rank="45245">
    <nct_id>NCT03648164</nct_id>
    <title>CREATION Health Assessment Tool for College Students</title>
    <acronym>CHAT-CS</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Health Behavior</condition>
      <condition>Well Being</condition>
    </conditions>
    <interventions>
      <intervention type="Other">CHAT-CS Survey</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Establish reliability using Cronbach's alpha</outcome_measure>
      <outcome_measure>Item deduction</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Florida Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>1238224</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>April 30, 2019</primary_completion_date>
    <completion_date>June 30, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>February 15, 2019</last_update_posted>
    <locations>
      <location>Oakwood University, Huntsville, Alabama, United States</location>
      <location>Andrews University, Berrien Springs, Michigan, United States</location>
      <location>Union College, Lincoln, Nebraska, United States</location>
      <location>Kettering College, Kettering, Ohio, United States</location>
      <location>Southern Adventist University, Collegedale, Tennessee, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648164</url>
  </study>
  <study rank="45246">
    <nct_id>NCT03648151</nct_id>
    <title>Influence of PET/CT Radiomic Features on the Outcome of Lung Cancer Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lung Cancer</condition>
      <condition>Image, Body</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Overall survival (OS) of lung cancer patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The First Affiliated Hospital of Shanxi Medical University</lead_sponsor>
      <collaborator>The First Affiliated Hospital of Anhui Medical University</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>20170501</other_id>
    </other_ids>
    <start_date>January 1, 2010</start_date>
    <primary_completion_date>December 31, 2019</primary_completion_date>
    <completion_date>December 31, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China</location>
      <location>First Affiliated Hospital of Shanxi Medical University, Taiyuan, Shanxi, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648151</url>
  </study>
  <study rank="45247">
    <nct_id>NCT03648138</nct_id>
    <title>Testing the Influence of Different Sugary Drink Warning Label Designs</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Obesity</condition>
      <condition>Weight Gain</condition>
      <condition>Diabetes Type 2</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Sugary drink warning labels</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hypothetical beverage choice</outcome_measure>
      <outcome_measure>Likely to serve or buy these beverages:</outcome_measure>
      <outcome_measure>Parent feels good serving the beverages</outcome_measure>
      <outcome_measure>Child enjoyment of beverages</outcome_measure>
      <outcome_measure>Health beliefs and risk perceptions index</outcome_measure>
      <outcome_measure>Estimate of how many teaspoons of added sugar are in the beverages</outcome_measure>
      <outcome_measure>Perceived amount of added sugar in beverages</outcome_measure>
      <outcome_measure>Noticing the label</outcome_measure>
      <outcome_measure>Perceived label influence</outcome_measure>
      <outcome_measure>Favor or oppose sugary drink warning label policy</outcome_measure>
      <outcome_measure>Likelihood of label changing thoughts</outcome_measure>
      <outcome_measure>Encourage you to give fewer beverages to your child</outcome_measure>
      <outcome_measure>How much do you trust the information on this label</outcome_measure>
      <outcome_measure>Negative reactions to the label</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>Drexel University</collaborator>
      <collaborator>New York University</collaborator>
      <collaborator>University of Connecticut</collaborator>
      <collaborator>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>828087</other_id>
      <other_id>R01DK111558</other_id>
    </other_ids>
    <start_date>January 2020</start_date>
    <primary_completion_date>January 2020</primary_completion_date>
    <completion_date>January 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 18, 2020</last_update_posted>
    <locations>
      <location>Online study with GfK, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648138</url>
  </study>
  <study rank="45248">
    <nct_id>NCT03648125</nct_id>
    <title>Influence of Dental Occlusion on the Performance of High Level Rowers (IODPR)</title>
    <acronym>IODPR</acronym>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dental Occlusion, Traumatic</condition>
    </conditions>
    <interventions>
      <intervention type="Device">with artificial occlusal disturbance</intervention>
      <intervention type="Device">without artificial occlusal disturbance</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Muscular power</outcome_measure>
      <outcome_measure>Surface of the pressure center of the rower's feet</outcome_measure>
      <outcome_measure>Velocity of the pressure center of the rower's feet</outcome_measure>
      <outcome_measure>Tonicity of the para-vertebral muscles</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rennes University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>15 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>7</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>35RC17_8823_IODPR</other_id>
    </other_ids>
    <start_date>October 27, 2017</start_date>
    <primary_completion_date>November 22, 2017</primary_completion_date>
    <completion_date>November 22, 2017</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>CREPS de Wattignies, Wattignies, Hauts-de-France, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648125</url>
  </study>
  <study rank="45249">
    <nct_id>NCT03648112</nct_id>
    <title>Effects of Beta-glucan From Barley and Oats on Glucose and Lipid Metabolism, and Satiety</title>
    <acronym>gLUCAn</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lipid Metabolism</condition>
      <condition>Glucose Metabolism</condition>
      <condition>Satiety</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Intervention 1</intervention>
      <intervention type="Dietary Supplement">Intervention 2</intervention>
      <intervention type="Dietary Supplement">Intervention 3</intervention>
      <intervention type="Dietary Supplement">Intervention 4</intervention>
      <intervention type="Dietary Supplement">Control</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>LDL cholesterol</outcome_measure>
      <outcome_measure>total cholesterol</outcome_measure>
      <outcome_measure>HDL cholesterol</outcome_measure>
      <outcome_measure>triacylglycerides</outcome_measure>
      <outcome_measure>HOMA-index</outcome_measure>
      <outcome_measure>fasting blood glucose</outcome_measure>
      <outcome_measure>kinetic of glycemic answer</outcome_measure>
      <outcome_measure>kinetic of satiety hormones</outcome_measure>
      <outcome_measure>short chain fatty acids in fecal water</outcome_measure>
      <outcome_measure>composition of microbiome</outcome_measure>
      <outcome_measure>blood pressure</outcome_measure>
      <outcome_measure>height</outcome_measure>
      <outcome_measure>weight</outcome_measure>
      <outcome_measure>body-mass index</outcome_measure>
      <outcome_measure>bioelectrical impedance analysis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Jena</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>H7_18</other_id>
    </other_ids>
    <start_date>May 2, 2018</start_date>
    <primary_completion_date>May 31, 2018</primary_completion_date>
    <completion_date>July 31, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 25, 2019</last_update_posted>
    <locations>
      <location>Friedrich-Schiller-University, Jena, Thuringia, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648112</url>
  </study>
  <study rank="45250">
    <nct_id>NCT03648099</nct_id>
    <title>Effect of Labor Dance and Music on Labor Pain and Fear of Childbirth</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Labor Pain</condition>
      <condition>Fear of Childbirth</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Labor dance</intervention>
      <intervention type="Behavioral">Music</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Visual Analogue Scale Score,</outcome_measure>
      <outcome_measure>Version A of the Wijma Delivery Expectancy Questionnaire Score</outcome_measure>
      <outcome_measure>Recurrence of Fear of Childbirth</outcome_measure>
      <outcome_measure>Recurrence of perceived pain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ankara University</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>99</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Care Provider)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>Study of Labor Dance and Music</other_id>
    </other_ids>
    <start_date>February 15, 2018</start_date>
    <primary_completion_date>June 15, 2018</primary_completion_date>
    <completion_date>June 15, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Ankara University, Altındağ, Ankara, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648099</url>
  </study>
  <study rank="45251">
    <nct_id>NCT03648086</nct_id>
    <title>Intestinal Microbiota Transplantation for Nonalcoholic Fatty Liver Disease</title>
    <acronym>NAFLD</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Non-alcoholic Fatty Liver Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">intestinal microbiota transplantation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The change of CT ratio of liver/spleen</outcome_measure>
      <outcome_measure>biochemical indicators</outcome_measure>
      <outcome_measure>Fibroscan E value</outcome_measure>
      <outcome_measure>Changes of gut microbiota</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Zhongshan Hospital Xiamen University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2017005</other_id>
    </other_ids>
    <start_date>November 14, 2017</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>November 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian, China</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03648086/ICF_000.pdf</url>
      </study_document>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT03648086/Prot_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03648086</url>
  </study>
  <study rank="45252">
    <nct_id>NCT03648073</nct_id>
    <title>[68Ga]DOTATATE-PET/MRI in Hepatocellular Carcinoma</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatocellular Carcinoma</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">[68Ga]DOTATATE-PET/MRI</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients demonstrating somatostatin receptor positivity in hepatocellular carcinoma using [68Ga]DOTATATE-PET</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Alabama at Birmingham</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>R18-107</other_id>
    </other_ids>
    <start_date>January 30, 2019</start_date>
    <primary_completion_date>March 1, 2020</primary_completion_date>
    <completion_date>March 1, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>March 27, 2019</last_update_posted>
    <locations>
      <location>University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648073</url>
  </study>
  <study rank="45253">
    <nct_id>NCT03648060</nct_id>
    <title>Efficacy of a Digital Biofeedback System for Home-based Rehabilitation After Total Joint Replacement</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hip Osteoarthritis</condition>
      <condition>Knee Osteoarthritis</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Digital kinematic biofeedback system</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in the Timed up and Go Test score</outcome_measure>
      <outcome_measure>Change in the Hip Osteoarthritis Outcome Score/Knee Osteoarthritis Outcome Score</outcome_measure>
      <outcome_measure>Change in Hip/Knee Range of Motion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sword Health, SA</lead_sponsor>
      <collaborator>Hospital da Prelada</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SH-SA-TJR-01</other_id>
    </other_ids>
    <start_date>October 8, 2018</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>November 21, 2018</last_update_posted>
    <locations>
      <location>Hospital da Prelada, Porto, Portugal</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT03648060/Prot_SAP_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03648060</url>
  </study>
  <study rank="45254">
    <nct_id>NCT03648047</nct_id>
    <title>Digital Biofeedback System Versus Conventional Rehabilitation After Rotator Cuff Repair</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Rotator Cuff Tear</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Digital kinematic biofeedback device</intervention>
      <intervention type="Other">Conventional rehabilitation</intervention>
      <intervention type="Other">Additional face-to-face rehabilitation sessions</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Constant Score Test</outcome_measure>
      <outcome_measure>Change in QuickDASH score</outcome_measure>
      <outcome_measure>Change in Shoulder Range of Motion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sword Health, SA</lead_sponsor>
      <collaborator>Hospital da Prelada</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SH-RCT-ARCR-01</other_id>
    </other_ids>
    <start_date>November 11, 2018</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>February 6, 2019</last_update_posted>
    <locations>
      <location>Hospital da Prelada, Porto, Portugal</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT03648047/Prot_SAP_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03648047</url>
  </study>
  <study rank="45255">
    <nct_id>NCT03648034</nct_id>
    <title>Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Meningioma</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">ropivacaine</intervention>
      <intervention type="Procedure">saline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>KPS score</outcome_measure>
      <outcome_measure>serum TNF-α levels</outcome_measure>
      <outcome_measure>serum IL-6 levels</outcome_measure>
      <outcome_measure>serum IL-1β levels</outcome_measure>
      <outcome_measure>Iowa Satisfaction with Anesthesia Scale (ISAS)</outcome_measure>
      <outcome_measure>white blood cell</outcome_measure>
      <outcome_measure>serum levels of CRP</outcome_measure>
      <outcome_measure>VAS score</outcome_measure>
      <outcome_measure>pain-relief medications</outcome_measure>
      <outcome_measure>Hospitalization Days</outcome_measure>
      <outcome_measure>out of pocket expenditure for hospitalisation</outcome_measure>
      <outcome_measure>complications</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>RenJi Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>SNB20180813</other_id>
    </other_ids>
    <start_date>September 18, 2018</start_date>
    <primary_completion_date>December 31, 2019</primary_completion_date>
    <completion_date>January 31, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 23, 2019</last_update_posted>
    <locations>
      <location>Renji Hospital affliated to Shanghai Jiaotong University School of Medicine, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648034</url>
  </study>
  <study rank="45256">
    <nct_id>NCT03648021</nct_id>
    <title>The Effect of Paracetamol on Brain Temperature</title>
    <acronym>NEUROTHERM</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Brain Injuries</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Paracetamol</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Comparison of mean brain temperature measured between H0 and H6 following administration of treatment between the two groups (the group treated with paracetamol and the placebo group)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fondation Ophtalmologique Adolphe de Rothschild</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MDY_2017_19</other_id>
    </other_ids>
    <start_date>April 10, 2018</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>December 9, 2019</last_update_posted>
    <locations>
      <location>Fondation Ophtalmologique Adolphe de Rothschild, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648021</url>
  </study>
  <study rank="45257">
    <nct_id>NCT03648008</nct_id>
    <title>Postoperative Analgesic Effect of Hydromorphone on Partial Pulmonary Resection Under Video-assisted Thoracoscopy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pain, Postoperative</condition>
      <condition>Thoracic Surgery, Video-Assisted</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydromorphone</intervention>
      <intervention type="Drug">Morphine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rest pain assessment at 0.5 hour after tracheal extubation</outcome_measure>
      <outcome_measure>Rest pain assessment at 8 p.m. surgery day</outcome_measure>
      <outcome_measure>Activity pain assessment at 8 p.m. surgery day</outcome_measure>
      <outcome_measure>Rest pain assessment at 8 a.m. at first day after surgery</outcome_measure>
      <outcome_measure>Activity pain assessment at 8 a.m. at first day after surgery</outcome_measure>
      <outcome_measure>Rest pain assessment at 8 p.m. at first day after surgery</outcome_measure>
      <outcome_measure>Activity pain assessment at 8 p.m. at first day after surgery</outcome_measure>
      <outcome_measure>Rest pain assessment at 8 a.m. at second day after surgery</outcome_measure>
      <outcome_measure>Activity pain assessment at 8 a.m. at second day after surgery</outcome_measure>
      <outcome_measure>Rest pain assessment at 8 p.m. at second day after surgery</outcome_measure>
      <outcome_measure>Activity pain assessment at 8 p.m. at second day after surgery</outcome_measure>
      <outcome_measure>Rest pain assessment at 8 a.m. at third day after surgery</outcome_measure>
      <outcome_measure>Activity pain assessment at 8 a.m. at third day after surgery</outcome_measure>
      <outcome_measure>Rest pain assessment at 8 p.m. at third day after surgery</outcome_measure>
      <outcome_measure>Activity pain assessment at 8 p.m. at third day after surgery</outcome_measure>
      <outcome_measure>Ratio of Nausea</outcome_measure>
      <outcome_measure>Ratio of Vomiting</outcome_measure>
      <outcome_measure>Total Analgesia usage</outcome_measure>
      <outcome_measure>Total Antiemetic usage</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Second Affiliated Hospital, School of Medicine, Zhejiang University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>171</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018-014</other_id>
    </other_ids>
    <start_date>May 5, 2018</start_date>
    <primary_completion_date>September 1, 2018</primary_completion_date>
    <completion_date>September 1, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 26, 2018</last_update_posted>
    <locations>
      <location>The second affiliated hospital of Zhejiang University, Hangzhou, Zhejiang, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648008</url>
  </study>
  <study rank="45258">
    <nct_id>NCT03647995</nct_id>
    <title>Probiotics in the Prevention of Antibiotic Induced Diarrhea and Clostridium Difficile Associated Diarrhea.</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diarrhea, Clostridium Difficile</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Probiolife by Green Made (Pharma M)</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Occurrence of an antibiotic-associated diarrhea.</outcome_measure>
      <outcome_measure>Presence of Clostridium difficile toxins in stool culture.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yara El Helou</lead_sponsor>
      <collaborator>Pharma M</collaborator>
      <collaborator>Saint-Joseph University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>190</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>ProbioSJU</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>December 31, 2018</primary_completion_date>
    <completion_date>March 31, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647995</url>
  </study>
  <study rank="45259">
    <nct_id>NCT03647982</nct_id>
    <title>Anhidrotic Area and Safety of MEDITOXIN in Healthy Male Valunteers</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anhidrotic Area</condition>
      <condition>Hyperhidrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Meditoxin</intervention>
      <intervention type="Drug">Botox</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>anhidrotic area</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medy-Tox</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>20 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MT01-KR17PAH110</other_id>
    </other_ids>
    <start_date>March 20, 2018</start_date>
    <primary_completion_date>October 20, 2018</primary_completion_date>
    <completion_date>November 20, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>March 26, 2019</last_update_posted>
    <locations>
      <location>Catholic University St. Paul Hospital, Seoul, Dongdaemun-gu, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647982</url>
  </study>
  <study rank="45260">
    <nct_id>NCT03647969</nct_id>
    <title>Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Adenocarcinoma of the Stomach</condition>
      <condition>GastroEsophageal Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">mFOLFOX, Nivolumab, Ipilimumab</intervention>
      <intervention type="Drug">mFOLFOX</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Progression-free survival (PFS)</outcome_measure>
      <outcome_measure>Overall Response Rate (ORR)</outcome_measure>
      <outcome_measure>Duration of response and disease stabilization</outcome_measure>
      <outcome_measure>Overall survival (OS)</outcome_measure>
      <outcome_measure>Incidence and severity of adverse events</outcome_measure>
      <outcome_measure>Patient reported outcomes: Quality of life</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>119</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>AIO-STO-0417</other_id>
      <other_id>2017-002080-18</other_id>
      <other_id>CA209-9KG</other_id>
    </other_ids>
    <start_date>November 7, 2018</start_date>
    <primary_completion_date>July 2022</primary_completion_date>
    <completion_date>December 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 14, 2020</last_update_posted>
    <locations>
      <location>Krankenhaus Nordwest, Frankfurt, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647969</url>
  </study>
  <study rank="45261">
    <nct_id>NCT03647956</nct_id>
    <title>Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>NSCLC Stage IIIB</condition>
      <condition>NSCLC Stage IV</condition>
      <condition>EGFR Activating Mutation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Atezolizumab</intervention>
      <intervention type="Drug">Bevacizumab</intervention>
      <intervention type="Drug">Carboplatin</intervention>
      <intervention type="Drug">Pemetrexed</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Objective response rate (ORR)</outcome_measure>
      <outcome_measure>Progression-free Survival (PFS)</outcome_measure>
      <outcome_measure>Time to progression (TTP)</outcome_measure>
      <outcome_measure>Duration of response (DoR)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML40560</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>December 31, 2019</primary_completion_date>
    <completion_date>April 3, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>April 17, 2019</last_update_posted>
    <locations>
      <location>Department of Clinical Oncology, Hong Kong, Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647956</url>
  </study>
  <study rank="45262">
    <nct_id>NCT03647943</nct_id>
    <title>Neuromodulation Augmented Cognitive Training to Improve Cognitive Flexibility in Anorexia Nervosa</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Active tDCS</condition>
      <condition>Sham tDCS</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Transcranial direct current stimulation</intervention>
      <intervention type="Device">Sham transcranial direct current stimulation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 and rate of treatment dropout in treatment-seeking adults with AN receiving treatment in a residential treatment program for eating disorders.</outcome_measure>
      <outcome_measure>Change from Baseline to End of Treatment Set-Shifting Task Performance Following 10-session tDCS + Cognitive Training Intervention Protocol.</outcome_measure>
      <outcome_measure>Change from Baseline to End of Treatment Resting State and Task-based Functional Magnetic Resonance Imaging (fMRI) Activation during Reversal Learning Task Following 10-session tDCS + Cognitive Training Intervention Protocol.</outcome_measure>
      <outcome_measure>Change in Eating Disorder Examination (EDE) Scores from Baseline to End of Treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Minnesota</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>STUDY00002867</other_id>
    </other_ids>
    <start_date>August 30, 2019</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 13, 2019</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647943</url>
  </study>
  <study rank="45263">
    <nct_id>NCT03647930</nct_id>
    <title>The Effect of Arista on Post-Operative Bleeding and Wound Drainage Following Mastectomy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Seroma</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Microporous Polysaccharide Hemospheres (MPH)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Total Drain Days</outcome_measure>
      <outcome_measure>Total Drain Output</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Memorial Health University Medical Center</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>MHUMC 2012.05.05</other_id>
    </other_ids>
    <start_date>May 15, 2012</start_date>
    <primary_completion_date>March 6, 2015</primary_completion_date>
    <completion_date>March 6, 2015</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Memorial Health University Medical Center, Savannah, Georgia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647930</url>
  </study>
  <study rank="45264">
    <nct_id>NCT03647917</nct_id>
    <title>A Pilot Study on the Use of Platelet Rich Plasma (PRP) for Facial and Hand Skin Rejuvenation</title>
    <acronym>PRP</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Skin Aging of Face and Hands</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Platelet Rich Plasma</intervention>
      <intervention type="Biological">Platelet Rich Plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Wrinkle Severity Rating Scale (WSRS)</outcome_measure>
      <outcome_measure>Hand Grading Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>45 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>17-005431</other_id>
    </other_ids>
    <start_date>June 18, 2019</start_date>
    <primary_completion_date>March 31, 2020</primary_completion_date>
    <completion_date>March 31, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>November 19, 2019</last_update_posted>
    <locations>
      <location>Mayo Clinic in Florida, Jacksonville, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647917</url>
  </study>
  <study rank="45265">
    <nct_id>NCT03647904</nct_id>
    <title>The SEMS Project: Staying Employed With MS</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Multiple Sclerosis</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">SEMS Project</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Work Commitment</outcome_measure>
      <outcome_measure>Change in adjustment to MS</outcome_measure>
      <outcome_measure>Change in self-efficacy</outcome_measure>
      <outcome_measure>Change in mood</outcome_measure>
      <outcome_measure>Change in anxiety</outcome_measure>
      <outcome_measure>Change in psychological well-being</outcome_measure>
      <outcome_measure>Changes in stress</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kessler Foundation</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>E-944-16</other_id>
    </other_ids>
    <start_date>October 1, 2017</start_date>
    <primary_completion_date>October 2018</primary_completion_date>
    <completion_date>October 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Kessler Foundation, East Hanover, New Jersey, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647904</url>
  </study>
  <study rank="45266">
    <nct_id>NCT03647891</nct_id>
    <title>Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized Cardiac Patients</title>
    <acronym>CV Readmit</acronym>
    <status open="N">Suspended</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>OSA</condition>
      <condition>Heart Failure</condition>
      <condition>Myocardial Infarction</condition>
      <condition>Arrhythmia, Cardiac</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Continuous Positive Airway Pressure</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hospital readmission</outcome_measure>
      <outcome_measure>Mortality rates</outcome_measure>
      <outcome_measure>Clinic and urgent care visits</outcome_measure>
      <outcome_measure>Off work orders</outcome_measure>
      <outcome_measure>STOP BANG</outcome_measure>
      <outcome_measure>Epworth Sleepiness Scale (ESS)</outcome_measure>
      <outcome_measure>EQ5D-5L</outcome_measure>
      <outcome_measure>PROMIS</outcome_measure>
      <outcome_measure>Comparing inpatient portable monitor versus 30-day follow up portable monitor results in usual care group</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kaiser Permanente</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>KPSleep-003</other_id>
    </other_ids>
    <start_date>February 28, 2020</start_date>
    <primary_completion_date>February 28, 2020</primary_completion_date>
    <completion_date>April 23, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 19, 2019</last_update_posted>
    <locations>
      <location>Sleep Center; San Bernardino County Medical Center, Kaiser Permanente, Fontana, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647891</url>
  </study>
  <study rank="45267">
    <nct_id>NCT03647878</nct_id>
    <title>Study of Cabozantinib in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.</title>
    <acronym>CABOCARE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Advanced or Metastatic Renal Cell Carcinoma</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>The proportion of subjects with dose reduction due to Serious Adverse Events/Adverse Events (SAEs/AEs)</outcome_measure>
      <outcome_measure>The proportion of subjects with dose interruption due to SAEs/AEs</outcome_measure>
      <outcome_measure>The proportion of subjects with termination of Cabozantinib due to SAEs/AEs</outcome_measure>
      <outcome_measure>Progression free survival (PFS)</outcome_measure>
      <outcome_measure>Best overall response - Overall Response Rate (ORR)</outcome_measure>
      <outcome_measure>Best overall response - Disease Control Rate (DCR)</outcome_measure>
      <outcome_measure>All non-serious and serious adverse events (AEs / SAEs) and fatal outcomes</outcome_measure>
      <outcome_measure>Impact of the activity level at baseline on the occurrence of adverse events (AEs)</outcome_measure>
      <outcome_measure>The proportion of subjects with termination due to SAEs/AEs in sub-group</outcome_measure>
      <outcome_measure>The proportion of subjects with dose interruption due to SAEs/AEs in sub-group</outcome_measure>
      <outcome_measure>The proportion of subjects with dose reduction due to SAEs/AEs in sub-group</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ipsen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>105</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>A-DE-60000-009</other_id>
    </other_ids>
    <start_date>September 24, 2018</start_date>
    <primary_completion_date>August 30, 2022</primary_completion_date>
    <completion_date>August 30, 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>November 29, 2019</last_update_posted>
    <locations>
      <location>Landeskrankenhaus Hochsteiermark, Leoben, Austria</location>
      <location>Uniklinikum Salzburg, Salzburg, Austria</location>
      <location>Salzkammergutklinikum Vöcklabruck, Vöcklabruck, Austria</location>
      <location>Onkologie aschaffenburg, Aschaffenburg, Germany</location>
      <location>Klinikum am Bruderwald Medizinische Klinik V, Bamberg, Germany</location>
      <location>Praxis für Urologie, Berlin, Germany</location>
      <location>Onkologie am Segelfliegerdamm, Berlin, Germany</location>
      <location>überörtl. Praxis für Urologie &amp; Onkologie, Berlin, Germany</location>
      <location>Franziskus Hospital Bielefeld, Bielefeld, Germany</location>
      <location>Centrum für Operative Urologie, Bremen, Germany</location>
      <location>Edia.med MVZ, Chemnitz, Germany</location>
      <location>Onkologisches Zentrum Donauwörth, Donauwörth, Germany</location>
      <location>Onkozentrum Dresden/Freiberg, Dresden, Germany</location>
      <location>Urologische Gemeinschaftspraxis, Dresden, Germany</location>
      <location>St. Georg Klinikum, Eisenach, Germany</location>
      <location>Universitatmedizin Göttingen, Göttingen, Germany</location>
      <location>Evangelisches Krankenhaus Hamm gGmbH, Hamm, Germany</location>
      <location>Onkologisches Studienzentrum am Raschplatz, Hannover, Germany</location>
      <location>Immunologisch onkologisches MVZ, Hannover, Germany</location>
      <location>Praxis für Hämatologie, Onkologie und Gerinnung, Kronach, Germany</location>
      <location>Urologische Arztpraxis, Lutherstadt Eisleben, Germany</location>
      <location>Universitätsklinikum Magdeburg, Magdeburg, Germany</location>
      <location>Praxis für Urologie, Andrologie, Onkologie und medikamentöse Tumortherapie, Markkleeberg, Germany</location>
      <location>Urologische Gemeischaftspraxis Hochsauerland, Meschede, Germany</location>
      <location>Onkologische Praxis Moers, Moers, Germany</location>
      <location>Kliniken Maria Hilf GmbH, Mönchengladbach, Germany</location>
      <location>Facharztpraxis für Hämatologie und Internistische Onkologie, München, Germany</location>
      <location>Universitätsklinikum Münster, Münster, Germany</location>
      <location>Praxis für Hämatologie und Internistische Onkologie, Neustadt Am Rübenberge, Germany</location>
      <location>MVZ Kreis Olpe, Olpe, Germany</location>
      <location>Brüderkrankenhaus St. Josef Paderborn, Paderborn, Germany</location>
      <location>Urologische Praxis, Parchim, Germany</location>
      <location>Elblandklinikum Riesa, Riesa, Germany</location>
      <location>Wissenschaftskontor Nord GmbH &amp;Co KG, Rostock, Germany</location>
      <location>MVZ MP Saaletal, Saalfeld/Saale, Germany</location>
      <location>Klinikum Sindelfingen-Böblingen, Sindelfingen, Germany</location>
      <location>Krankenhaus der Barmherzigen Brüder Trier, Trier, Germany</location>
      <location>Medizinische Studiengesellschaft Nord-West GmbH, Westerstede, Germany</location>
      <location>Praxisgemeinschaft für Onkologie und Urologie, Wilhelmshaven, Germany</location>
      <location>GIM - Gemeinschaftspraxis Innere Medizin, Witten, Germany</location>
      <location>Onkologische Schwerpunktpraxis Wolfsburg, Wolfsburg, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647878</url>
  </study>
  <study rank="45268">
    <nct_id>NCT03647865</nct_id>
    <title>Evaluation of The Accuracy of CAD-CAM Custom Made Titanium Miniplates In Positioning of the Genial Segment in Computer Guided Genioplasty</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Macrogenia</condition>
      <condition>Microgenia</condition>
      <condition>Miniplate</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Osseous Genioplasty</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Accuracy Of the Custom Made Miniplate</outcome_measure>
      <outcome_measure>Patient Satisfaction (Esthetics)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cairo University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018</other_id>
    </other_ids>
    <start_date>September 2018</start_date>
    <primary_completion_date>September 2019</primary_completion_date>
    <completion_date>October 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 18, 2018</last_update_posted>
    <locations>
      <location>Cairo University, Cairo, Manial, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647865</url>
  </study>
  <study rank="45269">
    <nct_id>NCT03647852</nct_id>
    <title>Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Henoch-Schönlein Purpura</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methylprednisolone</intervention>
      <intervention type="Drug">IVIG</intervention>
      <intervention type="Drug">other basic supportive treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>sustained abdominal pain relief</outcome_measure>
      <outcome_measure>other treatment rather than assigned intervention</outcome_measure>
      <outcome_measure>tolarable food type</outcome_measure>
      <outcome_measure>the number of days of taking fasting</outcome_measure>
      <outcome_measure>Drug-related side effects</outcome_measure>
      <outcome_measure>hypertension</outcome_measure>
      <outcome_measure>infection</outcome_measure>
      <outcome_measure>ocular hypertension</outcome_measure>
      <outcome_measure>steroid-related diabetes</outcome_measure>
      <outcome_measure>cost of treatment</outcome_measure>
      <outcome_measure>The number of days in hospital</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Children's Hospital of Fudan University</lead_sponsor>
      <collaborator>Shanghai Children's Hospital</collaborator>
      <collaborator>Shanghai Children's Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>2 Years</min_age>
    <max_age>16 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>chfuHSP 1.0</other_id>
    </other_ids>
    <start_date>September 1, 2019</start_date>
    <primary_completion_date>October 30, 2021</primary_completion_date>
    <completion_date>October 30, 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>November 13, 2019</last_update_posted>
    <locations>
      <location>Children's Hospital of Fudan University, Shanghai, China</location>
      <location>Children's Hospital of Shanghai, Shanghai, China</location>
      <location>Shanghai Children's Medical Centre, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647852</url>
  </study>
  <study rank="45270">
    <nct_id>NCT03647839</nct_id>
    <title>Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer</title>
    <acronym>MODULATE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Colorectal Cancer Metastatic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nivolumab 10 MG/ML</intervention>
      <intervention type="Drug">BNC 105</intervention>
      <intervention type="Drug">BBI608</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Objective response per iRECIST</outcome_measure>
      <outcome_measure>Objective response per RECIST1.1</outcome_measure>
      <outcome_measure>Progression free survival (PFS).</outcome_measure>
      <outcome_measure>Adverse event assessed using CTCAE version 5.0</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Australasian Gastro-Intestinal Trials Group</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CA209‐99U</other_id>
    </other_ids>
    <start_date>September 6, 2018</start_date>
    <primary_completion_date>August 2022</primary_completion_date>
    <completion_date>August 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>February 5, 2019</last_update_posted>
    <locations>
      <location>Border Cancer Hospital, Albury, New South Wales, Australia</location>
      <location>Newcastle Private Hospital, Newcastle, New South Wales, Australia</location>
      <location>Northern Cancer Institute, St Leonards, New South Wales, Australia</location>
      <location>Westmead Hospital, Westmead, New South Wales, Australia</location>
      <location>Royal Brisbane Hospital, Herston, Queensland, Australia</location>
      <location>Flinders Medical Centre, Bedford Park, South Australia, Australia</location>
      <location>Ashford Cancer Centre Research, Kurralta Park, South Australia, Australia</location>
      <location>Queen Elizabeth Hospital, Woodville South, South Australia, Australia</location>
      <location>Ballarat Health Service, Ballarat, Victoria, Australia</location>
      <location>Eastern Health, Box Hill, Victoria, Australia</location>
      <location>Monash Health, Clayton, Victoria, Australia</location>
      <location>Olivia Newton-John Cancer Wellness and Research Centre, Heidelberg, Victoria, Australia</location>
      <location>Peninsula Health/Frankston Hospital, Mornington Peninsula, Victoria, Australia</location>
      <location>Western Health, Saint Albans, Victoria, Australia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647839</url>
  </study>
  <study rank="45271">
    <nct_id>NCT03647826</nct_id>
    <title>Mind Power - A CBT Based Program for Adolescents</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mental Depression</condition>
      <condition>Mental Stress</condition>
      <condition>Mental Health Wellness 1</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Mind Power Intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hopkins Symptom Checklist (HSCL-Short form, 8 items)</outcome_measure>
      <outcome_measure>Rosenberg Self-Esteem Scale (RSES, short form, 4 items)</outcome_measure>
      <outcome_measure>Lindsley self-regulation (13 items)</outcome_measure>
      <outcome_measure>The Warwick-Edinburgh Mental Well-being Scale (WEMWBS, 14 items)</outcome_measure>
      <outcome_measure>The Norwegian Version of the General Perceived Self-Efficacy Scale (short form, 5 items)</outcome_measure>
      <outcome_measure>Reynolds Adolescent Depression Scale, 2nd Ed. Short Form (10 items)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Norwegian Institute of Public Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>2200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>2510</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>June 10, 2020</primary_completion_date>
    <completion_date>June 10, 2037</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>November 5, 2018</last_update_posted>
    <locations>
      <location>Gry Anette Sælid, Oslo, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647826</url>
  </study>
  <study rank="45272">
    <nct_id>NCT03647813</nct_id>
    <title>Effects of Photobiomodulation in Salivary Analysis of Chronic Renal Failure Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Xerostomia</condition>
      <condition>Chronic Renal Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Radiation">Photobiomodulation</intervention>
      <intervention type="Radiation">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline Sialometry (measurement of the amount of produced saliva before and after treatment)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Nove de Julho</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>44</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Vanessa</other_id>
    </other_ids>
    <start_date>July 1, 2016</start_date>
    <primary_completion_date>September 15, 2017</primary_completion_date>
    <completion_date>September 30, 2017</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 29, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647813</url>
  </study>
  <study rank="45273">
    <nct_id>NCT03647800</nct_id>
    <title>Study of APVO436 in Patients With AML or MDS</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>AML</condition>
      <condition>MDS</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">APVO436</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Maximum Tolerated Dose</outcome_measure>
      <outcome_measure>Frequency and severity of adverse events as assessed by CTCAE v5.0</outcome_measure>
      <outcome_measure>Maximum serum drug concentration</outcome_measure>
      <outcome_measure>Area under the concentration-time curve (AUC)</outcome_measure>
      <outcome_measure>Elimination of half-life</outcome_measure>
      <outcome_measure>Changes in T-cell populations to measure pharmacodynamics of APVO436</outcome_measure>
      <outcome_measure>Changes in peripheral blasts to measure pharmacodynamics of APVO436</outcome_measure>
      <outcome_measure>Immunogenicity of APVO436</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Aptevo Research and Development LLC</lead_sponsor>
      <collaborator>Aptevo Therapeutics</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>108</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>Protocol 5001</other_id>
    </other_ids>
    <start_date>December 13, 2018</start_date>
    <primary_completion_date>August 15, 2020</primary_completion_date>
    <completion_date>December 15, 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 22, 2020</last_update_posted>
    <locations>
      <location>Sylvester Comprehensive Cancer Center/UMHC, Miami, Florida, United States</location>
      <location>The University of Kansas Clinical Research Center, Westwood, Kansas, United States</location>
      <location>Roswell Park Cancer Institute, Buffalo, New York, United States</location>
      <location>The Ohio State University Wexner Medical Center/James Cancer Hospital, Columbus, Ohio, United States</location>
      <location>Greenville Health System, Institute for Translational Oncology Research, Greenville, South Carolina, United States</location>
      <location>University of Texas Southwestern Medical Center, Dallas, Texas, United States</location>
      <location>University of Utah, Huntsman Cancer Institute, Salt Lake City, Utah, United States</location>
      <location>Fred Hutchinson Cancer Research Center, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647800</url>
  </study>
  <study rank="45274">
    <nct_id>NCT03647787</nct_id>
    <title>White Matter Integrity According to BDNF Genotype After Stroke</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Stroke</condition>
    </conditions>
    <interventions>
      <intervention type="Other">observational study</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Fractional anisotropy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Samsung Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018-04-146</other_id>
    </other_ids>
    <start_date>May 25, 2018</start_date>
    <primary_completion_date>April 5, 2019</primary_completion_date>
    <completion_date>April 5, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 19, 2019</last_update_posted>
    <locations>
      <location>Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647787</url>
  </study>
  <study rank="45275">
    <nct_id>NCT03647774</nct_id>
    <title>Long Acting Naltrexone for Opioid Addiction: Focus on Sustained Abstinence and Recovery</title>
    <acronym>NaltRec</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Opioid-use Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Extended release naltrexone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Perceived change in recovery</outcome_measure>
      <outcome_measure>Use of illicit substances</outcome_measure>
      <outcome_measure>Retention in the study</outcome_measure>
      <outcome_measure>Craving for heroin</outcome_measure>
      <outcome_measure>Treatment satisfaction</outcome_measure>
      <outcome_measure>Economic cost analyses</outcome_measure>
      <outcome_measure>Change in mental health status</outcome_measure>
      <outcome_measure>Perceived change in quality of life</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lars Tanum</lead_sponsor>
      <collaborator>Haukeland University Hospital</collaborator>
      <collaborator>Hospital of Southern Norway Trust</collaborator>
      <collaborator>The Hospital of Vestfold</collaborator>
      <collaborator>University Hospital, Akershus</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2017-004706-18</other_id>
      <other_id>269864</other_id>
    </other_ids>
    <start_date>August 1, 2018</start_date>
    <primary_completion_date>August 2023</primary_completion_date>
    <completion_date>December 2025</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 14, 2020</last_update_posted>
    <locations>
      <location>Akershus University Hospital, Loerenskog, Akershus, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647774</url>
  </study>
  <study rank="45276">
    <nct_id>NCT03647761</nct_id>
    <title>Does Wearing Tetra-Grip Improve Arm Function in Children Diagnosed With Neonatal Brachial Plexus Palsy?</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Neonatal Brachial Plexus Palsy</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Tetra-grip</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Assisting Hand Assessment (AHA)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Texas Southwestern Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>3 Years</min_age>
    <max_age>7 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>STU 022018-069</other_id>
    </other_ids>
    <start_date>May 1, 2019</start_date>
    <primary_completion_date>September 2022</primary_completion_date>
    <completion_date>September 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>May 31, 2019</last_update_posted>
    <locations>
      <location>Children's Medical Center Dallas, Dallas, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647761</url>
  </study>
  <study rank="45277">
    <nct_id>NCT03647748</nct_id>
    <title>Effects of Green Light Therapy on Body Contouring and Cellulite</title>
    <acronym>Cellulize</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fat Reduction</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Sham Comparator</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Average Change in Inches of Total Circumference Measurements</outcome_measure>
      <outcome_measure>Durability of Effect</outcome_measure>
      <outcome_measure>Change in appearance of cellulite</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ward Photonics LLC</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CP16-02</other_id>
    </other_ids>
    <start_date>January 2017</start_date>
    <primary_completion_date>August 2018</primary_completion_date>
    <completion_date>August 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Wunderlich Chiropractic Clinic, Cape Coral, Florida, United States</location>
      <location>Mobile Laser Slimming, Cocoa Beach, Florida, United States</location>
      <location>Lake Mary Health and Wellness, Lake Mary, Florida, United States</location>
      <location>Michigan Center for Cosmetic Surgery, Ann Arbor, Michigan, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647748</url>
  </study>
  <study rank="45278">
    <nct_id>NCT03647735</nct_id>
    <title>Patient-controlled Sedation Versus Target-controlled Infusion in Orthopaedic Surgery Under Central Neuraxial Block</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Patient-controlled Sedation</condition>
    </conditions>
    <interventions>
      <intervention type="Other">patient-controlled sedation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>total propofol requirement between PCS versus TCI sedation (TCIS)</outcome_measure>
      <outcome_measure>Patient satisfaction assessed by a 10-point numerical scale</outcome_measure>
      <outcome_measure>Complications including incidence of hypotension, bradycardia, hypopnea, oxygen desaturation and over sedation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universiti Kebangsaan Malaysia Medical Centre</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>78</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <other_ids>
      <other_id>FF-2017-265</other_id>
    </other_ids>
    <start_date>June 22, 2017</start_date>
    <primary_completion_date>May 3, 2018</primary_completion_date>
    <completion_date>May 3, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Pusat Perubatan Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/35/NCT03647735/Prot_SAP_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03647735</url>
  </study>
  <study rank="45279">
    <nct_id>NCT03647722</nct_id>
    <title>Assessing the Induction of Long-term Immune Regulation Following Treatment With Lemtrada® (Alemtuzumab).</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Multiple Sclerosis</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Assessment of leukocyte function.</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Assess changes in the circulating regulatory B-cell population.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Southern California</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>125</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>LemRegUSC</other_id>
    </other_ids>
    <start_date>November 2, 2018</start_date>
    <primary_completion_date>September 2022</primary_completion_date>
    <completion_date>September 2023</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>March 1, 2019</last_update_posted>
    <locations>
      <location>University of Southern California, Department of Neurology, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647722</url>
  </study>
  <study rank="45280">
    <nct_id>NCT03647709</nct_id>
    <title>Opioid-free Accelerated Recovery Total Knee Arthroplasty</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Arthropathy of Knee Joint</condition>
    </conditions>
    <interventions>
      <intervention type="Other">opioids</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Total knee replacement performed without opioids</outcome_measure>
      <outcome_measure>Opiate Drugs</outcome_measure>
      <outcome_measure>Site of Service Procedure Shift</outcome_measure>
      <outcome_measure>comparison of change in patient's pain before surgery (baseline) versus after surgery pain when patient is at rest or with activity</outcome_measure>
      <outcome_measure>Knee Injury and Osteoarthritis Outcome Score short form (KOOS JR)</outcome_measure>
      <outcome_measure>To prove nearly all patients can be treated as outpatient joint replacements using Swiftpath (an educational tool for patient undergoing total joint replacement)</outcome_measure>
      <outcome_measure>Protocol Adherence</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>St. Elizabeth Medical Center, Utica, NY</lead_sponsor>
      <collaborator>Halyard Health</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>qllS</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>October 30, 2019</primary_completion_date>
    <completion_date>March 30, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>December 12, 2019</last_update_posted>
    <locations>
      <location>St Elizabeth Medical Center, Utica, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647709</url>
  </study>
  <study rank="45281">
    <nct_id>NCT03647696</nct_id>
    <title>Incidence of Opioid-Induced Respiratory Depression in Medical and Trauma Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Depression</condition>
      <condition>Sedation</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Hypoventilation</outcome_measure>
      <outcome_measure>Hypoxemia</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Poudre Valley Health System</lead_sponsor>
      <collaborator>University of Colorado Health</collaborator>
      <collaborator>University of California, Los Angeles</collaborator>
      <collaborator>Medtronic</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>89 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PoudreVHS</other_id>
    </other_ids>
    <start_date>August 27, 2018</start_date>
    <primary_completion_date>November 30, 2018</primary_completion_date>
    <completion_date>November 30, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647696</url>
  </study>
  <study rank="45282">
    <nct_id>NCT03647683</nct_id>
    <title>Self-Compassion and Acute Pain</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Self-Compassion</intervention>
      <intervention type="Other">Acceptance</intervention>
      <intervention type="Other">Distraction</intervention>
      <intervention type="Other">Heat pain</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Individual heat pain tolerance</outcome_measure>
      <outcome_measure>Pain intensity</outcome_measure>
      <outcome_measure>Change in pain unpleasantness scale</outcome_measure>
      <outcome_measure>Change in self-compassion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Philipps University Marburg Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2017-60v</other_id>
    </other_ids>
    <start_date>April 15, 2018</start_date>
    <primary_completion_date>November 30, 2018</primary_completion_date>
    <completion_date>November 30, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>April 10, 2019</last_update_posted>
    <locations>
      <location>Philipps-University of Marburg, Marburg, Hessen, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647683</url>
  </study>
  <study rank="45283">
    <nct_id>NCT03647670</nct_id>
    <title>A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy Volunteers</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Phase 1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PF-04965842</intervention>
      <intervention type="Drug">Midazolam</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>AUCinf of midazolam.</outcome_measure>
      <outcome_measure>AUClast of midazolam</outcome_measure>
      <outcome_measure>Blood Pressure</outcome_measure>
      <outcome_measure>Cmax of midazolam.</outcome_measure>
      <outcome_measure>Tmax of midazolam.</outcome_measure>
      <outcome_measure>t1/2 of midazolam.</outcome_measure>
      <outcome_measure>Pulse</outcome_measure>
      <outcome_measure>Temperature</outcome_measure>
      <outcome_measure>Adverse Events</outcome_measure>
      <outcome_measure>Laboratory tests</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pfizer</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>B7451022</other_id>
      <other_id>2018-001198-26</other_id>
    </other_ids>
    <start_date>July 3, 2018</start_date>
    <primary_completion_date>October 16, 2018</primary_completion_date>
    <completion_date>October 16, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>October 18, 2019</last_update_posted>
    <locations>
      <location>Pfizer Clinical Research Unit, Brussels, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647670</url>
  </study>
  <study rank="45284">
    <nct_id>NCT03647657</nct_id>
    <title>177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Thyroid Cancer, Medullary</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">177Lu-PP-F11N</intervention>
      <intervention type="Drug">Sacuitril</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Tumor radiation doses</outcome_measure>
      <outcome_measure>Kidney radiation doses</outcome_measure>
      <outcome_measure>Organ radiation doses</outcome_measure>
      <outcome_measure>In-vivo stability</outcome_measure>
      <outcome_measure>Autoradiography</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Basel, Switzerland</lead_sponsor>
      <collaborator>Krebsforschung Schweiz, Bern, Switzerland</collaborator>
      <collaborator>Center for Proton Therapy, Paul Scherrer Institute, Villigen,Switzerland</collaborator>
      <collaborator>University Hospital, Zürich</collaborator>
      <collaborator>University Hospital Freiburg</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018-00972</other_id>
    </other_ids>
    <start_date>December 13, 2018</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 23, 2019</last_update_posted>
    <locations>
      <location>University Hospital Basel, Clinic for radiology and nuclear medicine, Basel, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647657</url>
  </study>
  <study rank="45285">
    <nct_id>NCT03647644</nct_id>
    <title>Coagulation Test Changes Associated With Acute Normovolemic Hemodilution in Cardiac Surgery</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coagulation Disorder</condition>
      <condition>Bleeding</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Coagulation Laboratory Testing</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Platelet count</outcome_measure>
      <outcome_measure>Change in Fibrinogen</outcome_measure>
      <outcome_measure>Change in Prothrombin Time/international normalized ratio (PT/INR)</outcome_measure>
      <outcome_measure>Change in aPTT</outcome_measure>
      <outcome_measure>Change in Thromboelastogram</outcome_measure>
      <outcome_measure>Allogenic Blood Transfusion</outcome_measure>
      <outcome_measure>Chest Tube Output</outcome_measure>
      <outcome_measure>Re-operation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>16-003298</other_id>
    </other_ids>
    <start_date>January 31, 2018</start_date>
    <primary_completion_date>October 11, 2018</primary_completion_date>
    <completion_date>October 11, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 7, 2019</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647644</url>
  </study>
  <study rank="45286">
    <nct_id>NCT03647631</nct_id>
    <title>Sentinel Lymph Node Biopsy in Porocarcinoma</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Porocarcinoma</condition>
      <condition>Sentinel Lymph Node</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">sentinel lymph node biopsy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Role of SNLB in porocarcinoma in two patients evaluating the percentage of positive lymph nodes removed.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ospedale Policlinico San Martino</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>Chirurgia1</other_id>
    </other_ids>
    <start_date>July 17, 2018</start_date>
    <primary_completion_date>August 1, 2018</primary_completion_date>
    <completion_date>August 17, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Denise Palombo, Genoa, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647631</url>
  </study>
  <study rank="45287">
    <nct_id>NCT03647618</nct_id>
    <title>Anatomy Guidance for Regional Anaesthesia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ultrasound Imaging</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Ultrasound</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Phase 1 Outcome Measures: - Training/Verification •</outcome_measure>
      <outcome_measure>Phase II Validation Outcome Measures - Validation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medaphor Limited</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>ML2018_AG_02</other_id>
    </other_ids>
    <start_date>December 20, 2018</start_date>
    <primary_completion_date>April 1, 2020</primary_completion_date>
    <completion_date>April 1, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 14, 2020</last_update_posted>
    <locations>
      <location>St Woolos Hospital, Newport, Wales, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647618</url>
  </study>
  <study rank="45288">
    <nct_id>NCT03647605</nct_id>
    <title>Pilot Study: VR Mind and VR Mind+ Intervention</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Social Phobia</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">VR Mind</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Feasibility_1: Number of participants, who have completed 4 laboratory sessions within 2 weeks.</outcome_measure>
      <outcome_measure>Feasibility_2: Number of virtual reality exposure sessions completed in predefined time.</outcome_measure>
      <outcome_measure>Usability_ 3: immersion, perceived reality and engagement</outcome_measure>
      <outcome_measure>Safety_1: occurrence and severity of simulator sickness</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tomorrow Sp. z o.o.</lead_sponsor>
      <collaborator>The National Centre for Research and Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>POIR.01.01.01-00-0636/16-00</other_id>
    </other_ids>
    <start_date>September 13, 2018</start_date>
    <primary_completion_date>January 31, 2019</primary_completion_date>
    <completion_date>January 31, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>February 12, 2019</last_update_posted>
    <locations>
      <location>Instytut Psychiatrii i Neurologii, Warszawa, Mazowieckie, Poland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647605</url>
  </study>
  <study rank="45289">
    <nct_id>NCT03647592</nct_id>
    <title>Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Efficacy and Safety of Erlotinib/Gefitinib Combined With Bevacizumab in EGFR Mutation Positive Advanced Non-squamous Non-small Cell Lung Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Erlotinib/Gefitinib combined with Bevacizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>PFS</outcome_measure>
      <outcome_measure>OS</outcome_measure>
      <outcome_measure>DCR</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hunan Province Tumor Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>WECAN</other_id>
    </other_ids>
    <start_date>June 1, 2018</start_date>
    <primary_completion_date>August 31, 2019</primary_completion_date>
    <completion_date>December 1, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 25, 2019</last_update_posted>
    <locations>
      <location>Hunan Provincal Tumor Hospital, Changsha, Hunan, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647592</url>
  </study>
  <study rank="45290">
    <nct_id>NCT03647579</nct_id>
    <title>Dexmedetomidine Versus Midazolam Added to Ketamine in Pediatric Patients Undergoing Bone Marrow Aspiration and Biopsy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Procedural Sedation and Analgesia During Bone Marrow Aspiration and Biopsy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">midazolam intravenous infusion of 0.05 mg/kg plus 1 mg/kg ketamine</intervention>
      <intervention type="Drug">Dexmedetomidine intravenous infusion of 2mic/kg plus 1 mg/kg ketamine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>efficacy of drug mixture on procedural sedation and analgesia: Ramsay sedation score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assiut University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>3 Years</min_age>
    <max_age>12 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>17100208</other_id>
    </other_ids>
    <start_date>August 30, 2018</start_date>
    <primary_completion_date>December 15, 2018</primary_completion_date>
    <completion_date>April 20, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>October 3, 2019</last_update_posted>
    <locations>
      <location>South Egypt Cancer Institute, Assiut University, Assiut, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647579</url>
  </study>
  <study rank="45291">
    <nct_id>NCT03647566</nct_id>
    <title>18F Sodium Fluoride PET/CT in Acute Aortic Syndrome</title>
    <acronym>FAASt</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Aortic Syndrome</condition>
      <condition>Aortic Dissection</condition>
      <condition>Penetrating Aortic Ulcer</condition>
      <condition>Intramural Hematoma</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">18F Sodium Fluoride Positron Emission Tomography / Computed Tomography</intervention>
      <intervention type="Diagnostic Test">CT Aortic Angiogram</intervention>
      <intervention type="Diagnostic Test">Aortic MRI</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Aortic diameter</outcome_measure>
      <outcome_measure>18F Sodium Fluoride uptake in the aorta</outcome_measure>
      <outcome_measure>Hospital admissions</outcome_measure>
      <outcome_measure>Surgical Intervention</outcome_measure>
      <outcome_measure>Change in renal function</outcome_measure>
      <outcome_measure>Short Form-12 (SF12) questionnaire score</outcome_measure>
      <outcome_measure>Disease related survival</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Edinburgh</lead_sponsor>
      <collaborator>NHS Lothian</collaborator>
      <collaborator>British Heart Foundation</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>AC18044</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>October 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>October 30, 2018</last_update_posted>
    <locations>
      <location>Royal Infirmary of Edinburgh, Edinburgh, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647566</url>
  </study>
  <study rank="45292">
    <nct_id>NCT03647553</nct_id>
    <title>The Nash-wo-Numa (Childhood Growth &amp; Development) Study</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Adolescent Development</condition>
      <condition>Stunting</condition>
      <condition>Depression</condition>
      <condition>Micronutrient Deficiency</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Stunting</outcome_measure>
      <outcome_measure>Factors associated with impaired linear growth</outcome_measure>
      <outcome_measure>Anemia and micronutrient deficiencies</outcome_measure>
      <outcome_measure>Household Dietary Diversity Scale (HDDS)</outcome_measure>
      <outcome_measure>Food Insecurity Experience Scale (FIES)</outcome_measure>
      <outcome_measure>Anxiety</outcome_measure>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Pubertal status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Aga Khan University</lead_sponsor>
      <collaborator>The Hospital for Sick Children</collaborator>
      <collaborator>Centre for Addiction and Mental Health</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>9 Years</min_age>
    <max_age>15 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>1425</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>5251-WCH-ERC-18</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>December 31, 2019</primary_completion_date>
    <completion_date>December 31, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>October 12, 2018</last_update_posted>
    <locations>
      <location>Matiari Research and Training Centre, Matiari, Sindh, Pakistan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647553</url>
  </study>
  <study rank="45293">
    <nct_id>NCT03647540</nct_id>
    <title>The Application of Fluorescence Laparoscopy in the Treatment of Adenocarcinoma of the Esophagogastric Junction</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fluorescence Laparoscopy</condition>
      <condition>Adenocarcinoma of the Esophagogastric Junction</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">fluorescent laparoscopic radical gastrectomy</intervention>
      <intervention type="Procedure">traditional laparoscopic radical gastrectomy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>the number of the dissected lymph nodes</outcome_measure>
      <outcome_measure>3-year disease-free survival</outcome_measure>
      <outcome_measure>the incidence of complications</outcome_measure>
      <outcome_measure>the operation time</outcome_measure>
      <outcome_measure>the blood loss during the operation</outcome_measure>
      <outcome_measure>Postoperative recovery of intestinal peristalsis</outcome_measure>
      <outcome_measure>cases converted to open surgery</outcome_measure>
      <outcome_measure>The mean postoperative hospital stay</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dong Yang</lead_sponsor>
      <collaborator>Wang Quan</collaborator>
      <collaborator>Jilin University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>164</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>130020</other_id>
    </other_ids>
    <start_date>August 30, 2018</start_date>
    <primary_completion_date>September 30, 2019</primary_completion_date>
    <completion_date>August 30, 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>the First Hospital of Jilin University, Ch'ang-ch'un, JI Lin, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647540</url>
  </study>
  <study rank="45294">
    <nct_id>NCT03647527</nct_id>
    <title>Predictor Analysis of Acute Radiation Oral Mucositis in NPC Patients Treated With IMRT/TOMO Combined Chemotherapy</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Nasopharyngeal Carcinoma</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>the highest grade of oral mucositis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Zhejiang Cancer Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PF-AROM-NPC-IMRT/TOMO</other_id>
    </other_ids>
    <start_date>September 1, 2016</start_date>
    <primary_completion_date>November 30, 2018</primary_completion_date>
    <completion_date>January 31, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647527</url>
  </study>
  <study rank="45295">
    <nct_id>NCT03647514</nct_id>
    <title>Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Breast Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Abraxane</intervention>
      <intervention type="Drug">Xeloda</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>ORR(CR+PR)</outcome_measure>
      <outcome_measure>Side Effects.</outcome_measure>
      <outcome_measure>Event Free Survival(DFS)</outcome_measure>
      <outcome_measure>Overall Survival(OS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Zhejiang Cancer Hospital</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>dingxwyh01</other_id>
    </other_ids>
    <start_date>December 1, 2018</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>December 10, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647514</url>
  </study>
  <study rank="45296">
    <nct_id>NCT03647501</nct_id>
    <title>Lumbar Fusion With Nexxt Spine 3D-Printed Titanium Interbody Cages</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lumbar Degenerative Disc Disease</condition>
      <condition>Lumbar Spinal Stenosis</condition>
      <condition>Lumbar Spondylolisthesis</condition>
      <condition>Lumbar Spinal Deformity</condition>
      <condition>Lumbar Spondylosis</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Interbody cage (titanium)</intervention>
      <intervention type="Device">Interbody cage (PEEK)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Interbody radiographic fusion rate</outcome_measure>
      <outcome_measure>Post-operative timing of fusion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ohio State University</lead_sponsor>
      <collaborator>Nexxt Spine, LLC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018H0008</other_id>
    </other_ids>
    <start_date>August 22, 2018</start_date>
    <primary_completion_date>August 1, 2022</primary_completion_date>
    <completion_date>September 1, 2024</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 19, 2019</last_update_posted>
    <locations>
      <location>The Ohio State University Wexner Medical Center, Columbus, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647501</url>
  </study>
  <study rank="45297">
    <nct_id>NCT03647488</nct_id>
    <title>Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Carcinoma, Non-Small-Cell Lung</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">capmatinib</intervention>
      <intervention type="Drug">spartalizumab</intervention>
      <intervention type="Drug">docetaxel</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Run in part: Number of participants with adverse events as a measure of safety and tolerability</outcome_measure>
      <outcome_measure>Randomized part: Overall survival (OS)</outcome_measure>
      <outcome_measure>Objective response rate</outcome_measure>
      <outcome_measure>Disease control rate</outcome_measure>
      <outcome_measure>Progression free survival</outcome_measure>
      <outcome_measure>Time to response</outcome_measure>
      <outcome_measure>Duration of response</outcome_measure>
      <outcome_measure>AUClast</outcome_measure>
      <outcome_measure>AUCtau</outcome_measure>
      <outcome_measure>Cmax</outcome_measure>
      <outcome_measure>Ctrough</outcome_measure>
      <outcome_measure>Tmax</outcome_measure>
      <outcome_measure>T 1/2</outcome_measure>
      <outcome_measure>Immunogenicity, characterized by tabulating anti-drug antibodies (ADA) prevalence at baseline and ADA incidence on-treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>105</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>CINC280D2201</other_id>
      <other_id>2018-001420-19</other_id>
    </other_ids>
    <start_date>December 26, 2018</start_date>
    <primary_completion_date>July 19, 2022</primary_completion_date>
    <completion_date>July 19, 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 14, 2020</last_update_posted>
    <locations>
      <location>Highlands Oncology Group, Fayetteville, Arkansas, United States</location>
      <location>H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States</location>
      <location>Levine Cancer Institute SC, Charlotte, North Carolina, United States</location>
      <location>Novartis Investigative Site, Leuven, Belgium</location>
      <location>Novartis Investigative Site, Grenoble, France</location>
      <location>Novartis Investigative Site, LILLE Cédex, France</location>
      <location>Novartis Investigative Site, Koeln, Germany</location>
      <location>Novartis Investigative Site, Athens, GR, Greece</location>
      <location>Novartis Investigative Site, Tel Aviv, Israel</location>
      <location>Novartis Investigative Site, Sunto Gun, Shizuoka, Japan</location>
      <location>Novartis Investigative Site, Nijmegen, Netherland, Netherlands</location>
      <location>Novartis Investigative Site, Barcelona, Catalunya, Spain</location>
      <location>Novartis Investigative Site, Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647488</url>
  </study>
  <study rank="45298">
    <nct_id>NCT03647475</nct_id>
    <title>A Single Arm Study With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)</title>
    <acronym>Onyx ONE Clear</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Combination Product">Device: Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System Treatment Followed by one-month DAPT</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Composite endpoint: Cardiac Death and Myocardial Infarction [Time Frame: One year post procedure]</outcome_measure>
      <outcome_measure>Target Lesion Failure</outcome_measure>
      <outcome_measure>Procedure Success</outcome_measure>
      <outcome_measure>Number of Patients with Cardiac Death</outcome_measure>
      <outcome_measure>Number of Patients with Major Cardiac Event</outcome_measure>
      <outcome_measure>Number of Patients with Myocardial Infarction</outcome_measure>
      <outcome_measure>Number of Patients with Target Vessel Failure</outcome_measure>
      <outcome_measure>Number of Patients with Revascularization</outcome_measure>
      <outcome_measure>Number of Patients with Stent Thrombosis</outcome_measure>
      <outcome_measure>Number of Patients with Bleeding</outcome_measure>
      <outcome_measure>Number of Patients with Stroke</outcome_measure>
      <outcome_measure>Lesion Success</outcome_measure>
      <outcome_measure>Device Success</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medtronic Vascular</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>752</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>MDT18015RES008</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>October 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 7, 2020</last_update_posted>
    <locations>
      <location>Saint Joseph's Hospital Health Center, East Syracuse, New York, United States</location>
      <location>New York- Presbyterian Hospital/Columbia University Medical Center, New York, New York, United States</location>
      <location>AnMed Health Medical Center, Anderson, South Carolina, United States</location>
      <location>Houston Methodist Hospital, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647475</url>
  </study>
  <study rank="45299">
    <nct_id>NCT03647462</nct_id>
    <title>Impact of Early Diagnosis and Treatment of OSA on Hospital Readmission in Hospitalized COPD Patients</title>
    <acronym>COPD Readmit</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Obstructive Sleep Apnea</condition>
      <condition>Chronic Obstructive Pulmonary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Continuous Positive Airway Pressure</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hospital readmission and mortality rates</outcome_measure>
      <outcome_measure>Clinic and urgent care visits</outcome_measure>
      <outcome_measure>Off work orders</outcome_measure>
      <outcome_measure>STOP BANG</outcome_measure>
      <outcome_measure>Epworth Sleepiness Scale (ESS)</outcome_measure>
      <outcome_measure>Patient Reported Outcome Measurement Information System (PROMIS)</outcome_measure>
      <outcome_measure>Chronic Obstructive Pulmonary Disease Assessment Tool (CAT)</outcome_measure>
      <outcome_measure>Comparing inpatient portable monitor versus 30-day follow up portable monitor results in usual care group</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kaiser Permanente</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>KPSleep-004</other_id>
    </other_ids>
    <start_date>February 28, 2019</start_date>
    <primary_completion_date>February 28, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 9, 2019</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647462</url>
  </study>
  <study rank="45300">
    <nct_id>NCT03647449</nct_id>
    <title>Examining the Effects of Juice Fasting</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Epigenetics</condition>
      <condition>Microbiome</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Juice</intervention>
      <intervention type="Behavioral">Caloric restriction via Plant-based meals</intervention>
      <intervention type="Dietary Supplement">Plant-based meal</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change DNA Methylation at Day 7</outcome_measure>
      <outcome_measure>Baseline DNA Methylation</outcome_measure>
      <outcome_measure>Change DNA Methylation at Day 4</outcome_measure>
      <outcome_measure>Change DNA Methylation at Day 21</outcome_measure>
      <outcome_measure>PROMIS Global Health self-report</outcome_measure>
      <outcome_measure>PROMIS Global Health self-report, repeatable</outcome_measure>
      <outcome_measure>Baseline Blood Pressure</outcome_measure>
      <outcome_measure>Blood Pressure at Day 4</outcome_measure>
      <outcome_measure>Change in Blood Pressure at Day 7</outcome_measure>
      <outcome_measure>Change in Blood Pressure at Day 21</outcome_measure>
      <outcome_measure>Baseline Waist Circumference</outcome_measure>
      <outcome_measure>Waist Circumference at Day 4</outcome_measure>
      <outcome_measure>Change in Waist Circumference at Day 7</outcome_measure>
      <outcome_measure>Change in Waist Circumference at Day 21</outcome_measure>
      <outcome_measure>Baseline Weight</outcome_measure>
      <outcome_measure>Weight at Day 4</outcome_measure>
      <outcome_measure>Change in Weight at Day 7</outcome_measure>
      <outcome_measure>Change in Weight at Day 21</outcome_measure>
      <outcome_measure>Baseline C-Reactive Protein</outcome_measure>
      <outcome_measure>C-Reactive Protein at Day 4</outcome_measure>
      <outcome_measure>Change in C-Reactive Protein at Day 7</outcome_measure>
      <outcome_measure>Change in C-Reactive Protein at Day 21</outcome_measure>
      <outcome_measure>Baseline Interleukin-6</outcome_measure>
      <outcome_measure>Interleukin-6 at Day 4</outcome_measure>
      <outcome_measure>Change in Interleukin-6 at Day 7</outcome_measure>
      <outcome_measure>Change in Interleukin-6 at Day 21</outcome_measure>
      <outcome_measure>Baseline Insulin Level</outcome_measure>
      <outcome_measure>Insulin Level at Day 4</outcome_measure>
      <outcome_measure>Change in Insulin Level at Day 7</outcome_measure>
      <outcome_measure>Change in Insulin Level at Day 21</outcome_measure>
      <outcome_measure>Baseline Leptin</outcome_measure>
      <outcome_measure>Leptin at Day 4</outcome_measure>
      <outcome_measure>Change in Leptin at Day 7</outcome_measure>
      <outcome_measure>Change in Leptin at Day 21</outcome_measure>
      <outcome_measure>Baseline Gut microbiota</outcome_measure>
      <outcome_measure>Gut microbiota at Day 4</outcome_measure>
      <outcome_measure>Change in Gut microbiota at Day 7</outcome_measure>
      <outcome_measure>Change in Gut microbiota at Day 21</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Northwestern University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>35 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>STU00206611</other_id>
    </other_ids>
    <start_date>July 10, 2018</start_date>
    <primary_completion_date>March 11, 2019</primary_completion_date>
    <completion_date>December 31, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 21, 2019</last_update_posted>
    <locations>
      <location>Northwestern University, Chicago, Illinois, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03647449/ICF_000.pdf</url>
      </study_document>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT03647449/Prot_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03647449</url>
  </study>
  <study rank="45301">
    <nct_id>NCT03647436</nct_id>
    <title>Incidence of Geriatric Syndromes Overlap</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>GERIATRIC SYNDROMES</condition>
      <condition>Hip Fractures</condition>
      <condition>GERIATRIC ASSESSMENT</condition>
      <condition>Delirium</condition>
      <condition>Depression</condition>
      <condition>Malnutrition</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Comprehensive Geriatric Assessment. Both groups.</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Depression and delirium overlap</outcome_measure>
      <outcome_measure>Hospital complications</outcome_measure>
      <outcome_measure>Hospital length of stay (days)</outcome_measure>
      <outcome_measure>Functional recovery.</outcome_measure>
      <outcome_measure>Survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital de la Ribera</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>70 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>506</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>HULRCP31072018</other_id>
    </other_ids>
    <start_date>August 1, 2018</start_date>
    <primary_completion_date>August 31, 2019</primary_completion_date>
    <completion_date>December 31, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Hospital Universitario de la Ribera, Alzira,, Kingdom Of Valéncia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647436</url>
  </study>
  <study rank="45302">
    <nct_id>NCT03647423</nct_id>
    <title>QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chordoma</condition>
      <condition>Unresectable Malignant Neoplasm</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Aldoxorubicin Hydrochloride</intervention>
      <intervention type="Biological">ALT-803</intervention>
      <intervention type="Biological">ETBX-051</intervention>
      <intervention type="Biological">ETBX-061</intervention>
      <intervention type="Biological">GI-6301</intervention>
      <intervention type="Biological">haNK</intervention>
      <intervention type="Drug">Avelumab</intervention>
      <intervention type="Drug">Cetuximab</intervention>
      <intervention type="Drug">Cyclophosphamide</intervention>
      <intervention type="Radiation">SBRT</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03.</outcome_measure>
      <outcome_measure>Progression-free survival (PFS) by RECIST v1.1</outcome_measure>
      <outcome_measure>Objective response rate by RECIST v1.1</outcome_measure>
      <outcome_measure>Objective response rate by irRC</outcome_measure>
      <outcome_measure>Progression-free survival (PFS) by irRC</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Disease control rate by RECIST v1.1 and irRC.</outcome_measure>
      <outcome_measure>Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months) by RECIST v1.1 and irRC.</outcome_measure>
      <outcome_measure>Patient-reported outcomes of Chordoma cancer symptoms</outcome_measure>
      <outcome_measure>Objective response rate by RECIST 1.1</outcome_measure>
      <outcome_measure>Duration of response by RECIST and irRC</outcome_measure>
      <outcome_measure>Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months) by RECIST and irRC.</outcome_measure>
      <outcome_measure>Patient-reported outcomes of Chordoma cancer</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NantKwest, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>QUILT-3.091</other_id>
    </other_ids>
    <start_date>August 31, 2018</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>August 30, 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>May 14, 2019</last_update_posted>
    <locations>
      <location>Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647423</url>
  </study>
  <study rank="45303">
    <nct_id>NCT03647410</nct_id>
    <title>Lumbopelvic Fixation Versus Novel Adjustable Plate for Displaced Sacral Fracture</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Reduction Deformity of Limb</condition>
    </conditions>
    <interventions>
      <intervention type="Device">lumbopelvic fixation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>postoperative reduction quality of sacral fractures after different surgical techniques</outcome_measure>
      <outcome_measure>the incidence of complication</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hebei Medical University Third Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>RPZ2018</other_id>
    </other_ids>
    <start_date>June 2011</start_date>
    <primary_completion_date>September 2018</primary_completion_date>
    <completion_date>September 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Hebei Medical University Third Hospital, Shijiazhuang, Hebei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647410</url>
  </study>
  <study rank="45304">
    <nct_id>NCT03647397</nct_id>
    <title>PECO Air Purification in Hospital Rooms to Improve Health Outcomes for Pediatric Respiratory Distress</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Asthma</condition>
      <condition>Pneumonia</condition>
      <condition>Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Photo Electrochemical Oxidation (PECO) for Air Purification</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Length of stay</outcome_measure>
      <outcome_measure>Readmission rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Molekule</lead_sponsor>
      <collaborator>Mercy Health System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>1 Year</min_age>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>274</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>Molekule-08082018</other_id>
    </other_ids>
    <start_date>August 8, 2018</start_date>
    <primary_completion_date>December 31, 2018</primary_completion_date>
    <completion_date>December 31, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>May 17, 2019</last_update_posted>
    <locations>
      <location>Mercyhealth Hospital - Rockton Avenue, Rockford, Illinois, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT03647397/Prot_003.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03647397</url>
  </study>
  <study rank="45305">
    <nct_id>NCT03647384</nct_id>
    <title>Guilingji Capsule for Mild-to-moderate Cognitive Impairment</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cognitive Dysfunction</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Gulingji capsules</intervention>
      <intervention type="Drug">Ginko Biloba Extract tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The Change From Baseline in Mini-Mental State Examination (MMSE) Total Score at Week 12 and 24</outcome_measure>
      <outcome_measure>The Change From Baseline in Montreal Cognitive Assessment (MoCA) Total Score at Week 12 and 24</outcome_measure>
      <outcome_measure>The Change From Baseline in Clinical Dementia Rating (CDR) Total Score at Week 12 and 24</outcome_measure>
      <outcome_measure>The Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Total Score at Week 12 and 24</outcome_measure>
      <outcome_measure>The Change From Baseline in Activities of Daily Living (ADL) Total Score at Week 12 and 24</outcome_measure>
      <outcome_measure>The Change From Baseline in The Chinese Medicine Symptom Scale (CM-SS) Total Score at Week 12 and 24</outcome_measure>
      <outcome_measure>The Change From Baseline in The Serum Level of Acetylcholine and Acetylcholinesterase at Week 24</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Xiyuan Hospital of China Academy of Chinese Medical Sciences</lead_sponsor>
      <collaborator>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</collaborator>
      <collaborator>Beijing Xuanwu Traditional Chinese Medicine Hospital</collaborator>
      <collaborator>Beijing Hospital</collaborator>
      <collaborator>Beijing Shijitan Hospital</collaborator>
      <collaborator>Peking University First Hospital</collaborator>
      <collaborator>Huadong Hospital</collaborator>
      <collaborator>Longhua Hospital</collaborator>
      <collaborator>The First Affiliated Hospital of Henan University of Traditional Chinese Medicine</collaborator>
      <collaborator>Shandong University of Traditional Chinese Medicine</collaborator>
      <collaborator>Shanxi Dayi Hospital</collaborator>
      <collaborator>Shaanxi Hospital of Traditional Chinese Medicine</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>60 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>348</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018XLA039-2</other_id>
    </other_ids>
    <start_date>August 22, 2018</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Li Hao, Beijing, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647384</url>
  </study>
  <study rank="45306">
    <nct_id>NCT03647371</nct_id>
    <title>TMHT - Difficult Intubation Prediction Using Videolaryngoscopy</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Predictive Value of Tests</condition>
      <condition>Intubation</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Macintosh laryngoscope</intervention>
      <intervention type="Device">McGrath Videolaryngoscope</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Thyromental height</outcome_measure>
      <outcome_measure>score in Cormack-Lehane scale</outcome_measure>
      <outcome_measure>Thyromental distance</outcome_measure>
      <outcome_measure>Sternomental distance</outcome_measure>
      <outcome_measure>core in modified Mallampati test</outcome_measure>
      <outcome_measure>distance of mouth opening</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of Silesia</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>TMHT-03</other_id>
    </other_ids>
    <start_date>August 6, 2018</start_date>
    <primary_completion_date>September 5, 2019</primary_completion_date>
    <completion_date>September 5, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 10, 2019</last_update_posted>
    <locations>
      <location>Samodzielny Publiczny Szpital Kliniczny nr 1, Zabrze, Silesia, Poland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647371</url>
  </study>
  <study rank="45307">
    <nct_id>NCT03647358</nct_id>
    <title>Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Thyroid Carcinoma</condition>
      <condition>Metastatic Thyroid Carcinoma</condition>
    </conditions>
    <interventions>
      <intervention type="Device">PET/CT Scan</intervention>
      <intervention type="Drug">Iodine-124</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>number of individual lesions response</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Memorial Sloan Kettering Cancer Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>18-253</other_id>
    </other_ids>
    <start_date>August 21, 2018</start_date>
    <primary_completion_date>August 2022</primary_completion_date>
    <completion_date>August 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 23, 2019</last_update_posted>
    <locations>
      <location>Memorial Sloan Kettering Cancer Center, New York, New York, United States</location>
      <location>Weill Cornell Medical Center, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647358</url>
  </study>
  <study rank="45308">
    <nct_id>NCT03647345</nct_id>
    <title>Noninvasive Dual-mode Stimulation Therapy for Neurorehabilitation in Mild Cognitive Impairment</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mild Cognitive Impairment</condition>
    </conditions>
    <interventions>
      <intervention type="Device">High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC</intervention>
      <intervention type="Device">High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC</intervention>
      <intervention type="Device">High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Accuracy of 2-back verbal working memory task</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Samsung Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>21</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2015-01-132-005</other_id>
    </other_ids>
    <start_date>April 26, 2015</start_date>
    <primary_completion_date>July 5, 2018</primary_completion_date>
    <completion_date>July 5, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 20, 2019</last_update_posted>
    <locations>
      <location>Samsung Medical Center, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647345</url>
  </study>
  <study rank="45309">
    <nct_id>NCT03647332</nct_id>
    <title>Use of Cooled Radiofrequency for the Treatment of Hip Pain Associated With OA of the Hip Compared to Intra-articular Steroid Injections</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Osteo Arthritis of Hip</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Cooled RFA treatment</intervention>
      <intervention type="Drug">Steroid Drug</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rothman Institute Orthopaedics</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>86</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018Stolzenberg</other_id>
    </other_ids>
    <start_date>July 5, 2017</start_date>
    <primary_completion_date>December 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Rothman Institute, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647332</url>
  </study>
  <study rank="45310">
    <nct_id>NCT03647319</nct_id>
    <title>Noninvasive Dual-mode Stimulation Therapy for Neurorehabilitation in Post-stroke Cognitive Impairment</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Post-stroke Cognitive Impairment</condition>
    </conditions>
    <interventions>
      <intervention type="Device">High-frequency rTMS on left DLPFC+anodal tDCS on right DLPFC</intervention>
      <intervention type="Device">High-frequency rTMS on left DLPFC+cathodal tDCS on right DLPFC</intervention>
      <intervention type="Device">High-frequency rTMS on left DLPFC+sham tDCS on right DLPFC</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Accuracy of 2-back verbal working memory task</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Samsung Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>29</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2013-06-002-016</other_id>
    </other_ids>
    <start_date>April 11, 2013</start_date>
    <primary_completion_date>November 10, 2016</primary_completion_date>
    <completion_date>November 10, 2016</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 20, 2019</last_update_posted>
    <locations>
      <location>Samsung Medical Center, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647319</url>
  </study>
  <study rank="45311">
    <nct_id>NCT03647306</nct_id>
    <title>Behavioral Chronotype: Impact on Sleep and Metabolism</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Type2 Diabetes Mellitus</condition>
      <condition>Cardiovascular Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Early Total Caloric Intake</intervention>
      <intervention type="Behavioral">Late Total Caloric Intake</intervention>
      <intervention type="Behavioral">Extended Overnight Fast</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>MI-IS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
      <collaborator>National Institute on Aging (NIA)</collaborator>
      <collaborator>Northwestern University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>30 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB17-1768</other_id>
      <other_id>P01AG011412</other_id>
    </other_ids>
    <start_date>February 2, 2018</start_date>
    <primary_completion_date>January 1, 2022</primary_completion_date>
    <completion_date>January 1, 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 14, 2020</last_update_posted>
    <locations>
      <location>University of Chicago, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647306</url>
  </study>
  <study rank="45312">
    <nct_id>NCT03647293</nct_id>
    <title>Less Pain in Neonates During Central Lines Insertion</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Central Venous Catheter</condition>
      <condition>Neonates</condition>
      <condition>Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Ultrasound Guided Central Catheter Insertion</intervention>
      <intervention type="Procedure">Peripherally Inserted Central Catheter</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain score difference</outcome_measure>
      <outcome_measure>The number of first successful attempts</outcome_measure>
      <outcome_measure>Number of total attempts</outcome_measure>
      <outcome_measure>Procedure duration</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Saint George Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>1 Month</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>61</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB/O/036-16/1916</other_id>
    </other_ids>
    <start_date>November 2016</start_date>
    <primary_completion_date>May 2017</primary_completion_date>
    <completion_date>May 2017</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647293</url>
  </study>
  <study rank="45313">
    <nct_id>NCT03647280</nct_id>
    <title>The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Breast Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Abraxane</intervention>
      <intervention type="Drug">Epirubicin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>ORR(CR+PR)</outcome_measure>
      <outcome_measure>Side Effects.</outcome_measure>
      <outcome_measure>Event Free Survival(DFS)</outcome_measure>
      <outcome_measure>Overall Survival(OS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Zhejiang Cancer Hospital</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>dingxwyh02</other_id>
    </other_ids>
    <start_date>December 1, 2018</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>December 7, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647280</url>
  </study>
  <study rank="45314">
    <nct_id>NCT03647267</nct_id>
    <title>Effects of Pneumatic Vitreolysis on Vitreomacular Traction</title>
    <acronym>AG</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Vitreomacular Traction</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Pneumatic Vitreolysis (C3F8 injection)</intervention>
      <intervention type="Other">Observation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of eyes with central vitreomacular traction release</outcome_measure>
      <outcome_measure>Proportion of eyes with central vitreomacular traction release (time-to-event analysis)</outcome_measure>
      <outcome_measure>Proportion of eyes with central vitreomacular traction release and vitreopapillary traction release</outcome_measure>
      <outcome_measure>Mean change in E-ETDRS visual acuity letter score</outcome_measure>
      <outcome_measure>Proportion of eyes with at least 10-letter gain (increase) or loss (decrease) in visual acuity</outcome_measure>
      <outcome_measure>Proportion of eyes receiving vitrectomy or for which vitrectomy is planned</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Jaeb Center for Health Research</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
      <collaborator>National Eye Institute (NEI)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>124</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DRCR.net Protocol AG</other_id>
      <other_id>U10EY014231</other_id>
      <other_id>U10EY023207</other_id>
    </other_ids>
    <start_date>October 16, 2018</start_date>
    <primary_completion_date>May 30, 2021</primary_completion_date>
    <completion_date>May 30, 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>October 24, 2019</last_update_posted>
    <locations>
      <location>Retinal Diagnostic Center, Campbell, California, United States</location>
      <location>Atlantis Eye Care, Huntington Beach, California, United States</location>
      <location>Northern California Retina Vitreous Associates, Mountain View, California, United States</location>
      <location>East Bay Retina Consultants, Inc, Oakland, California, United States</location>
      <location>Southern California Desert Retina Consultants, MC, Palm Desert, California, United States</location>
      <location>National Ophthalmic Research Institute, Fort Myers, Florida, United States</location>
      <location>University of Florida College of Med., Dept of Ophthalmology, Jacksonville Hlth Sci Ctr, Jacksonville, Florida, United States</location>
      <location>Florida Retina Consultants, Lakeland, Florida, United States</location>
      <location>Florida Retina Institute, Orlando, Florida, United States</location>
      <location>Southeast Eye Institute, PA dba Eye Associates of Pinellas, Pinellas Park, Florida, United States</location>
      <location>Sarasota Retina Institute, Sarasota, Florida, United States</location>
      <location>Southeast Retina Center, PC, Augusta, Georgia, United States</location>
      <location>Thomas Eye Group, Sandy Springs, Georgia, United States</location>
      <location>Gailey Eye Clinic, Bloomington, Illinois, United States</location>
      <location>University of Illinois at Chicago Medical Center, Chicago, Illinois, United States</location>
      <location>Illinois Retina Associates, S.C., Oak Park, Illinois, United States</location>
      <location>Raj K. Maturi, M.D., P.C., Indianapolis, Indiana, United States</location>
      <location>Wolfe Eye Clinic, West Des Moines, Iowa, United States</location>
      <location>Mid-America Retina Consultants, P.A., Overland Park, Kansas, United States</location>
      <location>Paducah Retinal Center, Paducah, Kentucky, United States</location>
      <location>Eye Associates of Northeast Louisiana dba Haik Humble Eye Center, West Monroe, Louisiana, United States</location>
      <location>Elman Retina Group, PA, Baltimore, Maryland, United States</location>
      <location>Valley Eye Physicians and Surgeons, Ayer, Massachusetts, United States</location>
      <location>Joslin Diabetes Center, Boston, Massachusetts, United States</location>
      <location>Vitreo-Retinal Associates, PC, Worcester, Massachusetts, United States</location>
      <location>Retina Specialists of Michigan, Grand Rapids, Michigan, United States</location>
      <location>Mayo Clinic Department of Opthalmology, Rochester, Minnesota, United States</location>
      <location>The Retina Institute, Saint Louis, Missouri, United States</location>
      <location>Western Carolina Clinical Research, LLC, Asheville, North Carolina, United States</location>
      <location>Charlotte Eye, Ear, Nose, and Throat Assoc., PA, Charlotte, North Carolina, United States</location>
      <location>Retina Associates of Cleveland, Inc, Beachwood, Ohio, United States</location>
      <location>Retina Vitreous Center, Edmond, Oklahoma, United States</location>
      <location>Oregon Retina, LLP, Eugene, Oregon, United States</location>
      <location>Retina Northwest, PC, Portland, Oregon, United States</location>
      <location>Southeastern Retina Associates, Chattanooga, Tennessee, United States</location>
      <location>Southeastern Retina Associates, PC, Knoxville, Tennessee, United States</location>
      <location>Austin Retina Associates, Austin, Texas, United States</location>
      <location>Retina Research Center, Austin, Texas, United States</location>
      <location>Retinal Consultants of San Antonio, San Antonio, Texas, United States</location>
      <location>Spokane Eye Clinic, Spokane, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647267</url>
  </study>
  <study rank="45315">
    <nct_id>NCT03647254</nct_id>
    <title>Efficacy of a Didactic Intervention in Anticoagulated Patients (TAOPE Study)</title>
    <acronym>TAOPE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Health Education</condition>
      <condition>Patient Education as Topic</condition>
      <condition>Blood Coagulation Tests</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Patient education group</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time on INR therapeutic levels in the last six months receiving VKA treatment</outcome_measure>
      <outcome_measure>Sociodemographic</outcome_measure>
      <outcome_measure>Body mass index (BMI)</outcome_measure>
      <outcome_measure>Diastolic and systolic blood pressure</outcome_measure>
      <outcome_measure>Heart rate</outcome_measure>
      <outcome_measure>Smoking habit</outcome_measure>
      <outcome_measure>diabetes</outcome_measure>
      <outcome_measure>Arterial hypertension</outcome_measure>
      <outcome_measure>Dyslipidemia</outcome_measure>
      <outcome_measure>Chronic renal failure</outcome_measure>
      <outcome_measure>Atrial fibrillation</outcome_measure>
      <outcome_measure>Interventional cardiac valve diseases with or without atrial fibrillation</outcome_measure>
      <outcome_measure>Ischemic cardiopathy</outcome_measure>
      <outcome_measure>Thromboembolic diseases history (stroke, transient ischemic attack)</outcome_measure>
      <outcome_measure>Hemorrhagic stroke</outcome_measure>
      <outcome_measure>Congestive heart failure</outcome_measure>
      <outcome_measure>Glomerular filtration rates</outcome_measure>
      <outcome_measure>Total cholesterol</outcome_measure>
      <outcome_measure>HDL Cholesterol</outcome_measure>
      <outcome_measure>LDL cholesterol</outcome_measure>
      <outcome_measure>Triglycerides</outcome_measure>
      <outcome_measure>Total number of drugs</outcome_measure>
      <outcome_measure>Anticoagulant type</outcome_measure>
      <outcome_measure>Consumption of &quot;gastric protector&quot;</outcome_measure>
      <outcome_measure>Usual consumption of food rich in vitamin K</outcome_measure>
      <outcome_measure>Alcohol consumption</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Francisco Javier Navarro Moya</lead_sponsor>
      <collaborator>Andaluz Health Service</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>AndaluzHS</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>September 1, 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 27, 2018</last_update_posted>
    <locations>
      <location>Distrito Sanitario Málaga. Servicio Andaluz de Salud, Málaga, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647254</url>
  </study>
  <study rank="45316">
    <nct_id>NCT03647241</nct_id>
    <title>Evaluation of Self-ligating Brackets Plus Minor Surgery in Treating Crowded Cases of Malocclusion</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Malocclusion of Anterior Teeth</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Self-Ligating Brackets</intervention>
      <intervention type="Device">Traditionally-Ligated Brackets</intervention>
      <intervention type="Procedure">Corticotomy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Duration of Alignment</outcome_measure>
      <outcome_measure>Change in Little's Index</outcome_measure>
      <outcome_measure>Change in inter-canine width lingually</outcome_measure>
      <outcome_measure>Change in inter-canine width</outcome_measure>
      <outcome_measure>Change in Canine Rotation Angle</outcome_measure>
      <outcome_measure>Change in Lateral Incisor Rotation Angle</outcome_measure>
      <outcome_measure>Change in Central Incisor Rotation Angle</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Damascus University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>17 Years</min_age>
    <max_age>28 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>UDDS-Ortho-10-2018</other_id>
    </other_ids>
    <start_date>August 15, 2018</start_date>
    <primary_completion_date>November 10, 2019</primary_completion_date>
    <completion_date>February 19, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>July 18, 2019</last_update_posted>
    <locations>
      <location>Department of Orthodontics, University of Damascus Dental School, Damascus, Syrian Arab Republic</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647241</url>
  </study>
  <study rank="45317">
    <nct_id>NCT03647228</nct_id>
    <title>A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Subjects</condition>
      <condition>Cystic Fibrosis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">IONIS-ENaCRx</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Safety and Tolerability as Measured by the Number of Participants with at least one Treatment-Emergent Adverse Event</outcome_measure>
      <outcome_measure>Cmax: maximum observed drug concentration in plasma of IONIS-ENaCRx</outcome_measure>
      <outcome_measure>Tmax: time taken to reach maximal concentration in plasma of IONIS-ENaCRx</outcome_measure>
      <outcome_measure>AUCt: area under the plasma concentration-time curve from time zero to time t for IONIS-ENaCRx</outcome_measure>
      <outcome_measure>CL/F: apparent total clearance of IONIS-ENaCRx</outcome_measure>
      <outcome_measure>t1/2λz: termination half-life of IONIS-ENaCRx</outcome_measure>
      <outcome_measure>The amount of administered dose of IONIS-ENaCRx excreted in urine over a 24-hour period</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ionis Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>88</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ION-827359-CS1</other_id>
      <other_id>2018-002621-27</other_id>
    </other_ids>
    <start_date>December 13, 2018</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 22, 2020</last_update_posted>
    <locations>
      <location>Universitätsmedizin Essen, Essen, Germany</location>
      <location>Universitätsklinikum Frankfurt, Frankfurt, Germany</location>
      <location>Lungenheilkunde München-Pasing, München, Germany</location>
      <location>Medicines Evaluation Unit, Wythenshawe, Manchester, United Kingdom</location>
      <location>Celerion, Belfast, Northern Ireland, United Kingdom</location>
      <location>Western General Hospital, Edinburgh, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647228</url>
  </study>
  <study rank="45318">
    <nct_id>NCT03647215</nct_id>
    <title>CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Phase Chronic Myelogenous Leukemia</condition>
      <condition>Accelerated Phase Chronic Myelogenous Leukemia</condition>
      <condition>Blastic Phase Chronic Myelogenous Leukemia</condition>
      <condition>Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Percentage of participants with any mutation</outcome_measure>
      <outcome_measure>Frequency of all specific mutations</outcome_measure>
      <outcome_measure>Percentage of participants with individual mutations in chronic phase (CP)-CML, accelerated phase (AP)-CML, and blast phase (BP)-CML</outcome_measure>
      <outcome_measure>Frequency of individual mutations in chronic phase (CP)-CML, accelerated phase (AP)-CML, and blast phase (BP)-CML</outcome_measure>
      <outcome_measure>Percentage of participants with individual mutations in Ph+ ALL</outcome_measure>
      <outcome_measure>Frequency of individual mutations in Ph+ ALL</outcome_measure>
      <outcome_measure>Percentage of participants with individual mutations by whether a participant is intolerant or resistant to their previous TKI</outcome_measure>
      <outcome_measure>Frequency of individual mutations by whether a patient is intolerant or resistant to their previous TKI</outcome_measure>
      <outcome_measure>Percentage of participants with individual mutations by BCR-ABL level</outcome_measure>
      <outcome_measure>Frequency of individual mutations by BCR-ABL level</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Incyte Biosciences UK</lead_sponsor>
      <collaborator>Incyte Corporation</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>INCB 84344-401</other_id>
    </other_ids>
    <start_date>December 18, 2017</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>October 29, 2019</last_update_posted>
    <locations>
      <location>Limerick University Hospital, Limerick, Dooradoyle, Ireland</location>
      <location>University Hospital Waterford, Waterford, Ireland</location>
      <location>Royal Cornwall Hospital, Truro, Cornwall, United Kingdom</location>
      <location>Royal Devon &amp; Exeter Hospital, Exeter, Devon, United Kingdom</location>
      <location>Derriford Hospital, Plymouth, Devon, United Kingdom</location>
      <location>Broomfield Hospital Chelmsford, Chelmsford, Essex, United Kingdom</location>
      <location>Queen's Hospital, Romford, Essex, United Kingdom</location>
      <location>Aberdeen Royal Infirmary, Aberdeen, Foresterhill, United Kingdom</location>
      <location>Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom</location>
      <location>Medway Maritime Hospital, Gillingham, Kent, United Kingdom</location>
      <location>Blackpool Victoria Hospital, Blackpool, Lancashire, United Kingdom</location>
      <location>Royal Oldham Hospital, Manchester, Lancashire, United Kingdom</location>
      <location>Queens Medical Centre, Nottingham, Nottinghamshire, United Kingdom</location>
      <location>Ipswich Hospital, Ipswich, Suffolk, United Kingdom</location>
      <location>Heart of England NHS Foundation Trust, Birmingham, West Midlands, United Kingdom</location>
      <location>Russells Hall Hospital, Dudley, West Midlands, United Kingdom</location>
      <location>St Bartholomew's Hospital, London, West Smithfield, United Kingdom</location>
      <location>Bradford Royal Infirmary, Bradford, West Yorkshire, United Kingdom</location>
      <location>St James's University Hospital, Leeds, West Yorkshire, United Kingdom</location>
      <location>Monklands Hospital, Airdrie, United Kingdom</location>
      <location>Bristol Haematology and Oncology Centre, Bristol, United Kingdom</location>
      <location>Addenbrooke's Hospital, Cambridge, United Kingdom</location>
      <location>University Hospital Wales, Cardiff, United Kingdom</location>
      <location>Croydon University Hospital, Croydon Health Services NHS Trust, Croydon, United Kingdom</location>
      <location>Western General Hospital, Edinburgh, United Kingdom</location>
      <location>Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom</location>
      <location>Guy's Hospital, London, United Kingdom</location>
      <location>King's College Hospital, London, United Kingdom</location>
      <location>The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, United Kingdom</location>
      <location>Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom</location>
      <location>Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS FT, Sheffield, United Kingdom</location>
      <location>Royal Stoke University Hospital, Cancer Centre, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom</location>
      <location>Singleton Hospital, Swansea, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647215</url>
  </study>
  <study rank="45319">
    <nct_id>NCT03647202</nct_id>
    <title>Food Effects on Milademetan Pharmacokinetics in Healthy Participants</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Food Effects on Pharmacokinetics</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Milademetan Treatment A</intervention>
      <intervention type="Drug">Milademetan Treatment B</intervention>
      <intervention type="Drug">Milademetan Treatment C</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Maximum plasma concentration (Cmax) of milademetan</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve (AUC) extrapolated to infinity (AUCinf) for milademetan</outcome_measure>
      <outcome_measure>Time to teach maximum plasma concentration (Tmax) of milademetan</outcome_measure>
      <outcome_measure>AUC from time 0 to the time of last measurable concentration (AUClast) for milademetan</outcome_measure>
      <outcome_measure>Lag time (tlag) for milademetan</outcome_measure>
      <outcome_measure>Terminal elimination half-life (t½) of milademetan</outcome_measure>
      <outcome_measure>Apparent total body clearance (CL/F) of milademetan clearance (CL/F),</outcome_measure>
      <outcome_measure>Apparent volume of distribution (Vz/F) of milademetan</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Daiichi Sankyo, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>DS3032-A-U115</other_id>
    </other_ids>
    <start_date>August 16, 2018</start_date>
    <primary_completion_date>September 13, 2018</primary_completion_date>
    <completion_date>September 13, 2018</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>February 12, 2019</last_update_posted>
    <locations>
      <location>Covance Clinical Research Unit, Inc., Dallas, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647202</url>
  </study>
  <study rank="45320">
    <nct_id>NCT03647189</nct_id>
    <title>Randomized, Controlled Trial With Hybrid Fractional Laser</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Vaginal Atrophy, Sexual Dysfunction, Vaginal Dryness, Dyspareunia</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Hybrid Fractional Laser</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline in Vaginal health index score (VHIS)</outcome_measure>
      <outcome_measure>Change from baseline in Female sexual function index questionnaire (FSFI)</outcome_measure>
      <outcome_measure>Change from baseline in day-to-day impact of vaginal aging questionnaire</outcome_measure>
      <outcome_measure>Change from baseline in histology</outcome_measure>
      <outcome_measure>Change from baseline in photography</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sciton</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>40 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DIVA-001</other_id>
    </other_ids>
    <start_date>August 10, 2018</start_date>
    <primary_completion_date>January 30, 2020</primary_completion_date>
    <completion_date>January 30, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>December 4, 2019</last_update_posted>
    <locations>
      <location>Miamim Dermatology, Miami, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647189</url>
  </study>
  <study rank="45321">
    <nct_id>NCT03647176</nct_id>
    <title>A Comparison of the Resection Rate of Cold Snare Polypectomy for Large (10-15 mm) and Small (4-9 mm) Colorectal Polyps</title>
    <acronym>CSP</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Adenomatous Polyps</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Cold snare polypectomy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percent of Incompletely Resected Adenomatous Polyps</outcome_measure>
      <outcome_measure>adequate assessment of the polyp lateral margin</outcome_measure>
      <outcome_measure>tissue retrieval per polyp</outcome_measure>
      <outcome_measure>polypectomy procedure times</outcome_measure>
      <outcome_measure>the rates of procedure-related complications</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yuqi He</lead_sponsor>
      <collaborator>General Hospital of Beijing PLA Military Region</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>40 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>PLA GH-CSP-1</other_id>
    </other_ids>
    <start_date>September 10, 2018</start_date>
    <primary_completion_date>September 1, 2019</primary_completion_date>
    <completion_date>September 1, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>July 22, 2019</last_update_posted>
    <locations>
      <location>Department of Gastroenterology, PLA Army General Hospital, Beijing, Dongcheng District, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647176</url>
  </study>
  <study rank="45322">
    <nct_id>NCT03647163</nct_id>
    <title>Combination Therapy With Intravenous VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and HNSCC</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Solid Tumor</condition>
      <condition>Head and Neck Squamous Cell Carcinoma</condition>
      <condition>Non Small Cell Lung Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">VSV-IFNβ-NIS</intervention>
      <intervention type="Biological">Pembrolizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Expansion arms: Overall response rate (ORR)</outcome_measure>
      <outcome_measure>Safety run-in arm: Number of participants with treatment related adverse events (NCI CTCAE; Version 4.03)</outcome_measure>
      <outcome_measure>Overall Survival (OS)</outcome_measure>
      <outcome_measure>Progression Free Survival (PFS)</outcome_measure>
      <outcome_measure>Duration of response</outcome_measure>
      <outcome_measure>Disease Control Rate (DCR)</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vyriad, Inc.</lead_sponsor>
      <collaborator>Mayo Clinic</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>23</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>VYR-VSV2-202</other_id>
    </other_ids>
    <start_date>April 9, 2019</start_date>
    <primary_completion_date>November 1, 2020</primary_completion_date>
    <completion_date>March 30, 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 9, 2019</last_update_posted>
    <locations>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647163</url>
  </study>
  <study rank="45323">
    <nct_id>NCT03647150</nct_id>
    <title>Treatment of High-Risk Moderate Acute Malnutrition Using Expanded Admission Criteria</title>
    <acronym>Hi-MAM</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Malnutrition</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">amoxicillin</intervention>
      <intervention type="Dietary Supplement">Ready-to-use therapeutic food (RUTF)</intervention>
      <intervention type="Behavioral">Mother Care group</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Recovery from moderate acute malnutrition (MAM)</outcome_measure>
      <outcome_measure>Participant survival rates</outcome_measure>
      <outcome_measure>Participants deterioration to severe acute malnutrition(SAM)</outcome_measure>
      <outcome_measure>Morbidity, history of recent illness</outcome_measure>
      <outcome_measure>Participants that remain or become underweight using weight for age z-score</outcome_measure>
      <outcome_measure>Participants that remain or become Stunted</outcome_measure>
      <outcome_measure>Participants that remain or become Wasted</outcome_measure>
      <outcome_measure>Eye tracking performance for cognitive development</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Washington University School of Medicine</lead_sponsor>
      <collaborator>Centre for Global Child Health, Hospital for Sick Kids, Toronto, Canada</collaborator>
      <collaborator>Department of Psychology, University of Tampere, Finland</collaborator>
      <collaborator>Project Peanut Butter, Sierra Leone</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Months</min_age>
    <max_age>59 Months</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>201807153</other_id>
    </other_ids>
    <start_date>November 13, 2018</start_date>
    <primary_completion_date>November 1, 2019</primary_completion_date>
    <completion_date>November 1, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>July 17, 2019</last_update_posted>
    <locations>
      <location>Project Peanut Butter, Freetown, Sierra Leone</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647150</url>
  </study>
  <study rank="45324">
    <nct_id>NCT03647137</nct_id>
    <title>Amyloidopathy, Choinopathy, Dopamine Responsiveness and Freezing of Gait in PD</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson's Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Detailed motor testing, including FoG, in PD subjects</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Freezing episodes during the FoG provocation protocol</outcome_measure>
      <outcome_measure>Quantitative correlation of freezing episodes to brain PET imaging</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
      <collaborator>University of Michigan</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>B1631-I</other_id>
      <other_id>HUM00110351</other_id>
    </other_ids>
    <start_date>June 7, 2016</start_date>
    <primary_completion_date>June 7, 2021</primary_completion_date>
    <completion_date>June 7, 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 14, 2019</last_update_posted>
    <locations>
      <location>VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647137</url>
  </study>
  <study rank="45325">
    <nct_id>NCT03647124</nct_id>
    <title>Non-Interventional Study in Patients With Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) to Investigate the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden</title>
    <acronym>PASS MCL-005</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lymphoma, Mantle-Cell</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lenalidomide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To quantify and characterize the event of TFR by tumor burden in R/R MCL patients treated with lenalidomide in a real-world setting.</outcome_measure>
      <outcome_measure>To quantify and characterize the proportion of early deaths by tumor burden in R/R MCL patients treated with lenalidomide in a real-world setting</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Celgene</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>560</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CC-5013-MCL-005</other_id>
      <other_id>U1111-1213-1816</other_id>
      <other_id>EUPAS23366</other_id>
    </other_ids>
    <start_date>October 2, 2018</start_date>
    <primary_completion_date>December 31, 2026</primary_completion_date>
    <completion_date>December 31, 2026</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 12, 2019</last_update_posted>
    <locations>
      <location>Salzburger Landeskliniken - Universitaetsklinikum Salzburg, Salzburger, Austria</location>
      <location>Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria</location>
      <location>AKH Wien, Universitaetsklinik fuer Innere Medizin III, Wien, Austria</location>
      <location>CHRU de Brest - Hopital Morvan, Brest, France</location>
      <location>CHU de Caen, institut d'hematologie de basse Nomandie, Caen Cedex 9, France</location>
      <location>Centre Hospitalier de Versailles André Mignot, Le Chesnay, France</location>
      <location>Clinique Victor Hugo, Le Mans, France</location>
      <location>Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Universitaire Pitie Salpetriere (Hopital Pitie-Salpetriere), Paris, France</location>
      <location>Centre Hospitalier de Saint-Quentin, Saint Quentin Picardie, France</location>
      <location>Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse Cedex 9, France</location>
      <location>Gesundheitszentrum St. Marien Gmbh, Amberg, Germany</location>
      <location>Studienzentrum Aschaffenburg, Aschaffenburg, Germany</location>
      <location>Berufsausuebungsgemeinschaft Kiehl/Stein, Frankfurt/ Oder Brandenburg, Germany</location>
      <location>Klinikum Garmisch-Partenkirchen Gmbh - Zentrum Fuer Innere Medizin, Garmisch-Partenkirchen Bavaria, Germany</location>
      <location>Praxis fuer Haematolgie, Onkologie und Palliativmedizin, Leipzig, Germany</location>
      <location>Private hospital &quot;Iatriko Psychikou&quot;, Athens, Athens, Greece</location>
      <location>General University Hospital of Athens &quot;LAIKO&quot;, Athens, Athens, Greece</location>
      <location>Metaxa Cancer Hospital, Athens, Piraeous, Greece</location>
      <location>Theageneio General Hospital, Thessaloniki, Thessaloniki, Greece</location>
      <location>HagaZiekenhuis van Den Haag - Juliana Kinderziekenhuis (JKZ) - Leyweg, Den Haag, Netherlands</location>
      <location>Hospital universitario de Alava, Alava País Vasco, Spain</location>
      <location>Hospital Universitario 12 de Octubre, Madrid, Spain</location>
      <location>Hospital Regional Universitario Carlos Haya, Malaga, Spain</location>
      <location>Hospital de Orense, Ourense, Spain</location>
      <location>Complejo Hospitalario de Navarra, Pamplona Navarra, Spain</location>
      <location>Hospital Clínico Universiatrio de Salamanca, Salamanca, Spain</location>
      <location>Nuestra Senora de Valme, Sevilla, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647124</url>
  </study>
  <study rank="45326">
    <nct_id>NCT03647111</nct_id>
    <title>Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Non-small Cell Lung Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Crizotinib</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>PFS</outcome_measure>
      <outcome_measure>OS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hunan Province Tumor Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>RECURE</other_id>
    </other_ids>
    <start_date>January 1, 2018</start_date>
    <primary_completion_date>December 31, 2019</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 25, 2019</last_update_posted>
    <locations>
      <location>Hunan Provincal Tumor Hospital, Changsha, Hunan, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647111</url>
  </study>
  <study rank="45327">
    <nct_id>NCT03647098</nct_id>
    <title>Analysis of Survival Status of KRAS Mutation Advanced Non-small Cell Lung Cancer</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>KRAS Gene Mutation Advanced Non-small Cell Lung Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">kras</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>OS</outcome_measure>
      <outcome_measure>PFS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hunan Province Tumor Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>KILLER</other_id>
    </other_ids>
    <start_date>August 1, 2018</start_date>
    <primary_completion_date>December 31, 2018</primary_completion_date>
    <completion_date>June 1, 2019</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Hunan Provincal Tumor Hospital, Changsha, Hunan, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647098</url>
  </study>
  <study rank="45328">
    <nct_id>NCT03647085</nct_id>
    <title>Data Collection Atrial Fibrillation Exploratory Study</title>
    <acronym>CAFE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Atrial Fibrillation</condition>
      <condition>Atrial Flutter</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Wearable cardiac monitor</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Physiologic Signal Detection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Boston Scientific Corporation</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>C2106</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>December 30, 2019</primary_completion_date>
    <completion_date>February 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>September 10, 2019</last_update_posted>
    <locations>
      <location>Mayo Clinic Foundation, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647085</url>
  </study>
  <study rank="45329">
    <nct_id>NCT03647072</nct_id>
    <title>PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lymphoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CHOP</intervention>
      <intervention type="Drug">CHOP Plus Lanzoprazole</intervention>
      <intervention type="Drug">CHOP Plus Famotidine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients eith radiological and clinical improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sherief Abd-Elsalam</lead_sponsor>
      <collaborator>Tanta University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>eman elberry</other_id>
    </other_ids>
    <start_date>August 1, 2018</start_date>
    <primary_completion_date>October 2027</primary_completion_date>
    <completion_date>December 2027</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Sherief Abd-Elsalam, Cairo, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647072</url>
  </study>
  <study rank="45330">
    <nct_id>NCT03647059</nct_id>
    <title>Rapid Assessment of Donor Liver Quality</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Transplant; Failure, Liver</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">LSCM examination</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>LSCM examination results</outcome_measure>
      <outcome_measure>HE section staining pathological examination</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <other_ids>
      <other_id>SHLTQC-2</other_id>
    </other_ids>
    <start_date>August 15, 2018</start_date>
    <primary_completion_date>August 15, 2020</primary_completion_date>
    <completion_date>August 15, 2022</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations>
      <location>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647059</url>
  </study>
  <study rank="45331">
    <nct_id>NCT03647046</nct_id>
    <title>Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Keratoconus</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Customized Scleral Lens</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of participants with normal vision</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Rochester</lead_sponsor>
      <collaborator>Ovitz Corporation</collaborator>
      <collaborator>Boston Sight</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>72749</other_id>
    </other_ids>
    <start_date>October 8, 2018</start_date>
    <primary_completion_date>February 1, 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>January 9, 2020</last_update_posted>
    <locations>
      <location>Flaum Eye Institute, University of Rochester Medical Center, Rochester, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647046</url>
  </study>
  <study rank="45332">
    <nct_id>NCT03647033</nct_id>
    <title>Phacoemulsification Versus Phacoemulsification With Micro-bypass Stent</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>Has Results</study_results>
    <conditions>
      <condition>Primary Angle-Closure Glaucoma</condition>
      <condition>Primary Angle Closure Without Glaucoma Damage</condition>
    </conditions>
    <interventions>
      <intervention type="Device">iStent implantation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Intraocular Pressure Between Baseline and 1 Year</outcome_measure>
      <outcome_measure>Change in Glaucoma Medications</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Khoo Teck Puat Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2015/00644</other_id>
    </other_ids>
    <start_date>October 14, 2015</start_date>
    <primary_completion_date>August 12, 2016</primary_completion_date>
    <completion_date>August 12, 2017</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <results_first_posted>October 2, 2018</results_first_posted>
    <last_update_posted>October 31, 2018</last_update_posted>
    <locations>
      <location>Khoo Teck Puat Hospital, Singapore, Singapore</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03647033/Prot_002.pdf</url>
      </study_document>
      <study_document>
        <label>Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT03647033/ICF_003.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03647033</url>
  </study>
  <study rank="45333">
    <nct_id>NCT03647020</nct_id>
    <title>Impact of Oocytes With CLCG on ICSI Outcomes and Their Potential Relation to Pesticide Exposure</title>
    <acronym>CLCG-ICSI</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pesticide Poisoning</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>ICS outcomes of couples presenting differetn CLCG prevalence</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire, Amiens</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>633</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PI2017_843_0044</other_id>
    </other_ids>
    <start_date>January 1, 2011</start_date>
    <primary_completion_date>June 6, 2017</primary_completion_date>
    <completion_date>June 6, 2017</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>August 27, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03647020</url>
  </study>
  <study rank="45334">
    <nct_id>NCT03647007</nct_id>
    <title>Short- and Long-term Health Effects of a Residential Stay in a Danish Christmas Seal Home.</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Overweight</condition>
    </conditions>
    <interventions>
      <intervention type="Other">FIFA 11 for health</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>changes in overweight</outcome_measure>
      <outcome_measure>aerobic fitness, measured with Andersen running test</outcome_measure>
      <outcome_measure>health knowledge, questionnaires</outcome_measure>
      <outcome_measure>well-being, questionnaires</outcome_measure>
      <outcome_measure>BMI z-scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Southern Denmark</lead_sponsor>
      <collaborator>University of Copenhagen</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>7 Years</min_age>
    <max_age>14 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>Christmas Seal Home Project</other_id>
    </other_ids>
    <start_date>September 11, 2018</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>December 18, 2019</last_update_posted>
    <locations>
      <location>Skælskør Julemærkehjem, Skælskør, Region Sjælland, Denmark</location>
      <location>Kildemose Julemærkehjem, Ølsted, Region Sjælland, Denmark</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT03647007/Prot_SAP_002.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03647007</url>
  </study>
  <study rank="45335">
    <nct_id>NCT03646994</nct_id>
    <title>Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Effectiveness and Safety for Real World Study on Crizotinib Used for ROS1 Arranged Non-squamous Non-small Cell Lung Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Crizotinib</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>PFS</outcome_measure>
      <outcome_measure>ORR</outcome_measure>
      <outcome_measure>OS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hunan Province Tumor Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CORE</other_id>
    </other_ids>
    <start_date>August 1, 2018</start_date>
    <primary_completion_date>December 31, 2018</primary_completion_date>
    <completion_date>June 1, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations>
      <location>Hunan Provincal Tumor Hospital, Changsha, Hunan, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646994</url>
  </study>
  <study rank="45336">
    <nct_id>NCT03646981</nct_id>
    <title>Evaluation of Antibody Detection Tests for Visceral Leishmaniasis Diagnosis in Eastern Africa</title>
    <acronym>VL-DX-EAFR</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Leishmaniasis, Visceral</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Leishmania Ab Rapid Test (CTK, Biotech)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>RDT performance</outcome_measure>
      <outcome_measure>Time to diagnosis</outcome_measure>
      <outcome_measure>New diagnostic algorithm</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Foundation for Innovative New Diagnostics, Switzerland</lead_sponsor>
      <collaborator>University of Gondar</collaborator>
      <collaborator>Kenya Medical Research Institute</collaborator>
      <collaborator>University of Khartoum</collaborator>
      <collaborator>Makerere University</collaborator>
      <collaborator>London School of Hygiene and Tropical Medicine</collaborator>
      <collaborator>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</collaborator>
      <collaborator>Drugs for Neglected Diseases</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>4 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1684</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>P08002-VL-DX-EAFR</other_id>
    </other_ids>
    <start_date>November 2018</start_date>
    <primary_completion_date>July 2019</primary_completion_date>
    <completion_date>December 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646981</url>
  </study>
  <study rank="45337">
    <nct_id>NCT03646968</nct_id>
    <title>Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous Non-small Cell Lung Cancer</title>
    <acronym>SAVE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Non-Squamous Non Small Cell Lung Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anlotinib and Docetaxel</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>ORR</outcome_measure>
      <outcome_measure>PFS</outcome_measure>
      <outcome_measure>OS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yongchang Zhang, MD</lead_sponsor>
      <collaborator>Hunan Province Tumor Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>43</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ANCVNSNCLC</other_id>
    </other_ids>
    <start_date>August 1, 2018</start_date>
    <primary_completion_date>December 31, 2018</primary_completion_date>
    <completion_date>June 1, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Hunan Provincal Tumor Hospital, Changsha, Hunan, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646968</url>
  </study>
  <study rank="45338">
    <nct_id>NCT03646955</nct_id>
    <title>Partial Breast Versus no Irradiation for Women With Early Breast Cancer</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Local Neoplasm Recurrence</condition>
      <condition>Distantly Metastatic Malignant Neoplasm</condition>
      <condition>Death</condition>
      <condition>Fibrosis Breast</condition>
      <condition>Depigmentation/Hyperpigmentation of Skin</condition>
      <condition>Telangiectasia</condition>
      <condition>Scar</condition>
      <condition>Pain</condition>
      <condition>PROMs</condition>
    </conditions>
    <interventions>
      <intervention type="Radiation">No partial breast irradiation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Invasive local recurrence</outcome_measure>
      <outcome_measure>Regional nodes recurrence</outcome_measure>
      <outcome_measure>Distant failure</outcome_measure>
      <outcome_measure>Death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Danish Breast Cancer Cooperative Group</lead_sponsor>
      <collaborator>Danish Cancer Society</collaborator>
      <collaborator>Danish Center for Interventional Research in Radiation Oncology (CIRRO)</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>926</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DBCG RT Natural Trial</other_id>
    </other_ids>
    <start_date>September 5, 2018</start_date>
    <primary_completion_date>September 1, 2033</primary_completion_date>
    <completion_date>September 1, 2035</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>September 6, 2018</last_update_posted>
    <locations>
      <location>Aalborg University Hospital, Aalborg, Denmark</location>
      <location>Aarhus University Hospital, Aarhus, Denmark</location>
      <location>Rigshospitalet, Copenhagen, Denmark</location>
      <location>Naestved Hospital, Naestved, Denmark</location>
      <location>Odense University Hospital, Odense, Denmark</location>
      <location>Vejle Hospital, Vejle, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646955</url>
  </study>
  <study rank="45339">
    <nct_id>NCT03646942</nct_id>
    <title>The Role of Low Level Laser Therapy in Acceleration of Teeth Alignment in Lingual Orthodontic Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Malocclusion, Angle Class I</condition>
      <condition>Crowding</condition>
    </conditions>
    <interventions>
      <intervention type="Radiation">low level laser therapy</intervention>
      <intervention type="Device">Lingual Orthodontics</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Duration of tooth alignment</outcome_measure>
      <outcome_measure>Change in Tooth Alignment at one month</outcome_measure>
      <outcome_measure>Change in Tooth Alignment at two months</outcome_measure>
      <outcome_measure>Change in Tooth Alignment at the end of Alignment Stage</outcome_measure>
      <outcome_measure>Change in the levels of pain and discomfort</outcome_measure>
      <outcome_measure>Change in Patients' Acceptance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Damascus University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>17 Years</min_age>
    <max_age>27 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>UDDS-Ortho-08-2018</other_id>
    </other_ids>
    <start_date>June 15, 2017</start_date>
    <primary_completion_date>October 1, 2018</primary_completion_date>
    <completion_date>February 1, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>July 18, 2019</last_update_posted>
    <locations>
      <location>Orthodontic Department, University of Damascus Dental School, Damascus, Syrian Arab Republic</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646942</url>
  </study>
  <study rank="45340">
    <nct_id>NCT03646929</nct_id>
    <title>Motor Evoked Potentials With Modified Facilitation Technique</title>
    <acronym>EP-F</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Multiple Sclerosis</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">MEP using standard facilitation technique</intervention>
      <intervention type="Diagnostic Test">MEP using modified facilitation technique</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Test- Re-Test reliability when using modified facilitation technique (compared to standard facilitation technique) in healthy individuals</outcome_measure>
      <outcome_measure>comparison of sensitivity and specificity of modified facilitation technique and standard facilitation technique in patients with multiple sclerosis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Basel, Switzerland</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>2017-01893; me18Hardmeier</other_id>
    </other_ids>
    <start_date>December 20, 2017</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>October 31, 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>December 10, 2019</last_update_posted>
    <locations>
      <location>Dep. of Neurology and Clinical Neurophysiology , Hospital of the University of Basel, Basel, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646929</url>
  </study>
  <study rank="45341">
    <nct_id>NCT03646916</nct_id>
    <title>Intraoperative Dexamethasone and Its Effect on Hyperglycemia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes Mellitus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dexamethasone</intervention>
      <intervention type="Other">No dexamethasone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Post-operative blood sugar</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ascension Genesys Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>GRMC160010</other_id>
    </other_ids>
    <start_date>October 2019</start_date>
    <primary_completion_date>June 30, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 8, 2019</last_update_posted>
    <locations>
      <location>Genesys Regional Medical Center, Grand Blanc, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646916</url>
  </study>
  <study rank="45342">
    <nct_id>NCT03646903</nct_id>
    <title>Reducing Help-Seeking Stigma in Young Adults at Elevated Suicide Risk</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Suicide</condition>
      <condition>Help-Seeking Behavior</condition>
      <condition>Health Behavior</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Cognitive Bias Modification</intervention>
      <intervention type="Behavioral">Psychoeducation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Perceived Stigma and Barriers to Care for Psychological Problems Scale (PS)</outcome_measure>
      <outcome_measure>Self-Stigma of Seeking Help (SSOSH)</outcome_measure>
      <outcome_measure>World Mental Health Composite International Diagnostic Interview (WMH-CIDI)</outcome_measure>
      <outcome_measure>Readiness to Change Scale</outcome_measure>
      <outcome_measure>Mental Health Treatment Survey</outcome_measure>
      <outcome_measure>Intervention Acceptability and Feasibility Questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Florida State University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>78</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PRG-0-141-17</other_id>
    </other_ids>
    <start_date>September 24, 2018</start_date>
    <primary_completion_date>April 1, 2020</primary_completion_date>
    <completion_date>September 1, 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>February 15, 2019</last_update_posted>
    <locations>
      <location>Florida State University, Tallahassee, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646903</url>
  </study>
  <study rank="45343">
    <nct_id>NCT03646890</nct_id>
    <title>Epidemiology and Clinical Features of Uveitis in a Tertiary Referral</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Uveitis</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Etiology of uveitis</outcome_measure>
      <outcome_measure>Demographic description of patients with uveitis</outcome_measure>
      <outcome_measure>Clinical description of patients with uveitis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Montpellier</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>985</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>RECHMPL18_0280</other_id>
    </other_ids>
    <start_date>January 1, 2002</start_date>
    <primary_completion_date>January 1, 2012</primary_completion_date>
    <completion_date>July 31, 2018</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations>
      <location>Uhmontpellier, Montpellier, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646890</url>
  </study>
  <study rank="45344">
    <nct_id>NCT03646877</nct_id>
    <title>Mechanisms of Ozone-Induced Alterations in Efferocytosis and Phagocytosis</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ozone</intervention>
      <intervention type="Other">Filtered Air</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>change in ozone induced efferocytosis of lung macrophages (ability to clear dead or dying cells)</outcome_measure>
      <outcome_measure>Change in ozone induced phagocytosis of lung macrophages (ability to clear debris or bacteria)</outcome_measure>
      <outcome_measure>Change in ozone induced increase in cell free hemoglobin in bronchoalveolar lavage fluid and serum</outcome_measure>
      <outcome_measure>Change in ozone induced increase in soluble CD163 in bronchoalveolar lavage fluid and serum</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Robert Tighe, MD</lead_sponsor>
      <collaborator>National Institutes of Health (NIH)</collaborator>
      <collaborator>East Carolina University</collaborator>
      <collaborator>Duke University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>35 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>PRO00100375</other_id>
    </other_ids>
    <start_date>February 19, 2019</start_date>
    <primary_completion_date>January 31, 2024</primary_completion_date>
    <completion_date>January 31, 2024</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>March 7, 2019</last_update_posted>
    <locations>
      <location>Duke University Medical Center, Durham, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646877</url>
  </study>
  <study rank="45345">
    <nct_id>NCT03646864</nct_id>
    <title>A Study to Evaluate the Effects of ACT-541468 on Respiration in Patients With Moderate Chronic Obstructive Pulmonary Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ACT-541468</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mean SaO2 during total sleep time (TST) after multiple-dose administration (i.e., at Night 5) as measured by finger pulse oximetry and PSG</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Idorsia Pharmaceuticals Ltd.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>28</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ID-078-109</other_id>
      <other_id>2018-001828-19</other_id>
    </other_ids>
    <start_date>November 15, 2018</start_date>
    <primary_completion_date>September 19, 2019</primary_completion_date>
    <completion_date>September 19, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>September 23, 2019</last_update_posted>
    <locations>
      <location>Advanced Sleep Research, Berlin, Germany</location>
      <location>Klinische Forschungsgruppe Nord, Dresden, Germany</location>
      <location>Klinische Forschungsgruppe Nord, Hannover, Germany</location>
      <location>framol-med GmbH, Lungenpraxis, Rheinau, Germany</location>
      <location>ZMS, Warendorf, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646864</url>
  </study>
  <study rank="45346">
    <nct_id>NCT03646851</nct_id>
    <title>Aspergillus and Chronic Obstructive Pulmonary Disease Evolution</title>
    <acronym>AspergBPCO</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Obstructive Pulmonary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Questionnaries</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>presence of aspergillus in sputum or respiratory samples</outcome_measure>
      <outcome_measure>Dyspnea with MMRC score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire, Amiens</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <other_ids>
      <other_id>PI2017_843_0024</other_id>
    </other_ids>
    <start_date>March 15, 2018</start_date>
    <primary_completion_date>March 15, 2018</primary_completion_date>
    <completion_date>March 15, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations>
      <location>CH Abbeville, Abbeville, France</location>
      <location>CHU Amiens-Picardie, Amiens, France</location>
      <location>Clinique de l'Europe, Amiens, France</location>
      <location>CHU St Quentin, Saint-Quentin, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646851</url>
  </study>
  <study rank="45347">
    <nct_id>NCT03646838</nct_id>
    <title>Family Experiences After International Adoption</title>
    <acronym>VF-ADIN</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Discrimination, Racial</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Number and type of micro-aggressions experienced by French families who have adopted internationally</outcome_measure>
      <outcome_measure>Number and type of micro-aggressions experienced by internationally adopted adolescents in France</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier St Anne</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>11 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>D17-P16</other_id>
    </other_ids>
    <start_date>November 22, 2017</start_date>
    <primary_completion_date>January 31, 2020</primary_completion_date>
    <completion_date>January 31, 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations>
      <location>Hospital Enfants CHU du BOCAGE, Dijon, France</location>
      <location>Hospital SAINTE ANNE, Paris, France</location>
      <location>Hospital NECKER, Paris, France</location>
      <location>Hospital MIGNOT, Versailles, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646838</url>
  </study>
  <study rank="45348">
    <nct_id>NCT03646825</nct_id>
    <title>Effect of Natural Antioxidant Supplement on Sperm DNA Fragmentation</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Observe Effect of Antioxidant on Sperm DNA Fragmention</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Natural Antioxidant supplement</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sperm DNA fragmentation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Colorado Center for Reproductive Medicine</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>20170532</other_id>
    </other_ids>
    <start_date>August 1, 2018</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>July 2021</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations>
      <location>Colorado Center for Reproductive Medicine, Lone Tree, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646825</url>
  </study>
  <study rank="45349">
    <nct_id>NCT03646812</nct_id>
    <title>Glycemic and Insulinemic Response of Pasta Products in Comparison to Asian Foods</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Glucose Reference 1</intervention>
      <intervention type="Other">Glucose Reference 2</intervention>
      <intervention type="Other">Glucose Reference 3</intervention>
      <intervention type="Other">Semolina Penne</intervention>
      <intervention type="Other">Wholegrain Penne</intervention>
      <intervention type="Other">Semolina Spaghetti</intervention>
      <intervention type="Other">Wholegrain Spaghetti</intervention>
      <intervention type="Other">Jasmine Rice</intervention>
      <intervention type="Other">Asian Noodles</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Glucose</outcome_measure>
      <outcome_measure>Insulin</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>JeyaKumar Henry</lead_sponsor>
      <collaborator>Barilla Singapore Pte Ltd</collaborator>
      <collaborator>Clinical Nutrition Research Centre, Singapore</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>40 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018/00622</other_id>
    </other_ids>
    <start_date>August 10, 2018</start_date>
    <primary_completion_date>February 29, 2020</primary_completion_date>
    <completion_date>February 29, 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>January 22, 2020</last_update_posted>
    <locations>
      <location>Clinical Nutrition Research Centre, Singapore, Singapore</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646812</url>
  </study>
  <study rank="45350">
    <nct_id>NCT03646799</nct_id>
    <title>Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy Adults</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Type II Diabetes</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CKD-387</intervention>
      <intervention type="Drug">D484</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cmax of Dapagliflozin</outcome_measure>
      <outcome_measure>Cmax of Metformin</outcome_measure>
      <outcome_measure>AUClast of Dapagliflozin</outcome_measure>
      <outcome_measure>AUClast of Metformin</outcome_measure>
      <outcome_measure>AUCinf of Dapagliflozin</outcome_measure>
      <outcome_measure>AUCinf of Metformin</outcome_measure>
      <outcome_measure>Tmax of Dapagliflozin</outcome_measure>
      <outcome_measure>Tmax of Metformin</outcome_measure>
      <outcome_measure>T1/2 of Dapagliflozin</outcome_measure>
      <outcome_measure>T1/2 of Metformin</outcome_measure>
      <outcome_measure>Vd/F of Dapagliflozin</outcome_measure>
      <outcome_measure>Vd/F of Metformin</outcome_measure>
      <outcome_measure>CL/F of Dapagliflozin</outcome_measure>
      <outcome_measure>CL/F of Metformin</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chong Kun Dang Pharmaceutical</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>36</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>184BE18012</other_id>
    </other_ids>
    <start_date>August 30, 2018</start_date>
    <primary_completion_date>September 9, 2018</primary_completion_date>
    <completion_date>September 14, 2018</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations>
      <location>Yonsei University Severance Hospital, Soeul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646799</url>
  </study>
  <study rank="45351">
    <nct_id>NCT03646786</nct_id>
    <title>Prospective Pilot Study of Multi-actor Tolerance Evaluation Using the VIRARE Device (VIrtual Reality Assisted Rehabilitation) in Visually Impaired Patients</title>
    <acronym>VIRARE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Visual Impairment</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Virtual reality tests</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>dizziness felt by the patient</outcome_measure>
      <outcome_measure>Nausea felt by the patient</outcome_measure>
      <outcome_measure>headache felt by the patient</outcome_measure>
      <outcome_measure>dazzle felt by the patient</outcome_measure>
      <outcome_measure>watering of the patient</outcome_measure>
      <outcome_measure>eye burns felt by the patient</outcome_measure>
      <outcome_measure>Pain due to the mobilization of the eyeballs felt by the patient</outcome_measure>
      <outcome_measure>Extraocular pain felt by the patient</outcome_measure>
      <outcome_measure>diplopia</outcome_measure>
      <outcome_measure>amaurosis</outcome_measure>
      <outcome_measure>Fear</outcome_measure>
      <outcome_measure>conformity of the session according to the patient point of view</outcome_measure>
      <outcome_measure>unpleasantness of the session from the patient point of view</outcome_measure>
      <outcome_measure>Difficulty of the session according to the patient point of view</outcome_measure>
      <outcome_measure>Willingness to continue the following tests according to the patient point of view</outcome_measure>
      <outcome_measure>Cervical pain felt by the patient</outcome_measure>
      <outcome_measure>oculomotricity of the patient according to the therapist</outcome_measure>
      <outcome_measure>head movements of the patient according to the therapist</outcome_measure>
      <outcome_measure>body movements of the patient according to the therapist</outcome_measure>
      <outcome_measure>target tracking by the patient according to the therapist</outcome_measure>
      <outcome_measure>Time lapse to find targets</outcome_measure>
      <outcome_measure>The patient asked for a pause during the test</outcome_measure>
      <outcome_measure>The patient asked to permanently stop the tests</outcome_measure>
      <outcome_measure>The patient went to the right place during the 3rd test</outcome_measure>
      <outcome_measure>The patient has correctly performed the requested task</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nīmes</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>IDIL/2016/LJ-01</other_id>
    </other_ids>
    <start_date>January 2019</start_date>
    <primary_completion_date>January 2020</primary_completion_date>
    <completion_date>January 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations>
      <location>Nimes University Hospital, Nîmes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646786</url>
  </study>
  <study rank="45352">
    <nct_id>NCT03646773</nct_id>
    <title>Microvascular Effects of Intravenous Esmolol During Postoperative Atrial Fibrillation</title>
    <acronym>FANI</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Postoperative Atrial Fibrillation</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>effects of POAF without hemodynamic instability on near infrared spectroscopy (NIRS) parameters in combination with a vascular occlusion test</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospices Civils de Lyon</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>69HCL16_0743_1</other_id>
    </other_ids>
    <start_date>December 2015</start_date>
    <primary_completion_date>September 2016</primary_completion_date>
    <completion_date>November 2016</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646773</url>
  </study>
  <study rank="45353">
    <nct_id>NCT03646760</nct_id>
    <title>The Improving ATTENDance in Cardiac Rehabilitation Trial</title>
    <acronym>iATTEND</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Myocardial Infarction</condition>
      <condition>Heart Failure</condition>
      <condition>Heart Valve Diseases</condition>
      <condition>Cardiac Event</condition>
      <condition>Angina Pectoris</condition>
      <condition>Coronary Artery Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">HYCR</intervention>
      <intervention type="Behavioral">CBCR</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The number of CR sessions completed within 6 months will be significantly greater in patients randomized to HYCR vs. patients randomized to traditional CBCR (usual care).</outcome_measure>
      <outcome_measure>The percentage of patients completing 36 CR sessions within 6 months will be significantly greater among patients randomized to the HYCR program vs. patients randomized to the CBCR program.</outcome_measure>
      <outcome_measure>The improvement in exercise capacity, as measured by distance walked during the six min walk (6MW) test, in patients randomized to HYCR will be equivalent (not inferior) to patients randomized to CBCR.</outcome_measure>
      <outcome_measure>The improvement in exercise capacity, as measured by peak oxygen uptake (VO2), in patients randomized to HYCR will be equivalent (not inferior) to patients randomized to CBCR.</outcome_measure>
      <outcome_measure>The improvement in quality of life (QOL), as measured by the Short Form Health Survey-12, in patients randomized to HYCR will be equivalent (not inferior) to patients randomized to CBCR.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Henry Ford Health System</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>270</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>HFHS iATTEND</other_id>
    </other_ids>
    <start_date>March 1, 2019</start_date>
    <primary_completion_date>March 31, 2023</primary_completion_date>
    <completion_date>July 31, 2023</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>February 25, 2019</last_update_posted>
    <locations>
      <location>Henry Ford Health System, Detroit, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646760</url>
  </study>
  <study rank="45354">
    <nct_id>NCT03646747</nct_id>
    <title>Oxygen Enhanced MRI Measurement in Head and Neck Cancer: Validation and Efficacy of Response.</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Head and Neck Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">MRI scan</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Assessment of hypoxia in head and neck squamous cell cancer using oxygen enhanced Magnetic resonance imaging (using a range of different MR sequences)</outcome_measure>
      <outcome_measure>Optimal MRI sequence to image participants with head and neck cancer, based on tumour and organ at risk visualisation.</outcome_measure>
      <outcome_measure>Treatment response in a number of participants with head and neck cancer treated with radiotherapy +/- systemic therapy</outcome_measure>
      <outcome_measure>Treatment related toxicities in a number of participants with head and neck cancer as assessed during and after treatment completion</outcome_measure>
      <outcome_measure>Survival outcomes in a number of participants treated with radiotherapy +/- systemic therapy for head and neck cancer</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sally Falk</lead_sponsor>
      <collaborator>University of Manchester</collaborator>
      <collaborator>The Christie NHS Foundation Trust</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <other_ids>
      <other_id>18_RADIO_133</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646747</url>
  </study>
  <study rank="45355">
    <nct_id>NCT03646734</nct_id>
    <title>Guided Bone Regeneration With Particulate Versus Block Graft</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Surgery</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>bone gain</outcome_measure>
      <outcome_measure>Pain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>TC Erciyes University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>30 Years</min_age>
    <max_age>62 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>Zek</other_id>
    </other_ids>
    <start_date>January 10, 2017</start_date>
    <primary_completion_date>January 10, 2018</primary_completion_date>
    <completion_date>April 10, 2018</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646734</url>
  </study>
  <study rank="45356">
    <nct_id>NCT03646721</nct_id>
    <title>A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Diabetes Mellitus, Type 2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DA-1241</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Sitagliptin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>12-lead ECGs</outcome_measure>
      <outcome_measure>Blood pressure</outcome_measure>
      <outcome_measure>Heart rate</outcome_measure>
      <outcome_measure>Body temperature</outcome_measure>
      <outcome_measure>Respiratory rate</outcome_measure>
      <outcome_measure>Physical examination</outcome_measure>
      <outcome_measure>Clinical laboratory testing</outcome_measure>
      <outcome_measure>Adverse event</outcome_measure>
      <outcome_measure>Maximum concentration of DA-1241 (Cmax)</outcome_measure>
      <outcome_measure>Time of maximum plasma DA-1241 concentration (Tmax)</outcome_measure>
      <outcome_measure>Area under the concentration-time curve (AUC)</outcome_measure>
      <outcome_measure>Apparent terminal elimination half-life (t½)</outcome_measure>
      <outcome_measure>Apparent total systemic clearance after oral administration (CL/F)</outcome_measure>
      <outcome_measure>Apparent volume of distribution (Vz/F)</outcome_measure>
      <outcome_measure>Accumulation ratio (Last dosing day AUCtau / First dosing day AUCtau)</outcome_measure>
      <outcome_measure>Amount of DA-1241 excreted unchanged in the urine in each collection interval(Ae)</outcome_measure>
      <outcome_measure>Cumulative amount of DA-1241 excreted unchanged in the urine (Cum Ae)</outcome_measure>
      <outcome_measure>Percentage fraction of DA-1241 excreted unchanged in the urine in each collection interval(Fe)</outcome_measure>
      <outcome_measure>Cumulative percentage fraction of DA-1241 excreted unchanged in the urine (Cum Fe)</outcome_measure>
      <outcome_measure>Renal clearance (CLR)</outcome_measure>
      <outcome_measure>Fasting Plasma Glucose (FPG)</outcome_measure>
      <outcome_measure>2h-Postprandial glucose</outcome_measure>
      <outcome_measure>Area under the measurements versus (vs) time curve(AUE)</outcome_measure>
      <outcome_measure>Incremental AUEs after meal (iAUE)</outcome_measure>
      <outcome_measure>Weighted mean glucose (WMG)</outcome_measure>
      <outcome_measure>Incremental WMG (iWMG)</outcome_measure>
      <outcome_measure>Fasting Insulin</outcome_measure>
      <outcome_measure>Glycated albumin</outcome_measure>
      <outcome_measure>HbA1c</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dong-A ST Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>99</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>DA1241_DM_Ib</other_id>
    </other_ids>
    <start_date>August 29, 2018</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>December 23, 2019</last_update_posted>
    <locations>
      <location>Clinical Site, Chula Vista, California, United States</location>
      <location>Clinical Pharmacology of Miami, Miami, Florida, United States</location>
      <location>High Point Clinical Trials Center, High Point, North Carolina, United States</location>
      <location>Rainier Clinical Research Center, Renton, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646721</url>
  </study>
  <study rank="45357">
    <nct_id>NCT03646708</nct_id>
    <title>Response Assessment in SB CD</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Small Bowel Crohn's Disease</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Corticosteroid free remission (CFR)</outcome_measure>
      <outcome_measure>Mucosal healing (MH)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Washington University School of Medicine</lead_sponsor>
      <collaborator>American College of Gastroenterology</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>201805058</other_id>
    </other_ids>
    <start_date>May 9, 2018</start_date>
    <primary_completion_date>May 30, 2023</primary_completion_date>
    <completion_date>May 30, 2023</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>September 4, 2019</last_update_posted>
    <locations>
      <location>Washington University School of Medicine, Saint Louis, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646708</url>
  </study>
  <study rank="45358">
    <nct_id>NCT03646695</nct_id>
    <title>ILM Flap Transposition Versus ILM Peeling for Macular Holes: a Pilot Study</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Macular Holes</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">ILM flap transposition</intervention>
      <intervention type="Procedure">ILM peeling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>closure of the macular hole</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vienna Institute for Research in Ocular Surgery</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>ILM flap</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>September 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>October 22, 2019</last_update_posted>
    <locations>
      <location>Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital, Vienna, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646695</url>
  </study>
  <study rank="45359">
    <nct_id>NCT03646682</nct_id>
    <title>Pharmakokinetik of Caffeine in Epiretinal Membranes After Oral Intake: a Pilot Study</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Epiretinal Membrane</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">vitrectomy with membrane peeling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>concentration of caffeine in vitreous probes and epiretinal membranes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vienna Institute for Research in Ocular Surgery</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <other_ids>
      <other_id>CaffERM</other_id>
    </other_ids>
    <start_date>August 13, 2018</start_date>
    <primary_completion_date>December 1, 2019</primary_completion_date>
    <completion_date>December 1, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>October 22, 2019</last_update_posted>
    <locations>
      <location>Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna, Vienna, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646682</url>
  </study>
  <study rank="45360">
    <nct_id>NCT03646669</nct_id>
    <title>Symptom Perception</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Asthma</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">PEF Feedback</intervention>
      <intervention type="Behavioral">Asthma education</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Beliefs about Illness Perception Questionnaire (BIPQ)</outcome_measure>
      <outcome_measure>Change in PEF</outcome_measure>
      <outcome_measure>Change in Beliefs about Medicines Questionnaire (BMQ)</outcome_measure>
      <outcome_measure>Change in Medication Adherence Rating Scale (MARS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Icahn School of Medicine at Mount Sinai</lead_sponsor>
      <collaborator>Albert Einstein College of Medicine</collaborator>
      <collaborator>Jacobi Medical Center</collaborator>
      <collaborator>National Heart, Lung, and Blood Institute (NHLBI)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <other_ids>
      <other_id>GCO 15-0667</other_id>
      <other_id>R01HL131418</other_id>
    </other_ids>
    <start_date>February 15, 2019</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>February 21, 2019</last_update_posted>
    <locations>
      <location>Albert Einstein College of Medicine/Yeshiva University, Bronx, New York, United States</location>
      <location>Jacobi Medical Center, Bronx, New York, United States</location>
      <location>Icahn School of Medicine at Mount Sinai, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646669</url>
  </study>
  <study rank="45361">
    <nct_id>NCT03646656</nct_id>
    <title>Heart Health Buddies: Peer Support to Decrease CVD Risk</title>
    <acronym>HHB</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">reciprocal peer support and non reciprocal coach support</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>feasibility enrollment</outcome_measure>
      <outcome_measure>feasibility retention</outcome_measure>
      <outcome_measure>acceptability</outcome_measure>
      <outcome_measure>gender differences</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>35 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDX 18-005</other_id>
    </other_ids>
    <start_date>September 26, 2018</start_date>
    <primary_completion_date>March 15, 2019</primary_completion_date>
    <completion_date>March 15, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>March 22, 2019</last_update_posted>
    <locations>
      <location>Durham VA Medical Center, Durham, NC, Durham, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646656</url>
  </study>
  <study rank="45362">
    <nct_id>NCT03646643</nct_id>
    <title>Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial</title>
    <acronym>PRECAF</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Atrial Fibrillation</condition>
      <condition>Arrhythmias, Cardiac</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Standard Atrial fibrillation ablation</intervention>
      <intervention type="Procedure">Coronary sinus to left atrium connection elimination</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to recurrence of atrial arrhythmias</outcome_measure>
      <outcome_measure>Atrial fibrillation burden</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>829990</other_id>
    </other_ids>
    <start_date>August 18, 2018</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>August 2021</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>September 10, 2019</last_update_posted>
    <locations>
      <location>Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646643</url>
  </study>
  <study rank="45363">
    <nct_id>NCT03646630</nct_id>
    <title>Quadratus Lumborum Block Versus Caudal Block for Pediatric Postoperative Analgesia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pain, Postoperative</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Quadratus Lumborum Block</intervention>
      <intervention type="Procedure">Caudal Block</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time at which the first analgesia required</outcome_measure>
      <outcome_measure>Pain assessment by the aid of FLACC score</outcome_measure>
      <outcome_measure>number of analgesic doses for each patient</outcome_measure>
      <outcome_measure>The general satisfaction score of parents</outcome_measure>
      <outcome_measure>Preoperative heart rate</outcome_measure>
      <outcome_measure>Preoperative systolic blood pressure</outcome_measure>
      <outcome_measure>Preoperative diastolic blood pressure</outcome_measure>
      <outcome_measure>Intraoperative systolic blood pressure</outcome_measure>
      <outcome_measure>Intraoperative diastolic blood pressure</outcome_measure>
      <outcome_measure>Intraoperative heart rate</outcome_measure>
      <outcome_measure>Incidence of hypotension</outcome_measure>
      <outcome_measure>Incidence of bradycardia</outcome_measure>
      <outcome_measure>Incidence of vascular puncture</outcome_measure>
      <outcome_measure>Incidence of convulsions</outcome_measure>
      <outcome_measure>Incidence of arrhythmias</outcome_measure>
      <outcome_measure>Incidence of paresthesia</outcome_measure>
      <outcome_measure>Incidence of hematoma formation</outcome_measure>
      <outcome_measure>Incidence of injury to the underlying structures</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fayoum University Hospital</lead_sponsor>
      <collaborator>Cairo University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>1 Year</min_age>
    <max_age>7 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>D141</other_id>
    </other_ids>
    <start_date>May 2, 2019</start_date>
    <primary_completion_date>October 1, 2019</primary_completion_date>
    <completion_date>October 15, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>May 6, 2019</last_update_posted>
    <locations>
      <location>Fayoum University hospital, Madīnat al Fayyūm, Faiyum Governorate, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646630</url>
  </study>
  <study rank="45364">
    <nct_id>NCT03646617</nct_id>
    <title>Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma</title>
    <acronym>RadVax</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Metastatic Melanoma</condition>
    </conditions>
    <interventions>
      <intervention type="Radiation">Hypofractionated Radiation Therapy (HFRT)</intervention>
      <intervention type="Drug">Nivolumab</intervention>
      <intervention type="Drug">Ipilimumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Adverse Events</outcome_measure>
      <outcome_measure>progression-free survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Abramson Cancer Center of the University of Pennsylvania</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>UPCC 05618</other_id>
      <other_id>829922</other_id>
    </other_ids>
    <start_date>August 23, 2018</start_date>
    <primary_completion_date>February 23, 2022</primary_completion_date>
    <completion_date>February 23, 2023</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations>
      <location>Abramson Cancer Center, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646617</url>
  </study>
  <study rank="45365">
    <nct_id>NCT03646604</nct_id>
    <title>A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Subjects With Severe Atopic Dermatitis</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Atopic Dermatitis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Upadacitinib (ABT-494)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Maximum Plasma Concentration (Cmax)</outcome_measure>
      <outcome_measure>Time to Maximum Observed Plasma Concentration (Tmax)</outcome_measure>
      <outcome_measure>Area under the plasma concentration-time curve within a dosing interval (AUC)</outcome_measure>
      <outcome_measure>Oral Clearance</outcome_measure>
      <outcome_measure>Treatment Emergent Adverse Events (TEAE)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>AbbVie</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>2 Years</min_age>
    <max_age>11 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>M16-049</other_id>
      <other_id>2018-004409-17</other_id>
    </other_ids>
    <start_date>January 31, 2019</start_date>
    <primary_completion_date>December 29, 2021</primary_completion_date>
    <completion_date>July 25, 2024</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>November 13, 2019</last_update_posted>
    <locations>
      <location>Beach Pediatrics /ID# 207834, Huntington Beach, California, United States</location>
      <location>Childrens Hospital LA /ID# 206042, Los Angeles, California, United States</location>
      <location>Pediatric Skin Research, LLC /ID# 213468, Coral Gables, Florida, United States</location>
      <location>Northwestern University Feinberg School of Medicine /ID# 206224, Chicago, Illinois, United States</location>
      <location>Dawes Fretzin, LLC /ID# 214958, Indianapolis, Indiana, United States</location>
      <location>Washington University of St. Louis /ID# 206972, Saint Louis, Missouri, United States</location>
      <location>University of New Mexico School of Medicine /ID# 206757, Albuquerque, New Mexico, United States</location>
      <location>Cincinnati Children's Hospital /ID# 207071, Cincinnati, Ohio, United States</location>
      <location>Oregon Health and Science University (OHSU) /ID# 206226, Portland, Oregon, United States</location>
      <location>Penn State University and Milton S. Hershey Medical Center /ID# 207096, Hershey, Pennsylvania, United States</location>
      <location>Paddington Testing Co., Inc. /ID# 207079, Philadelphia, Pennsylvania, United States</location>
      <location>West Virginia University /ID# 206792, Morgantown, West Virginia, United States</location>
      <location>Our Lady's Children's Hospital /ID# 211199, Dublin, Ireland</location>
      <location>Haukeland University Hospital /ID# 210162, Bergen, Hordaland, Norway</location>
      <location>Rikshospitalet OUS HF /ID# 210163, Oslo, Norway</location>
      <location>Cruz-Santana, Carolina, PR /ID# 214890, Carolina, Puerto Rico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646604</url>
  </study>
  <study rank="45366">
    <nct_id>NCT03646591</nct_id>
    <title>Feasibility and Safety of FLOT Regimen in Chinese Gastric Cancer Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chemotherapy Effect</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chemotherapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Completion rate of preoperative FLOT regimen</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Pathological response rate</outcome_measure>
      <outcome_measure>Postoperative morbidity</outcome_measure>
      <outcome_measure>Postoperative mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>BIRENDRA KUMAR SAH</lead_sponsor>
      <collaborator>Ruijin Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>Ruijin GCS-Neoadjuvant</other_id>
    </other_ids>
    <start_date>November 15, 2017</start_date>
    <primary_completion_date>August 20, 2018</primary_completion_date>
    <completion_date>August 20, 2018</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>December 19, 2019</last_update_posted>
    <locations>
      <location>Ruijin Hospital, Shanghai, Shanhgai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646591</url>
  </study>
  <study rank="45367">
    <nct_id>NCT03646578</nct_id>
    <title>Maternal Anxiety Related to How the Pediatrician Provided Prenatal Information About Preterm Birth</title>
    <acronym>Infoprema</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Preterm Birth</condition>
    </conditions>
    <interventions>
      <intervention type="Other">State of anxiety</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mesure of the State of anxiety of patients with a risk of premature delivery</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire, Amiens</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>65</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>PI2017_843_0038</other_id>
    </other_ids>
    <start_date>November 1, 2014</start_date>
    <primary_completion_date>August 1, 2017</primary_completion_date>
    <completion_date>August 1, 2017</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646578</url>
  </study>
  <study rank="45368">
    <nct_id>NCT03646565</nct_id>
    <title>Psychosocial Development of Children Undergoing Open Cardiac Surgery</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiac Surgery</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Well-being measured with the KidScreen52 questionnaire</outcome_measure>
      <outcome_measure>Illness representation measured with PRISM-D and person/organ test</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Semmelweis University Heart and Vascular Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>ChildrenHeart</other_id>
    </other_ids>
    <start_date>November 20, 2018</start_date>
    <primary_completion_date>March 20, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>April 16, 2019</last_update_posted>
    <locations>
      <location>Semmelweis University, Budapest, Hungary</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646565</url>
  </study>
  <study rank="45369">
    <nct_id>NCT03646552</nct_id>
    <title>A Study to Examine the Efficacy of a Therapeutic THX-110 for Obstructive Sleep Apnea</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Obstructive Sleep Apnea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">THX-110</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>A Significant Change in AHI Index</outcome_measure>
      <outcome_measure>A Change in Oxygen Desaturation Index (ODI)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Therapix Biosciences Ltd.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>0079-17-ASMC</other_id>
    </other_ids>
    <start_date>June 4, 2018</start_date>
    <primary_completion_date>April 2019</primary_completion_date>
    <completion_date>April 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations>
      <location>Assuta HaShalom, Tel Aviv, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646552</url>
  </study>
  <study rank="45370">
    <nct_id>NCT03646539</nct_id>
    <title>RCT of Automated Conversational Agent vs. Treatment as Usual for the Management of Perinatal Mood</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cognitive Therapy</condition>
      <condition>Depression, Postpartum</condition>
      <condition>Mental Health</condition>
      <condition>Depression</condition>
      <condition>Depressive Disorder</condition>
      <condition>Anxiety</condition>
      <condition>Telemedicine</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Use of smartphone application (app)</intervention>
      <intervention type="Other">Treatment as usual</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mean change from baseline in Patient Health Questionnaire (PHQ-9) scores at 6 weeks post-delivery</outcome_measure>
      <outcome_measure>Mean change from baseline in Edinburgh Postnatal Depression Scale Scores at 6 weeks</outcome_measure>
      <outcome_measure>Mean change from baseline in Patient Health Questionnaire (PHQ-9) scores at 2 weeks post-delivery</outcome_measure>
      <outcome_measure>Mean change from baseline in Patient Health Questionnaire (PHQ-9) scores at 4 weeks post-delivery</outcome_measure>
      <outcome_measure>Mean change from baseline in Edinburgh Postnatal Depression Scale Scores at 2 weeks</outcome_measure>
      <outcome_measure>Mean change from baseline in Edinburgh Postnatal Depression Scale Scores at 4 weeks</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>135</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB-46467</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>March 31, 2020</primary_completion_date>
    <completion_date>March 31, 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>April 4, 2019</last_update_posted>
    <locations>
      <location>Stanford University Department of Obstetrics and Gynecology, Stanford, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646539</url>
  </study>
  <study rank="45371">
    <nct_id>NCT03646526</nct_id>
    <title>Bioavailability Study of Amitriptyline Hydrochloride Tablets</title>
    <acronym>AMTL-BE</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Depressive Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Amitriptyline Hydrochloride 25Mg Tablet（Hunan Dongting）</intervention>
      <intervention type="Drug">Amitriptyline Hydrochloride 25Mg Tablet（Sandoz）</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cmax</outcome_measure>
      <outcome_measure>Tmax</outcome_measure>
      <outcome_measure>AUC(0-inf)</outcome_measure>
      <outcome_measure>AUC(0-144h)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>First Affiliated Hospital of Zhejiang University</lead_sponsor>
      <collaborator>Hunan DongtingPharm.Co.Ltd</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>ZYYY-AMTL-BE-2018-02</other_id>
    </other_ids>
    <start_date>April 4, 2018</start_date>
    <primary_completion_date>January 31, 2019</primary_completion_date>
    <completion_date>January 31, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 1, 2019</last_update_posted>
    <locations>
      <location>The First Affiliated Hospital,ZheJiang Univercity, Hanzhou, Zhejiang, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646526</url>
  </study>
  <study rank="45372">
    <nct_id>NCT03646513</nct_id>
    <title>A Safety Follow Up Study in Australian Subjects Implanted With the SMF Short Modular Femoral Stem Hip System</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Total Hip Arthroplasty (THA)</condition>
    </conditions>
    <interventions>
      <intervention type="Device">SMF Short Modular Femoral Hip System</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Metal Ion Analysis as a safety assessment</outcome_measure>
      <outcome_measure>MARS MRI/CT</outcome_measure>
      <outcome_measure>SMF Short Modular Femoral Stem Revision</outcome_measure>
      <outcome_measure>Standard of Care Radiographic assessments</outcome_measure>
      <outcome_measure>Radiographic assessments</outcome_measure>
      <outcome_measure>HOOS JR Questionnaire</outcome_measure>
      <outcome_measure>Adverse Events Assessment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Smith &amp; Nephew, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>55 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>18- 4550- 01</other_id>
    </other_ids>
    <start_date>August 28, 2018</start_date>
    <primary_completion_date>December 1, 2030</primary_completion_date>
    <completion_date>December 1, 2030</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>September 21, 2018</last_update_posted>
    <locations>
      <location>Malabar Orthopaedic Clinic, Windsor, Victoria, Australia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646513</url>
  </study>
  <study rank="45373">
    <nct_id>NCT03646500</nct_id>
    <title>Comparing Conscious Sedation to Retrobulbar Block Anesthetics During Trans-scleral Diode Laser</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Glaucoma</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Retrobulbar Block</intervention>
      <intervention type="Procedure">Remifentanil</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Leiden Perioperative Care Patient Satisfaction Questionnaire</outcome_measure>
      <outcome_measure>Core Measures of Outcomes of Anesthesia</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Queen's University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>18096</other_id>
    </other_ids>
    <start_date>July 2015</start_date>
    <primary_completion_date>August 2017</primary_completion_date>
    <completion_date>October 2017</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 28, 2018</last_update_posted>
    <locations>
      <location>Hotel Dieu Hospital, Kingston, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646500</url>
  </study>
  <study rank="45374">
    <nct_id>NCT03646487</nct_id>
    <title>A Randomized Placebo Controlled Pilot Study of Probiotic Supplementation in At-risk Pregnant Black Women</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Iron-deficiency</condition>
      <condition>Pregnancy, High Risk</condition>
      <condition>Stress, Psychological</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Probiotic LP299v 10x10 colony forming units in capsule form</intervention>
      <intervention type="Other">Placebo in capsule form</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>incidence of adherence to the supplement regimen</outcome_measure>
      <outcome_measure>incidence of treatment-emergent adverse events (safety and tolerability)</outcome_measure>
      <outcome_measure>maternal hemoglobin</outcome_measure>
      <outcome_measure>maternal iron</outcome_measure>
      <outcome_measure>maternal ferritin</outcome_measure>
      <outcome_measure>maternal transferrin</outcome_measure>
      <outcome_measure>maternal transferrin receptor</outcome_measure>
      <outcome_measure>maternal iron regulation</outcome_measure>
      <outcome_measure>infant hemoglobin (via cord blood)</outcome_measure>
      <outcome_measure>infant iron (via cord blood)</outcome_measure>
      <outcome_measure>infant ferritin (via cord blood)</outcome_measure>
      <outcome_measure>infant transferrin (via cord blood)</outcome_measure>
      <outcome_measure>infant transferrin receptor (via cord blood)</outcome_measure>
      <outcome_measure>infant iron regulation (via cord blood)</outcome_measure>
      <outcome_measure>maternal stress response</outcome_measure>
      <outcome_measure>self report maternal perceived stress measured by the Perceived Stress Scale (PSS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Illinois at Chicago</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>2016-0662</other_id>
    </other_ids>
    <start_date>November 19, 2018</start_date>
    <primary_completion_date>December 30, 2019</primary_completion_date>
    <completion_date>December 30, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 19, 2019</last_update_posted>
    <locations>
      <location>University of Illinois at Chicago, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646487</url>
  </study>
  <study rank="45375">
    <nct_id>NCT03646474</nct_id>
    <title>Single Dose Tranexamic Acid in Reducing Blood Loss During Cytoreductive Surgery and HIPEC</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cytoreductive Surgery</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">tranexamic Acid infusion</intervention>
      <intervention type="Drug">saline infusion</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>change in blood loss</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assiut University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>46</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>201617027.2p</other_id>
    </other_ids>
    <start_date>August 30, 2018</start_date>
    <primary_completion_date>January 31, 2020</primary_completion_date>
    <completion_date>January 31, 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>January 14, 2020</last_update_posted>
    <locations>
      <location>National Cancer Institute, Cairo University, Cairo, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646474</url>
  </study>
  <study rank="45376">
    <nct_id>NCT03646461</nct_id>
    <title>Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Head and Neck Cancer</condition>
      <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ibrutinib 560mg PO daily (Imbruvica)</intervention>
      <intervention type="Drug">Cetuximab</intervention>
      <intervention type="Drug">Nivolumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical Efficacy of Combined Therapies using RECIST v1.1</outcome_measure>
      <outcome_measure>Progression Free Survival</outcome_measure>
      <outcome_measure>Overall Survival</outcome_measure>
      <outcome_measure>Duration of Response</outcome_measure>
      <outcome_measure>Safety as assessed by the frequency of adverse events per CTCAE v4.0</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, San Diego</lead_sponsor>
      <collaborator>Pharmacyclics LLC.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>161755</other_id>
    </other_ids>
    <start_date>October 17, 2018</start_date>
    <primary_completion_date>May 30, 2021</primary_completion_date>
    <completion_date>May 30, 2022</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>March 5, 2019</last_update_posted>
    <locations>
      <location>UCSD Moores Cancer Center, La Jolla, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646461</url>
  </study>
  <study rank="45377">
    <nct_id>NCT03646448</nct_id>
    <title>Intervening in Problematic Internet Use</title>
    <acronym>iPIN</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Internet Use Disorders</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Motivational Interviewing</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change of DSM-5 criteria</outcome_measure>
      <outcome_measure>Change of time spent on the Internet</outcome_measure>
      <outcome_measure>Change of disabilities caused by the problematic Internet use</outcome_measure>
      <outcome_measure>Change of negative consequences caused by the problematic Internet use</outcome_measure>
      <outcome_measure>Readiness to change Internet use</outcome_measure>
      <outcome_measure>Self-efficacy to change Internet use</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Luebeck</lead_sponsor>
      <collaborator>Federal Ministry of Health, Germany</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>470</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>1504/68405</other_id>
    </other_ids>
    <start_date>October 1, 2017</start_date>
    <primary_completion_date>March 31, 2020</primary_completion_date>
    <completion_date>March 31, 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>September 25, 2019</last_update_posted>
    <locations>
      <location>University of Lübeck, Lübeck, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646448</url>
  </study>
  <study rank="45378">
    <nct_id>NCT03646435</nct_id>
    <title>Use of Wearables in Hospitalized General Medicine Patients</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hospitalizations</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Fitbit Charge 2</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Perceived usefulness of the wearable by patient</outcome_measure>
      <outcome_measure>Perceived usefulness of the wearable by nurses/physicians</outcome_measure>
      <outcome_measure>Correlation between Fitbit HR and HR obtained by nurses</outcome_measure>
      <outcome_measure>Correlation between Fitbit sleep and sleep information gathered by patients</outcome_measure>
      <outcome_measure>Correlation between Fitbit physical activity (number of steps taken) and activity information obtained by nurses</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <other_ids>
      <other_id>18-5621</other_id>
    </other_ids>
    <start_date>June 12, 2019</start_date>
    <primary_completion_date>October 5, 2019</primary_completion_date>
    <completion_date>November 1, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>December 3, 2019</last_update_posted>
    <locations>
      <location>Toronto General Hospital, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646435</url>
  </study>
  <study rank="45379">
    <nct_id>NCT03646422</nct_id>
    <title>AEDV Registry of Primary Cutaneous Lymphoma</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lymphoma, T-Cell, Cutaneous</condition>
      <condition>Lymphoma, B-Cell, Marginal Zone</condition>
      <condition>Lymphoma, Large B-Cell, Diffuse</condition>
      <condition>Sezary Syndrome</condition>
      <condition>Lymphoma, Extranodal NK-T-Cell</condition>
      <condition>Lymphoma, B-Cell</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Registry of patients (exposure is Cutaneous Lymphoma)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Maximum TNM stage</outcome_measure>
      <outcome_measure>Therapeutic groups used</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fundación Academia Española de Dermatología</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>FAE-LIN-2016-01</other_id>
    </other_ids>
    <start_date>September 1, 2016</start_date>
    <primary_completion_date>January 1, 2025</primary_completion_date>
    <completion_date>January 1, 2025</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>November 26, 2018</last_update_posted>
    <locations>
      <location>Hospital Clinic, Barcelona, Spain</location>
      <location>Hospital Universitario Basurto, Bilbao, Spain</location>
      <location>Hospital General de Ciudad Real, Ciudad Real, Spain</location>
      <location>hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Spain</location>
      <location>C.H.U. Insular-Materno Infantil, Las Palmas De Gran Canaria, Spain</location>
      <location>H.U. Fundación Jiménez Díaz, Madrid, Spain</location>
      <location>Hospital 12 de Octubre, Madrid, Spain</location>
      <location>Hospital Universitario Príncipe de Asturias, Madrid, Spain</location>
      <location>Complejo Hospitalario de Navarra, Pamplona, Spain</location>
      <location>CHOP-Hospital de Montecelo, Pontevedra, Spain</location>
      <location>H.U. Nuestra Señora de la Candelaria, Santa Cruz De Tenerife, Spain</location>
      <location>H.U. Virgen del Rocío, Sevilla, Spain</location>
      <location>Hospital General Universitario de Valencia, Valencia, Spain</location>
      <location>Hospital Valencia-Clínico Malva-Rosa, Valencia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646422</url>
  </study>
  <study rank="45380">
    <nct_id>NCT03646409</nct_id>
    <title>Venous Thromboembolism and Bleeding Risk in Patients With Esophageal Cancer</title>
    <acronym>VENETIA</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Venous Thromboembolism</condition>
      <condition>Esophagus Cancer</condition>
      <condition>Bleeding</condition>
      <condition>Chemotherapy Effect</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Venous thromboembolic event, arterial thromboembolic event, bleeding events</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>VTE- and bleeding incidence</outcome_measure>
      <outcome_measure>Predictive performance of VTE risk factors and known prediction models</outcome_measure>
      <outcome_measure>Predictive performance of bleeding risk factors and known prediction models</outcome_measure>
      <outcome_measure>Arterial thromboembolism (ATE) incidence</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>542</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>thromboembolism and bleeding</other_id>
    </other_ids>
    <start_date>June 11, 2018</start_date>
    <primary_completion_date>October 1, 2018</primary_completion_date>
    <completion_date>December 1, 2018</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>January 13, 2020</last_update_posted>
    <locations>
      <location>Amsterdam UMC, Amsterdam, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646409</url>
  </study>
  <study rank="45381">
    <nct_id>NCT03646396</nct_id>
    <title>Effect of Sofosbuvir-daclatasuvir on Angiogenesis</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HCV Coinfection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sofosbuvir-daclatasvir</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients with change in VEGF, TGFB1</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sherief Abd-Elsalam</lead_sponsor>
      <collaborator>Tanta University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>sofosbuvir angiogenesis</other_id>
    </other_ids>
    <start_date>August 1, 2018</start_date>
    <primary_completion_date>August 2025</primary_completion_date>
    <completion_date>December 2025</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations>
      <location>Sherief Abd-Elsalam, Tanta, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646396</url>
  </study>
  <study rank="45382">
    <nct_id>NCT03646383</nct_id>
    <title>Study of the Feasibility of Radiofrequency Ablation of Benign Thyroid Nodules</title>
    <acronym>TRAF</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Benign Thyroid Nodules</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Radiofrequency ablation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Procedure response rate</outcome_measure>
      <outcome_measure>Change in nodular volume</outcome_measure>
      <outcome_measure>volume change of nodules by at least 50 percent, at 6 months</outcome_measure>
      <outcome_measure>volume change of nodules by at least 50 percent, at 12 months</outcome_measure>
      <outcome_measure>complete disappearance of symptoms</outcome_measure>
      <outcome_measure>aesthetic change</outcome_measure>
      <outcome_measure>one or more complications</outcome_measure>
      <outcome_measure>Assessment of pain during the procedure with visual analogue scale</outcome_measure>
      <outcome_measure>patients requiring L-thyroxine replacement therapy</outcome_measure>
      <outcome_measure>Economic evaluation from the point of view of the hospital</outcome_measure>
      <outcome_measure>patients who have used analgesics</outcome_measure>
      <outcome_measure>Economic evaluation from the point of view of the health insurance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Toulouse</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RC31/17/0352</other_id>
      <other_id>2018-A00669-46</other_id>
    </other_ids>
    <start_date>January 29, 2019</start_date>
    <primary_completion_date>July 2021</primary_completion_date>
    <completion_date>July 2021</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>April 3, 2019</last_update_posted>
    <locations>
      <location>CHU Toulouse, Hôpital Larrey, Toulouse, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646383</url>
  </study>
  <study rank="45383">
    <nct_id>NCT03646370</nct_id>
    <title>Assessing Virologic Success and Metabolic Changes in Patients Switching From a TDF to TAF Containing Antiretroviral Therapy Regimen</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV-1-infection</condition>
      <condition>Metabolic Syndrome</condition>
      <condition>Cardiovascular Diseases</condition>
      <condition>Weight Gain</condition>
      <condition>Renal Function Abnormal</condition>
      <condition>Hyperglycemia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tenofovir Alafenamide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in weight</outcome_measure>
      <outcome_measure>Changes in metabolic syndrome</outcome_measure>
      <outcome_measure>Changes in glycemic control</outcome_measure>
      <outcome_measure>Changes in kidney function</outcome_measure>
      <outcome_measure>Changes in cholesterol</outcome_measure>
      <outcome_measure>Changes in 10-year cardiovascular disease risk</outcome_measure>
      <outcome_measure>Treatment success</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Thomas Jefferson University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>18G.433</other_id>
    </other_ids>
    <start_date>July 25, 2018</start_date>
    <primary_completion_date>July 24, 2019</primary_completion_date>
    <completion_date>July 24, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>September 23, 2019</last_update_posted>
    <locations>
      <location>Thomas Jeffeson University, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646370</url>
  </study>
  <study rank="45384">
    <nct_id>NCT03646357</nct_id>
    <title>BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function</title>
    <acronym>BETAMI</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Myocardial Infarction</condition>
      <condition>Non-ST Elevation Myocardial Infarction</condition>
      <condition>ST Elevation Myocardial Infarction</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Non-betablocker</intervention>
      <intervention type="Drug">Betablocker</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to the composite of death of any cause and non-fatal myocardial infarction</outcome_measure>
      <outcome_measure>Non-fatal MI</outcome_measure>
      <outcome_measure>All-cause death</outcome_measure>
      <outcome_measure>Ventricular arrhythmia</outcome_measure>
      <outcome_measure>Hospitalization for heart failure</outcome_measure>
      <outcome_measure>Cardiovascular death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Oslo University Hospital</lead_sponsor>
      <collaborator>Drammen sykehus</collaborator>
      <collaborator>The Hospital of Vestfold</collaborator>
      <collaborator>University of Oslo</collaborator>
      <collaborator>Helse Stavanger HF</collaborator>
      <collaborator>Haukeland University Hospital</collaborator>
      <collaborator>St. Olavs Hospital</collaborator>
      <collaborator>University Hospital of North Norway</collaborator>
      <collaborator>Sorlandet Hospital HF</collaborator>
      <collaborator>Feiringklinikken</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018-000590-75</other_id>
    </other_ids>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>October 1, 2022</primary_completion_date>
    <completion_date>October 1, 2023</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>October 2, 2018</last_update_posted>
    <locations>
      <location>Sørlandet Sykehus, Arendal, Norway</location>
      <location>Drammen Hospital, Drammen, Norway</location>
      <location>AHUS, Lørenskog, Norway</location>
      <location>Vestfold hospital, Tønsberg, Norway</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT03646357/Prot_ICF_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03646357</url>
  </study>
  <study rank="45385">
    <nct_id>NCT03646344</nct_id>
    <title>Heme Arginate in Transplantation Study</title>
    <acronym>HOT2</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Renal Transplant Rejection</condition>
      <condition>Renal Transplant Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Heme Arginate 25 MG/ML</intervention>
      <intervention type="Drug">0.9% Sodium-chloride</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Delayed Graft Function</outcome_measure>
      <outcome_measure>Requirement for dialysis</outcome_measure>
      <outcome_measure>Time to functioning graft</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Creatinine levels</outcome_measure>
      <outcome_measure>Acute rejection</outcome_measure>
      <outcome_measure>SF36 Quality of Life</outcome_measure>
      <outcome_measure>Cost per QALY gained</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Edinburgh</lead_sponsor>
      <collaborator>Kidney Cancer UK</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>AC17065</other_id>
    </other_ids>
    <start_date>March 12, 2019</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>April 17, 2019</last_update_posted>
    <locations>
      <location>NHS Lothian - Royal Infirmary of Edinburgh, Edinburgh, Lothian, United Kingdom</location>
      <location>Edinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646344</url>
  </study>
  <study rank="45386">
    <nct_id>NCT03646331</nct_id>
    <title>Bioequivalence of Imeglimin Tablet Formulations</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Bioequivalence</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Imeglimin Reference product</intervention>
      <intervention type="Drug">Imeglimin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pk parameters of imeglimin</outcome_measure>
      <outcome_measure>PK parameters of Imeglimin</outcome_measure>
      <outcome_measure>Incidence of treatment emergent adverse events (Safety and tolerability)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Poxel SA</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>PXL008-022</other_id>
    </other_ids>
    <start_date>September 3, 2018</start_date>
    <primary_completion_date>September 27, 2018</primary_completion_date>
    <completion_date>October 2, 2018</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>January 11, 2019</last_update_posted>
    <locations>
      <location>Hammersmith Medicines Research (HMR), London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646331</url>
  </study>
  <study rank="45387">
    <nct_id>NCT03646318</nct_id>
    <title>Ketanserin Effects on Peripheral Temperature and Lactate</title>
    <acronym>KoPTaL</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Critical Illness</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ketanserin</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Delta Temperature</outcome_measure>
      <outcome_measure>Lactate clearance</outcome_measure>
      <outcome_measure>hospital length of stay</outcome_measure>
      <outcome_measure>mortality</outcome_measure>
      <outcome_measure>ICU length of stay</outcome_measure>
      <outcome_measure>ICU mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Onze Lieve Vrouwe Gasthuis</lead_sponsor>
      <collaborator>Medical Centre Leeuwarden</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>WO 17.123 oost</other_id>
    </other_ids>
    <start_date>September 1, 2018</start_date>
    <primary_completion_date>April 1, 2019</primary_completion_date>
    <completion_date>May 1, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646318</url>
  </study>
  <study rank="45388">
    <nct_id>NCT03646305</nct_id>
    <title>Singing Your Negative Body-Related Thoughts</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Body Dissatisfaction</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Cognitive Defusion</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Self-Ratings of Thought Appraisals (Visual Analogue Scales)</outcome_measure>
      <outcome_measure>Self-Ratings of Cognitive Fusion (Cognitive Fusion Questionnaire)</outcome_measure>
      <outcome_measure>Self-ratings of Body Image Cognitions: Body Image Distress (Body Image State Scale)</outcome_measure>
      <outcome_measure>Self-Ratings of Body Image Cognitions: Drive for Thinness (Drive for Thinness Subscale of the Eating Disorder Inventory)</outcome_measure>
      <outcome_measure>Self-Ratings of Body Image Cognitions: Body Dissatisfaction (Visual Analogue Scales)</outcome_measure>
      <outcome_measure>Self-Ratings of Mood (Visual Analogue Scales)</outcome_measure>
      <outcome_measure>Self-Ratings of Self-Esteem (State Self Esteem Scale)</outcome_measure>
      <outcome_measure>Self-Rating of Homework Adherence (Homework Adherence Questionnaire)</outcome_measure>
      <outcome_measure>Self-Rating of Thought-Shape Fusion (Thought-Shape Fusion Questionnaire)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>York University</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>17 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>133</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <other_ids>
      <other_id>2018-111</other_id>
    </other_ids>
    <start_date>October 3, 2018</start_date>
    <primary_completion_date>January 30, 2019</primary_completion_date>
    <completion_date>June 27, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>July 9, 2019</last_update_posted>
    <locations>
      <location>York University, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646305</url>
  </study>
  <study rank="45389">
    <nct_id>NCT03646292</nct_id>
    <title>Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>NAFLD - Nonalcoholic Fatty Liver Disease</condition>
      <condition>Type2 Diabetes</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pioglitazone</intervention>
      <intervention type="Drug">Empagliflozin</intervention>
      <intervention type="Drug">Combination of pioglitazone and empagliflozin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>liver fat change measured by MRI-PDFF in co-localized regions of interest within each of nine liver segments</outcome_measure>
      <outcome_measure>Liver fibrosis measured by magnetic resonance elastography</outcome_measure>
      <outcome_measure>The changes in lipid profile</outcome_measure>
      <outcome_measure>The changes in liver enzyme</outcome_measure>
      <outcome_measure>The changes in glucose metabolism</outcome_measure>
      <outcome_measure>The changes in inflammation status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yonsei University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>4-2018-0655</other_id>
    </other_ids>
    <start_date>March 2019</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>February 2021</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>February 8, 2019</last_update_posted>
    <locations>
      <location>Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes Center, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646292</url>
  </study>
  <study rank="45390">
    <nct_id>NCT03646279</nct_id>
    <title>Thoracolumbar Brace for Individuals With Parkinson's Disease</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Parkinson Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Calibrace</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Postural Alignment - Neck Position</outcome_measure>
      <outcome_measure>Postural Alignment - Trunk Position</outcome_measure>
      <outcome_measure>Postural Alignment - Hip/Knee Position</outcome_measure>
      <outcome_measure>Postural Sway - Center of pressure position</outcome_measure>
      <outcome_measure>Postural Sway - Center of pressure velocity</outcome_measure>
      <outcome_measure>Study Developed Survey on the Experience of the Brace</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Duquesne University</lead_sponsor>
      <collaborator>AbiliLife</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>50 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Device Feasibility</study_design>
    </study_designs>
    <other_ids>
      <other_id>2015/06/7</other_id>
    </other_ids>
    <start_date>September 17, 2015</start_date>
    <primary_completion_date>March 31, 2016</primary_completion_date>
    <completion_date>March 31, 2016</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>October 10, 2018</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646279</url>
  </study>
  <study rank="45391">
    <nct_id>NCT03646266</nct_id>
    <title>Partial Neuromuscular Blockade for Lung Protective Mechanical Ventilation</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Insufficiency</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Rocuronium Bromide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The percentage of breaths with tidal volume 6ml/kg predicted body weight (PBW)</outcome_measure>
      <outcome_measure>Incidence of directly related serious adverse events</outcome_measure>
      <outcome_measure>Number of patients completing the study without meeting the stopping criteria</outcome_measure>
      <outcome_measure>Effect on partial carbon dioxide (pCO2)</outcome_measure>
      <outcome_measure>Effect on pH</outcome_measure>
      <outcome_measure>Effect on heart rate</outcome_measure>
      <outcome_measure>Effect on blood pressure</outcome_measure>
      <outcome_measure>Effect on respiratory rate</outcome_measure>
      <outcome_measure>Effect on peripheral capillary oxygen saturation (SpO2)</outcome_measure>
      <outcome_measure>Effect on partial oxygen pressure (pO2)</outcome_measure>
      <outcome_measure>Effect on work of breathing (WOB)</outcome_measure>
      <outcome_measure>Effect on pressure time product (PTP)</outcome_measure>
      <outcome_measure>Effect on tumor necrosis factor (TNF)-alfa</outcome_measure>
      <outcome_measure>Effect on interleukin(IL)-6 and IL-8</outcome_measure>
      <outcome_measure>Amount of days on mechanical ventilation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>VU University Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>NL65192.029.18</other_id>
    </other_ids>
    <start_date>August 15, 2018</start_date>
    <primary_completion_date>March 30, 2019</primary_completion_date>
    <completion_date>March 30, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>November 6, 2018</last_update_posted>
    <locations>
      <location>VUmc, Amsterdam, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646266</url>
  </study>
  <study rank="45392">
    <nct_id>NCT03646253</nct_id>
    <title>Analysis of Four-fragment Fractures of the Proximal Humerus: the Interest of 2D and 3D Imagery and Inter- and Intra-observer Reproducibility</title>
    <acronym>REPROD-HUMERUS</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Reproducibility</condition>
      <condition>Four Part Fracture</condition>
      <condition>Proximal Humerus Fracture</condition>
      <condition>Hertel's Criteria</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Analysis of radiology (standard radiographies, 2D scan sections and 3D reconstructions)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Inter-rater reproducibility concerning displacement of the humeral head on the frontal plane for 3D reconstructions</outcome_measure>
      <outcome_measure>Inter-rater reproducibility concerning displacement of the humeral head on the sagittal plane for 3D reconstructions</outcome_measure>
      <outcome_measure>Inter-rater reproducibility concerning humeral head split for 3D reconstructions</outcome_measure>
      <outcome_measure>Inter-rater reproducibility concerning calcar comminution for 3D reconstructions</outcome_measure>
      <outcome_measure>Inter-rater reproducibility concerning medial hinge for 3D reconstructions</outcome_measure>
      <outcome_measure>Inter-rater reproducibility concerning length of metaphyseal extension for 3D reconstructions</outcome_measure>
      <outcome_measure>Inter-rater reproducibility concerning displacement of the greater tuberosity for 3D reconstructions</outcome_measure>
      <outcome_measure>Inter-rater reproducibility concerning displacement of the lesser tuberosity for 3D reconstructions</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>CHU de Reims</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>2017Ao005</other_id>
    </other_ids>
    <start_date>June 1, 2016</start_date>
    <primary_completion_date>September 1, 2016</primary_completion_date>
    <completion_date>December 1, 2016</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations>
      <location>Damien JOLLY, Reims, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646253</url>
  </study>
  <study rank="45393">
    <nct_id>NCT03646240</nct_id>
    <title>ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Epilepsy Intractable</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ABI-009</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Maximum tolerated dose</outcome_measure>
      <outcome_measure>Percentage reduction in seizure rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Seattle Children's Hospital</lead_sponsor>
      <collaborator>Aadi, LLC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>3 Years</min_age>
    <max_age>26 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>RaSuRE</other_id>
    </other_ids>
    <start_date>July 31, 2018</start_date>
    <primary_completion_date>July 2019</primary_completion_date>
    <completion_date>July 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>January 9, 2019</last_update_posted>
    <locations>
      <location>Seattle Children's Hospital, Seattle, Washington, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT03646240/Prot_SAP_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT03646240</url>
  </study>
  <study rank="45394">
    <nct_id>NCT03646227</nct_id>
    <title>Multi-Drug Resistant Organism Network</title>
    <acronym>MDRO Network</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infections Resistant to Multiple Drugs</condition>
      <condition>Bacterial Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Standard of Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Disposition at Discharge</outcome_measure>
      <outcome_measure>Charlson Score</outcome_measure>
      <outcome_measure>Pitt Bacteremia Score</outcome_measure>
      <outcome_measure>Source of positive culture</outcome_measure>
      <outcome_measure>Length of Stay</outcome_measure>
      <outcome_measure>ICU Admissions</outcome_measure>
      <outcome_measure>Antibiotic Summary</outcome_measure>
      <outcome_measure>Survival Status</outcome_measure>
      <outcome_measure>Readmission Status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>7000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>Pro00071149</other_id>
      <other_id>UM1AI104681</other_id>
    </other_ids>
    <start_date>June 16, 2016</start_date>
    <primary_completion_date>April 1, 2020</primary_completion_date>
    <completion_date>April 1, 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>December 23, 2019</last_update_posted>
    <locations>
      <location>Duke Clinical Research Institute, Durham, North Carolina, United States</location>
      <location>The University of Queensland Centre for Clinical Research, Herston, Queensland, Australia</location>
      <location>Huashan Hospital, Shanghai, Shanghai, China</location>
      <location>Universidad El Bosque, Bogota, Colombia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646227</url>
  </study>
  <study rank="45395">
    <nct_id>NCT03646214</nct_id>
    <title>Improving Sleep Quality During Pregnancy Using an Oral Appliance</title>
    <acronym>PREGNCCT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Snoring</condition>
      <condition>Sleep Fragmentation</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Midline traction oral appliance</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sleep quality</outcome_measure>
      <outcome_measure>Snoring</outcome_measure>
      <outcome_measure>Pittsburgh Sleep Quality Index (PSQI)</outcome_measure>
      <outcome_measure>Insomnia Sleep Questionnaire (ISQ)</outcome_measure>
      <outcome_measure>Hamilton Depression Rating Scale (HDRS)</outcome_measure>
      <outcome_measure>Fatigue Severity Scale (FSS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Texas A&amp;M University</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>IRB2018-0048</other_id>
    </other_ids>
    <start_date>February 1, 2018</start_date>
    <primary_completion_date>January 31, 2019</primary_completion_date>
    <completion_date>August 31, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations>
      <location>Texas A&amp;M University College of Dentistry, Dallas, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646214</url>
  </study>
  <study rank="45396">
    <nct_id>NCT03646201</nct_id>
    <title>Feeding, Fun, and Families Study</title>
    <acronym>FFF</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Childhood Obesity</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">FFF</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Children's combined energy intake from solid fat and added sugars</outcome_measure>
      <outcome_measure>Children's total daily energy intake</outcome_measure>
      <outcome_measure>Children's total daily solid fat intake</outcome_measure>
      <outcome_measure>Children's total daily added sugar intake</outcome_measure>
      <outcome_measure>BMI status</outcome_measure>
      <outcome_measure>Meal Observation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Temple University</lead_sponsor>
      <collaborator>Virginia Polytechnic Institute and State University</collaborator>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>131</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>USDA-310138</other_id>
      <other_id>USDA AFRI 2011-68001-30148</other_id>
    </other_ids>
    <start_date>July 2012</start_date>
    <primary_completion_date>September 2015</primary_completion_date>
    <completion_date>March 2016</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 24, 2018</last_update_posted>
    <locations>
      <location>Temple University- Center for Obesity Research and Education, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646201</url>
  </study>
  <study rank="45397">
    <nct_id>NCT03646188</nct_id>
    <title>Open-Label Dose Escalation Trial to Evaluate Dose Limiting Toxicity and Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in BCC</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Basal Cell Carcinoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebo-containing MNA</intervention>
      <intervention type="Drug">25 µg doxorubicin-containing MNA</intervention>
      <intervention type="Drug">50 µg doxorubicin-containing MNA</intervention>
      <intervention type="Drug">100 µg doxorubicin-containing MNA</intervention>
      <intervention type="Drug">200 µg doxorubicin-containing MNA</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Dose limiting toxicity (DLT) and maximum tolerated dose (MTD)</outcome_measure>
      <outcome_measure>Efficacy as measured by histological analysis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>SkinJect, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SKNJCT-001</other_id>
    </other_ids>
    <start_date>January 15, 2020</start_date>
    <primary_completion_date>October 31, 2020</primary_completion_date>
    <completion_date>October 31, 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>January 13, 2020</last_update_posted>
    <locations>
      <location>The Center for Clinical and Cosmetic Research, Aventura, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646188</url>
  </study>
  <study rank="45398">
    <nct_id>NCT03646175</nct_id>
    <title>Choline Supplementation and Cardiovascular Health</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Risk Factor</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Choline</intervention>
      <intervention type="Dietary Supplement">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in brachial artery function after supplementation</outcome_measure>
      <outcome_measure>Change in arterial stiffness after supplementation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Virginia Polytechnic Institute and State University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <other_ids>
      <other_id>17-562</other_id>
    </other_ids>
    <start_date>September 24, 2018</start_date>
    <primary_completion_date>April 2, 2019</primary_completion_date>
    <completion_date>February 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>October 2, 2019</last_update_posted>
    <locations>
      <location>Virginia Polytechnic and State University, Blacksburg, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646175</url>
  </study>
  <study rank="45399">
    <nct_id>NCT03646162</nct_id>
    <title>Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Prostate Cancer Metastatic</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Veru-944</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in frequency of moderate to severe hot flashes at 6 weeks Day 42</outcome_measure>
      <outcome_measure>Change in severity of moderate to severe hot flashes at 6 Weeks Day 42</outcome_measure>
      <outcome_measure>Change of frequency of moderate to severe hot flashes at weeks 4,8,10 and 12</outcome_measure>
      <outcome_measure>Change in severity of moderate to severe hot flashes at weeks 4,8.10 and 12</outcome_measure>
      <outcome_measure>Change in bone turnover markers C-telopeptide (CTX)</outcome_measure>
      <outcome_measure>Change in bone turnover markers alkaline phosphatase</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Veru Inc.</lead_sponsor>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>V72203</other_id>
    </other_ids>
    <start_date>September 14, 2018</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>January 22, 2020</last_update_posted>
    <locations>
      <location>Gen1 Research, Glendale, Arizona, United States</location>
      <location>Tower Urology, Los Angeles, California, United States</location>
      <location>Urology of San Bernardino, San Bernardino, California, United States</location>
      <location>The Urology Center of Colorado, Denver, Colorado, United States</location>
      <location>Foothills Urology, Golden, Colorado, United States</location>
      <location>Universal Axon Clinical Research, Doral, Florida, United States</location>
      <location>Medical Research Center, Miami, Florida, United States</location>
      <location>North Idaho Urology, Coeur d'Alene, Idaho, United States</location>
      <location>First Urology, Jeffersonville, Indiana, United States</location>
      <location>Regional Urology LLC, Shreveport, Louisiana, United States</location>
      <location>Chesapeake Urology, Towson, Maryland, United States</location>
      <location>Coastal Urology, Brick, New Jersey, United States</location>
      <location>Premier Urology Group, Edison, New Jersey, United States</location>
      <location>Advance Urology, Elmont, New York, United States</location>
      <location>AccuMed Research, Garden City, New York, United States</location>
      <location>Premier Medical Group of the Hudson Valley, Poughkeepsie, New York, United States</location>
      <location>Associated Medical Professionals, Syracuse, New York, United States</location>
      <location>Clinical Research Solutions, Middleburg Heights, Ohio, United States</location>
      <location>Urologic Consultants, Bala-Cynwyd, Pennsylvania, United States</location>
      <location>Mary Crowley Cancer Research, Dallas, Texas, United States</location>
      <location>Urology Clinics of North Texas, Dallas, Texas, United States</location>
      <location>Houston Urology Partners, Houston, Texas, United States</location>
      <location>Urology San Antonio, San Antonio, Texas, United States</location>
      <location>Urology of Virginia, Virginia Beach, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646162</url>
  </study>
  <study rank="45400">
    <nct_id>NCT03646149</nct_id>
    <title>Improving Housing Outcomes for Homeless Veterans</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Veterans</condition>
      <condition>Homeless Persons</condition>
      <condition>Mentally Ill Persons</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Housing Attainment-Residential Timeline Follow-Back</outcome_measure>
      <outcome_measure>Housing Retention-Residential Timeline Follow-Back</outcome_measure>
      <outcome_measure>Serious Mental Illness Symptom Severity-Illness Management and Recovery Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>VA Office of Research and Development</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <other_ids>
      <other_id>CDX 18-004</other_id>
      <other_id>CDA 15-074</other_id>
    </other_ids>
    <start_date>June 26, 2018</start_date>
    <primary_completion_date>August 23, 2021</primary_completion_date>
    <completion_date>August 23, 2021</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>August 22, 2019</last_update_posted>
    <locations>
      <location>VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646149</url>
  </study>
  <study rank="45401">
    <nct_id>NCT03646136</nct_id>
    <title>Post Hysterectomy Benefits of Retained Cystoscopy Fluid</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Urinary Retention</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Retained fluid</intervention>
      <intervention type="Procedure">Emptied fluid</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to spontaneous void</outcome_measure>
      <outcome_measure>Foley catheter insertion rate</outcome_measure>
      <outcome_measure>Length of recovery room stay</outcome_measure>
      <outcome_measure>4-Item Patient Satisfaction Measure</outcome_measure>
      <outcome_measure>2-Item Patient Satisfaction Measure</outcome_measure>
      <outcome_measure>3-Item Bladder Symptoms Measure</outcome_measure>
      <outcome_measure>2-Item Bladder pain Measure</outcome_measure>
      <outcome_measure>3-Item Bladder pain Measure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Arizona</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: Single (Care Provider)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <other_ids>
      <other_id>UA IRB# 1808885089</other_id>
    </other_ids>
    <start_date>October 10, 2018</start_date>
    <primary_completion_date>October 30, 2019</primary_completion_date>
    <completion_date>October 30, 2019</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>July 24, 2019</last_update_posted>
    <locations>
      <location>Banner University Medical Center Phoenix, Phoenix, Arizona, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646136</url>
  </study>
  <study rank="45402">
    <nct_id>NCT03646123</nct_id>
    <title>Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hodgkin Lymphoma</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">brentuximab vedotin</intervention>
      <intervention type="Drug">doxorubicin</intervention>
      <intervention type="Drug">vinblastine</intervention>
      <intervention type="Drug">dacarbazine</intervention>
      <intervention type="Drug">G-CSF</intervention>
      <intervention type="Drug">nivolumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Febrile Neutropenia (FN) Rate (Part A)</outcome_measure>
      <outcome_measure>Complete response (CR) rate (Part B)</outcome_measure>
      <outcome_measure>Primary Refractory Disease Rate (Part A)</outcome_measure>
      <outcome_measure>CR Rate (Part A)</outcome_measure>
      <outcome_measure>Physician-reported Progression Free Survival (PFS) (Part A)</outcome_measure>
      <outcome_measure>Subsequent Anticancer Therapy Utilization Rate (Part A)</outcome_measure>
      <outcome_measure>Mean Dose Intensity (Part A)</outcome_measure>
      <outcome_measure>Rate of Dose Reduction and Delays (Part A)</outcome_measure>
      <outcome_measure>Incidence of adverse events (Part B)</outcome_measure>
      <outcome_measure>Incidence of laboratory abnormalities (Part B)</outcome_measure>
      <outcome_measure>Overall response rate (ORR) at EOT (Part B)</outcome_measure>
      <outcome_measure>Duration of response (DOR) (Part B)</outcome_measure>
      <outcome_measure>Duration of complete response (DOCR) (Part B)</outcome_measure>
      <outcome_measure>Event-free survival (EFS) (Part B)</outcome_measure>
      <outcome_measure>PFS (Part B)</outcome_measure>
      <outcome_measure>Overall survival (OS) (Part B)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Seattle Genetics, Inc.</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>SGN35-027</other_id>
    </other_ids>
    <start_date>January 28, 2019</start_date>
    <primary_completion_date>November 30, 2021</primary_completion_date>
    <completion_date>August 31, 2024</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>January 18, 2020</last_update_posted>
    <locations>
      <location>Compassionate Care Research Group, Fountain Valley, California, United States</location>
      <location>University of Colorado Health Memorial Hospital, Colorado Springs, Colorado, United States</location>
      <location>Poudre Valley Health System (PVHS), Fort Collins, Colorado, United States</location>
      <location>Florida Cancer Specialists - North Region, Saint Petersburg, Florida, United States</location>
      <location>New Jersey Hematology Oncology Associates, LLC, Brick, New Jersey, United States</location>
      <location>Regional Cancer Care Associates - Freehold, Freehold, New Jersey, United States</location>
      <location>Regional Cancer Care Associates - Howell, Howell, New Jersey, United States</location>
      <location>Regional Cancer Care Associates - Mount Holly, Mount Holly, New Jersey, United States</location>
      <location>Regional Cancer Care Associates - Central Jersey, Somerville, New Jersey, United States</location>
      <location>Regional Cancer Care Associates - Sparta, Sparta, New Jersey, United States</location>
      <location>Clinical Research Alliance - Morton Coleman, MD, Lake Success, New York, United States</location>
      <location>CareMount Medical Group, Mount Kisco, New York, United States</location>
      <location>Clinical Research Alliance - Abraham Mittelman, MD, LLC, Purchase, New York, United States</location>
      <location>Case Western Reserve University / University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States</location>
      <location>Tennessee Oncology - Nashville, Nashville, Tennessee, United States</location>
      <location>Brooke Army Medical Center, Fort Sam Houston, Texas, United States</location>
      <location>Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646123</url>
  </study>
  <study rank="45403">
    <nct_id>NCT03646110</nct_id>
    <title>The Comparison of Single and Multi-incision MIE for Esophageal Cancer</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Esophageal Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Minimally invasive esophagectomy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Overall survival rate</outcome_measure>
      <outcome_measure>Pain score as assessed by the face rating scale</outcome_measure>
      <outcome_measure>Ratio of ambulation</outcome_measure>
      <outcome_measure>Postoperative force vital capacity</outcome_measure>
      <outcome_measure>Post operative forced expiratory volume in one second</outcome_measure>
      <outcome_measure>Postoperative pulmonary complication</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Taiwan University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>35 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>201804074RINA</other_id>
    </other_ids>
    <start_date>August 17, 2018</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>August 24, 2018</study_first_posted>
    <last_update_posted>October 31, 2019</last_update_posted>
    <locations>
      <location>Jang-Ming Lee, Taipei City, Zhongzheng Dist., Taiwan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03646110</url>
  </study>
  <study rank="45404">
    <nct_id>NCT03646097</nct_id>
    <title>Impact of Real-time Angiographic Co-registered OCT on PCI Results - the OPTICO-integration II Study</title>
    <acronym>Integration-II</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ischaemic Heart Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Angio-PCI</intervention>
      <intervention type="Procedure">OCT-PCI</intervention>
      <intervention type="Procedure">ACR-PCI</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of a combined endpoint based on &quot;major edge dissections&quot; (I) AND/OR &quot;geographical mismatch&quot; (II) [%]</outcome_measure>
      <outcome_measure>Incidence of &quot;major edge dissections&quot; [%]</outcome_measure>
      <outcome_measure>Incidence of &quot;all e